{"c577c9dcc4a351e325d77ffd273dfc15bd38f40a": [["and avoid over burning the nation's health system as much of the virus remains unknown and obscured [1] .", [["the virus", "PROBLEM", 61, 70]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint introduction of recovery MCO which is part of the exit strategy that allows resumption of most economic 49 sectors.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Despite Malaysia is currently under recovery stage, there is no doubt that the COVID-19 50 pandemic has not only affected the global health and economy, but also the world of education.", [["the COVID", "TEST", 75, 84], ["no doubt", "UNCERTAINTY", 61, 69]]], ["Up to 140 51 country-wide closures of schools and universities affecting more than 1 billion students were reported by 52 the United Nations Education, Scientific and Cultural Organization (UNESCO).", [["wide", "OBSERVATION_MODIFIER", 21, 25], ["closures", "OBSERVATION", 26, 34]]], ["There is no exception to 53 Malaysia as all learning is forced to move onto online space since the commencement of MCO.54Regardless of the reopening of economic sectors, the Ministry of Higher Education Malaysia has 55 announced that online learning will be continued in all universities until 31st of December 2020.", [["no exception", "UNCERTAINTY", 9, 21]]], ["The 56 sudden shift away from conventional medical education into solely virtual learning possesses a great 57 challenge for both medical educators and medical students as medicine is well-known to be an evidence-58 based field that involves internships or clerkships to learn from real patients [2] .", [["patients", "ORGANISM", 287, 295], ["patients", "SPECIES", 287, 295]]], ["Apart from that, issues 59 concerning internet connection and unavailability of clinical equipment among medical students further 60 increase the pressure and challenge in delivering medical education.", [["the pressure", "TREATMENT", 142, 154], ["medical education", "TREATMENT", 183, 200], ["pressure", "OBSERVATION_MODIFIER", 146, 154]]], ["Nevertheless, looking at the bright 61 side, the COVID-19 pandemic has actually created a platform for medical educators to be more creative 62 and innovative, exploring new learning designs or pedagogies to provide medical students with the best 63 possible learning experiences [3] .", [["the COVID", "TEST", 45, 54], ["medical educators", "TREATMENT", 103, 120]]], ["Learning has also become more student-centered, encouraging self- CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)54The copyright holder for this preprint this version posted July 8, 2020.", [["CC", "CHEMICAL", 66, 68], ["med", "ANATOMY", 171, 174]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)54The copyright holder for this preprint this version posted July 8, 2020. was used, and respondents were asked to rate their agreement for each statement as follows: 1=strongly 114 disagree, 2=disagree, 3=no opinion, 4=agree, and 5=strongly agree.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["The questionnaire has been 116 modified for medical students and minor adjustments in grammar were made to avoid confusion among 117 the medical students (S1 Appendix).", [["confusion", "DISEASE", 113, 122], ["medical students", "TREATMENT", 44, 60], ["minor adjustments in grammar", "TREATMENT", 65, 93], ["confusion", "PROBLEM", 113, 122], ["Appendix", "ANATOMY", 158, 166]]], ["A pilot study was done on 35 UKM medical students (Cronbach's 118 Alpha; =0.91).", [["A pilot study", "TEST", 0, 13], ["Cronbach", "TEST", 51, 59], ["Alpha", "TEST", 66, 71]]], ["Demographic data and education background of samples were collected including age of 119 the respondents, year of study, and phase of study.", [["samples", "ANATOMY", 45, 52], ["Demographic data", "TEST", 0, 16], ["study", "TEST", 114, 119], ["phase of study", "TEST", 125, 139]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)54The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint p<0.05.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 204, 224], ["medRxiv preprint p", "TREATMENT", 328, 346], ["med", "ANATOMY", 105, 108]]], ["The relationship between total score as 131 dependent variable and education background as independent variables was analyzed using cross 132 tabulation analysis.", [["total score", "TEST", 25, 36], ["cross 132 tabulation analysis", "TEST", 132, 161]]], ["Descriptive 133 analyses were included for frequencies and percentages of digital learning usage while Student's t-test 134 and Chi-Square analysis were utilized to determine the difference between groups for selected variables.", [["Student's t-test", "TEST", 103, 119], ["Chi-Square analysis", "TEST", 128, 147]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)144The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint as medical education has fully transformed to entirely online teaching and learning, all respondents have 150 employed digital learning in their studies with an increased number of respondents using more than 5 151 times per week (58.55%) as compared to 50% prior to the COVID-19 outbreak ( Fig 1A) .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["the COVID", "TEST", 613, 622], ["med", "ANATOMY", 105, 108]]], ["Overall, most of the respondents 155 had high usage before and during COVID-19 period and there was a rise in high usage during COVID-19 156 period (86.8%) as compared to pre-COVID-19 period (76.7%) (Fig 1B) .", [["COVID", "TEST", 128, 133], ["pre-COVID", "TEST", 171, 180]]], ["Difference in digital learning 157 usage between pre-COVID-19 and COVID-19 period was assessed using Chi-Square analysis ( Fig 1C) 158 which showed a significant difference (p<0.05) as students during the COVID-19 period had a higher 159 frequency of digital learning usage as compared to prior COVID-19 period.", [["pre-COVID", "TEST", 49, 58], ["COVID", "TEST", 66, 71], ["Chi-Square analysis", "TEST", 101, 120], ["the COVID", "TEST", 201, 210], ["significant", "OBSERVATION_MODIFIER", 150, 161]]], ["Among all the respondents 160 who use digital learning, e-books were the most preferred choice for the source of digital learning 161 (40.67%) while audiotapes (6.00%) was the least preferred one before the COVID-19 period.", [["audiotapes", "TEST", 149, 159]]], ["However, 162 videos (38.16%) were the most preferred choice during COVID-19 period.", [["videos", "TEST", 13, 19]]], ["A reduction in preference for e-163 books (36.84%) and online research articles (11.84%) with an increase in preference for videos (38.16%), 164 online courses (21.05%), games (16.45%), simulation software (11.84%) and audiotapes (9.97%) were 165 noted during this pandemic period ( Fig 1D) .168Descriptive statistics were used to provide an overall picture of the learning motivation of this 169 study.", [["videos", "TEST", 124, 130], ["simulation software", "TEST", 186, 205], ["audiotapes", "TEST", 219, 229], ["this 169 study", "TEST", 388, 402], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["increase", "OBSERVATION_MODIFIER", 97, 105]]], ["As for prior to COVID-19 period, the samples were CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint percentage of respondents with high learning motivation (67.80%) (Fig 2A) .", [["samples", "ANATOMY", 37, 44], ["CC", "CHEMICAL", 50, 52], ["COVID", "TEST", 16, 21], ["the samples", "TEST", 33, 44], ["CC", "TEST", 50, 52], ["The copyright holder", "TREATMENT", 251, 271], ["med", "ANATOMY", 155, 158]]], ["Difference in level of learning 178 motivation among different variables was analyzed using the Student's t test.", [["the Student's t test", "TEST", 92, 112]]], ["Results showed that the 179 level of learning motivation was significantly different (p<0.01) across the frequency of digital learning 180 usage during the COVID-19 period as higher total scores were obtained with higher frequency of digital 181 learning usage ( Fig 2B) .", [["the COVID", "TEST", 152, 161]]], ["Nevertheless, the level of learning motivation between before and during 182 COVID-19 period (Fig 2A) , and level of learning motivation across frequency of digital learning usage 183 prior to COVID-19 period showed no significant difference ( Fig 2B) .", [["COVID", "TEST", 193, 198], ["significant difference", "PROBLEM", 219, 241], ["no", "UNCERTAINTY", 216, 218], ["significant", "OBSERVATION_MODIFIER", 219, 230]]], ["We have gathered feedback and reflections and further collated them into 11 emerging themes 201 that featured the learning motivation of UKM medical students during COVID-19 period (Table 2) , which 202 were further summarized into 2 main themes; intrinsic and extrinsic motivations (Fig 4) .", [["extrinsic motivations", "OBSERVATION", 261, 282]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint whereas extrinsic learning motivation pertains to learning to attain some other outcomes that are 205 unrelated to the action.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["(R54) Digital learning using different resources \"Always remind myself about the pro exam.\"", [["the pro exam", "TEST", 77, 89]]], ["(R14) Examination \"Ask motivation from friends and family\" (R11) Family \"By continuously keeping in touch with my friends, making a checklist of the subjects that I need to cover, having a conducive study area, online group study with friends.\"", [["Examination", "TEST", 6, 17]]], ["(R31) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020.256For example, one remark was, \"Ask motivation from friends and family.\"", [["The copyright holder", "TREATMENT", 140, 160], ["med", "ANATOMY", 44, 47]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["History taking can be carried out by doing video conferencing with patients whose condition was stable to 296 be interviewed as suggested by two students.", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint skills\" (R14) 304 Three responses suggested virtual reality to replace the clinical exposure learning for medical students.305\"We need virtual reality; it will make it a lot more fun but then again not realistic at all\" (R51) 306 There were two students who wished to subscribe to more learning apps during this COVID-19 period.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Previously, it has also been reported that there was no 400 significant difference in the level of intrinsic motivation among medical students who participated in high-401 fidelity mannequin simulation, as the medical students were found to be originally highly intrinsically 402 motivated [37] .", [["no", "UNCERTAINTY", 53, 55], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["difference", "OBSERVATION", 72, 82]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint they learn something every day.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["medRxiv", "TREATMENT", 325, 332], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["However, the significantly higher learning motivation with high digital 407 learning usage during the pandemic period could be explained as online learning being the only source of 408 learning during COVID-19.", [["COVID", "TEST", 201, 206]]], ["Thus, medical students with pre-existing high intrinsic motivation will use all 409 available resources for their study and lean towards digital sources. times.", [["their study", "TEST", 108, 119]]], ["This may be due to the sudden change in learning environment and methodology thus the need to 426 adapt with such changes.", [["the sudden change in learning environment", "PROBLEM", 19, 60], ["may be due to", "UNCERTAINTY", 5, 18]]], ["This could be due to inaccessibility of certain learning 428 materials such as online research articles or certain online learning platforms that are only accessible at 429 the university area.", [["could be due to", "UNCERTAINTY", 5, 20]]], ["Besides, as suggested by our students, an ideal LMS that enables 432 students to access all learning materials while encouraging discussions between lecturers and students 433 .", [["LMS", "CANCER", 48, 51]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint via online assessments such as quizzes and viva sessions are required if the university were to embark 434 on a successful digital learning experience.435This study was conducted with a few potential limitations.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 242, 262], ["online assessments", "TEST", 387, 405], ["This study", "TEST", 537, 547], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Since this was a cross-sectional study,459.", [["a cross-sectional study", "TEST", 15, 38]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)459The copyright holder for this preprint this version posted July 8, 2020. . https://doi.org/10.1101/2020.07.07.20147918 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 205, 225], ["medRxiv", "TREATMENT", 329, 336], ["med", "ANATOMY", 105, 108]]]], "e50ddf4993ee18bcc608c8fea29a1ee47a77ea4a": [], "073d6557ccb048fe248c2d4c09a21c33f8632371": [["IntroductionLipid rafts (LRs) are small (10-200 nM) , highly dynamic, detergent-resistant membrane fractions enriched in cholesterol and glycosphingolipid content on the plasma membranes of eukaryotic cells 1, 2 .", [["membrane fractions", "ANATOMY", 90, 108], ["plasma membranes", "ANATOMY", 170, 186], ["cells", "ANATOMY", 201, 206], ["cholesterol", "CHEMICAL", 121, 132], ["cholesterol", "CHEMICAL", 121, 132], ["cholesterol", "SIMPLE_CHEMICAL", 121, 132], ["glycosphingolipid", "SIMPLE_CHEMICAL", 137, 154], ["plasma membranes", "CELLULAR_COMPONENT", 170, 186], ["cells", "CELL", 201, 206], ["eukaryotic cells", "CELL_TYPE", 190, 206], ["resistant membrane fractions", "PROBLEM", 80, 108], ["small", "OBSERVATION_MODIFIER", 34, 39], ["resistant membrane fractions", "OBSERVATION", 80, 108], ["glycosphingolipid content", "OBSERVATION", 137, 162], ["eukaryotic cells", "OBSERVATION", 190, 206]]], ["Although LRs comprise only a small percentage of the cell surface area 3 , their sizes can increase by coalescence with other raft units 4, 5 , providing spatiotemporal platforms for many molecular entities 6 .", [["cell surface area", "ANATOMY", 53, 70], ["cell", "CELL", 53, 57], ["LRs", "PROTEIN", 9, 12], ["small", "OBSERVATION_MODIFIER", 29, 34], ["percentage", "OBSERVATION_MODIFIER", 35, 45], ["cell", "OBSERVATION", 53, 57], ["surface", "OBSERVATION_MODIFIER", 58, 65], ["area", "OBSERVATION_MODIFIER", 66, 70], ["sizes", "OBSERVATION_MODIFIER", 81, 86], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["coalescence", "OBSERVATION_MODIFIER", 103, 114]]], ["LRs play crucial roles in complex physiological processes, such as phagocytosis, receptor-receptor associations, receptor-pathogen associations, and signal transduction in many pathological situations 1,2,7-9 , modulating innate and acquired immune responses 10 .IntroductionThe complement system is important for several innate and adaptive resistance mechanisms and consists of a highly regulated cascade of more than 30 serum complement proteins that can be triggered by the recognition of a microbe 11 .", [["serum", "ANATOMY", 423, 428], ["1,2,7-9", "CHEMICAL", 201, 208], ["receptor-receptor", "GENE_OR_GENE_PRODUCT", 81, 98], ["1,2,7-9", "SIMPLE_CHEMICAL", 201, 208], ["serum", "ORGANISM_SUBSTANCE", 423, 428], ["LRs", "PROTEIN", 0, 3], ["serum complement proteins", "PROTEIN", 423, 448], ["complex physiological processes", "PROBLEM", 26, 57], ["signal transduction", "TEST", 149, 168], ["adaptive resistance mechanisms", "TREATMENT", 333, 363], ["30 serum complement proteins", "PROBLEM", 420, 448], ["complex", "OBSERVATION_MODIFIER", 26, 33], ["physiological processes", "OBSERVATION", 34, 57]]], ["This system can be activated through classical, soluble mannose-binding lectin (MBL), and alternative pathways 12, 13 .", [["mannose", "CHEMICAL", 56, 63], ["mannose-binding lectin", "GENE_OR_GENE_PRODUCT", 56, 78], ["MBL", "GENE_OR_GENE_PRODUCT", 80, 83], ["soluble mannose-binding lectin", "PROTEIN", 48, 78], ["MBL", "PROTEIN", 80, 83]]], ["A pivotal step in the complement pathways is assembly of a C3 convertase, which digests C3 to form microbial binding C3 fragments Because C3 fragments 14 , such as C3b, C3bi, and C3d, serve as ligands for complement receptors, their reciprocal binding promotes the uptake and killing of microbes by phagocytes 15 .", [["phagocytes", "ANATOMY", 299, 309], ["C3 convertase", "GENE_OR_GENE_PRODUCT", 59, 72], ["C3", "GENE_OR_GENE_PRODUCT", 88, 90], ["C3b", "GENE_OR_GENE_PRODUCT", 164, 167], ["C3bi", "GENE_OR_GENE_PRODUCT", 169, 173], ["C3d", "GENE_OR_GENE_PRODUCT", 179, 182], ["complement receptors", "GENE_OR_GENE_PRODUCT", 205, 225], ["phagocytes", "CELL", 299, 309], ["C3 convertase", "PROTEIN", 59, 72], ["C3", "PROTEIN", 88, 90], ["microbial binding C3 fragments", "PROTEIN", 99, 129], ["C3 fragments 14", "PROTEIN", 138, 153], ["C3b", "PROTEIN", 164, 167], ["C3bi", "PROTEIN", 169, 173], ["C3d", "PROTEIN", 179, 182], ["complement receptors", "PROTEIN", 205, 225], ["a C3 convertase", "PROBLEM", 57, 72], ["microbial binding C3 fragments", "PROBLEM", 99, 129], ["C3 fragments", "PROBLEM", 138, 150], ["C3b", "TEST", 164, 167], ["C3bi", "TEST", 169, 173], ["complement receptors", "TEST", 205, 225], ["C3 fragments", "OBSERVATION", 117, 129]]], ["Thus, the complement system provides a major extracellular defense mechanism against infectious organisms 16 Various immune receptors in LRs, such as Fc receptors 17, 18 , cytokine receptors [19] [20] [21] , B cell receptors 22 , and T cell receptors 23 , increase their binding capacity through clustering 24 and facilitate signaling to favor the clearance of intracellular pathogens 10 .", [["extracellular", "ANATOMY", 45, 58], ["B cell", "ANATOMY", 208, 214], ["T cell", "ANATOMY", 234, 240], ["intracellular", "ANATOMY", 361, 374], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 58], ["LRs", "GENE_OR_GENE_PRODUCT", 137, 140], ["Fc receptors 17", "GENE_OR_GENE_PRODUCT", 150, 165], ["18", "GENE_OR_GENE_PRODUCT", 167, 169], ["B cell receptors 22", "GENE_OR_GENE_PRODUCT", 208, 227], ["T cell receptors 23", "GENE_OR_GENE_PRODUCT", 234, 253], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 361, 374], ["immune receptors", "PROTEIN", 117, 133], ["LRs", "PROTEIN", 137, 140], ["Fc receptors 17, 18 , cytokine receptors [19] [20] [21] , B cell receptors 22", "PROTEIN", 150, 227], ["T cell receptors 23", "PROTEIN", 234, 253], ["a major extracellular defense mechanism", "PROBLEM", 37, 76], ["infectious organisms", "PROBLEM", 85, 105], ["LRs", "TEST", 137, 140], ["Fc receptors", "TEST", 150, 162], ["cytokine receptors", "TEST", 172, 190], ["B cell receptors", "TEST", 208, 224], ["T cell receptors", "TEST", 234, 250], ["their binding capacity", "PROBLEM", 265, 287], ["intracellular pathogens", "PROBLEM", 361, 384], ["intracellular pathogens", "OBSERVATION", 361, 384]]], ["Some innate pattern recognition receptors, such as Toll-like receptors and transmembrane C-type lectins, translocate to LRs upon stimulation with specific agonists [25] [26] [27] [28] [29] [30] , thus demonstrating the importance of this membrane partitioning for the innate immune recognition of various pathogens 3 .", [["membrane", "ANATOMY", 238, 246], ["[25] [26] [27] [28] [29] [30]", "CHEMICAL", 164, 193], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 51, 70], ["C-type lectins", "GENE_OR_GENE_PRODUCT", 89, 103], ["LRs", "GENE_OR_GENE_PRODUCT", 120, 123], ["[25] [26] [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 164, 193], ["membrane", "CELLULAR_COMPONENT", 238, 246], ["innate pattern recognition receptors", "PROTEIN", 5, 41], ["Toll-like receptors", "PROTEIN", 51, 70], ["transmembrane C-type lectins", "PROTEIN", 75, 103], ["LRs", "PROTEIN", 120, 123], ["transmembrane C-type lectins", "TREATMENT", 75, 103], ["specific agonists", "TEST", 146, 163], ["this membrane partitioning", "TREATMENT", 233, 259], ["various pathogens", "PROBLEM", 297, 314]]], ["In addition, various complement receptors (CR2, CR3, and globular C1q receptor (gC1qR)) 31,32 and complement regulatory proteins (CD46, CD55, and CD59) 33, 34 are distributed in the LRs of immune cells.IntroductionTransmembrane C-type lectin human dendritic cellspecific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN, CD209) and its murine homolog SIGN-R1 exhibit several common specificities, such as acting as the principal receptors for the pneumococcal capsular polysaccharide of S. pneumoniae (CPS) 35, 36 and human immunodeficiency virus-1 37, 38 , binding to the complement C1q 24, 39 , and showing distribution in LRs in vitro 29, 30 .", [["immune cells", "ANATOMY", 189, 201], ["human immunodeficiency virus", "DISEASE", 533, 561], ["CR2", "GENE_OR_GENE_PRODUCT", 43, 46], ["CR3", "GENE_OR_GENE_PRODUCT", 48, 51], ["globular C1q receptor (gC1qR)) 31,32", "GENE_OR_GENE_PRODUCT", 57, 93], ["complement regulatory proteins", "GENE_OR_GENE_PRODUCT", 98, 128], ["CD46", "GENE_OR_GENE_PRODUCT", 130, 134], ["CD55", "GENE_OR_GENE_PRODUCT", 136, 140], ["CD59", "GENE_OR_GENE_PRODUCT", 146, 150], ["immune cells", "CELL", 189, 201], ["dendritic cellspecific intercellular adhesion molecule-3", "GENE_OR_GENE_PRODUCT", 248, 304], ["nonintegrin", "GENE_OR_GENE_PRODUCT", 314, 325], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 327, 334], ["CD209", "GENE_OR_GENE_PRODUCT", 336, 341], ["murine", "ORGANISM", 351, 357], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 366, 373], ["S. pneumoniae", "ORGANISM", 502, 515], ["CPS) 35", "ORGANISM", 517, 524], ["human immunodeficiency virus-1 37", "ORGANISM", 533, 566], ["complement receptors", "PROTEIN", 21, 41], ["CR2", "PROTEIN", 43, 46], ["CR3", "PROTEIN", 48, 51], ["globular C1q receptor (gC1qR)) 31,32", "PROTEIN", 57, 93], ["complement regulatory proteins", "PROTEIN", 98, 128], ["CD46", "PROTEIN", 130, 134], ["CD55", "PROTEIN", 136, 140], ["CD59", "PROTEIN", 146, 150], ["immune cells", "CELL_TYPE", 189, 201], ["Transmembrane C-type lectin human dendritic cellspecific intercellular adhesion molecule-3", "PROTEIN", 214, 304], ["grabbing nonintegrin", "PROTEIN", 305, 325], ["DC", "PROTEIN", 327, 329], ["SIGN", "PROTEIN", 330, 334], ["CD209", "PROTEIN", 336, 341], ["SIGN", "PROTEIN", 366, 370], ["R1", "PROTEIN", 371, 373], ["complement C1q 24, 39", "PROTEIN", 588, 609], ["human", "SPECIES", 242, 247], ["murine", "SPECIES", 351, 357], ["S. pneumoniae", "SPECIES", 502, 515], ["human immunodeficiency virus-1", "SPECIES", 533, 563], ["human", "SPECIES", 242, 247], ["pneumococcal", "SPECIES", 462, 474], ["S. pneumoniae", "SPECIES", 502, 515], ["human immunodeficiency virus-1", "SPECIES", 533, 563], ["various complement receptors", "TEST", 13, 41], ["CR2", "TEST", 43, 46], ["CR3", "TEST", 48, 51], ["globular C1q receptor", "TEST", 57, 78], ["complement regulatory proteins", "TEST", 98, 128], ["CD46", "TEST", 130, 134], ["CD55", "TEST", 136, 140], ["CD59", "TEST", 146, 150], ["Transmembrane C-type lectin human dendritic cellspecific intercellular adhesion molecule", "TREATMENT", 214, 302], ["its murine homolog SIGN", "TEST", 347, 370], ["several common specificities", "PROBLEM", 382, 410], ["the pneumococcal capsular polysaccharide", "TEST", 458, 498], ["S. pneumoniae", "PROBLEM", 502, 515], ["CPS", "TEST", 517, 520], ["human immunodeficiency virus", "TEST", 533, 561], ["the complement C1q", "TEST", 584, 602], ["vitro", "TEST", 647, 652], ["immune cells", "OBSERVATION", 189, 201], ["intercellular adhesion", "OBSERVATION", 271, 293], ["pneumoniae", "OBSERVATION", 505, 515]]], ["Additionally, SIGN-R1 can initiate an immunoglobulin (Ig)-independent classical complement pathway by interacting with C1q against S. pneumoniae, particularly on the cellular surface of splenic marginal zone (MZ) macrophages, facilitating their rapid clearance 39 .", [["cellular surface", "ANATOMY", 166, 182], ["splenic marginal zone (MZ) macrophages", "ANATOMY", 186, 224], ["SIGN-R1", "CHEMICAL", 14, 21], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 14, 21], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 38, 52], ["Ig", "GENE_OR_GENE_PRODUCT", 54, 56], ["C1q", "GENE_OR_GENE_PRODUCT", 119, 122], ["S. pneumoniae", "ORGANISM", 131, 144], ["cellular surface", "CELLULAR_COMPONENT", 166, 182], ["splenic marginal zone (MZ) macrophages", "CELL", 186, 224], ["SIGN", "PROTEIN", 14, 18], ["R1", "PROTEIN", 19, 21], ["Ig", "PROTEIN", 54, 56], ["C1q", "PROTEIN", 119, 122], ["splenic marginal zone (MZ) macrophages", "CELL_TYPE", 186, 224], ["S. pneumoniae", "SPECIES", 131, 144], ["S. pneumoniae", "SPECIES", 131, 144], ["an immunoglobulin (Ig", "TREATMENT", 35, 56], ["S. pneumoniae", "PROBLEM", 131, 144], ["pneumoniae", "OBSERVATION", 134, 144], ["surface", "OBSERVATION_MODIFIER", 175, 182], ["splenic", "ANATOMY", 186, 193], ["marginal", "ANATOMY_MODIFIER", 194, 202], ["zone", "ANATOMY_MODIFIER", 203, 207]]], ["Similarly, the DC-SIGN-C1q complex may provide an initiation site for the classical complement pathway under pathogenic conditions 24 .IntroductionAlthough disruption of LRs significantly reduces DC-SIGN-and SIGN-R1-mediated pneumococcal phagocytosis, the specific mechanisms are still unknown.", [["DC", "ANATOMY", 15, 17], ["DC", "ANATOMY", 196, 198], ["C1q", "GENE_OR_GENE_PRODUCT", 23, 26], ["LRs", "GENE_OR_GENE_PRODUCT", 170, 173], ["SIGN", "GENE_OR_GENE_PRODUCT", 199, 203], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 208, 215], ["pneumococcal", "ORGANISM", 225, 237], ["DC", "CELL_TYPE", 15, 17], ["SIGN", "PROTEIN", 18, 22], ["C1q complex", "PROTEIN", 23, 34], ["LRs", "PROTEIN", 170, 173], ["DC", "CELL_TYPE", 196, 198], ["SIGN", "PROTEIN", 199, 203], ["SIGN", "PROTEIN", 208, 212], ["R1", "PROTEIN", 213, 215], ["pneumococcal", "SPECIES", 225, 237], ["disruption of LRs", "PROBLEM", 156, 173], ["DC", "TEST", 196, 198], ["SIGN", "TEST", 199, 203], ["SIGN", "TEST", 208, 212], ["pneumococcal phagocytosis", "PROBLEM", 225, 250], ["pneumococcal phagocytosis", "OBSERVATION", 225, 250]]], ["Accordingly, in this study, the role of LRs was examined in C-type lectin-mediated phagocytosis in order to elucidate the role of DC-SIGN in the human spleen.ResultsLRs on splenic MZ DC-SIGN + macrophages may be important for DC-SIGN-mediated uptake and decomposition of S. pneumoniae DC-SIGN transfectants were immunostained for DC-SIGN and the raft protein GM-1 ganglioside with fluorescein isothiocyanate (FITC)/cholera toxin B (CTB) subunit.", [["DC", "ANATOMY", 130, 132], ["spleen", "ANATOMY", 151, 157], ["splenic MZ DC-SIGN + macrophages", "ANATOMY", 172, 204], ["DC", "ANATOMY", 226, 228], ["DC", "ANATOMY", 285, 287], ["transfectants", "ANATOMY", 293, 306], ["DC", "ANATOMY", 330, 332], ["raft", "ANATOMY", 346, 350], ["MZ", "CHEMICAL", 180, 182], ["fluorescein isothiocyanate", "CHEMICAL", 381, 407], ["cholera toxin B", "CHEMICAL", 415, 430], ["ganglioside", "CHEMICAL", 364, 375], ["fluorescein isothiocyanate", "CHEMICAL", 381, 407], ["FITC", "CHEMICAL", 409, 413], ["LRs", "GENE_OR_GENE_PRODUCT", 40, 43], ["C-type lectin", "GENE_OR_GENE_PRODUCT", 60, 73], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 130, 137], ["human", "ORGANISM", 145, 150], ["spleen", "ORGAN", 151, 157], ["ResultsLRs", "SIMPLE_CHEMICAL", 158, 168], ["splenic MZ DC-SIGN + macrophages", "CELL", 172, 204], ["SIGN", "GENE_OR_GENE_PRODUCT", 229, 233], ["S. pneumoniae", "ORGANISM", 271, 284], ["SIGN transfectants", "CELL", 288, 306], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 330, 337], ["GM-1 ganglioside", "GENE_OR_GENE_PRODUCT", 359, 375], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 381, 407], ["FITC", "SIMPLE_CHEMICAL", 409, 413], ["cholera toxin B", "GENE_OR_GENE_PRODUCT", 415, 430], ["CTB", "GENE_OR_GENE_PRODUCT", 432, 435], ["LRs", "PROTEIN", 40, 43], ["lectin", "PROTEIN", 67, 73], ["DC", "CELL_TYPE", 130, 132], ["SIGN", "PROTEIN", 133, 137], ["ResultsLRs", "PROTEIN", 158, 168], ["splenic MZ DC", "CELL_TYPE", 172, 185], ["SIGN", "CELL_TYPE", 186, 190], ["macrophages", "CELL_TYPE", 193, 204], ["DC", "CELL_TYPE", 226, 228], ["SIGN", "PROTEIN", 229, 233], ["S. pneumoniae DC-SIGN transfectants", "CELL_LINE", 271, 306], ["DC", "CELL_TYPE", 330, 332], ["SIGN", "PROTEIN", 333, 337], ["raft protein GM-1 ganglioside", "PROTEIN", 346, 375], ["fluorescein isothiocyanate (FITC)/cholera toxin B (CTB) subunit", "PROTEIN", 381, 444], ["human", "SPECIES", 145, 150], ["S. pneumoniae", "SPECIES", 271, 284], ["human", "SPECIES", 145, 150], ["S. pneumoniae", "SPECIES", 271, 284], ["this study", "TEST", 16, 26], ["splenic MZ DC", "TEST", 172, 185], ["macrophages", "PROBLEM", 193, 204], ["mediated uptake", "PROBLEM", 234, 249], ["S. pneumoniae", "PROBLEM", 271, 284], ["SIGN transfectants", "TEST", 288, 306], ["DC", "TEST", 330, 332], ["the raft protein GM", "TEST", 342, 361], ["ganglioside", "TEST", 364, 375], ["fluorescein isothiocyanate (FITC)/cholera toxin B (CTB)", "TREATMENT", 381, 436], ["human spleen", "ANATOMY", 145, 157], ["splenic", "ANATOMY", 172, 179]]], ["Large aggregates of DC-SIGN were strongly distributed in CTB-enriched vertex regions of the cells (Fig. 1a) .", [["DC", "ANATOMY", 20, 22], ["vertex regions", "ANATOMY", 70, 84], ["cells", "ANATOMY", 92, 97], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 20, 27], ["CTB", "SIMPLE_CHEMICAL", 57, 60], ["cells", "CELL", 92, 97], ["DC", "CELL_TYPE", 20, 22], ["SIGN", "PROTEIN", 23, 27], ["CTB", "PROTEIN", 57, 60], ["aggregates", "OBSERVATION", 6, 16], ["vertex", "ANATOMY_MODIFIER", 70, 76], ["cells", "ANATOMY", 92, 97]]], ["Moreover, DC-SIGN monomers and dimers were obviously enriched in LR fractions (fractions 4-6) compared with non-LR fractions (Fig. 1a) .", [["DC", "ANATOMY", 10, 12], ["LR fractions", "ANATOMY", 65, 77], ["DC", "CELL_TYPE", 10, 12], ["LR fractions", "TEST", 65, 77], ["fractions", "TEST", 79, 88], ["LR fractions", "OBSERVATION", 65, 77]]], ["Isolation of detergent-resistant raft fractions was confirmed with immunoblotting for flotillin-1 and caveolin-1 as representative markers of planar LRs and caveolae, respectively 40 .", [["raft fractions", "ANATOMY", 33, 47], ["caveolae", "ANATOMY", 157, 165], ["flotillin-1", "GENE_OR_GENE_PRODUCT", 86, 97], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 102, 112], ["caveolae", "CELLULAR_COMPONENT", 157, 165], ["flotillin-1", "PROTEIN", 86, 97], ["caveolin-1", "PROTEIN", 102, 112], ["Isolation of detergent", "TREATMENT", 0, 22], ["resistant raft fractions", "PROBLEM", 23, 47], ["immunoblotting", "TEST", 67, 81], ["flotillin", "TREATMENT", 86, 95], ["caveolin", "TREATMENT", 102, 110], ["planar LRs", "TEST", 142, 152], ["resistant", "OBSERVATION_MODIFIER", 23, 32], ["raft fractions", "OBSERVATION", 33, 47]]], ["The same experiment was performed with SIGN-R1 depletion and DC-SIGN transgenic mice (DC-SIGN BMT / SIGN-R1 TKO ; Fig. 1b and Supplementary Fig. S1a , b) or human cadavers ( Supplementary Fig. S1c ).", [["DC", "ANATOMY", 61, 63], ["DC", "ANATOMY", 86, 88], ["cadavers", "ANATOMY", 163, 171], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 39, 46], ["DC-SIGN", "CELL", 61, 68], ["mice", "ORGANISM", 80, 84], ["DC-SIGN", "CELL", 86, 93], ["SIGN-R1 TKO", "CELL", 100, 111], ["human", "ORGANISM", 157, 162], ["cadavers", "ORGANISM_SUBDIVISION", 163, 171], ["SIGN", "PROTEIN", 39, 43], ["DC", "CELL_TYPE", 61, 63], ["mice", "SPECIES", 80, 84], ["human", "SPECIES", 157, 162], ["mice", "SPECIES", 80, 84], ["human", "SPECIES", 157, 162], ["SIGN-R1 depletion", "TREATMENT", 39, 56], ["SIGN", "TEST", 100, 104], ["human cadavers", "TREATMENT", 157, 171]]], ["DC-SIGN was obviously expressed in LRs of splenic MZ DC-SIGN + cells (Fig. 1c , d and Supplementary Fig. S1d) .ResultsDisruption of LRs with methyl-\u03b2-cyclodextrin (M\u03b2CD), a cholesterol-extracting agent, did not reduce DC-SIGN expression on the cellular surface, but altered its surface distribution pattern (Fig. 1e) .", [["DC", "ANATOMY", 0, 2], ["splenic MZ DC-SIGN + cells", "ANATOMY", 42, 68], ["DC", "ANATOMY", 218, 220], ["cellular surface", "ANATOMY", 244, 260], ["surface", "ANATOMY", 278, 285], ["MZ", "CHEMICAL", 50, 52], ["methyl-\u03b2-cyclodextrin", "CHEMICAL", 141, 162], ["M\u03b2CD", "CHEMICAL", 164, 168], ["cholesterol", "CHEMICAL", 173, 184], ["methyl-\u03b2-cyclodextrin", "CHEMICAL", 141, 162], ["M\u03b2CD", "CHEMICAL", 164, 168], ["cholesterol", "CHEMICAL", 173, 184], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 0, 7], ["splenic MZ DC-SIGN + cells", "CELL", 42, 68], ["methyl-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 141, 162], ["M\u03b2CD", "SIMPLE_CHEMICAL", 164, 168], ["cholesterol", "SIMPLE_CHEMICAL", 173, 184], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 218, 225], ["cellular surface", "CELLULAR_COMPONENT", 244, 260], ["surface", "CELLULAR_COMPONENT", 278, 285], ["DC", "CELL_TYPE", 0, 2], ["SIGN", "PROTEIN", 3, 7], ["splenic MZ DC", "CELL_TYPE", 42, 55], ["SIGN + cells", "CELL_LINE", 56, 68], ["DC", "CELL_TYPE", 218, 220], ["SIGN", "PROTEIN", 221, 225], ["splenic MZ DC", "TEST", 42, 55], ["SIGN + cells", "PROBLEM", 56, 68], ["Fig.", "TEST", 70, 74], ["methyl-\u03b2-cyclodextrin", "TREATMENT", 141, 162], ["a cholesterol-extracting agent", "TREATMENT", 171, 201], ["splenic", "ANATOMY", 42, 49], ["+ cells", "OBSERVATION", 61, 68], ["surface", "OBSERVATION_MODIFIER", 253, 260], ["surface", "OBSERVATION_MODIFIER", 278, 285]]], ["Moreover, when DC-SIGN transfectants were incubated with carboxyfluorescein succinimidyl ester (CFSE)-labeled S. pneumoniae, pneumococcal uptake and decomposition were obvious in the cytoplasm, showing disintegrated particles of the pneumococcal capsular polysaccharide of S. pneumoniae serotype 14 (CPS14) around the phagocytosed bacterium ( Fig. 1f and Supplementary Fig. S1e ).", [["DC-SIGN transfectants", "ANATOMY", 15, 36], ["cytoplasm", "ANATOMY", 183, 192], ["carboxyfluorescein succinimidyl ester", "CHEMICAL", 57, 94], ["CFSE", "CHEMICAL", 96, 100], ["carboxyfluorescein succinimidyl ester", "CHEMICAL", 57, 94], ["CFSE", "CHEMICAL", 96, 100], ["DC-SIGN transfectants", "CELL", 15, 36], ["carboxyfluorescein succinimidyl ester", "SIMPLE_CHEMICAL", 57, 94], ["CFSE", "SIMPLE_CHEMICAL", 96, 100], ["S. pneumoniae", "ORGANISM", 110, 123], ["pneumococcal", "ORGANISM", 125, 137], ["cytoplasm", "ORGANISM_SUBSTANCE", 183, 192], ["S. pneumoniae serotype 14", "ORGANISM", 273, 298], ["CPS14", "ORGANISM", 300, 305], ["DC", "CELL_TYPE", 15, 17], ["SIGN transfectants", "CELL_LINE", 18, 36], ["S. pneumoniae", "SPECIES", 110, 123], ["S. pneumoniae serotype", "SPECIES", 273, 295], ["S. pneumoniae", "SPECIES", 110, 123], ["pneumococcal", "SPECIES", 125, 137], ["pneumococcal", "SPECIES", 233, 245], ["S. pneumoniae", "SPECIES", 273, 286], ["carboxyfluorescein succinimidyl ester", "TREATMENT", 57, 94], ["S. pneumoniae", "PROBLEM", 110, 123], ["pneumococcal uptake", "PROBLEM", 125, 144], ["decomposition", "PROBLEM", 149, 162], ["the cytoplasm", "PROBLEM", 179, 192], ["the pneumococcal capsular polysaccharide", "TREATMENT", 229, 269], ["S. pneumoniae serotype", "PROBLEM", 273, 295], ["the phagocytosed bacterium", "PROBLEM", 314, 340], ["pneumoniae", "OBSERVATION", 113, 123], ["pneumococcal uptake", "OBSERVATION", 125, 144], ["pneumococcal", "OBSERVATION_MODIFIER", 233, 245], ["capsular", "OBSERVATION_MODIFIER", 246, 254], ["polysaccharide", "OBSERVATION_MODIFIER", 255, 269], ["pneumoniae", "OBSERVATION", 276, 286]]], ["Similar results were observed after pretreatment with actinomycin-D or cycloheximide, which did not affect the plasma membrane structure (Fig. 1f) .", [["plasma membrane", "ANATOMY", 111, 126], ["actinomycin-D", "CHEMICAL", 54, 67], ["cycloheximide", "CHEMICAL", 71, 84], ["actinomycin-D", "CHEMICAL", 54, 67], ["cycloheximide", "CHEMICAL", 71, 84], ["actinomycin-D", "SIMPLE_CHEMICAL", 54, 67], ["cycloheximide", "SIMPLE_CHEMICAL", 71, 84], ["plasma membrane", "CELLULAR_COMPONENT", 111, 126], ["actinomycin", "TREATMENT", 54, 65], ["cycloheximide", "TREATMENT", 71, 84]]], ["However, pneumococcal uptake and decomposition were dramatically reduced with disruption of LRs using M\u03b2CD ( Fig. 1f and Supplementary Fig. S1f ) or with inhibition of LR-dependent endocytosis using dynamin inhibitory peptide (DIP) or transfection with dominant-negative dynamin (K44A; Fig. 1g and h, respectively), only permitting microbial binding to the cellular surface of DC-SIGN transfectants.", [["cellular surface", "ANATOMY", 357, 373], ["DC-SIGN transfectants", "ANATOMY", 377, 398], ["S1f", "GENE_OR_GENE_PRODUCT", 140, 143], ["LR", "GENE_OR_GENE_PRODUCT", 168, 170], ["dynamin inhibitory peptide", "SIMPLE_CHEMICAL", 199, 225], ["DIP", "SIMPLE_CHEMICAL", 227, 230], ["dynamin", "GENE_OR_GENE_PRODUCT", 271, 278], ["cellular surface", "CELLULAR_COMPONENT", 357, 373], ["DC-SIGN transfectants", "CELL", 377, 398], ["M\u03b2CD", "PROTEIN", 102, 106], ["S1f", "PROTEIN", 140, 143], ["LR", "PROTEIN", 168, 170], ["dominant-negative dynamin", "PROTEIN", 253, 278], ["K44A", "PROTEIN", 280, 284], ["DC", "CELL_TYPE", 377, 379], ["SIGN transfectants", "CELL_LINE", 380, 398], ["pneumococcal", "SPECIES", 9, 21], ["pneumococcal uptake", "PROBLEM", 9, 28], ["M\u03b2CD ( Fig. 1f", "TREATMENT", 102, 116], ["LR", "TREATMENT", 168, 170], ["dependent endocytosis", "PROBLEM", 171, 192], ["dynamin inhibitory peptide", "TREATMENT", 199, 225], ["SIGN transfectants", "PROBLEM", 380, 398], ["pneumococcal uptake", "OBSERVATION", 9, 28], ["dependent endocytosis", "OBSERVATION", 171, 192]]], ["The bacterial decomposition ratios were quantitatively calculated ( Fig. 1f-h) .ResultsLRs on splenic MZ SIGN-R1 + macrophages may be important for SIGN-R1-mediated uptake and decomposition of S. pneumoniae Large aggregates of SIGN-R1 were observed in CTBenriched vertex regions of SIGN-R1 transfectants and strong distribution of SIGN-R1 monomers and dimers were obvious in LR fractions (Fig. 2a) .", [["splenic MZ SIGN-R1 + macrophages", "ANATOMY", 94, 126], ["SIGN-R1 transfectants", "ANATOMY", 282, 303], ["MZ", "CHEMICAL", 102, 104], ["splenic MZ SIGN-R1 + macrophages", "CELL", 94, 126], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 148, 155], ["S. pneumoniae", "ORGANISM", 193, 206], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 227, 234], ["SIGN-R1 transfectants", "CELL", 282, 303], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 331, 338], ["ResultsLRs", "PROTEIN", 80, 90], ["macrophages", "CELL_TYPE", 115, 126], ["SIGN", "PROTEIN", 148, 152], ["R1", "PROTEIN", 153, 155], ["SIGN", "PROTEIN", 227, 231], ["CTBenriched vertex regions", "DNA", 252, 278], ["SIGN-R1 transfectants", "CELL_LINE", 282, 303], ["SIGN", "PROTEIN", 331, 335], ["S. pneumoniae", "SPECIES", 193, 206], ["S. pneumoniae", "SPECIES", 193, 206], ["The bacterial decomposition ratios", "TEST", 0, 34], ["splenic MZ SIGN", "TEST", 94, 109], ["macrophages", "PROBLEM", 115, 126], ["SIGN-R1-mediated uptake", "PROBLEM", 148, 171], ["S. pneumoniae", "PROBLEM", 193, 206], ["SIGN", "TEST", 282, 286], ["R1 transfectants", "PROBLEM", 287, 303], ["bacterial", "OBSERVATION_MODIFIER", 4, 13], ["splenic", "ANATOMY", 94, 101], ["macrophages", "OBSERVATION", 115, 126], ["R1 transfectants", "OBSERVATION", 287, 303], ["LR fractions", "OBSERVATION", 375, 387]]], ["In particular, multimers of SIGN-R1 were preformed in LRs (inset in Fig. 2a) .", [["SIGN-R1", "GENE_OR_GENE_PRODUCT", 28, 35], ["SIGN", "PROTEIN", 28, 32], ["R1", "PROTEIN", 33, 35]]], ["In whole fractions of spleens or lymph nodes from wild-type (WT) mice, SIGN-R1 was evident only in LRs of both tissues of WT mice with a higher concentration of SIGN-R1 multimers in LRs than in non-LRs (Fig. 2b ), but not from SIGN-R1-knockout (KO) mice ( Fig. 2c and Supplementary Fig. S2a ).", [["whole fractions", "ANATOMY", 3, 18], ["spleens", "ANATOMY", 22, 29], ["lymph nodes", "ANATOMY", 33, 44], ["tissues", "ANATOMY", 111, 118], ["non-LRs", "ANATOMY", 194, 201], ["spleens", "ORGAN", 22, 29], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 33, 44], ["wild-type (WT) mice", "ORGANISM", 50, 69], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 71, 78], ["tissues", "TISSUE", 111, 118], ["mice", "ORGANISM", 125, 129], ["SIGN-R1 multimers", "GENE_OR_GENE_PRODUCT", 161, 178], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 227, 234], ["mice", "ORGANISM", 249, 253], ["SIGN", "PROTEIN", 71, 75], ["SIGN", "PROTEIN", 161, 165], ["R1 multimers", "PROTEIN", 166, 178], ["non-LRs", "CELL_TYPE", 194, 201], ["SIGN", "PROTEIN", 227, 231], ["R1", "PROTEIN", 232, 234], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 249, 253], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 249, 253], ["lymph nodes", "PROBLEM", 33, 44], ["SIGN", "TEST", 227, 231], ["spleens", "ANATOMY", 22, 29], ["lymph nodes", "OBSERVATION", 33, 44]]], ["Fig. 1 Distribution of DC-SIGN in splenic lipid rafts and its role in the uptake and decomposition of S. pneumoniae. a (Left) DCEK_DC-SIGN transfectants were immunostained for DC-SIGN (red), cholera toxin B (green), and DAPI (blue).", [["DC", "ANATOMY", 23, 25], ["splenic lipid rafts", "ANATOMY", 34, 53], ["DC", "ANATOMY", 176, 178], ["cholera toxin B", "CHEMICAL", 191, 206], ["DAPI", "CHEMICAL", 220, 224], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 23, 30], ["splenic lipid rafts", "MULTI-TISSUE_STRUCTURE", 34, 53], ["S. pneumoniae", "ORGANISM", 102, 115], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 176, 183], ["cholera toxin B", "SIMPLE_CHEMICAL", 191, 206], ["green)", "SIMPLE_CHEMICAL", 208, 214], ["DAPI", "SIMPLE_CHEMICAL", 220, 224], ["blue", "SIMPLE_CHEMICAL", 226, 230], ["DC", "CELL_TYPE", 23, 25], ["SIGN", "PROTEIN", 26, 30], ["(Left) DCEK_DC-SIGN transfectants", "CELL_LINE", 119, 152], ["DC", "CELL_TYPE", 176, 178], ["SIGN", "PROTEIN", 179, 183], ["red", "PROTEIN", 185, 188], ["cholera toxin B", "PROTEIN", 191, 206], ["S. pneumoniae", "SPECIES", 102, 115], ["S. pneumoniae", "SPECIES", 102, 115], ["DC", "TEST", 23, 25], ["splenic lipid rafts", "TREATMENT", 34, 53], ["the uptake", "PROBLEM", 70, 80], ["S. pneumoniae", "PROBLEM", 102, 115], ["a (Left) DCEK_DC", "TEST", 117, 133], ["SIGN transfectants", "TEST", 134, 152], ["cholera toxin B", "TEST", 191, 206], ["Distribution", "OBSERVATION_MODIFIER", 7, 19], ["DC", "OBSERVATION", 23, 25], ["splenic", "ANATOMY", 34, 41], ["lipid rafts", "OBSERVATION", 42, 53], ["uptake", "OBSERVATION", 74, 80], ["pneumoniae", "OBSERVATION", 105, 115], ["Left", "ANATOMY_MODIFIER", 120, 124]]], ["Arrowheads (yellow) indicate the colocalization of DC-SIGN and cholera toxin B. (Right) After sucrose gradient ultracentrifugation of whole-cell lysates from DCEK_DC-SIGN transfectants, fractions were immunoblotted for DC-SIGN, flotilin-1, and caveolin-1. b DC-SIGN BMT /WT mice were intravenously injected with hamster IgG or 22D1 anti-SIGN-R1 monoclonal antibodies (100 \u03bcg, 24 h), and splenic cryosections were immunostained for SIGN-R1 (green), DC-SIGN (red), and SER4/CD169 (blue). c As in (a) (right), but spleens from DC-SIGN BMT /SIGN-R1 TKO mice were used, and immunoblotting for SIGN-R1 was performed. d As in a (right), but cadaver spleens were used, and representative results (#11-148) are presented. e (Left) DCEK_DC-SIGN transfectants were treated with M\u03b2CD (10 mM, 3 h), immunostained for DC-SIGN without permeabilization, and assessed by FACS.", [["DC", "ANATOMY", 51, 53], ["whole-cell lysates", "ANATOMY", 134, 152], ["DCEK_DC-SIGN transfectants", "ANATOMY", 158, 184], ["fractions", "ANATOMY", 186, 195], ["DC", "ANATOMY", 219, 221], ["DC", "ANATOMY", 258, 260], ["hamster", "ANATOMY", 312, 319], ["splenic cryosections", "ANATOMY", 387, 407], ["DC", "ANATOMY", 448, 450], ["spleens", "ANATOMY", 511, 518], ["DC", "ANATOMY", 524, 526], ["spleens", "ANATOMY", 642, 649], ["DC", "ANATOMY", 804, 806], ["sucrose", "CHEMICAL", 94, 101], ["M\u03b2CD", "CHEMICAL", 767, 771], ["sucrose", "CHEMICAL", 94, 101], ["M\u03b2CD", "CHEMICAL", 767, 771], ["Arrowheads", "CELLULAR_COMPONENT", 0, 10], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 51, 58], ["cholera toxin B.", "ORGANISM", 63, 79], ["sucrose", "SIMPLE_CHEMICAL", 94, 101], ["cell lysates", "ORGANISM_SUBSTANCE", 140, 152], ["DCEK_DC-SIGN transfectants", "CELL", 158, 184], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 219, 226], ["flotilin-1", "GENE_OR_GENE_PRODUCT", 228, 238], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 244, 254], ["WT mice", "ORGANISM", 271, 278], ["hamster", "ORGANISM", 312, 319], ["IgG", "ORGANISM", 320, 323], ["splenic cryosections", "MULTI-TISSUE_STRUCTURE", 387, 407], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 431, 438], ["green)", "GENE_OR_GENE_PRODUCT", 440, 446], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 448, 455], ["SER4", "GENE_OR_GENE_PRODUCT", 467, 471], ["CD169", "GENE_OR_GENE_PRODUCT", 472, 477], ["c As", "GENE_OR_GENE_PRODUCT", 486, 490], ["spleens", "ORGAN", 511, 518], ["SIGN-R1 TKO mice", "ORGANISM", 537, 553], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 588, 595], ["spleens", "ORGAN", 642, 649], ["M\u03b2CD", "SIMPLE_CHEMICAL", 767, 771], ["DC", "CELL_TYPE", 51, 53], ["SIGN", "PROTEIN", 54, 58], ["DCEK_DC-SIGN transfectants", "CELL_LINE", 158, 184], ["DC", "CELL_TYPE", 219, 221], ["SIGN", "PROTEIN", 222, 226], ["flotilin-1", "PROTEIN", 228, 238], ["caveolin-1", "PROTEIN", 244, 254], ["DC", "CELL_TYPE", 258, 260], ["hamster IgG", "PROTEIN", 312, 323], ["22D1 anti-SIGN-R1 monoclonal antibodies", "PROTEIN", 327, 366], ["SIGN", "PROTEIN", 431, 435], ["R1", "PROTEIN", 436, 438], ["DC", "CELL_TYPE", 448, 450], ["SIGN", "PROTEIN", 451, 455], ["red", "PROTEIN", 457, 460], ["SER4", "PROTEIN", 467, 471], ["CD169", "PROTEIN", 472, 477], ["DC", "CELL_TYPE", 524, 526], ["SIGN", "PROTEIN", 588, 592], ["e (Left) DCEK_DC-SIGN transfectants", "CELL_LINE", 713, 748], ["DC", "CELL_TYPE", 804, 806], ["SIGN", "PROTEIN", 807, 811], ["mice", "SPECIES", 274, 278], ["hamster", "SPECIES", 312, 319], ["mice", "SPECIES", 549, 553], ["mice", "SPECIES", 274, 278], ["hamster", "SPECIES", 312, 319], ["mice", "SPECIES", 549, 553], ["cholera toxin B.", "PROBLEM", 63, 79], ["sucrose gradient ultracentrifugation", "TREATMENT", 94, 130], ["whole-cell lysates", "TREATMENT", 134, 152], ["DCEK_DC", "TEST", 158, 165], ["SIGN transfectants", "TEST", 166, 184], ["DC", "TEST", 219, 221], ["flotilin", "TEST", 228, 236], ["caveolin", "TEST", 244, 252], ["SIGN BMT /WT mice", "TREATMENT", 261, 278], ["hamster IgG", "TEST", 312, 323], ["R1 monoclonal antibodies", "TEST", 342, 366], ["splenic cryosections", "TEST", 387, 407], ["SIGN", "TEST", 431, 435], ["SER4", "TEST", 467, 471], ["immunoblotting", "TEST", 569, 583], ["SIGN-R1", "TEST", 588, 595], ["SIGN transfectants", "PROBLEM", 730, 748], ["M\u03b2CD", "TREATMENT", 767, 771], ["permeabilization", "PROBLEM", 820, 836], ["Right", "ANATOMY_MODIFIER", 81, 86], ["splenic", "ANATOMY", 387, 394], ["right", "ANATOMY_MODIFIER", 499, 504], ["spleens", "ANATOMY", 511, 518], ["right", "ANATOMY_MODIFIER", 622, 627], ["spleens", "ANATOMY", 642, 649], ["Left", "ANATOMY_MODIFIER", 716, 720]]], ["(Right) As in (left), but cells were immunostained for cholera toxin B (green) and DC-SIGN (red), followed by microscopic analysis. f-h (Left) DCEK_DC-SIGN transfectants were pretreated with f M\u03b2CD, actinomycin-D (AD; 5 \u03bcg/mL, 24 h), or cycloheximide (CH; 20 \u03bcg/mL, 24 h) or with g the myristoylated dynamin inhibitory peptide (50 \u03bcM, 1 h) 70 and washed out, or h transfected with empty vector or dominant-negative dynamin (K44A).", [["left", "ANATOMY", 15, 19], ["cells", "ANATOMY", 26, 31], ["DC", "ANATOMY", 83, 85], ["cholera toxin B", "CHEMICAL", 55, 70], ["M\u03b2CD", "CHEMICAL", 193, 197], ["actinomycin-D", "CHEMICAL", 199, 212], ["AD", "CHEMICAL", 214, 216], ["cycloheximide", "CHEMICAL", 237, 250], ["CH", "CHEMICAL", 252, 254], ["M\u03b2CD", "CHEMICAL", 193, 197], ["actinomycin-D", "CHEMICAL", 199, 212], ["cycloheximide", "CHEMICAL", 237, 250], ["CH", "CHEMICAL", 252, 254], ["cells", "CELL", 26, 31], ["cholera toxin B", "GENE_OR_GENE_PRODUCT", 55, 70], ["green", "SIMPLE_CHEMICAL", 72, 77], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 83, 90], ["M\u03b2CD", "SIMPLE_CHEMICAL", 193, 197], ["actinomycin-D", "SIMPLE_CHEMICAL", 199, 212], ["AD", "SIMPLE_CHEMICAL", 214, 216], ["cycloheximide", "SIMPLE_CHEMICAL", 237, 250], ["dynamin", "GENE_OR_GENE_PRODUCT", 300, 307], ["dynamin", "GENE_OR_GENE_PRODUCT", 415, 422], ["cholera toxin B", "PROTEIN", 55, 70], ["DC", "CELL_TYPE", 83, 85], ["SIGN", "PROTEIN", 86, 90], ["f-h (Left) DCEK_DC-SIGN transfectants", "CELL_LINE", 132, 169], ["dominant-negative dynamin", "PROTEIN", 397, 422], ["K44A", "PROTEIN", 424, 428], ["cholera toxin B", "TEST", 55, 70], ["microscopic analysis", "TEST", 110, 130], ["SIGN transfectants", "PROBLEM", 151, 169], ["f M\u03b2CD", "TREATMENT", 191, 197], ["actinomycin-D (AD", "TREATMENT", 199, 216], ["cycloheximide (CH", "TREATMENT", 237, 254], ["g the myristoylated dynamin inhibitory peptide", "TREATMENT", 280, 326], ["Right", "ANATOMY_MODIFIER", 1, 6], ["left", "ANATOMY_MODIFIER", 15, 19], ["Left", "ANATOMY_MODIFIER", 137, 141]]], ["Samples were then incubated with mitomycin C-treated S. pneumoniae type 14 (MitC-Pn14; 1 \u00d7 10 6 , 15 h, 37\u00b0C), followed by immunostaining for f, g DC-SIGN (green) and CPS14 (red) or h dynamin (green) and CPS14 (red).", [["Samples", "ANATOMY", 0, 7], ["mitomycin C", "CHEMICAL", 33, 44], ["mitomycin C", "CHEMICAL", 33, 44], ["mitomycin C", "SIMPLE_CHEMICAL", 33, 44], ["S. pneumoniae type 14", "ORGANISM", 53, 74], ["green)", "SIMPLE_CHEMICAL", 156, 162], ["CPS14", "SIMPLE_CHEMICAL", 167, 172], ["dynamin", "GENE_OR_GENE_PRODUCT", 184, 191], ["DC", "CELL_TYPE", 147, 149], ["SIGN", "PROTEIN", 150, 154], ["CPS14", "PROTEIN", 167, 172], ["red", "PROTEIN", 174, 177], ["dynamin", "PROTEIN", 184, 191], ["CPS14", "PROTEIN", 204, 209], ["S. pneumoniae", "SPECIES", 53, 66], ["S. pneumoniae", "SPECIES", 53, 66], ["Samples", "TEST", 0, 7], ["mitomycin C", "TREATMENT", 33, 44], ["S. pneumoniae type", "TEST", 53, 71], ["MitC", "TEST", 76, 80], ["CPS14", "TEST", 167, 172], ["CPS14", "TEST", 204, 209]]], ["(Right) The average percentage of pneumococcal decomposition of total pneumococcal binding on DC-SIGN transfectants was calculated in five areas from each sample in five independent experiments.", [["DC", "ANATOMY", 94, 96], ["DC", "CELL_TYPE", 94, 96], ["SIGN transfectants", "CELL_LINE", 97, 115], ["pneumococcal", "SPECIES", 34, 46], ["pneumococcal", "SPECIES", 70, 82], ["pneumococcal decomposition", "TREATMENT", 34, 60], ["total pneumococcal binding", "PROBLEM", 64, 90], ["SIGN transfectants", "PROBLEM", 97, 115], ["Right", "ANATOMY_MODIFIER", 1, 6], ["average", "OBSERVATION_MODIFIER", 12, 19], ["percentage", "OBSERVATION_MODIFIER", 20, 30], ["pneumococcal", "OBSERVATION_MODIFIER", 34, 46], ["total", "OBSERVATION_MODIFIER", 64, 69], ["pneumococcal binding", "OBSERVATION", 70, 90]]], ["Data are shown as mean \u00b1 SD. n.s., Not significant; p < 0.001.", [["Not", "UNCERTAINTY", 35, 38], ["significant", "OBSERVATION_MODIFIER", 39, 50]]], ["Scale bars a, f, g, h, 20 \u00b5m; b, 200 \u00b5m; e, 10 \u00b5m Disruption of LRs with M\u03b2CD did not reduce SIGN-R1 expression on the transfectant cellular surface, but altered its surface distribution pattern (Fig. 2d) .", [["cellular surface", "ANATOMY", 132, 148], ["surface", "ANATOMY", 166, 173], ["M\u03b2CD", "CHEMICAL", 73, 77], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 93, 100], ["cellular surface", "CELLULAR_COMPONENT", 132, 148], ["SIGN", "PROTEIN", 93, 97], ["R1", "PROTEIN", 98, 100], ["R1 expression", "OBSERVATION", 98, 111], ["surface", "OBSERVATION_MODIFIER", 141, 148], ["surface", "OBSERVATION_MODIFIER", 166, 173]]], ["However, M\u03b2CD treatment of SIGN-R1 transfectants reduced the uptake of dextran or CPS14, representative ligands of SIGN-R1 41,42 (Fig. 2e) .", [["SIGN-R1 transfectants", "ANATOMY", 27, 48], ["M\u03b2CD", "CHEMICAL", 9, 13], ["SIGN-R1", "CHEMICAL", 27, 34], ["dextran", "CHEMICAL", 71, 78], ["CPS14", "CHEMICAL", 82, 87], ["M\u03b2CD", "CHEMICAL", 9, 13], ["M\u03b2CD", "SIMPLE_CHEMICAL", 9, 13], ["SIGN-R1 transfectants", "CELL", 27, 48], ["dextran", "SIMPLE_CHEMICAL", 71, 78], ["CPS14", "SIMPLE_CHEMICAL", 82, 87], ["SIGN-R1 transfectants", "CELL_LINE", 27, 48], ["SIGN", "PROTEIN", 115, 119], ["SIGN", "TEST", 27, 31], ["dextran", "TREATMENT", 71, 78], ["SIGN", "TEST", 115, 119]]], ["Similarly, when SIGN-R1 transfectants were incubated with S. pneumonia type 14, which has strong binding affinity for SIGN-R1 41 , the uptake and decomposition of the organism were evident under control conditions ( Fig. 2f and Supplementary Fig. S2b ) and in the presence of actinomycin-D or cycloheximide (Fig. 2f) .", [["pneumonia", "DISEASE", 61, 70], ["SIGN-R1", "CHEMICAL", 118, 125], ["actinomycin-D", "CHEMICAL", 276, 289], ["cycloheximide", "CHEMICAL", 293, 306], ["actinomycin-D", "CHEMICAL", 276, 289], ["cycloheximide", "CHEMICAL", 293, 306], ["S. pneumonia type 14", "ORGANISM", 58, 78], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 118, 125], ["actinomycin-D", "SIMPLE_CHEMICAL", 276, 289], ["cycloheximide", "SIMPLE_CHEMICAL", 293, 306], ["SIGN-R1 transfectants", "CELL_LINE", 16, 37], ["SIGN", "PROTEIN", 118, 122], ["S. pneumonia", "SPECIES", 58, 70], ["S. pneumonia type 14", "SPECIES", 58, 78], ["SIGN-R1 transfectants", "PROBLEM", 16, 37], ["S. pneumonia type 14", "PROBLEM", 58, 78], ["SIGN", "TEST", 118, 122], ["the uptake", "PROBLEM", 131, 141], ["the organism", "PROBLEM", 163, 175], ["actinomycin", "TREATMENT", 276, 287], ["cycloheximide", "TREATMENT", 293, 306], ["pneumonia", "OBSERVATION", 61, 70]]], ["However, M\u03b2CD treatment of SIGN-R1 transfectants inhibited the uptake and decomposition of S. pneumoniae, only permitting microbial binding to the cellular surface As in a (right), but spleens from wild-type and SIGN-R1-KO mice were used and immunoblotted for SIGN-R1, flotilin-1, and caveolin-1. d (Left) DCEK_SIGN-R1 transfectants were treated with M\u03b2CD (10 mM, 3 h), immunostained for SIGN-R1 without permeabilization, and assessed by FACS.", [["cellular surface", "ANATOMY", 147, 163], ["spleens", "ANATOMY", 185, 192], ["M\u03b2CD", "CHEMICAL", 9, 13], ["SIGN-R1", "CHEMICAL", 27, 34], ["M\u03b2CD", "CHEMICAL", 351, 355], ["M\u03b2CD", "CHEMICAL", 9, 13], ["M\u03b2CD", "CHEMICAL", 351, 355], ["M\u03b2CD", "SIMPLE_CHEMICAL", 9, 13], ["SIGN-R1 transfectants", "CELL", 27, 48], ["S. pneumoniae", "ORGANISM", 91, 104], ["cellular", "CELL", 147, 155], ["spleens", "ORGAN", 185, 192], ["SIGN-R1-KO mice", "ORGANISM", 212, 227], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 260, 267], ["flotilin-1", "GENE_OR_GENE_PRODUCT", 269, 279], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 285, 295], ["M\u03b2CD", "SIMPLE_CHEMICAL", 351, 355], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 388, 395], ["SIGN-R1 transfectants", "CELL_LINE", 27, 48], ["R1", "PROTEIN", 217, 219], ["SIGN", "PROTEIN", 260, 264], ["R1", "PROTEIN", 265, 267], ["flotilin-1", "PROTEIN", 269, 279], ["caveolin-1", "PROTEIN", 285, 295], ["d (Left) DCEK_SIGN-R1 transfectants", "CELL_LINE", 297, 332], ["SIGN", "PROTEIN", 388, 392], ["S. pneumoniae", "SPECIES", 91, 104], ["mice", "SPECIES", 223, 227], ["S. pneumoniae", "SPECIES", 91, 104], ["mice", "SPECIES", 223, 227], ["SIGN", "TEST", 27, 31], ["R1 transfectants", "PROBLEM", 32, 48], ["the uptake", "PROBLEM", 59, 69], ["S. pneumoniae", "PROBLEM", 91, 104], ["permitting microbial binding", "PROBLEM", 111, 139], ["SIGN", "TEST", 212, 216], ["SIGN", "TEST", 260, 264], ["flotilin", "TEST", 269, 277], ["d (Left) DCEK_SIGN-R1 transfectants", "TREATMENT", 297, 332], ["M\u03b2CD", "TREATMENT", 351, 355], ["permeabilization", "PROBLEM", 404, 420], ["pneumoniae", "OBSERVATION", 94, 104], ["microbial binding", "OBSERVATION", 122, 139], ["cellular", "OBSERVATION_MODIFIER", 147, 155], ["surface", "OBSERVATION_MODIFIER", 156, 163], ["right", "ANATOMY_MODIFIER", 173, 178], ["spleens", "ANATOMY", 185, 192], ["Left", "ANATOMY_MODIFIER", 300, 304]]], ["(Right) As in (left), but cells were immunostained for cholera toxin B (green) and SIGN-R1 (red) and followed by microscopic analysis. e Cells in d were further incubated with FITC-dextran (5 \u03bcg, 30 min) or CPS14 (10 \u03bcg, 2 h), and their uptake was assessed by FACS (green or pink lines for uptake without or with M\u03b2CD, respectively). f-h (Left) DCEK_SIGN-R1 transfectants were pretreated with f M\u03b2CD, actinomycin-D (AD; 5 \u03bcg/mL, 24 h), cycloheximide (CD; 20 \u03bcg/mL, 24 h) or with g myristoylated dynamin inhibitory peptide (50 \u03bcM, 1 h) 71 and washed out, or h transfected with dominant-negative dynamin (K44A) and incubated with mitomycin C-treated S. pneumoniae type 14 (MitC-Pn14; 1 \u00d7 10 6 , 15 h, 37\u00b0C), followed by immunostaining for f, g SIGN-R1 (green) and CPS14 (red) or (H) dynamin (green) and CPS14 (red).", [["left", "ANATOMY", 15, 19], ["cells", "ANATOMY", 26, 31], ["Cells", "ANATOMY", 137, 142], ["cholera toxin B", "CHEMICAL", 55, 70], ["FITC-dextran", "CHEMICAL", 176, 188], ["CPS14", "CHEMICAL", 207, 212], ["actinomycin-D", "CHEMICAL", 401, 414], ["AD", "CHEMICAL", 416, 418], ["cycloheximide", "CHEMICAL", 436, 449], ["CD", "CHEMICAL", 451, 453], ["mitomycin C", "CHEMICAL", 628, 639], ["FITC", "CHEMICAL", 176, 180], ["CPS14", "CHEMICAL", 207, 212], ["M\u03b2CD", "CHEMICAL", 395, 399], ["actinomycin-D", "CHEMICAL", 401, 414], ["cycloheximide", "CHEMICAL", 436, 449], ["mitomycin C", "CHEMICAL", 628, 639], ["cells", "CELL", 26, 31], ["cholera toxin B", "GENE_OR_GENE_PRODUCT", 55, 70], ["green", "SIMPLE_CHEMICAL", 72, 77], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 83, 90], ["Cells", "CELL", 137, 142], ["FITC-dextran", "SIMPLE_CHEMICAL", 176, 188], ["CPS14", "SIMPLE_CHEMICAL", 207, 212], ["M\u03b2CD", "SIMPLE_CHEMICAL", 395, 399], ["actinomycin-D", "SIMPLE_CHEMICAL", 401, 414], ["AD", "SIMPLE_CHEMICAL", 416, 418], ["cycloheximide", "SIMPLE_CHEMICAL", 436, 449], ["dynamin", "GENE_OR_GENE_PRODUCT", 495, 502], ["dynamin", "GENE_OR_GENE_PRODUCT", 594, 601], ["mitomycin C", "SIMPLE_CHEMICAL", 628, 639], ["S. pneumoniae type 14", "ORGANISM", 648, 669], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 742, 749], ["green)", "SIMPLE_CHEMICAL", 751, 757], ["CPS14", "SIMPLE_CHEMICAL", 762, 767], ["dynamin", "GENE_OR_GENE_PRODUCT", 781, 788], ["green)", "SIMPLE_CHEMICAL", 790, 796], ["CPS14", "SIMPLE_CHEMICAL", 801, 806], ["cholera toxin B", "PROTEIN", 55, 70], ["SIGN", "PROTEIN", 83, 87], ["R1", "PROTEIN", 88, 90], ["f-h (Left) DCEK_SIGN-R1 transfectants", "CELL_LINE", 334, 371], ["dominant-negative dynamin", "PROTEIN", 576, 601], ["K44A", "PROTEIN", 603, 607], ["SIGN", "PROTEIN", 742, 746], ["R1", "PROTEIN", 747, 749], ["CPS14", "PROTEIN", 762, 767], ["red", "PROTEIN", 769, 772], ["dynamin", "PROTEIN", 781, 788], ["CPS14", "PROTEIN", 801, 806], ["S. pneumoniae", "SPECIES", 648, 661], ["S. pneumoniae", "SPECIES", 648, 661], ["cholera toxin B", "TEST", 55, 70], ["SIGN", "TEST", 83, 87], ["microscopic analysis", "TEST", 113, 133], ["FITC-dextran", "TREATMENT", 176, 188], ["CPS14", "TEST", 207, 212], ["-h (Left) DCEK_SIGN-R1 transfectants", "TREATMENT", 335, 371], ["f M\u03b2CD", "TREATMENT", 393, 399], ["actinomycin-D (AD", "TREATMENT", 401, 418], ["cycloheximide (CD", "TREATMENT", 436, 453], ["g myristoylated dynamin inhibitory peptide", "TREATMENT", 479, 521], ["mitomycin C", "TREATMENT", 628, 639], ["S. pneumoniae type", "TEST", 648, 666], ["MitC", "TEST", 671, 675], ["g SIGN", "TEST", 740, 746], ["CPS14", "TEST", 762, 767], ["CPS14", "TEST", 801, 806], ["Right", "ANATOMY_MODIFIER", 1, 6], ["left", "ANATOMY_MODIFIER", 15, 19], ["pink lines", "OBSERVATION", 275, 285], ["Left", "ANATOMY_MODIFIER", 339, 343]]], ["(Right) The average percentage of pneumococcal decomposition of total pneumococcal binding on SIGN-R1 transfectants was calculated in five areas from each sample in five independent experiments.", [["SIGN-R1 transfectants", "CELL", 94, 115], ["SIGN-R1 transfectants", "CELL_LINE", 94, 115], ["pneumococcal", "SPECIES", 34, 46], ["pneumococcal", "SPECIES", 70, 82], ["pneumococcal decomposition", "TREATMENT", 34, 60], ["total pneumococcal binding", "PROBLEM", 64, 90], ["SIGN-R1 transfectants", "TREATMENT", 94, 115], ["Right", "ANATOMY_MODIFIER", 1, 6], ["average", "OBSERVATION_MODIFIER", 12, 19], ["percentage", "OBSERVATION_MODIFIER", 20, 30], ["pneumococcal", "OBSERVATION_MODIFIER", 34, 46], ["total", "OBSERVATION_MODIFIER", 64, 69], ["pneumococcal binding", "OBSERVATION", 70, 90]]], ["Data are shown as mean \u00b1 SD. n.s., Not significant; p < 0.001., Scale bars a, f, g, h, 20 \u00b5m; d, 10 \u00b5m (Fig. 2f) .", [["Not", "UNCERTAINTY", 35, 38], ["significant", "OBSERVATION_MODIFIER", 39, 50]]], ["Moreover, inhibition of LR-dependent endocytosis using DIP or K44A dramatically reduced the uptake and decomposition of the organism (Fig. 2g, h) .", [["DIP", "CHEMICAL", 55, 58], ["K44A", "CHEMICAL", 62, 66], ["LR", "GENE_OR_GENE_PRODUCT", 24, 26], ["DIP", "GENE_OR_GENE_PRODUCT", 55, 58], ["K44A", "SIMPLE_CHEMICAL", 62, 66], ["LR", "PROTEIN", 24, 26], ["LR", "TEST", 24, 26], ["dependent endocytosis", "PROBLEM", 27, 48], ["DIP or K44A", "TREATMENT", 55, 66], ["the uptake", "PROBLEM", 88, 98], ["the organism", "PROBLEM", 120, 132], ["dependent", "OBSERVATION_MODIFIER", 27, 36], ["endocytosis", "OBSERVATION", 37, 48]]], ["The bacterial decomposition ratios were quantitatively calculated ( Fig. 2f-h) .ResultsLRs of splenic MZ SIGN-R1 + macrophages may provide an optimal location for innate recruitment of SIGN-R1 against S. pneumoniae in vivo SIGN-R1 transfectants were incubated with S. pneumoniae at 37\u00b0C or 4\u00b0C or in the presence of M\u03b2CD, and abundant SIGN-R1 aggregation was observed on the cell surface only at 37\u00b0C (Fig. 3a, b) .", [["splenic MZ SIGN-R1 + macrophages", "ANATOMY", 94, 126], ["cell surface", "ANATOMY", 375, 387], ["MZ", "CHEMICAL", 102, 104], ["M\u03b2CD", "CHEMICAL", 316, 320], ["splenic MZ SIGN-R1 + macrophages", "CELL", 94, 126], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 185, 192], ["S. pneumoniae", "ORGANISM", 201, 214], ["SIGN-R1 transfectants", "CELL", 223, 244], ["S. pneumoniae", "ORGANISM", 265, 278], ["C", "GENE_OR_GENE_PRODUCT", 292, 293], ["M\u03b2CD", "GENE_OR_GENE_PRODUCT", 316, 320], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 335, 342], ["cell surface", "CELLULAR_COMPONENT", 375, 387], ["macrophages", "CELL_TYPE", 115, 126], ["SIGN", "PROTEIN", 185, 189], ["R1", "DNA", 190, 192], ["SIGN-R1 transfectants", "CELL_LINE", 223, 244], ["M\u03b2CD", "PROTEIN", 316, 320], ["SIGN", "PROTEIN", 335, 339], ["R1", "PROTEIN", 340, 342], ["S. pneumoniae", "SPECIES", 201, 214], ["S. pneumoniae", "SPECIES", 265, 278], ["S. pneumoniae", "SPECIES", 201, 214], ["S. pneumoniae", "SPECIES", 265, 278], ["The bacterial decomposition ratios", "TEST", 0, 34], ["splenic MZ SIGN", "TEST", 94, 109], ["macrophages", "PROBLEM", 115, 126], ["SIGN", "TEST", 185, 189], ["S. pneumoniae", "PROBLEM", 201, 214], ["S. pneumoniae", "PROBLEM", 265, 278], ["M\u03b2CD", "PROBLEM", 316, 320], ["R1 aggregation", "PROBLEM", 340, 354], ["the cell surface", "TEST", 371, 387], ["bacterial", "OBSERVATION_MODIFIER", 4, 13], ["splenic", "ANATOMY", 94, 101], ["MZ", "OBSERVATION", 102, 104], ["pneumoniae", "OBSERVATION", 204, 214], ["R1 aggregation", "OBSERVATION", 340, 354]]], ["When these cells were then fractionated and their LR fractions were immunoblotted for SIGN-R1, SIGN-R1 monomers and multimers were obviously increased in LRs (Fig. 3c) .", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 86, 93], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 95, 102], ["multimers", "GENE_OR_GENE_PRODUCT", 116, 125], ["SIGN", "PROTEIN", 86, 90], ["R1", "PROTEIN", 91, 93], ["SIGN", "PROTEIN", 95, 99], ["their LR fractions", "TEST", 44, 62], ["SIGN", "TEST", 86, 90], ["SIGN", "TEST", 95, 99], ["multimers", "TEST", 116, 125], ["increased", "OBSERVATION_MODIFIER", 141, 150]]], ["Because SIGN-R1 + macrophages rapidly recognized S. pneumoniae in splenic MZs within 1 h (Fig. 3d) , SIGN-R1 distribution in splenic LRs was examined 1 h after intravenous injection of S. pneumoniae.", [["SIGN-R1 + macrophages", "ANATOMY", 8, 29], ["splenic MZs", "ANATOMY", 66, 77], ["splenic LRs", "ANATOMY", 125, 136], ["intravenous", "ANATOMY", 160, 171], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 8, 15], ["S. pneumoniae", "ORGANISM", 49, 62], ["splenic MZs", "CELL", 66, 77], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 101, 108], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 125, 136], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 160, 171], ["S. pneumoniae", "ORGANISM", 185, 198], ["SIGN-R1 + macrophages", "CELL_LINE", 8, 29], ["splenic MZs", "CELL_TYPE", 66, 77], ["SIGN", "PROTEIN", 101, 105], ["S. pneumoniae", "SPECIES", 49, 62], ["S. pneumoniae", "SPECIES", 185, 198], ["S. pneumoniae", "SPECIES", 49, 62], ["S. pneumoniae", "SPECIES", 185, 198], ["SIGN", "TEST", 8, 12], ["macrophages", "PROBLEM", 18, 29], ["pneumoniae", "PROBLEM", 52, 62], ["splenic MZs", "PROBLEM", 66, 77], ["S. pneumoniae", "PROBLEM", 185, 198], ["macrophages", "ANATOMY", 18, 29], ["pneumoniae", "OBSERVATION", 52, 62], ["splenic", "ANATOMY", 66, 73], ["R1", "OBSERVATION_MODIFIER", 106, 108], ["distribution", "OBSERVATION_MODIFIER", 109, 121], ["splenic", "ANATOMY", 125, 132], ["pneumoniae", "OBSERVATION", 188, 198]]], ["SIGN-R1 complex was obviously increased only in splenic LRs following S. pneumoniae stimulation (Fig. 3e) , as confirmed in separate experiments ( Supplementary Fig. S3a , cases 1-4).ResultsSimilar experiments using intravenous injection of an unencapsulated mutant of S. pneumoniae serotype 14 (mt-Pn14) or Staphylococcus aureus, another grampositive coccal bacterium that does not bind SIGN-R1 41, 43 showed no increase in SIGN-R1 complex in splenic LRs (Fig. 3f, g) , confirming the CPS14 dependent recruitment of SIGN-R1 complex against S. pneumoniae.", [["splenic LRs", "ANATOMY", 48, 59], ["intravenous", "ANATOMY", 216, 227], ["splenic", "ANATOMY", 444, 451], ["Staphylococcus aureus", "DISEASE", 308, 329], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 0, 7], ["S. pneumoniae", "ORGANISM", 70, 83], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 216, 227], ["S. pneumoniae serotype 14", "ORGANISM", 269, 294], ["mt-Pn14", "ORGANISM", 296, 303], ["Staphylococcus aureus", "ORGANISM", 308, 329], ["coccal bacterium", "ORGANISM", 352, 368], ["SIGN-R1 complex", "GENE_OR_GENE_PRODUCT", 425, 440], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 444, 455], ["CPS14", "GENE_OR_GENE_PRODUCT", 486, 491], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 517, 524], ["S. pneumoniae", "ORGANISM", 541, 554], ["SIGN-R1 complex", "PROTEIN", 0, 15], ["SIGN", "PROTEIN", 388, 392], ["SIGN", "PROTEIN", 425, 429], ["R1 complex", "PROTEIN", 430, 440], ["SIGN", "PROTEIN", 517, 521], ["R1 complex", "PROTEIN", 522, 532], ["S. pneumoniae", "SPECIES", 70, 83], ["S. pneumoniae serotype", "SPECIES", 269, 291], ["Staphylococcus aureus", "SPECIES", 308, 329], ["S. pneumoniae", "SPECIES", 541, 554], ["S. pneumoniae", "SPECIES", 70, 83], ["S. pneumoniae", "SPECIES", 269, 282], ["Staphylococcus aureus", "SPECIES", 308, 329], ["S. pneumoniae", "SPECIES", 541, 554], ["splenic LRs", "TREATMENT", 48, 59], ["S. pneumoniae stimulation", "TREATMENT", 70, 95], ["intravenous injection", "TREATMENT", 216, 237], ["S. pneumoniae serotype", "PROBLEM", 269, 291], ["Staphylococcus aureus", "PROBLEM", 308, 329], ["another grampositive coccal bacterium", "PROBLEM", 331, 368], ["bind SIGN", "TEST", 383, 392], ["increase in SIGN", "PROBLEM", 413, 429], ["S. pneumoniae", "PROBLEM", 541, 554], ["R1 complex", "OBSERVATION_MODIFIER", 5, 15], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["splenic", "ANATOMY", 48, 55], ["pneumoniae", "OBSERVATION", 73, 83], ["Staphylococcus aureus", "OBSERVATION", 308, 329], ["no", "UNCERTAINTY", 410, 412], ["increase", "OBSERVATION_MODIFIER", 413, 421], ["R1 complex", "OBSERVATION_MODIFIER", 430, 440], ["splenic", "ANATOMY", 444, 451], ["pneumoniae", "OBSERVATION", 544, 554]]], ["Next, we examined whether MARCO, a scavenger receptor expressed on partial SIGN-R1 + MZ macrophages 44 , or SER4/CD169, a cell adhesion molecule expressed on MZ metallophils, were recruited in splenic LRs following S. pneumoniae exposure.", [["SIGN-R1 + MZ macrophages", "ANATOMY", 75, 99], ["cell", "ANATOMY", 122, 126], ["MZ metallophils", "ANATOMY", 158, 173], ["splenic LRs", "ANATOMY", 193, 204], ["MARCO", "GENE_OR_GENE_PRODUCT", 26, 31], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 75, 82], ["MZ macrophages 44", "GENE_OR_GENE_PRODUCT", 85, 102], ["SER4", "GENE_OR_GENE_PRODUCT", 108, 112], ["CD169", "GENE_OR_GENE_PRODUCT", 113, 118], ["cell", "CELL", 122, 126], ["MZ metallophils", "CELL", 158, 173], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 193, 204], ["S. pneumoniae", "ORGANISM", 215, 228], ["MARCO", "PROTEIN", 26, 31], ["scavenger receptor", "PROTEIN", 35, 53], ["SIGN-R1 + MZ macrophages 44", "CELL_LINE", 75, 102], ["SER4", "PROTEIN", 108, 112], ["CD169", "PROTEIN", 113, 118], ["cell adhesion molecule", "PROTEIN", 122, 144], ["S. pneumoniae", "SPECIES", 215, 228], ["S. pneumoniae", "SPECIES", 215, 228], ["a scavenger receptor", "TEST", 33, 53], ["partial SIGN", "TEST", 67, 79], ["MZ macrophages", "PROBLEM", 85, 99], ["SER4", "TEST", 108, 112], ["a cell adhesion molecule", "PROBLEM", 120, 144], ["MZ metallophils", "TREATMENT", 158, 173], ["S. pneumoniae exposure", "PROBLEM", 215, 237], ["cell", "OBSERVATION", 122, 126], ["adhesion molecule", "OBSERVATION", 127, 144], ["splenic", "ANATOMY", 193, 200], ["pneumoniae", "OBSERVATION", 218, 228]]], ["Neither target was recruited in splenic LRs following exposure to S. pneumoniae (Fig. 3h ).ResultsC1q and C4 are distributed in LRs of splenic MZ SIGN-R1 + macrophages and increased following S. pneumoniae exposure in a SIGN-R1-dependent manner in vivoResultsThe expression levels of C1q and C4 in whole-cell lysates from the spleens, livers, and lungs of control mice were similar in all tissues ( Supplementary Fig. S4b ).", [["splenic", "ANATOMY", 32, 39], ["splenic MZ SIGN-R1 + macrophages", "ANATOMY", 135, 167], ["whole-cell lysates", "ANATOMY", 298, 316], ["spleens", "ANATOMY", 326, 333], ["livers", "ANATOMY", 335, 341], ["lungs", "ANATOMY", 347, 352], ["tissues", "ANATOMY", 389, 396], ["MZ", "CHEMICAL", 143, 145], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 32, 43], ["S. pneumoniae", "ORGANISM", 66, 79], ["ResultsC1q", "GENE_OR_GENE_PRODUCT", 91, 101], ["C4", "GENE_OR_GENE_PRODUCT", 106, 108], ["splenic MZ SIGN-R1 + macrophages", "CELL", 135, 167], ["S. pneumoniae", "ORGANISM", 192, 205], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 220, 227], ["C1q", "GENE_OR_GENE_PRODUCT", 284, 287], ["C4", "GENE_OR_GENE_PRODUCT", 292, 294], ["cell lysates", "ORGANISM_SUBSTANCE", 304, 316], ["spleens", "ORGAN", 326, 333], ["livers", "ORGAN", 335, 341], ["lungs", "ORGAN", 347, 352], ["mice", "ORGANISM", 364, 368], ["tissues", "TISSUE", 389, 396], ["ResultsC1q", "PROTEIN", 91, 101], ["C4", "PROTEIN", 106, 108], ["splenic MZ SIGN-R1", "CELL_LINE", 135, 153], ["macrophages", "CELL_TYPE", 156, 167], ["C1q", "PROTEIN", 284, 287], ["C4", "PROTEIN", 292, 294], ["S. pneumoniae", "SPECIES", 66, 79], ["S. pneumoniae", "SPECIES", 192, 205], ["mice", "SPECIES", 364, 368], ["S. pneumoniae", "SPECIES", 66, 79], ["S. pneumoniae", "SPECIES", 192, 205], ["mice", "SPECIES", 364, 368], ["splenic LRs", "TREATMENT", 32, 43], ["S. pneumoniae", "PROBLEM", 66, 79], ["splenic MZ SIGN", "TEST", 135, 150], ["macrophages", "PROBLEM", 156, 167], ["S. pneumoniae exposure", "PROBLEM", 192, 214], ["The expression levels", "TEST", 259, 280], ["C1q", "TEST", 284, 287], ["splenic", "ANATOMY", 32, 39], ["pneumoniae", "OBSERVATION", 69, 79], ["C4", "ANATOMY", 106, 108], ["splenic", "ANATOMY", 135, 142], ["macrophages", "ANATOMY", 156, 167], ["increased", "OBSERVATION_MODIFIER", 172, 181], ["C4", "ANATOMY", 292, 294], ["cell lysates", "OBSERVATION", 304, 316], ["spleens", "ANATOMY", 326, 333], ["livers", "ANATOMY", 335, 341], ["lungs", "ANATOMY", 347, 352], ["all tissues", "OBSERVATION_MODIFIER", 385, 396]]], ["However, higher levels of C1q and C4 were found in splenic LRs than in hepatic or pulmonary LRs or in non-LRs from all tissues (Fig. 4a ).", [["splenic LRs", "ANATOMY", 51, 62], ["hepatic", "ANATOMY", 71, 78], ["pulmonary LRs", "ANATOMY", 82, 95], ["non-LRs", "ANATOMY", 102, 109], ["tissues", "ANATOMY", 119, 126], ["C1q", "GENE_OR_GENE_PRODUCT", 26, 29], ["C4", "GENE_OR_GENE_PRODUCT", 34, 36], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 51, 62], ["hepatic", "ORGAN", 71, 78], ["pulmonary", "ORGAN", 82, 91], ["tissues", "TISSUE", 119, 126], ["C1q", "PROTEIN", 26, 29], ["C4", "PROTEIN", 34, 36], ["higher levels of C1q and C4", "PROBLEM", 9, 36], ["splenic LRs", "PROBLEM", 51, 62], ["higher", "OBSERVATION_MODIFIER", 9, 15], ["C4", "ANATOMY", 34, 36], ["splenic", "ANATOMY", 51, 58], ["hepatic", "ANATOMY", 71, 78], ["pulmonary", "ANATOMY", 82, 91], ["all tissues", "ANATOMY", 115, 126]]], ["Other traditional mediators in different complement pathways (IgM, MBL-C, and factor B) were barely present in LRs from all tissues (Fig. 4b ), but were variable in non-LRs ( Supplementary Fig. S4c ).", [["tissues", "ANATOMY", 124, 131], ["IgM", "GENE_OR_GENE_PRODUCT", 62, 65], ["MBL-C", "GENE_OR_GENE_PRODUCT", 67, 72], ["factor B", "GENE_OR_GENE_PRODUCT", 78, 86], ["tissues", "TISSUE", 124, 131], ["IgM", "PROTEIN", 62, 65], ["MBL", "PROTEIN", 67, 70], ["C", "PROTEIN", 71, 72], ["factor B", "PROTEIN", 78, 86], ["different complement pathways", "TEST", 31, 60], ["IgM", "TEST", 62, 65], ["MBL", "TEST", 67, 70], ["all tissues", "ANATOMY", 120, 131]]], ["Following intravenous injection of phosphatebuffered saline (PBS) or S. pneumoniae, simultaneous increases in C1q and C4 were obvious only in splenic LRs, whereas no changes were found in hepatic or pulmonary LRs or in non-LRs (Fig. 4c) .", [["intravenous", "ANATOMY", 10, 21], ["splenic LRs", "ANATOMY", 142, 153], ["hepatic", "ANATOMY", 188, 195], ["pulmonary", "ANATOMY", 199, 208], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 21], ["phosphatebuffered saline", "SIMPLE_CHEMICAL", 35, 59], ["S. pneumoniae", "ORGANISM", 69, 82], ["C1q", "GENE_OR_GENE_PRODUCT", 110, 113], ["C4", "GENE_OR_GENE_PRODUCT", 118, 120], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 142, 153], ["hepatic", "MULTI-TISSUE_STRUCTURE", 188, 195], ["pulmonary", "ORGAN", 199, 208], ["C1q", "PROTEIN", 110, 113], ["C4", "PROTEIN", 118, 120], ["S. pneumoniae", "SPECIES", 69, 82], ["S. pneumoniae", "SPECIES", 69, 82], ["intravenous injection of phosphatebuffered saline (PBS", "TREATMENT", 10, 64], ["S. pneumoniae", "PROBLEM", 69, 82], ["simultaneous increases in C1q and C4", "PROBLEM", 84, 120], ["splenic LRs", "TEST", 142, 153], ["pneumoniae", "OBSERVATION", 72, 82], ["increases", "OBSERVATION_MODIFIER", 97, 106], ["C4", "ANATOMY", 118, 120], ["splenic", "ANATOMY", 142, 149], ["hepatic", "ANATOMY", 188, 195], ["pulmonary", "ANATOMY", 199, 208]]], ["Additionally, no differences in IgM, MBL-C, or factor B levels were found in any fraction ( Fig. 4d and Supplementary Fig. S4d ).ResultsIn SIGN-R1-KO mice, the levels of C1q and C4 in whole-cell lysates of all tissues were the same as those in control mice ( Supplementary Fig. S4e, b) .", [["whole-cell lysates", "ANATOMY", 184, 202], ["tissues", "ANATOMY", 210, 217], ["IgM", "GENE_OR_GENE_PRODUCT", 32, 35], ["MBL-C", "GENE_OR_GENE_PRODUCT", 37, 42], ["factor B", "GENE_OR_GENE_PRODUCT", 47, 55], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 139, 146], ["C1q", "GENE_OR_GENE_PRODUCT", 170, 173], ["C4", "GENE_OR_GENE_PRODUCT", 178, 180], ["cell lysates", "ORGANISM_SUBSTANCE", 190, 202], ["tissues", "TISSUE", 210, 217], ["mice", "ORGANISM", 252, 256], ["IgM", "PROTEIN", 32, 35], ["MBL", "PROTEIN", 37, 40], ["factor B", "PROTEIN", 47, 55], ["SIGN", "PROTEIN", 139, 143], ["R1", "PROTEIN", 144, 146], ["C1q", "PROTEIN", 170, 173], ["C4", "PROTEIN", 178, 180], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 252, 256], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 252, 256], ["IgM", "TEST", 32, 35], ["MBL", "TEST", 37, 40], ["factor B levels", "TEST", 47, 62], ["the levels", "TEST", 156, 166], ["C1q", "TEST", 170, 173], ["no", "UNCERTAINTY", 14, 16], ["C4", "ANATOMY", 178, 180], ["all tissues", "ANATOMY", 206, 217]]], ["However, both complements were not increased at all following S. pneumoniae exposure (Fig. 4e) .", [["S. pneumoniae", "ORGANISM", 62, 75], ["S. pneumoniae", "SPECIES", 62, 75], ["S. pneumoniae", "SPECIES", 62, 75], ["S. pneumoniae exposure", "PROBLEM", 62, 84], ["pneumoniae", "OBSERVATION", 65, 75]]], ["Moreover, increases in C1q and C4 were completely abolished in splenic LRs from SIGN-R1 TKO mice exposed to S. pneumoniae ( Supplementary Fig. S4f ).", [["splenic LRs", "ANATOMY", 63, 74], ["C1q", "GENE_OR_GENE_PRODUCT", 23, 26], ["C4", "GENE_OR_GENE_PRODUCT", 31, 33], ["SIGN-R1 TKO mice", "ORGANISM", 80, 96], ["S. pneumoniae", "ORGANISM", 108, 121], ["C1q", "PROTEIN", 23, 26], ["C4", "PROTEIN", 31, 33], ["mice", "SPECIES", 92, 96], ["S. pneumoniae", "SPECIES", 108, 121], ["mice", "SPECIES", 92, 96], ["S. pneumoniae", "SPECIES", 108, 121], ["increases in C1q and C4", "PROBLEM", 10, 33], ["splenic LRs", "TEST", 63, 74], ["SIGN", "TEST", 80, 84], ["S. pneumoniae", "PROBLEM", 108, 121], ["increases", "OBSERVATION_MODIFIER", 10, 19], ["C4", "ANATOMY", 31, 33], ["splenic", "ANATOMY", 63, 70], ["pneumoniae", "OBSERVATION", 111, 121]]], ["To determine whether the specific recognition of CPS14 by SIGN-R1 was required for upregulation of C1q and C4 in splenic LRs, splenic fractions were immunoblotted for C1q and C4.", [["splenic LRs", "ANATOMY", 113, 124], ["splenic fractions", "ANATOMY", 126, 143], ["CPS14", "GENE_OR_GENE_PRODUCT", 49, 54], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 58, 65], ["C1q", "GENE_OR_GENE_PRODUCT", 99, 102], ["C4", "GENE_OR_GENE_PRODUCT", 107, 109], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 113, 124], ["splenic fractions", "MULTI-TISSUE_STRUCTURE", 126, 143], ["C1q", "GENE_OR_GENE_PRODUCT", 167, 170], ["C4", "GENE_OR_GENE_PRODUCT", 175, 177], ["CPS14", "PROTEIN", 49, 54], ["SIGN", "PROTEIN", 58, 62], ["R1", "DNA", 63, 65], ["C1q", "PROTEIN", 99, 102], ["C4", "PROTEIN", 107, 109], ["C1q", "PROTEIN", 167, 170], ["C4", "PROTEIN", 175, 177], ["CPS14", "TEST", 49, 54], ["upregulation of C1q and C4 in splenic LRs", "PROBLEM", 83, 124], ["C1q and C4", "PROBLEM", 167, 177], ["C4", "ANATOMY", 107, 109], ["splenic", "ANATOMY", 113, 120], ["splenic", "ANATOMY", 126, 133], ["C4", "ANATOMY_MODIFIER", 175, 177]]], ["Both complements were not upregulated at all in any splenic fraction following exposure to mt-Pn14 or S. aureus ( Fig. 4f , g).ResultsLRs from splenic MZ SIGN-R1 + macrophages may provide an optimal location for dominant C3 activation in response to S. pneumoniae in a SIGN-R1-dependent manner in vivoResultsWe examined C3 levels in whole-cell lysates from the spleen, liver, and lung of WT mice, and the lowest expression was observed in the spleen ( Supplementary Fig. S5a ).", [["splenic fraction", "ANATOMY", 52, 68], ["splenic MZ SIGN-R1 + macrophages", "ANATOMY", 143, 175], ["whole-cell lysates", "ANATOMY", 333, 351], ["spleen", "ANATOMY", 361, 367], ["liver", "ANATOMY", 369, 374], ["lung", "ANATOMY", 380, 384], ["spleen", "ANATOMY", 443, 449], ["MZ", "CHEMICAL", 151, 153], ["mt-Pn14", "GENE_OR_GENE_PRODUCT", 91, 98], ["S. aureus", "ORGANISM", 102, 111], ["splenic MZ SIGN-R1 + macrophages", "CELL", 143, 175], ["C3", "GENE_OR_GENE_PRODUCT", 221, 223], ["S. pneumoniae", "ORGANISM", 250, 263], ["C3", "GENE_OR_GENE_PRODUCT", 320, 322], ["cell lysates", "ORGANISM_SUBSTANCE", 339, 351], ["spleen", "ORGAN", 361, 367], ["liver", "ORGAN", 369, 374], ["lung", "ORGAN", 380, 384], ["mice", "ORGANISM", 391, 395], ["spleen", "ORGAN", 443, 449], ["S5a", "GENE_OR_GENE_PRODUCT", 471, 474], ["splenic fraction", "CELL_TYPE", 52, 68], ["ResultsLRs", "PROTEIN", 127, 137], ["splenic MZ SIGN-R1 + macrophages", "CELL_LINE", 143, 175], ["C3", "PROTEIN", 221, 223], ["C3", "PROTEIN", 320, 322], ["S. aureus", "SPECIES", 102, 111], ["S. pneumoniae", "SPECIES", 250, 263], ["mice", "SPECIES", 391, 395], ["S. aureus", "SPECIES", 102, 111], ["S. pneumoniae", "SPECIES", 250, 263], ["mice", "SPECIES", 391, 395], ["S. aureus", "PROBLEM", 102, 111], ["ResultsLRs", "TEST", 127, 137], ["splenic MZ SIGN", "TEST", 143, 158], ["macrophages", "PROBLEM", 164, 175], ["dominant C3 activation", "PROBLEM", 212, 234], ["S. pneumoniae", "PROBLEM", 250, 263], ["C3 levels", "TEST", 320, 329], ["whole-cell lysates", "TEST", 333, 351], ["splenic", "ANATOMY", 52, 59], ["aureus", "OBSERVATION", 105, 111], ["splenic", "ANATOMY", 143, 150], ["macrophages", "OBSERVATION", 164, 175], ["C3 activation", "OBSERVATION", 221, 234], ["pneumoniae", "OBSERVATION", 253, 263], ["cell lysates", "OBSERVATION", 339, 351], ["spleen", "ANATOMY", 361, 367], ["liver", "ANATOMY", 369, 374], ["lung", "ANATOMY", 380, 384], ["spleen", "ANATOMY", 443, 449]]], ["However, immunoblotting of their fractions for C3 showed that constitutive distribution of C3 was the highest in splenic LRs among LRs of all tissues (Fig. 5a) .", [["splenic LRs", "ANATOMY", 113, 124], ["tissues", "ANATOMY", 142, 149], ["C3", "GENE_OR_GENE_PRODUCT", 47, 49], ["C3", "GENE_OR_GENE_PRODUCT", 91, 93], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 113, 124], ["tissues", "TISSUE", 142, 149], ["C3", "PROTEIN", 47, 49], ["C3", "PROTEIN", 91, 93], ["constitutive distribution of C3", "PROBLEM", 62, 93], ["C3", "OBSERVATION_MODIFIER", 91, 93], ["highest", "OBSERVATION_MODIFIER", 102, 109], ["splenic", "ANATOMY", 113, 120], ["all tissues", "ANATOMY", 138, 149]]], ["Furthermore, following intravenous injection of PBS or S. pneumoniae, the initial activation of C3 was most dominant in splenic LRs exposed to S. pneumoniae with a dramatic decrease in \u03b1C3, but a relatively minor decrease was observed in splenic non-LRs (Fig. 5b) .", [["intravenous", "ANATOMY", 23, 34], ["splenic LRs", "ANATOMY", 120, 131], ["splenic non-LRs", "ANATOMY", 238, 253], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 23, 34], ["S. pneumoniae", "ORGANISM", 55, 68], ["C3", "GENE_OR_GENE_PRODUCT", 96, 98], ["S. pneumoniae", "ORGANISM", 143, 156], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 185, 188], ["C3", "PROTEIN", 96, 98], ["\u03b1C3", "PROTEIN", 185, 188], ["splenic non-LRs", "CELL_TYPE", 238, 253], ["S. pneumoniae", "SPECIES", 55, 68], ["S. pneumoniae", "SPECIES", 143, 156], ["S. pneumoniae", "SPECIES", 55, 68], ["S. pneumoniae", "SPECIES", 143, 156], ["intravenous injection of PBS", "TREATMENT", 23, 51], ["S. pneumoniae", "PROBLEM", 55, 68], ["splenic LRs", "PROBLEM", 120, 131], ["S. pneumoniae", "PROBLEM", 143, 156], ["a dramatic decrease in \u03b1C3", "PROBLEM", 162, 188], ["a relatively minor decrease", "PROBLEM", 194, 221], ["pneumoniae", "OBSERVATION", 58, 68], ["most dominant", "OBSERVATION_MODIFIER", 103, 116], ["splenic", "ANATOMY", 120, 127], ["pneumoniae", "OBSERVATION", 146, 156], ["dramatic", "OBSERVATION_MODIFIER", 164, 172], ["decrease", "OBSERVATION_MODIFIER", 173, 181], ["C3", "OBSERVATION_MODIFIER", 186, 188], ["relatively", "OBSERVATION_MODIFIER", 196, 206], ["minor", "OBSERVATION_MODIFIER", 207, 212], ["decrease", "OBSERVATION", 213, 221], ["splenic", "ANATOMY", 238, 245], ["non-LRs", "ANATOMY_MODIFIER", 246, 253]]], ["These results in spleen fractions were confirmed in separate experiments (Supplementary S5b, c).ResultsIn sera or splenic fractions from SIGN-R1-KO or SIGN-R1 TKO mice, SIGN-R1 deficiency did not affect C3 levels in sera (Supplementary S5g) or distribution in splenic LRs without pneumococcal challenge (Fig. 5c , top, Supplementary Fig. S5f , g, top), but abolished C3 activation with pneumococcal challenge (Fig. 5c , bottom and Supplementary Fig. S5g, bottom) .", [["spleen fractions", "ANATOMY", 17, 33], ["sera", "ANATOMY", 106, 110], ["splenic fractions", "ANATOMY", 114, 131], ["sera", "ANATOMY", 216, 220], ["splenic", "ANATOMY", 260, 267], ["spleen", "ORGAN", 17, 23], ["sera", "ORGANISM_SUBSTANCE", 106, 110], ["splenic fractions", "ORGANISM_SUBSTANCE", 114, 131], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 137, 144], ["SIGN-R1 TKO mice", "ORGANISM", 151, 167], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 169, 176], ["C3", "GENE_OR_GENE_PRODUCT", 203, 205], ["sera", "ORGANISM_SUBSTANCE", 216, 220], ["S5g", "GENE_OR_GENE_PRODUCT", 236, 239], ["S5f", "GENE_OR_GENE_PRODUCT", 338, 341], ["C3", "GENE_OR_GENE_PRODUCT", 367, 369], ["C3", "PROTEIN", 203, 205], ["S5f , g, top", "PROTEIN", 338, 350], ["C3", "PROTEIN", 367, 369], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 163, 167], ["pneumococcal", "SPECIES", 280, 292], ["pneumococcal", "SPECIES", 386, 398], ["ResultsIn sera", "TEST", 96, 110], ["splenic fractions", "TEST", 114, 131], ["SIGN", "TEST", 137, 141], ["SIGN", "TEST", 151, 155], ["R1 deficiency", "PROBLEM", 174, 187], ["C3 levels", "TEST", 203, 212], ["sera", "TEST", 216, 220], ["pneumococcal challenge", "TREATMENT", 280, 302], ["pneumococcal challenge", "TREATMENT", 386, 408], ["bottom", "TREATMENT", 420, 426], ["Supplementary Fig. S5g, bottom", "TREATMENT", 431, 461], ["spleen", "ANATOMY", 17, 23], ["splenic", "ANATOMY", 114, 121], ["R1 deficiency", "OBSERVATION", 174, 187], ["splenic", "ANATOMY", 260, 267], ["without", "UNCERTAINTY", 272, 279], ["pneumococcal", "OBSERVATION_MODIFIER", 280, 292], ["bottom", "ANATOMY", 455, 461]]], ["Moreover, CPS14 was essential for SIGN-R1-mediated C3 activation in splenic LRs because C3 activation was significantly decreased or abolished in all splenic fractions from WT mice following mt-Pn14 or S. aureus challenge, yielding abundant intact C3\u03b1 and weak or no increases in 43 kDa iC3b (Fig. 5d, e) .", [["splenic LRs", "ANATOMY", 68, 79], ["splenic fractions", "ANATOMY", 150, 167], ["mt-Pn14", "CHEMICAL", 191, 198], ["CPS14", "GENE_OR_GENE_PRODUCT", 10, 15], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 34, 41], ["C3", "GENE_OR_GENE_PRODUCT", 51, 53], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 68, 79], ["C3", "GENE_OR_GENE_PRODUCT", 88, 90], ["mice", "ORGANISM", 176, 180], ["mt-Pn14", "GENE_OR_GENE_PRODUCT", 191, 198], ["S. aureus", "ORGANISM", 202, 211], ["C3\u03b1", "GENE_OR_GENE_PRODUCT", 248, 251], ["iC3b", "GENE_OR_GENE_PRODUCT", 287, 291], ["CPS14", "PROTEIN", 10, 15], ["SIGN", "PROTEIN", 34, 38], ["C3", "PROTEIN", 51, 53], ["C3", "PROTEIN", 88, 90], ["C3\u03b1", "PROTEIN", 248, 251], ["43 kDa iC3b", "PROTEIN", 280, 291], ["mice", "SPECIES", 176, 180], ["S. aureus", "SPECIES", 202, 211], ["mice", "SPECIES", 176, 180], ["S. aureus", "SPECIES", 202, 211], ["CPS14", "TEST", 10, 15], ["SIGN", "TEST", 34, 38], ["C3 activation", "PROBLEM", 51, 64], ["splenic LRs", "TREATMENT", 68, 79], ["C3 activation", "PROBLEM", 88, 101], ["S. aureus challenge", "PROBLEM", 202, 221], ["splenic", "ANATOMY", 68, 75], ["splenic", "ANATOMY", 150, 157], ["aureus", "OBSERVATION", 205, 211], ["abundant", "OBSERVATION_MODIFIER", 232, 240], ["intact", "OBSERVATION", 241, 247], ["no", "UNCERTAINTY", 264, 266], ["increases", "OBSERVATION_MODIFIER", 267, 276]]], ["In C3-depleted mice, C3 deficiency in splenic LRs had no effect on the constitutive distribution of SIGN-R1, C1q, or C4 in splenic LRs or their increases against S. pneumoniae (Fig. 5f ).ResultsWhen WT cells or SIGN-R1 transfectants were incubated with mouse serum, fixation of C4 and C3 was observed only on SIGN-R1 transfectants and was significantly enhanced in SIGN-R1 transfectants in the Accumulation and multimerization of SIGN-R1 in splenic lipid rafts following exposure to CPS14 from S. pneumoniae in vivo. a DCEK_SIGN-R1 transfectants were incubated with mitomycin C-treated S. pneumoniae type 14 (MitC-Pn14; 1 \u00d7 10 6 , 10 min) at 37\u00b0C or 4\u00b0C and immunostained for SIGN-R1 without permeabilization. b As in a, but cells were pretreated with M\u03b2CD (10 mM, 3 h) and incubated only at 37\u00b0C. c As in a, but cell lysates at 37\u00b0C were fractionated with sucrose gradient ultracentrifugation, and fractions of LRs were immunoblotted for SIGN-R1, flotilin-1, or caveolin-1.", [["splenic", "ANATOMY", 38, 45], ["splenic LRs", "ANATOMY", 123, 134], ["WT cells", "ANATOMY", 199, 207], ["SIGN-R1 transfectants", "ANATOMY", 211, 232], ["serum", "ANATOMY", 259, 264], ["SIGN-R1 transfectants", "ANATOMY", 309, 330], ["SIGN-R1 transfectants", "ANATOMY", 365, 386], ["splenic lipid rafts", "ANATOMY", 441, 460], ["cells", "ANATOMY", 725, 730], ["cell lysates", "ANATOMY", 813, 825], ["CPS14", "CHEMICAL", 483, 488], ["mitomycin C", "CHEMICAL", 566, 577], ["M\u03b2CD", "CHEMICAL", 752, 756], ["sucrose", "CHEMICAL", 857, 864], ["mitomycin C", "CHEMICAL", 566, 577], ["M\u03b2CD", "CHEMICAL", 752, 756], ["sucrose", "CHEMICAL", 857, 864], ["C3", "GENE_OR_GENE_PRODUCT", 3, 5], ["mice", "ORGANISM", 15, 19], ["C3", "GENE_OR_GENE_PRODUCT", 21, 23], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 38, 49], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 100, 107], ["C1q", "GENE_OR_GENE_PRODUCT", 109, 112], ["C4", "GENE_OR_GENE_PRODUCT", 117, 119], ["splenic LRs", "SIMPLE_CHEMICAL", 123, 134], ["S. pneumoniae", "ORGANISM", 162, 175], ["WT cells", "CELL", 199, 207], ["SIGN-R1 transfectants", "CELL", 211, 232], ["mouse", "ORGANISM", 253, 258], ["serum", "ORGANISM_SUBSTANCE", 259, 264], ["C4", "GENE_OR_GENE_PRODUCT", 278, 280], ["C3", "GENE_OR_GENE_PRODUCT", 285, 287], ["SIGN-R1 transfectants", "CELL", 309, 330], ["SIGN-R1 transfectants", "CELL", 365, 386], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 430, 437], ["CPS14", "GENE_OR_GENE_PRODUCT", 483, 488], ["S. pneumoniae", "ORGANISM", 494, 507], ["DCEK_SIGN-R1 transfectants", "CELL", 519, 545], ["mitomycin C", "SIMPLE_CHEMICAL", 566, 577], ["S. pneumoniae type 14", "ORGANISM", 586, 607], ["C", "GENE_OR_GENE_PRODUCT", 652, 653], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 676, 683], ["cells", "CELL", 725, 730], ["M\u03b2CD", "SIMPLE_CHEMICAL", 752, 756], ["cell lysates", "CELL", 813, 825], ["sucrose", "SIMPLE_CHEMICAL", 857, 864], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 939, 946], ["flotilin-1", "GENE_OR_GENE_PRODUCT", 948, 958], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 963, 973], ["C3", "PROTEIN", 3, 5], ["C3", "PROTEIN", 21, 23], ["SIGN", "PROTEIN", 100, 104], ["R1", "PROTEIN", 105, 107], ["C1q", "PROTEIN", 109, 112], ["C4", "PROTEIN", 117, 119], ["WT cells", "CELL_LINE", 199, 207], ["SIGN-R1 transfectants", "CELL_LINE", 211, 232], ["C4", "PROTEIN", 278, 280], ["C3", "PROTEIN", 285, 287], ["SIGN-R1 transfectants", "CELL_LINE", 309, 330], ["SIGN-R1 transfectants", "CELL_LINE", 365, 386], ["SIGN", "PROTEIN", 430, 434], ["R1", "PROTEIN", 435, 437], ["DCEK_SIGN-R1 transfectants", "CELL_LINE", 519, 545], ["SIGN", "PROTEIN", 676, 680], ["R1", "PROTEIN", 681, 683], ["SIGN", "PROTEIN", 939, 943], ["R1", "PROTEIN", 944, 946], ["flotilin-1", "PROTEIN", 948, 958], ["caveolin-1", "PROTEIN", 963, 973], ["mice", "SPECIES", 15, 19], ["S. pneumoniae", "SPECIES", 162, 175], ["mouse", "SPECIES", 253, 258], ["S. pneumoniae", "SPECIES", 494, 507], ["S. pneumoniae", "SPECIES", 586, 599], ["mice", "SPECIES", 15, 19], ["S. pneumoniae", "SPECIES", 162, 175], ["mouse", "SPECIES", 253, 258], ["S. pneumoniae", "SPECIES", 494, 507], ["S. pneumoniae", "SPECIES", 586, 599], ["C3", "TEST", 3, 5], ["C3 deficiency", "PROBLEM", 21, 34], ["splenic LRs", "TEST", 38, 49], ["S. pneumoniae", "PROBLEM", 162, 175], ["WT cells", "TEST", 199, 207], ["SIGN", "TEST", 211, 215], ["mouse serum", "TEST", 253, 264], ["fixation of C4 and C3", "TEST", 266, 287], ["SIGN", "TEST", 365, 369], ["SIGN", "TEST", 430, 434], ["splenic lipid rafts", "TREATMENT", 441, 460], ["CPS14", "TREATMENT", 483, 488], ["S. pneumoniae", "PROBLEM", 494, 507], ["a DCEK_SIGN-R1 transfectants", "TREATMENT", 517, 545], ["mitomycin C", "TREATMENT", 566, 577], ["S. pneumoniae type", "TEST", 586, 604], ["MitC", "TEST", 609, 613], ["permeabilization", "PROBLEM", 692, 708], ["M\u03b2CD", "TREATMENT", 752, 756], ["cell lysates", "TEST", 813, 825], ["sucrose gradient ultracentrifugation", "TREATMENT", 857, 893], ["LRs", "TEST", 912, 915], ["SIGN", "TEST", 939, 943], ["flotilin", "TEST", 948, 956], ["caveolin", "TEST", 963, 971], ["depleted mice", "OBSERVATION", 6, 19], ["C3 deficiency", "OBSERVATION", 21, 34], ["splenic", "ANATOMY", 38, 45], ["no", "UNCERTAINTY", 54, 56], ["C4", "ANATOMY", 117, 119], ["splenic", "ANATOMY", 123, 130], ["pneumoniae", "OBSERVATION", 165, 175], ["C4", "ANATOMY", 278, 280], ["C3", "ANATOMY", 285, 287], ["R1 transfectants", "OBSERVATION", 370, 386], ["splenic", "ANATOMY", 441, 448], ["lipid rafts", "OBSERVATION", 449, 460], ["pneumoniae", "OBSERVATION", 497, 507]]], ["Multimers of SIGN-R1 are shown in the boxes. d In total, 1 \u00d7 10 8 CFSE-labeled MitC-Pn14 (green) were injected intravenously into wild-type mice for 0, 15, or 60 min, and splenic sections were immunostained for SIGN-R1 (blue).", [["intravenously", "ANATOMY", 111, 124], ["splenic sections", "ANATOMY", 171, 187], ["CFSE", "CHEMICAL", 66, 70], ["MitC-Pn14", "CHEMICAL", 79, 88], ["CFSE", "CHEMICAL", 66, 70], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 13, 20], ["CFSE", "SIMPLE_CHEMICAL", 66, 70], ["MitC-Pn14", "SIMPLE_CHEMICAL", 79, 88], ["mice", "ORGANISM", 140, 144], ["splenic sections", "MULTI-TISSUE_STRUCTURE", 171, 187], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 211, 218], ["SIGN", "PROTEIN", 13, 17], ["R1", "DNA", 18, 20], ["MitC", "PROTEIN", 79, 83], ["SIGN", "PROTEIN", 211, 215], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 140, 144], ["CFSE", "TEST", 66, 70], ["MitC", "TEST", 79, 83], ["splenic sections", "TEST", 171, 187], ["SIGN", "TEST", 211, 215], ["splenic", "ANATOMY", 171, 178]]], ["The binding or uptake of organisms into splenic MZs is shown in the boxes.", [["splenic MZs", "ANATOMY", 40, 51], ["splenic MZs", "CANCER", 40, 51], ["splenic MZs", "CELL_TYPE", 40, 51], ["organisms into splenic MZs", "PROBLEM", 25, 51], ["uptake", "OBSERVATION_MODIFIER", 15, 21], ["splenic", "ANATOMY", 40, 47], ["MZs", "OBSERVATION", 48, 51]]], ["(E) As in (C), but spleens were used before or after intravenous injection of live S. pneumoniae (Pn14; 1 \u00d7 10 8 , 1 hr) into wild-type mice.", [["spleens", "ANATOMY", 19, 26], ["intravenous", "ANATOMY", 53, 64], ["(E) As", "CHEMICAL", 0, 6], ["spleens", "ORGAN", 19, 26], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 64], ["S. pneumoniae", "ORGANISM", 83, 96], ["mice", "ORGANISM", 136, 140], ["S. pneumoniae", "SPECIES", 83, 96], ["mice", "SPECIES", 136, 140], ["S. pneumoniae", "SPECIES", 83, 96], ["intravenous injection", "TREATMENT", 53, 74], ["S. pneumoniae", "PROBLEM", 83, 96], ["spleens", "ANATOMY", 19, 26], ["pneumoniae", "OBSERVATION", 86, 96]]], ["(F and G) As in e, but mice were injected intravenously with PBS or 1 \u00d7 10 8 cells of an unencapsulated mutant of serotype 14 S. pneumoniae (mt-Pn14) or Staphylococcus aureus for 1 h, respectively. h As in e, but fractions were immunoblotted for MARCO, SER4/CD169, flotilin-1, and caveolin-1.", [["intravenously", "ANATOMY", 42, 55], ["cells", "ANATOMY", 77, 82], ["(F and G) As", "CHEMICAL", 0, 12], ["mice", "ORGANISM", 23, 27], ["cells", "CELL", 77, 82], ["serotype 14", "ORGANISM", 114, 125], ["S. pneumoniae", "ORGANISM", 126, 139], ["mt-Pn14", "ORGANISM", 141, 148], ["Staphylococcus aureus", "ORGANISM", 153, 174], ["MARCO", "GENE_OR_GENE_PRODUCT", 246, 251], ["SER4", "GENE_OR_GENE_PRODUCT", 253, 257], ["CD169", "GENE_OR_GENE_PRODUCT", 258, 263], ["flotilin-1", "GENE_OR_GENE_PRODUCT", 265, 275], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 281, 291], ["MARCO", "PROTEIN", 246, 251], ["SER4", "PROTEIN", 253, 257], ["CD169", "PROTEIN", 258, 263], ["flotilin-1", "PROTEIN", 265, 275], ["caveolin-1", "PROTEIN", 281, 291], ["mice", "SPECIES", 23, 27], ["S. pneumoniae", "SPECIES", 126, 139], ["Staphylococcus aureus", "SPECIES", 153, 174], ["mice", "SPECIES", 23, 27], ["S. pneumoniae", "SPECIES", 126, 139], ["Staphylococcus aureus", "SPECIES", 153, 174], ["PBS", "TEST", 61, 64], ["serotype 14 S. pneumoniae", "PROBLEM", 114, 139], ["Staphylococcus aureus", "PROBLEM", 153, 174], ["MARCO", "TEST", 246, 251], ["SER4", "TEST", 253, 257], ["CD169", "TEST", 258, 263], ["flotilin", "TEST", 265, 273], ["caveolin", "TEST", 281, 289], ["Staphylococcus aureus", "OBSERVATION", 153, 174]]], ["Scale bars a, b, 20 \u00b5m; d, 250 \u00b5m presence of S. pneumoniae (Fig. 5g) .", [["S. pneumoniae", "ORGANISM", 46, 59], ["S. pneumoniae", "SPECIES", 46, 59], ["S. pneumoniae", "SPECIES", 46, 59], ["S. pneumoniae", "PROBLEM", 46, 59], ["pneumoniae", "OBSERVATION", 49, 59]]], ["Furthermore, fluorescent microscopy revealed the colocalization of C4 and C3 only in SIGN-R1 transfectants ( Fig. 5h and Supplementary Fig. S5h ), indicating that C3 activation was specifically generated at the same location on SIGN-R1 + cells in which the SIGN-R1-mediated classical complement pathway was initiated.ResultsEnrichment of SIGN-R1 and C1q enhances the opsonization, uptake, and decomposition of S. pneumoniae Addition of SIGN-R1 significantly enhanced the fixation of C1q on the pneumococcal surface (Fig. 6a) .", [["SIGN-R1 transfectants", "ANATOMY", 85, 106], ["SIGN-R1 + cells", "ANATOMY", 228, 243], ["pneumococcal surface", "ANATOMY", 494, 514], ["SIGN-R1", "CHEMICAL", 436, 443], ["C4", "GENE_OR_GENE_PRODUCT", 67, 69], ["C3", "GENE_OR_GENE_PRODUCT", 74, 76], ["SIGN-R1 transfectants", "CELL", 85, 106], ["C3", "GENE_OR_GENE_PRODUCT", 163, 165], ["SIGN-R1 + cells", "CELL", 228, 243], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 257, 264], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 338, 345], ["C1q", "GENE_OR_GENE_PRODUCT", 350, 353], ["S. pneumoniae", "ORGANISM", 410, 423], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 436, 443], ["C1q", "GENE_OR_GENE_PRODUCT", 483, 486], ["C4", "PROTEIN", 67, 69], ["C3", "PROTEIN", 74, 76], ["SIGN-R1 transfectants", "CELL_LINE", 85, 106], ["C3", "PROTEIN", 163, 165], ["SIGN-R1 + cells", "CELL_LINE", 228, 243], ["SIGN", "PROTEIN", 257, 261], ["R1", "PROTEIN", 262, 264], ["SIGN", "PROTEIN", 338, 342], ["R1", "PROTEIN", 343, 345], ["C1q", "PROTEIN", 350, 353], ["SIGN", "PROTEIN", 436, 440], ["C1q", "PROTEIN", 483, 486], ["S. pneumoniae", "SPECIES", 410, 423], ["S. pneumoniae", "SPECIES", 410, 423], ["pneumococcal", "SPECIES", 494, 506], ["fluorescent microscopy", "TEST", 13, 35], ["the colocalization of C4 and C3", "PROBLEM", 45, 76], ["SIGN", "TEST", 85, 89], ["C3 activation", "PROBLEM", 163, 176], ["the SIGN", "TEST", 253, 261], ["SIGN", "TEST", 338, 342], ["S. pneumoniae", "PROBLEM", 410, 423], ["the fixation of C1q", "TREATMENT", 467, 486], ["the pneumococcal surface", "TREATMENT", 490, 514], ["C4", "ANATOMY_MODIFIER", 67, 69], ["R1 transfectants", "OBSERVATION", 90, 106], ["pneumoniae", "OBSERVATION", 413, 423], ["fixation", "OBSERVATION", 471, 479], ["pneumococcal", "OBSERVATION_MODIFIER", 494, 506], ["surface", "OBSERVATION_MODIFIER", 507, 514]]], ["Sequentially, the increased concentration of C1q also accelerated the opsonization of iC3b in response to Fig. 4 Predominant distribution of complement C1q and C4 in splenic lipid rafts and their upregulation after S. pneumoniae challenge in a SIGN-R1-dependent manner in vivo. a Spleens, livers, and lungs of control mice were fractionated with sucrose gradient ultracentrifugation, and fractions were immunoblotted for C1q, C4, flotilin-1, and caveolin-1. b As in a, but fractions were immunoblotted for IgM, MBL-C, or factor B. c As in a, but wild-type mice were injected intravenously with live S. pneumoniae (Pn14; 1 \u00d7 10 8 , 1 h). d As in c, but fractions were immunoblotted for IgM, MBL-C, or factor B. e As in a, c, but SIGN-R1-KO mice were used, and splenic fractions were analyzed. f, g As in c, but mice were injected intravenously with an unencapsulated mutant of serotype 14 S. pneumoniae (mt-Pn14) or Staphylococcus aureus (1 \u00d7 10 8 , 1 h).", [["splenic lipid rafts", "ANATOMY", 166, 185], ["Spleens", "ANATOMY", 280, 287], ["livers", "ANATOMY", 289, 295], ["lungs", "ANATOMY", 301, 306], ["intravenously", "ANATOMY", 575, 588], ["splenic fractions", "ANATOMY", 759, 776], ["intravenously", "ANATOMY", 829, 842], ["sucrose", "CHEMICAL", 346, 353], ["Staphylococcus aureus", "DISEASE", 915, 936], ["sucrose", "CHEMICAL", 346, 353], ["As", "CHEMICAL", 797, 799], ["C1q", "GENE_OR_GENE_PRODUCT", 45, 48], ["iC3b", "GENE_OR_GENE_PRODUCT", 86, 90], ["complement C1q", "GENE_OR_GENE_PRODUCT", 141, 155], ["C4", "GENE_OR_GENE_PRODUCT", 160, 162], ["S. pneumoniae", "ORGANISM", 215, 228], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 244, 251], ["livers", "ORGAN", 289, 295], ["lungs", "ORGAN", 301, 306], ["mice", "ORGANISM", 318, 322], ["sucrose", "SIMPLE_CHEMICAL", 346, 353], ["C1q", "GENE_OR_GENE_PRODUCT", 421, 424], ["C4", "GENE_OR_GENE_PRODUCT", 426, 428], ["flotilin-1", "GENE_OR_GENE_PRODUCT", 430, 440], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 446, 456], ["IgM", "GENE_OR_GENE_PRODUCT", 506, 509], ["MBL-C", "GENE_OR_GENE_PRODUCT", 511, 516], ["c As", "GENE_OR_GENE_PRODUCT", 531, 535], ["mice", "ORGANISM", 556, 560], ["S. pneumoniae", "ORGANISM", 599, 612], ["IgM", "GENE_OR_GENE_PRODUCT", 685, 688], ["MBL-C", "GENE_OR_GENE_PRODUCT", 690, 695], ["SIGN-R1-KO mice", "ORGANISM", 728, 743], ["splenic fractions", "MULTI-TISSUE_STRUCTURE", 759, 776], ["c", "GENE_OR_GENE_PRODUCT", 803, 804], ["mice", "ORGANISM", 810, 814], ["serotype 14", "ORGANISM", 876, 887], ["S. pneumoniae", "ORGANISM", 888, 901], ["mt-Pn14", "ORGANISM", 903, 910], ["Staphylococcus aureus", "ORGANISM", 915, 936], ["C1q", "PROTEIN", 45, 48], ["iC3b", "PROTEIN", 86, 90], ["complement C1q", "PROTEIN", 141, 155], ["C4", "PROTEIN", 160, 162], ["C1q", "PROTEIN", 421, 424], ["C4", "PROTEIN", 426, 428], ["flotilin-1", "PROTEIN", 430, 440], ["caveolin-1", "PROTEIN", 446, 456], ["IgM", "PROTEIN", 506, 509], ["MBL", "PROTEIN", 511, 514], ["C", "PROTEIN", 515, 516], ["factor B. c As", "PROTEIN", 521, 535], ["IgM", "PROTEIN", 685, 688], ["MBL", "PROTEIN", 690, 693], ["C", "PROTEIN", 694, 695], ["SIGN", "PROTEIN", 728, 732], ["R1", "PROTEIN", 733, 735], ["S. pneumoniae", "SPECIES", 215, 228], ["mice", "SPECIES", 318, 322], ["mice", "SPECIES", 556, 560], ["S. pneumoniae", "SPECIES", 599, 612], ["mice", "SPECIES", 739, 743], ["mice", "SPECIES", 810, 814], ["S. pneumoniae", "SPECIES", 888, 901], ["Staphylococcus aureus", "SPECIES", 915, 936], ["S. pneumoniae", "SPECIES", 215, 228], ["mice", "SPECIES", 318, 322], ["mice", "SPECIES", 556, 560], ["S. pneumoniae", "SPECIES", 599, 612], ["mice", "SPECIES", 739, 743], ["mice", "SPECIES", 810, 814], ["S. pneumoniae", "SPECIES", 888, 901], ["Staphylococcus aureus", "SPECIES", 915, 936], ["the increased concentration of C1q", "PROBLEM", 14, 48], ["complement C1q and C4", "PROBLEM", 141, 162], ["splenic lipid rafts", "TREATMENT", 166, 185], ["S. pneumoniae challenge", "TREATMENT", 215, 238], ["sucrose gradient ultracentrifugation", "TREATMENT", 346, 382], ["C1q", "TEST", 421, 424], ["C4", "TEST", 426, 428], ["flotilin", "TEST", 430, 438], ["IgM", "TEST", 506, 509], ["MBL", "TEST", 511, 514], ["C", "PROBLEM", 515, 516], ["factor B.", "PROBLEM", 521, 530], ["wild-type mice", "TREATMENT", 546, 560], ["live S. pneumoniae", "PROBLEM", 594, 612], ["IgM", "TEST", 685, 688], ["MBL", "TEST", 690, 693], ["SIGN", "TEST", 728, 732], ["serotype 14 S. pneumoniae", "PROBLEM", 876, 901], ["Staphylococcus aureus", "PROBLEM", 915, 936], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["concentration", "OBSERVATION_MODIFIER", 28, 41], ["Predominant", "OBSERVATION_MODIFIER", 113, 124], ["distribution", "OBSERVATION_MODIFIER", 125, 137], ["C4", "ANATOMY_MODIFIER", 160, 162], ["splenic", "ANATOMY", 166, 173], ["lipid rafts", "OBSERVATION", 174, 185], ["pneumoniae", "OBSERVATION", 218, 228], ["Spleens", "ANATOMY", 280, 287], ["livers", "ANATOMY", 289, 295], ["lungs", "ANATOMY", 301, 306], ["pneumoniae", "OBSERVATION", 602, 612], ["splenic", "ANATOMY", 759, 766], ["Staphylococcus aureus", "OBSERVATION", 915, 936]]], ["5 Dominant C3 activation in splenic lipid rafts in a SIGN-R1-dependent manner following S. pneumoniae challenge in vivo. a Spleens, livers, and lungs of control mice were fractionated with sucrose gradient ultracentrifugation, and fractions were immunoblotted for C3. b As in a, but wild-type mice were injected intravenously with PBS or live S. pneumoniae (Pn14; 1 \u00d7 10 8 , 1 h). c As in a, b, but SIGN-R1-KO mice were used, and splenic fractions were analyzed. d, e As in c, but mice were injected intravenously with an unencapsulated mutant of serotype 14 S. pneumoniae (mt-Pn14) or Staphylococcus aureus (1 \u00d7 10 8 , 1 h). f As in c, but CVF-treated mice were used, and splenic fractions were immunoblotted for C3, SIGN-R1, C1q, and C4. g DCEK_WT and DCEK_SIGN-R1 were incubated with mitomycin C-treated S. pneumoniae type 14 (MitC-Pn14; 1 \u00d7 10 7 , 1 h) without or with 5% NMS in TC buffer for 15 min at 37\u00b0C. Cells were immunostained for C4 or C3 with their respective isotype control IgGs and assessed by FACS. h As in g, but the binding of C4 (red) or C3 (green) was assessed by fluorescence microscopy after fixing DCEK-SIGN-R1 transfectants with 1% paraformaldehyde.", [["splenic lipid rafts", "ANATOMY", 28, 47], ["Spleens", "ANATOMY", 123, 130], ["livers", "ANATOMY", 132, 138], ["lungs", "ANATOMY", 144, 149], ["intravenously", "ANATOMY", 312, 325], ["splenic fractions", "ANATOMY", 430, 447], ["intravenously", "ANATOMY", 500, 513], ["splenic fractions", "ANATOMY", 673, 690], ["Cells", "ANATOMY", 913, 918], ["sucrose", "CHEMICAL", 189, 196], ["Staphylococcus aureus", "DISEASE", 586, 607], ["mitomycin C", "CHEMICAL", 787, 798], ["MitC-Pn14", "CHEMICAL", 830, 839], ["NMS", "DISEASE", 876, 879], ["sucrose", "CHEMICAL", 189, 196], ["mitomycin C", "CHEMICAL", 787, 798], ["paraformaldehyde", "CHEMICAL", 1157, 1173], ["C3", "GENE_OR_GENE_PRODUCT", 11, 13], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 53, 60], ["S. pneumoniae", "ORGANISM", 88, 101], ["livers", "ORGAN", 132, 138], ["lungs", "ORGAN", 144, 149], ["mice", "ORGANISM", 161, 165], ["sucrose", "SIMPLE_CHEMICAL", 189, 196], ["C3", "GENE_OR_GENE_PRODUCT", 264, 266], ["mice", "ORGANISM", 293, 297], ["S. pneumoniae", "ORGANISM", 343, 356], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 399, 406], ["mice", "ORGANISM", 410, 414], ["splenic fractions", "MULTI-TISSUE_STRUCTURE", 430, 447], ["c", "GENE_OR_GENE_PRODUCT", 474, 475], ["mice", "ORGANISM", 481, 485], ["serotype 14", "ORGANISM", 547, 558], ["S. pneumoniae", "ORGANISM", 559, 572], ["mt-Pn14", "ORGANISM", 574, 581], ["Staphylococcus aureus", "ORGANISM", 586, 607], ["CVF", "GENE_OR_GENE_PRODUCT", 641, 644], ["mice", "ORGANISM", 653, 657], ["C3", "GENE_OR_GENE_PRODUCT", 714, 716], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 718, 725], ["C1q", "GENE_OR_GENE_PRODUCT", 727, 730], ["C4", "GENE_OR_GENE_PRODUCT", 736, 738], ["DCEK_SIGN-R1", "CELL", 754, 766], ["mitomycin C", "SIMPLE_CHEMICAL", 787, 798], ["S. pneumoniae type 14", "ORGANISM", 807, 828], ["TC", "SIMPLE_CHEMICAL", 883, 885], ["Cells", "CELL", 913, 918], ["C4", "GENE_OR_GENE_PRODUCT", 942, 944], ["C3", "GENE_OR_GENE_PRODUCT", 948, 950], ["IgGs", "GENE_OR_GENE_PRODUCT", 989, 993], ["C4 (red)", "GENE_OR_GENE_PRODUCT", 1046, 1054], ["C3", "GENE_OR_GENE_PRODUCT", 1058, 1060], ["paraformaldehyde", "SIMPLE_CHEMICAL", 1157, 1173], ["C3", "PROTEIN", 11, 13], ["C3", "PROTEIN", 264, 266], ["SIGN", "PROTEIN", 399, 403], ["R1", "PROTEIN", 404, 406], ["CVF", "PROTEIN", 641, 644], ["C3", "PROTEIN", 714, 716], ["SIGN", "PROTEIN", 718, 722], ["R1", "PROTEIN", 723, 725], ["C1q", "PROTEIN", 727, 730], ["C4", "PROTEIN", 736, 738], ["DCEK_WT and DCEK_SIGN-R1", "DNA", 742, 766], ["C4", "PROTEIN", 942, 944], ["C3", "PROTEIN", 948, 950], ["isotype control IgGs", "PROTEIN", 973, 993], ["C4", "PROTEIN", 1046, 1048], ["red", "PROTEIN", 1050, 1053], ["C3", "PROTEIN", 1058, 1060], ["DCEK", "PROTEIN", 1122, 1126], ["SIGN", "PROTEIN", 1127, 1131], ["S. pneumoniae", "SPECIES", 88, 101], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 293, 297], ["S. pneumoniae", "SPECIES", 343, 356], ["mice", "SPECIES", 410, 414], ["mice", "SPECIES", 481, 485], ["S. pneumoniae", "SPECIES", 559, 572], ["Staphylococcus aureus", "SPECIES", 586, 607], ["mice", "SPECIES", 653, 657], ["S. pneumoniae", "SPECIES", 807, 820], ["S. pneumoniae", "SPECIES", 88, 101], ["mice", "SPECIES", 161, 165], ["mice", "SPECIES", 293, 297], ["S. pneumoniae", "SPECIES", 343, 356], ["mice", "SPECIES", 410, 414], ["mice", "SPECIES", 481, 485], ["S. pneumoniae", "SPECIES", 559, 572], ["Staphylococcus aureus", "SPECIES", 586, 607], ["mice", "SPECIES", 653, 657], ["S. pneumoniae", "SPECIES", 807, 820], ["Dominant C3 activation", "PROBLEM", 2, 24], ["splenic lipid rafts", "TREATMENT", 28, 47], ["S. pneumoniae challenge", "TREATMENT", 88, 111], ["sucrose gradient ultracentrifugation", "TREATMENT", 189, 225], ["C3", "PROBLEM", 264, 266], ["wild-type mice", "TREATMENT", 283, 297], ["PBS", "TREATMENT", 331, 334], ["live S. pneumoniae", "PROBLEM", 338, 356], ["SIGN", "TEST", 399, 403], ["serotype 14 S. pneumoniae", "PROBLEM", 547, 572], ["Staphylococcus aureus", "PROBLEM", 586, 607], ["CVF", "TEST", 641, 644], ["splenic fractions", "TEST", 673, 690], ["C3, SIGN-R1, C1q, and C4", "PROBLEM", 714, 738], ["DCEK_SIGN", "TEST", 754, 763], ["mitomycin C", "TREATMENT", 787, 798], ["S. pneumoniae type", "TEST", 807, 825], ["MitC", "TEST", 830, 834], ["5% NMS in TC buffer", "TREATMENT", 873, 892], ["Cells", "TEST", 913, 918], ["C4 or C3", "PROBLEM", 942, 950], ["their respective isotype control IgGs", "TREATMENT", 956, 993], ["fluorescence microscopy", "TEST", 1085, 1108], ["DCEK", "TEST", 1122, 1126], ["R1 transfectants", "TREATMENT", 1132, 1148], ["1% paraformaldehyde", "TREATMENT", 1154, 1173], ["Dominant", "OBSERVATION_MODIFIER", 2, 10], ["C3 activation", "OBSERVATION", 11, 24], ["splenic", "ANATOMY", 28, 35], ["lipid rafts", "OBSERVATION", 36, 47], ["pneumoniae", "OBSERVATION", 91, 101], ["Spleens", "ANATOMY", 123, 130], ["livers", "ANATOMY", 132, 138], ["lungs", "ANATOMY", 144, 149], ["pneumoniae", "OBSERVATION", 346, 356], ["splenic", "ANATOMY", 430, 437], ["Staphylococcus aureus", "OBSERVATION", 586, 607], ["splenic", "ANATOMY", 673, 680], ["R1", "ANATOMY_MODIFIER", 723, 725], ["C4", "ANATOMY_MODIFIER", 736, 738], ["C4", "ANATOMY", 1046, 1048], ["C3", "ANATOMY", 1058, 1060]]], ["Arrowheads indicate colocalization of C4 and C3.", [["Arrowheads", "CELLULAR_COMPONENT", 0, 10], ["C4", "CELLULAR_COMPONENT", 38, 40], ["C3", "GENE_OR_GENE_PRODUCT", 45, 47], ["C4", "PROTEIN", 38, 40], ["C3", "PROTEIN", 45, 47], ["colocalization of C4 and C3", "PROBLEM", 20, 47], ["colocalization", "OBSERVATION", 20, 34], ["C4", "ANATOMY_MODIFIER", 38, 40], ["C3", "ANATOMY_MODIFIER", 45, 47]]], ["Representative cells are shown in the box.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["Representative cells", "PROBLEM", 0, 20]]], ["Scale bars h, 10 \u00b5m S. pneumoniae and led to the formation of a membrane attack complex on S. pneumoniae (Fig. 6b) .", [["membrane", "ANATOMY", 64, 72], ["S. pneumoniae", "ORGANISM", 20, 33], ["membrane", "CELLULAR_COMPONENT", 64, 72], ["S. pneumoniae", "ORGANISM", 91, 104], ["membrane attack complex", "PROTEIN", 64, 87], ["S. pneumoniae", "SPECIES", 20, 33], ["S. pneumoniae", "SPECIES", 91, 104], ["S. pneumoniae", "SPECIES", 20, 33], ["S. pneumoniae", "SPECIES", 91, 104], ["pneumoniae", "PROBLEM", 23, 33], ["a membrane attack complex", "PROBLEM", 62, 87], ["S. pneumoniae", "PROBLEM", 91, 104], ["pneumoniae", "OBSERVATION", 23, 33], ["membrane attack", "OBSERVATION", 64, 79], ["pneumoniae", "OBSERVATION", 94, 104]]], ["Because the same amount of \u03b2C3 was used for fixation, the same amount of C3 was fixed on S. pneumoniae under all conditions.", [["\u03b2C3", "CHEMICAL", 27, 30], ["\u03b2C3", "GENE_OR_GENE_PRODUCT", 27, 30], ["C3", "GENE_OR_GENE_PRODUCT", 73, 75], ["S. pneumoniae", "ORGANISM", 89, 102], ["\u03b2C3", "PROTEIN", 27, 30], ["C3", "PROTEIN", 73, 75], ["S. pneumoniae", "SPECIES", 89, 102], ["S. pneumoniae", "SPECIES", 89, 102], ["fixation", "TREATMENT", 44, 52], ["S. pneumoniae", "PROBLEM", 89, 102], ["C3", "OBSERVATION_MODIFIER", 73, 75], ["pneumoniae", "OBSERVATION", 92, 102]]], ["However, C3 activation was dominant only with the addition of SIGN-R1, demonstrating the degradation of \u03b1C3 and increased fixation of small iC3b (43 kDa; Fig. 6c) .ResultsWith the addition of C1q or normal human serum (NHS) as a source of C1q, pneumococcal binding was increased only on SIGN-R1 transfectants (Fig. 6d) .", [["serum", "ANATOMY", 212, 217], ["SIGN-R1", "CHEMICAL", 62, 69], ["C3", "GENE_OR_GENE_PRODUCT", 9, 11], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 62, 69], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 104, 107], ["iC3b", "GENE_OR_GENE_PRODUCT", 140, 144], ["C1q", "GENE_OR_GENE_PRODUCT", 192, 195], ["human", "ORGANISM", 206, 211], ["serum", "ORGANISM_SUBSTANCE", 212, 217], ["NHS", "SIMPLE_CHEMICAL", 219, 222], ["C1q", "GENE_OR_GENE_PRODUCT", 239, 242], ["SIGN-R1 transfectants", "CELL", 287, 308], ["C3", "PROTEIN", 9, 11], ["SIGN", "PROTEIN", 62, 66], ["\u03b1C3", "PROTEIN", 104, 107], ["iC3b", "PROTEIN", 140, 144], ["Fig. 6c", "PROTEIN", 154, 161], ["C1q", "PROTEIN", 192, 195], ["C1q", "PROTEIN", 239, 242], ["SIGN-R1 transfectants", "CELL_LINE", 287, 308], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 206, 211], ["pneumococcal", "SPECIES", 244, 256], ["the degradation of \u03b1C3", "PROBLEM", 85, 107], ["increased fixation of small iC3b", "TREATMENT", 112, 144], ["C1q", "PROBLEM", 239, 242], ["pneumococcal binding", "PROBLEM", 244, 264], ["increased", "OBSERVATION_MODIFIER", 112, 121], ["fixation", "OBSERVATION", 122, 130], ["small", "OBSERVATION_MODIFIER", 134, 139]]], ["Moreover, pneumococcal uptake and sequential decomposition were observed on SIGN-R1 transfectants only with normal mouse serum (NMS), but not without serum or with C3-or C1q-depleted sera ( Fig. 6e and Supplementary Fig. S6a ).", [["transfectants", "ANATOMY", 84, 97], ["serum", "ANATOMY", 121, 126], ["serum", "ANATOMY", 150, 155], ["sera", "ANATOMY", 183, 187], ["NMS", "DISEASE", 128, 131], ["SIGN-R1 transfectants", "CELL", 76, 97], ["mouse", "ORGANISM", 115, 120], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["serum", "ORGANISM_SUBSTANCE", 150, 155], ["C3", "GENE_OR_GENE_PRODUCT", 164, 166], ["C1q", "GENE_OR_GENE_PRODUCT", 170, 173], ["sera", "ORGANISM_SUBSTANCE", 183, 187], ["S6a", "GENE_OR_GENE_PRODUCT", 221, 224], ["SIGN-R1 transfectants", "CELL_LINE", 76, 97], ["C3", "PROTEIN", 164, 166], ["C1q", "PROTEIN", 170, 173], ["mouse", "SPECIES", 115, 120], ["pneumococcal", "SPECIES", 10, 22], ["mouse", "SPECIES", 115, 120], ["pneumococcal uptake", "PROBLEM", 10, 29], ["sequential decomposition", "TEST", 34, 58], ["SIGN-R1 transfectants", "TEST", 76, 97], ["serum", "TEST", 150, 155], ["C3", "TEST", 164, 166], ["C1q", "TEST", 170, 173], ["pneumococcal uptake", "OBSERVATION", 10, 29]]], ["After intravenous injection of S. pneumoniae into WT, SIGN-R1-KO, or C3-KO mice, pneumococcal uptake and cytoplasmic decomposition were obvious only on splenic MZ SIGN-R1 + macrophages from control mice ( Fig. 6f and Supplementary Fig. S6b ), but completely abolished in splenic MZs from SIGN-R1-KO and C3-KO mice and red pulp from all mice (Fig. 6f) .", [["intravenous", "ANATOMY", 6, 17], ["cytoplasmic", "ANATOMY", 105, 116], ["splenic MZ SIGN-R1 + macrophages", "ANATOMY", 152, 184], ["splenic MZs", "ANATOMY", 271, 282], ["red pulp", "ANATOMY", 318, 326], ["MZ", "CHEMICAL", 160, 162], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 6, 17], ["S. pneumoniae", "ORGANISM", 31, 44], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 54, 61], ["C3", "GENE_OR_GENE_PRODUCT", 69, 71], ["cytoplasmic", "ORGANISM_SUBSTANCE", 105, 116], ["splenic MZ SIGN-R1 + macrophages", "CELL", 152, 184], ["mice", "ORGANISM", 198, 202], ["splenic MZs", "CANCER", 271, 282], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 288, 295], ["C3-KO mice", "ORGANISM", 303, 313], ["red pulp", "TISSUE", 318, 326], ["mice", "ORGANISM", 336, 340], ["SIGN", "PROTEIN", 54, 58], ["C3", "PROTEIN", 69, 71], ["splenic MZ SIGN-R1", "CELL_LINE", 152, 170], ["macrophages", "CELL_TYPE", 173, 184], ["splenic MZs", "CELL_TYPE", 271, 282], ["C3", "PROTEIN", 303, 305], ["S. pneumoniae", "SPECIES", 31, 44], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 309, 313], ["mice", "SPECIES", 336, 340], ["S. pneumoniae", "SPECIES", 31, 44], ["mice", "SPECIES", 75, 79], ["pneumococcal", "SPECIES", 81, 93], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 309, 313], ["mice", "SPECIES", 336, 340], ["intravenous injection", "TREATMENT", 6, 27], ["S. pneumoniae", "PROBLEM", 31, 44], ["WT", "TEST", 50, 52], ["SIGN", "TEST", 54, 58], ["C3", "TEST", 69, 71], ["pneumococcal uptake", "PROBLEM", 81, 100], ["cytoplasmic decomposition", "TEST", 105, 130], ["splenic MZ SIGN", "TEST", 152, 167], ["macrophages", "PROBLEM", 173, 184], ["mice ( Fig. 6f", "TREATMENT", 198, 212], ["Supplementary Fig. S6b", "TREATMENT", 217, 239], ["SIGN", "TEST", 288, 292], ["pneumococcal uptake", "OBSERVATION", 81, 100], ["cytoplasmic decomposition", "OBSERVATION", 105, 130], ["splenic", "ANATOMY", 152, 159], ["splenic", "ANATOMY", 271, 278], ["pulp", "ANATOMY", 322, 326]]], ["The signal specificity of CPS14 on splenic MZ SIGN-R1 + macrophages of control mice in Fig. 6f was confirmed by immunostaining with its respective isotype control immunoglobulins (Supplementary Fig. S6c ).ResultsDC-SIGN may mediate the classical complement pathway in LRs from splenic MZ DC-SIGN + macrophages following S. pneumoniae challenge via interactions with C1qResultsWhen DC-SIGN transfectants were treated with S. pneumoniae, DC-SIGN aggregates were dramatically increased on the cell surface (Fig. 7a) .", [["splenic MZ SIGN-R1 + macrophages", "ANATOMY", 35, 67], ["splenic MZ DC-SIGN + macrophages", "ANATOMY", 277, 309], ["DC-SIGN transfectants", "ANATOMY", 381, 402], ["DC", "ANATOMY", 436, 438], ["cell surface", "ANATOMY", 490, 502], ["MZ", "CHEMICAL", 43, 45], ["MZ", "CHEMICAL", 285, 287], ["CPS14", "SIMPLE_CHEMICAL", 26, 31], ["splenic MZ SIGN-R1 + macrophages", "CELL", 35, 67], ["mice", "ORGANISM", 79, 83], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 163, 178], ["ResultsDC-SIGN", "GENE_OR_GENE_PRODUCT", 205, 219], ["splenic MZ DC-SIGN + macrophages", "CELL", 277, 309], ["S. pneumoniae", "ORGANISM", 320, 333], ["C1qResults", "GENE_OR_GENE_PRODUCT", 366, 376], ["DC-SIGN transfectants", "CELL", 381, 402], ["S. pneumoniae", "ORGANISM", 421, 434], ["SIGN", "GENE_OR_GENE_PRODUCT", 439, 443], ["cell surface", "CELLULAR_COMPONENT", 490, 502], ["CPS14", "PROTEIN", 26, 31], ["splenic MZ SIGN-R1", "CELL_LINE", 35, 53], ["macrophages", "CELL_TYPE", 56, 67], ["isotype control immunoglobulins", "PROTEIN", 147, 178], ["Supplementary Fig. S6c", "PROTEIN", 180, 202], ["ResultsDC", "PROTEIN", 205, 214], ["SIGN", "PROTEIN", 215, 219], ["splenic MZ DC", "CELL_TYPE", 277, 290], ["SIGN", "CELL_TYPE", 291, 295], ["macrophages", "CELL_TYPE", 298, 309], ["C1qResults", "PROTEIN", 366, 376], ["DC", "CELL_TYPE", 381, 383], ["SIGN transfectants", "CELL_LINE", 384, 402], ["DC", "CELL_TYPE", 436, 438], ["mice", "SPECIES", 79, 83], ["S. pneumoniae", "SPECIES", 320, 333], ["S. pneumoniae", "SPECIES", 421, 434], ["mice", "SPECIES", 79, 83], ["S. pneumoniae", "SPECIES", 320, 333], ["S. pneumoniae", "SPECIES", 421, 434], ["The signal specificity", "TEST", 0, 22], ["CPS14", "TEST", 26, 31], ["splenic MZ SIGN", "TEST", 35, 50], ["its respective isotype control immunoglobulins", "TREATMENT", 132, 178], ["splenic MZ DC", "TREATMENT", 277, 290], ["macrophages", "PROBLEM", 298, 309], ["S. pneumoniae challenge", "TREATMENT", 320, 343], ["SIGN transfectants", "PROBLEM", 384, 402], ["S. pneumoniae", "PROBLEM", 421, 434], ["splenic", "ANATOMY", 35, 42], ["splenic", "ANATOMY", 277, 284], ["pneumoniae", "OBSERVATION", 424, 434], ["dramatically", "OBSERVATION_MODIFIER", 460, 472], ["increased", "OBSERVATION_MODIFIER", 473, 482]]], ["Additionally, when LR fractions of these cells were immunoblotted for DC-SIGN, monomers and dimers of DC-SIGN were obviously increased in LRs following S. pneumoniae challenge (Fig. 7b) .", [["cells", "ANATOMY", 41, 46], ["DC", "ANATOMY", 70, 72], ["DC", "ANATOMY", 102, 104], ["cells", "CELL", 41, 46], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 70, 77], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 102, 109], ["S. pneumoniae", "ORGANISM", 152, 165], ["DC", "CELL_TYPE", 70, 72], ["SIGN", "PROTEIN", 73, 77], ["DC", "CELL_TYPE", 102, 104], ["SIGN", "PROTEIN", 105, 109], ["S. pneumoniae", "SPECIES", 152, 165], ["S. pneumoniae", "SPECIES", 152, 165], ["LR fractions", "TREATMENT", 19, 31], ["these cells", "PROBLEM", 35, 46], ["S. pneumoniae challenge", "PROBLEM", 152, 175]]], ["Moreover, splenic MZ DC-SIGN + macrophages from DC-SIGN BMT /SIGN-R1 TKO mice recovered the rapid recognition of S. pneumoniae on splenic MZs, even at 15 min and 1 h after intravenous injection of the organisms (Fig. 7c) .", [["splenic MZ DC-SIGN + macrophages", "ANATOMY", 10, 42], ["DC", "ANATOMY", 48, 50], ["splenic MZs", "ANATOMY", 130, 141], ["intravenous", "ANATOMY", 172, 183], ["MZ", "CHEMICAL", 18, 20], ["splenic MZ DC-SIGN + macrophages", "CELL", 10, 42], ["DC-SIGN", "CELL", 48, 55], ["SIGN-R1 TKO mice", "ORGANISM", 61, 77], ["S. pneumoniae", "ORGANISM", 113, 126], ["splenic MZs", "MULTI-TISSUE_STRUCTURE", 130, 141], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 172, 183], ["splenic MZ DC", "CELL_TYPE", 10, 23], ["SIGN", "CELL_TYPE", 24, 28], ["macrophages", "CELL_TYPE", 31, 42], ["DC", "CELL_TYPE", 48, 50], ["splenic MZs", "CELL_TYPE", 130, 141], ["mice", "SPECIES", 73, 77], ["S. pneumoniae", "SPECIES", 113, 126], ["mice", "SPECIES", 73, 77], ["S. pneumoniae", "SPECIES", 113, 126], ["splenic MZ DC", "TEST", 10, 23], ["macrophages", "PROBLEM", 31, 42], ["DC", "TEST", 48, 50], ["SIGN BMT", "TEST", 51, 59], ["SIGN", "TEST", 61, 65], ["S. pneumoniae", "PROBLEM", 113, 126], ["splenic MZs", "TREATMENT", 130, 141], ["splenic", "ANATOMY", 10, 17], ["MZ", "OBSERVATION", 18, 20], ["macrophages", "OBSERVATION", 31, 42], ["pneumoniae", "OBSERVATION", 116, 126], ["splenic", "ANATOMY", 130, 137]]], ["In spleens at 1 h, DC-SIGN monomers and multimers were obviously upregulated only in splenic LRs following S. pneumoniae challenge (Fig. 7d) .ResultsDC-SIGN bound well to purified human C1q or human C1q from NHS (Fig. 7e) .", [["spleens", "ANATOMY", 3, 10], ["DC", "ANATOMY", 19, 21], ["splenic LRs", "ANATOMY", 85, 96], ["spleens", "ORGAN", 3, 10], ["SIGN", "GENE_OR_GENE_PRODUCT", 22, 26], ["multimers", "GENE_OR_GENE_PRODUCT", 40, 49], ["S. pneumoniae", "ORGANISM", 107, 120], ["ResultsDC-SIGN", "GENE_OR_GENE_PRODUCT", 142, 156], ["human", "ORGANISM", 180, 185], ["C1q", "GENE_OR_GENE_PRODUCT", 186, 189], ["human", "ORGANISM", 193, 198], ["C1q", "GENE_OR_GENE_PRODUCT", 199, 202], ["DC", "CELL_TYPE", 19, 21], ["SIGN monomers", "PROTEIN", 22, 35], ["ResultsDC", "PROTEIN", 142, 151], ["SIGN", "PROTEIN", 152, 156], ["purified human C1q", "PROTEIN", 171, 189], ["human C1q", "PROTEIN", 193, 202], ["S. pneumoniae", "SPECIES", 107, 120], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 193, 198], ["S. pneumoniae", "SPECIES", 107, 120], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 193, 198], ["DC-SIGN monomers", "TREATMENT", 19, 35], ["splenic LRs", "TREATMENT", 85, 96], ["S. pneumoniae challenge", "TREATMENT", 107, 130], ["SIGN bound", "PROBLEM", 152, 162], ["spleens", "ANATOMY", 3, 10], ["splenic", "ANATOMY", 85, 92], ["pneumoniae", "OBSERVATION", 110, 120]]], ["Additionally, DC-SIGN binding to mouse C1q from NMS was confirmed by immunoblotting and immunostaining ( Fig. 7e and Supplementary Fig. S7a) .", [["DC", "ANATOMY", 14, 16], ["NMS", "DISEASE", 48, 51], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 14, 21], ["mouse", "ORGANISM", 33, 38], ["C1q", "GENE_OR_GENE_PRODUCT", 39, 42], ["S7a", "GENE_OR_GENE_PRODUCT", 136, 139], ["DC", "CELL_TYPE", 14, 16], ["SIGN", "PROTEIN", 17, 21], ["mouse C1q", "PROTEIN", 33, 42], ["mouse", "SPECIES", 33, 38], ["mouse", "SPECIES", 33, 38], ["NMS", "PROBLEM", 48, 51], ["immunoblotting", "TEST", 69, 83], ["immunostaining", "TEST", 88, 102]]], ["We then examined whether DC-SIGN bound directly to C4, similar to SIGN-R1 39 ( Supplementary Fig. S4a ).", [["DC", "ANATOMY", 25, 27], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 25, 32], ["S4a", "GENE_OR_GENE_PRODUCT", 98, 101], ["DC", "CELL_TYPE", 25, 27], ["SIGN", "PROTEIN", 28, 32], ["C4", "PROTEIN", 51, 53], ["SIGN", "DNA", 66, 70], ["R1 39", "DNA", 71, 76], ["SIGN", "TEST", 66, 70], ["C4", "ANATOMY", 51, 53]]], ["DC-SIGN transfectants showed clear fixation of C4 (Fig. 7f) .", [["DC-SIGN transfectants", "ANATOMY", 0, 21], ["DC", "CELL_TYPE", 0, 2], ["SIGN transfectants", "CELL_LINE", 3, 21], ["C4", "PROTEIN", 47, 49], ["SIGN transfectants", "TEST", 3, 21], ["clear fixation of C4", "PROBLEM", 29, 49], ["clear fixation", "OBSERVATION", 29, 43], ["C4", "ANATOMY_MODIFIER", 47, 49]]], ["Additionally, DC-SIGN-transfected HEK293T cells also induced the fixation of C1q or C4 from NHS, confirming again the binding of DC-SIGN to C1q and C4 (Fig. 7g) , and their fixation was significantly increased following S. pneumoniae challenge (Fig. 7g) .ResultsIn splenic fractions from DC-SIGN BMT /SIGN-R1 TKO mice, upregulation of C1q and C4 was obvious following S. pneumoniae challenge (Fig. 7h) .", [["DC", "ANATOMY", 14, 16], ["HEK293T cells", "ANATOMY", 34, 47], ["DC", "ANATOMY", 129, 131], ["splenic fractions", "ANATOMY", 265, 282], ["DC", "ANATOMY", 288, 290], ["DC-SIGN", "CELL", 14, 21], ["HEK293T cells", "CELL", 34, 47], ["C1q", "GENE_OR_GENE_PRODUCT", 77, 80], ["C4", "GENE_OR_GENE_PRODUCT", 84, 86], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 129, 136], ["C1q", "GENE_OR_GENE_PRODUCT", 140, 143], ["C4", "GENE_OR_GENE_PRODUCT", 148, 150], ["S. pneumoniae", "ORGANISM", 220, 233], ["DC-SIGN", "CELL", 288, 295], ["SIGN-R1 TKO mice", "ORGANISM", 301, 317], ["C1q", "GENE_OR_GENE_PRODUCT", 335, 338], ["C4", "GENE_OR_GENE_PRODUCT", 343, 345], ["S. pneumoniae", "ORGANISM", 368, 381], ["DC-SIGN-transfected HEK293T cells", "CELL_LINE", 14, 47], ["C1q", "PROTEIN", 77, 80], ["C4", "PROTEIN", 84, 86], ["DC", "CELL_TYPE", 129, 131], ["SIGN", "PROTEIN", 132, 136], ["C1q", "PROTEIN", 140, 143], ["C4", "PROTEIN", 148, 150], ["Fig. 7g", "PROTEIN", 152, 159], ["DC", "CELL_TYPE", 288, 290], ["C1q", "PROTEIN", 335, 338], ["C4", "PROTEIN", 343, 345], ["S. pneumoniae", "SPECIES", 220, 233], ["mice", "SPECIES", 313, 317], ["S. pneumoniae", "SPECIES", 368, 381], ["S. pneumoniae", "SPECIES", 220, 233], ["mice", "SPECIES", 313, 317], ["S. pneumoniae", "SPECIES", 368, 381], ["the fixation of C1q", "TREATMENT", 61, 80], ["their fixation", "TREATMENT", 167, 181], ["S. pneumoniae challenge", "TREATMENT", 220, 243], ["SIGN", "TEST", 301, 305], ["upregulation of C1q and C4", "PROBLEM", 319, 345], ["S. pneumoniae challenge", "PROBLEM", 368, 391], ["fixation", "OBSERVATION", 65, 73], ["pneumoniae", "OBSERVATION", 223, 233], ["splenic", "ANATOMY", 265, 272], ["C4", "ANATOMY", 343, 345], ["pneumoniae", "OBSERVATION", 371, 381]]], ["Moreover, after intravenous injection of S. pneumoniae into DC-SIGN BMT / SIGN-R1 TKO mice, systemic C3 activation reappeared in SIGN-R1 TKO mice as in control mice, demonstrating gradual decrease in \u03b1C3 and larger iC3b and a rapid increase and sequential decrease in small iC3b (Fig. 7i) .", [["intravenous", "ANATOMY", 16, 27], ["DC", "ANATOMY", 60, 62], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 27], ["S. pneumoniae", "ORGANISM", 41, 54], ["DC-SIGN", "CELL", 60, 67], ["SIGN-R1 TKO mice", "ORGANISM", 74, 90], ["C3", "GENE_OR_GENE_PRODUCT", 101, 103], ["SIGN-R1 TKO", "ORGANISM", 129, 140], ["mice", "ORGANISM", 141, 145], ["mice", "ORGANISM", 160, 164], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 200, 203], ["iC3b", "GENE_OR_GENE_PRODUCT", 215, 219], ["iC3b", "GENE_OR_GENE_PRODUCT", 274, 278], ["DC", "CELL_TYPE", 60, 62], ["C3", "PROTEIN", 101, 103], ["\u03b1C3", "PROTEIN", 200, 203], ["iC3b", "PROTEIN", 215, 219], ["iC3b", "PROTEIN", 274, 278], ["S. pneumoniae", "SPECIES", 41, 54], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 141, 145], ["mice", "SPECIES", 160, 164], ["S. pneumoniae", "SPECIES", 41, 54], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 160, 164], ["S. pneumoniae", "PROBLEM", 41, 54], ["SIGN", "TEST", 74, 78], ["systemic C3 activation", "TEST", 92, 114], ["SIGN", "TEST", 129, 133], ["gradual decrease in \u03b1C3 and larger iC3b", "PROBLEM", 180, 219], ["a rapid increase", "PROBLEM", 224, 240], ["sequential decrease in small iC3b", "PROBLEM", 245, 278], ["gradual", "OBSERVATION_MODIFIER", 180, 187], ["decrease", "OBSERVATION_MODIFIER", 188, 196], ["larger", "OBSERVATION_MODIFIER", 208, 214], ["iC3b", "OBSERVATION", 215, 219], ["rapid", "OBSERVATION_MODIFIER", 226, 231], ["increase", "OBSERVATION_MODIFIER", 232, 240], ["decrease", "OBSERVATION_MODIFIER", 256, 264], ["small", "OBSERVATION_MODIFIER", 268, 273], ["iC3b", "OBSERVATION", 274, 278]]], ["C3 fixation was also completely recovered around splenic MZ DC-SIGN + macrophages in DC-SIGN BMT /SIGN-R1 TKO mice from SIGN-R1-KO or SIGN-R1 TKO mice as in control mice ( Fig. 7j and Supplementary Fig. S7b ), occurring rapidly within 15 min after challenge with S. pneumoniae and disappearing at 4 h ( Supplementary Fig. S7c ).", [["splenic MZ DC-SIGN + macrophages", "ANATOMY", 49, 81], ["DC", "ANATOMY", 85, 87], ["MZ", "CHEMICAL", 57, 59], ["C3", "GENE_OR_GENE_PRODUCT", 0, 2], ["splenic MZ DC-SIGN + macrophages", "CELL", 49, 81], ["DC-SIGN", "CELL", 85, 92], ["SIGN-R1 TKO mice", "ORGANISM", 98, 114], ["SIGN-R1-KO", "ORGANISM", 120, 130], ["SIGN-R1 TKO mice", "ORGANISM", 134, 150], ["mice", "ORGANISM", 165, 169], ["S. pneumoniae", "ORGANISM", 263, 276], ["splenic MZ DC", "CELL_TYPE", 49, 62], ["SIGN", "CELL_TYPE", 63, 67], ["macrophages", "CELL_TYPE", 70, 81], ["DC", "CELL_TYPE", 85, 87], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 146, 150], ["mice", "SPECIES", 165, 169], ["S. pneumoniae", "SPECIES", 263, 276], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 165, 169], ["S. pneumoniae", "SPECIES", 263, 276], ["C3 fixation", "TREATMENT", 0, 11], ["macrophages", "PROBLEM", 70, 81], ["SIGN", "TEST", 120, 124], ["SIGN", "TEST", 134, 138], ["S. pneumoniae", "PROBLEM", 263, 276], ["fixation", "OBSERVATION", 3, 11], ["splenic", "ANATOMY", 49, 56], ["pneumoniae", "OBSERVATION", 266, 276]]], ["Immunostaining with isotype control IgG for anti-C3 antibodies did not yield a C3 signal ( Supplementary Fig. S7d) .", [["IgG", "GENE_OR_GENE_PRODUCT", 36, 39], ["anti-C3", "GENE_OR_GENE_PRODUCT", 44, 51], ["isotype control IgG", "PROTEIN", 20, 39], ["anti-C3 antibodies", "PROTEIN", 44, 62], ["C3", "PROTEIN", 79, 81], ["Immunostaining", "TEST", 0, 14], ["isotype control IgG", "TEST", 20, 39], ["anti-C3 antibodies", "TEST", 44, 62]]], ["Moreover, immunoblotting of cadaver spleens for C1q, C4, and C3 revealed expression in human splenic LRs, with predominant expression of C1q and 104-kDa \u03b1C3\u2032 rather than 113-kDa \u03b1C3 (Fig. 7k and Supplementary Fig. S7e ).DiscussionAlthough DC-SIGN and SIGN-R1 professionally recognize and remove S. pneumonia 35, 41 , the disruption of LRs on both lectin transfectants resulted in serious impairment of the uptake and sequential decomposition of the organism.", [["spleens", "ANATOMY", 36, 43], ["splenic LRs", "ANATOMY", 93, 104], ["pneumonia", "DISEASE", 298, 307], ["cadaver spleens", "ORGANISM", 28, 43], ["C1q", "GENE_OR_GENE_PRODUCT", 48, 51], ["C4", "GENE_OR_GENE_PRODUCT", 53, 55], ["C3", "GENE_OR_GENE_PRODUCT", 61, 63], ["human", "ORGANISM", 87, 92], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 93, 104], ["C1q", "GENE_OR_GENE_PRODUCT", 137, 140], ["S7e", "GENE_OR_GENE_PRODUCT", 214, 217], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 251, 258], ["lectin", "GENE_OR_GENE_PRODUCT", 347, 353], ["C1q", "PROTEIN", 48, 51], ["C4", "PROTEIN", 53, 55], ["C3", "PROTEIN", 61, 63], ["C1q", "PROTEIN", 137, 140], ["\u03b1C3", "PROTEIN", 178, 181], ["S7e", "PROTEIN", 214, 217], ["DC", "CELL_TYPE", 239, 241], ["SIGN", "DNA", 242, 246], ["SIGN", "DNA", 251, 255], ["R1", "DNA", 256, 258], ["human", "SPECIES", 87, 92], ["S. pneumonia", "SPECIES", 295, 307], ["human", "SPECIES", 87, 92], ["immunoblotting of cadaver spleens", "TEST", 10, 43], ["C1q, C4, and C3", "TEST", 48, 63], ["C1q", "TEST", 137, 140], ["S. pneumonia", "PROBLEM", 295, 307], ["both lectin transfectants", "TREATMENT", 342, 367], ["serious impairment", "PROBLEM", 380, 398], ["the uptake", "PROBLEM", 402, 412], ["sequential decomposition of the organism", "PROBLEM", 417, 457], ["human splenic", "ANATOMY", 87, 100], ["pneumonia", "OBSERVATION", 298, 307], ["serious", "OBSERVATION_MODIFIER", 380, 387]]], ["Because the disruption of LRs did not alter the expression levels of both lectins on the respective transfectants, which would lead to normal binding of the organism to the cell surface, the structure of LRs may be more important for the function of both lectins and for removal of S. pneumoniae than previously thought.", [["transfectants", "ANATOMY", 100, 113], ["cell surface", "ANATOMY", 173, 185], ["lectins", "GENE_OR_GENE_PRODUCT", 74, 81], ["transfectants", "CELL", 100, 113], ["cell surface", "CELLULAR_COMPONENT", 173, 185], ["LRs", "GENE_OR_GENE_PRODUCT", 204, 207], ["lectins", "GENE_OR_GENE_PRODUCT", 255, 262], ["S. pneumoniae", "ORGANISM", 282, 295], ["lectins", "PROTEIN", 74, 81], ["LRs", "PROTEIN", 204, 207], ["lectins", "PROTEIN", 255, 262], ["S. pneumoniae", "SPECIES", 282, 295], ["S. pneumoniae", "SPECIES", 282, 295], ["the disruption of LRs", "PROBLEM", 8, 29], ["removal", "TREATMENT", 271, 278], ["S. pneumoniae", "PROBLEM", 282, 295], ["pneumoniae", "OBSERVATION", 285, 295]]], ["This (see figure on previous page) Fig. 6 SIGN-R1-mediated C3 activation and opsonization of S. pneumoniae enhances the uptake and decomposition of the bacteria by SIGN-R1 + cells in vitro and in vivo. a Live S. pneumoniae type 14 (Pn14) was incubated with 5% NHS at 37\u00b0C for 30 min in the presence of 10 \u03bcg bovine serum albumin, transferrin (Tfe), or purified SIGN-R1, immunostained for C1q, and analyzed by FACS. b As in a, but 10 \u03bcg Tfe or C1q was used, and organisms were immunostained for C1q, iC3b, or membrane attack complex (MAC). c As in a, but organisms were immunoblotted for C3. d In total, 1 \u00d7 10 8 mitomycin C-treated and PKH26-labeled S. pneumoniae (PKH26-MitC-Pn14) were incubated with CHO transfectants in the presence of 10 \u03bcg C1q or 5% NHS.", [["SIGN-R1 + cells", "ANATOMY", 164, 179], ["serum", "ANATOMY", 315, 320], ["membrane", "ANATOMY", 508, 516], ["CHO transfectants", "ANATOMY", 702, 719], ["mitomycin C", "CHEMICAL", 612, 623], ["PKH26", "CHEMICAL", 636, 641], ["mitomycin C", "CHEMICAL", 612, 623], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 42, 49], ["C3", "GENE_OR_GENE_PRODUCT", 59, 61], ["S. pneumoniae", "ORGANISM", 93, 106], ["SIGN-R1 + cells", "CELL", 164, 179], ["Live S. pneumoniae type 14", "ORGANISM", 204, 230], ["Pn14", "ORGANISM", 232, 236], ["NHS", "SIMPLE_CHEMICAL", 260, 263], ["bovine", "ORGANISM", 308, 314], ["serum", "ORGANISM_SUBSTANCE", 315, 320], ["albumin", "GENE_OR_GENE_PRODUCT", 321, 328], ["transferrin", "GENE_OR_GENE_PRODUCT", 330, 341], ["Tfe", "GENE_OR_GENE_PRODUCT", 343, 346], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 361, 368], ["C1q", "GENE_OR_GENE_PRODUCT", 388, 391], ["Tfe", "GENE_OR_GENE_PRODUCT", 436, 439], ["C1q", "GENE_OR_GENE_PRODUCT", 443, 446], ["C1q", "GENE_OR_GENE_PRODUCT", 494, 497], ["iC3b", "GENE_OR_GENE_PRODUCT", 499, 503], ["membrane attack complex", "GENE_OR_GENE_PRODUCT", 508, 531], ["C3", "GENE_OR_GENE_PRODUCT", 587, 589], ["mitomycin C", "SIMPLE_CHEMICAL", 612, 623], ["PKH26", "SIMPLE_CHEMICAL", 636, 641], ["S. pneumoniae", "ORGANISM", 650, 663], ["PKH26-MitC-Pn14", "CELL", 665, 680], ["CHO transfectants", "CELL", 702, 719], ["C1q", "GENE_OR_GENE_PRODUCT", 745, 748], ["NHS", "SIMPLE_CHEMICAL", 755, 758], ["C3", "PROTEIN", 59, 61], ["SIGN-R1 + cells", "CELL_LINE", 164, 179], ["transferrin", "PROTEIN", 330, 341], ["Tfe", "PROTEIN", 343, 346], ["SIGN", "PROTEIN", 361, 365], ["R1", "PROTEIN", 366, 368], ["C1q", "PROTEIN", 388, 391], ["Tfe", "PROTEIN", 436, 439], ["C1q", "PROTEIN", 443, 446], ["C1q", "PROTEIN", 494, 497], ["iC3b", "PROTEIN", 499, 503], ["membrane attack complex", "PROTEIN", 508, 531], ["MAC", "PROTEIN", 533, 536], ["C3", "PROTEIN", 587, 589], ["MitC", "PROTEIN", 671, 675], ["Pn14", "PROTEIN", 676, 680], ["CHO transfectants", "CELL_LINE", 702, 719], ["C1q", "PROTEIN", 745, 748], ["S. pneumoniae", "SPECIES", 93, 106], ["S. pneumoniae", "SPECIES", 209, 222], ["bovine", "SPECIES", 308, 314], ["S. pneumoniae", "SPECIES", 650, 663], ["S. pneumoniae", "SPECIES", 93, 106], ["S. pneumoniae", "SPECIES", 209, 222], ["bovine", "SPECIES", 308, 314], ["S. pneumoniae", "SPECIES", 650, 663], ["SIGN", "TEST", 42, 46], ["C3 activation", "PROBLEM", 59, 72], ["S. pneumoniae", "PROBLEM", 93, 106], ["the uptake", "PROBLEM", 116, 126], ["the bacteria", "PROBLEM", 148, 160], ["10 \u03bcg bovine serum albumin", "TREATMENT", 302, 328], ["organisms", "PROBLEM", 461, 470], ["C1q", "PROBLEM", 494, 497], ["organisms", "PROBLEM", 554, 563], ["C3", "PROBLEM", 587, 589], ["mitomycin C", "TREATMENT", 612, 623], ["PKH26", "TEST", 636, 641], ["S. pneumoniae", "PROBLEM", 650, 663], ["PKH26", "TEST", 665, 670], ["CHO transfectants", "TREATMENT", 702, 719], ["pneumoniae", "OBSERVATION", 96, 106], ["pneumoniae", "OBSERVATION", 212, 222], ["pneumoniae", "OBSERVATION", 653, 663]]], ["The binding of organisms to cells was assessed by FACS. e DCEK_SIGN transfectants were incubated with MitC-Pn14 (1 \u00d7 10 6 , 15 h, 37\u00b0C) without or with mouse sera (NMS or C3-or C1q-depleted mouse sera), and cells were immunostained for SIGN-R1 (green) or CPS14 (red), followed by microscopic analysis.", [["cells", "ANATOMY", 28, 33], ["transfectants", "ANATOMY", 68, 81], ["sera", "ANATOMY", 158, 162], ["sera", "ANATOMY", 196, 200], ["cells", "ANATOMY", 207, 212], ["MitC-Pn14", "CHEMICAL", 102, 111], ["MitC-Pn14", "CHEMICAL", 102, 111], ["cells", "CELL", 28, 33], ["DCEK_SIGN transfectants", "CELL", 58, 81], ["mouse", "ORGANISM", 152, 157], ["sera", "ORGANISM_SUBSTANCE", 158, 162], ["C3", "GENE_OR_GENE_PRODUCT", 171, 173], ["C1q", "GENE_OR_GENE_PRODUCT", 177, 180], ["mouse", "ORGANISM", 190, 195], ["sera", "ORGANISM_SUBSTANCE", 196, 200], ["cells", "CELL", 207, 212], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 236, 243], ["green)", "GENE_OR_GENE_PRODUCT", 245, 251], ["CPS14", "SIMPLE_CHEMICAL", 255, 260], ["DCEK_SIGN transfectants", "CELL_LINE", 58, 81], ["MitC", "PROTEIN", 102, 106], ["C3", "PROTEIN", 171, 173], ["C1q", "PROTEIN", 177, 180], ["SIGN", "PROTEIN", 236, 240], ["R1", "PROTEIN", 241, 243], ["CPS14", "PROTEIN", 255, 260], ["mouse", "SPECIES", 152, 157], ["mouse", "SPECIES", 190, 195], ["mouse", "SPECIES", 152, 157], ["mouse", "SPECIES", 190, 195], ["MitC", "TEST", 102, 106], ["mouse sera", "TEST", 152, 162], ["NMS", "TEST", 164, 167], ["C3", "TEST", 171, 173], ["C1q", "TEST", 177, 180], ["cells", "TEST", 207, 212], ["SIGN", "TEST", 236, 240], ["CPS14", "TEST", 255, 260], ["microscopic analysis", "TEST", 280, 300]]], ["Representative cells are shown in the boxes. f CFSE-MitC-Pn14 (1 \u00d7 10 8 , green) were injected intravenously into control, SIGN-R1-KO, or C3-KO mice for 1 h and spleen sections were immunostained for SIGN-R1 (blue) and CPS14 (red).", [["cells", "ANATOMY", 15, 20], ["intravenously", "ANATOMY", 95, 108], ["spleen sections", "ANATOMY", 161, 176], ["CFSE", "CHEMICAL", 47, 51], ["CFSE-MitC-Pn14", "CHEMICAL", 47, 61], ["cells", "CELL", 15, 20], ["CFSE", "SIMPLE_CHEMICAL", 47, 51], ["SIGN-R1-KO", "ORGANISM", 123, 133], ["C3-KO mice", "ORGANISM", 138, 148], ["spleen sections", "MULTI-TISSUE_STRUCTURE", 161, 176], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 200, 207], ["blue", "GENE_OR_GENE_PRODUCT", 209, 213], ["CPS14", "GENE_OR_GENE_PRODUCT", 219, 224], ["C3", "PROTEIN", 138, 140], ["SIGN", "PROTEIN", 200, 204], ["R1", "PROTEIN", 205, 207], ["CPS14", "PROTEIN", 219, 224], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 144, 148], ["Representative cells", "PROBLEM", 0, 20], ["CFSE", "TEST", 47, 51], ["MitC", "TEST", 52, 56], ["SIGN", "TEST", 123, 127], ["C3", "TEST", 138, 140], ["spleen sections", "TEST", 161, 176], ["SIGN", "TEST", 200, 204], ["CPS14", "TEST", 219, 224], ["spleen", "ANATOMY", 161, 167]]], ["Representative areas in splenic MZs are highlighted in the boxes (middle row).", [["splenic MZs", "ANATOMY", 24, 35], ["splenic MZs", "CANCER", 24, 35], ["Representative areas in splenic MZs", "PROBLEM", 0, 35], ["areas", "OBSERVATION_MODIFIER", 15, 20], ["splenic", "ANATOMY", 24, 31], ["MZs", "ANATOMY_MODIFIER", 32, 35], ["middle", "ANATOMY_MODIFIER", 66, 72]]], ["Organisms captured in the red pulp (arrowheads) are highlighted (bottom row).", [["red pulp", "ANATOMY", 26, 34], ["pulp", "TISSUE", 30, 34], ["Organisms", "PROBLEM", 0, 9], ["red pulp", "ANATOMY", 26, 34]]], ["First, multimers of DC-SIGN or SIGN-R1 were preformed in LRs of the respective transfectants, and even SIGN-R1 multimers were preformed in splenic LRs.", [["DC", "ANATOMY", 20, 22], ["transfectants", "ANATOMY", 79, 92], ["splenic LRs", "ANATOMY", 139, 150], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 20, 27], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 31, 38], ["transfectants", "CELL", 79, 92], ["SIGN-R1 multimers", "GENE_OR_GENE_PRODUCT", 103, 120], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 139, 150], ["DC", "CELL_TYPE", 20, 22], ["SIGN", "PROTEIN", 23, 27], ["SIGN", "PROTEIN", 31, 35], ["R1", "DNA", 36, 38], ["SIGN", "PROTEIN", 103, 107], ["R1 multimers", "PROTEIN", 108, 120], ["splenic", "ANATOMY", 139, 146]]], ["Additionally, DC-SIGN and SIGN-R1 multimers were increased only in LRs following S. pneumoniae challenge in vitro or in vivo, but not in non-LRs.", [["DC", "ANATOMY", 14, 16], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 14, 21], ["SIGN-R1 multimers", "GENE_OR_GENE_PRODUCT", 26, 43], ["S. pneumoniae", "ORGANISM", 81, 94], ["DC", "CELL_TYPE", 14, 16], ["SIGN", "PROTEIN", 17, 21], ["SIGN", "PROTEIN", 26, 30], ["R1 multimers", "PROTEIN", 31, 43], ["S. pneumoniae", "SPECIES", 81, 94], ["S. pneumoniae", "SPECIES", 81, 94], ["SIGN-R1 multimers", "TREATMENT", 26, 43], ["S. pneumoniae challenge", "PROBLEM", 81, 104], ["pneumoniae", "OBSERVATION", 84, 94]]], ["Therefore, LRs could provide a spatially confined and optimal platform for DC-SIGN and SIGN-R1 to facilitate clustering, increase their affinity and specificity to pathogens, and enhance their clearance, thus affecting their innate protective functions 7, 45 .DiscussionRaft locations for target antigens favor classical complement activation by concentrating the antigen-antibody complex into a comparatively small area, thus providing an ideal density for juxtaposed Fc regions to engage C1q 46, 47 .", [["DC", "ANATOMY", 75, 77], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 87, 94], ["C1q", "GENE_OR_GENE_PRODUCT", 490, 493], ["DC", "CELL_TYPE", 75, 77], ["SIGN", "PROTEIN", 78, 82], ["SIGN", "PROTEIN", 87, 91], ["R1", "PROTEIN", 92, 94], ["target antigens", "PROTEIN", 289, 304], ["antigen-antibody complex", "PROTEIN", 364, 388], ["Fc regions", "PROTEIN", 469, 479], ["C1q 46, 47", "PROTEIN", 490, 500], ["pathogens", "PROBLEM", 164, 173], ["target antigens", "PROBLEM", 289, 304], ["classical complement activation", "PROBLEM", 311, 342], ["the antigen", "TEST", 360, 371]]], ["Similarly, both C1q and C4 were exclusively distributed in splenic LRs among fractions from examined mouse tissues, showing a significant dependence on the existence of SIGN-R1.", [["splenic LRs", "ANATOMY", 59, 70], ["fractions", "ANATOMY", 77, 86], ["tissues", "ANATOMY", 107, 114], ["C1q", "GENE_OR_GENE_PRODUCT", 16, 19], ["C4", "GENE_OR_GENE_PRODUCT", 24, 26], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 59, 70], ["mouse", "ORGANISM", 101, 106], ["tissues", "TISSUE", 107, 114], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 169, 176], ["C1q", "PROTEIN", 16, 19], ["C4", "PROTEIN", 24, 26], ["SIGN", "PROTEIN", 169, 173], ["R1", "DNA", 174, 176], ["mouse", "SPECIES", 101, 106], ["mouse", "SPECIES", 101, 106], ["a significant dependence", "PROBLEM", 124, 148], ["both", "ANATOMY_MODIFIER", 11, 15], ["C1q", "ANATOMY_MODIFIER", 16, 19], ["C4", "ANATOMY_MODIFIER", 24, 26], ["splenic", "ANATOMY", 59, 66], ["mouse tissues", "OBSERVATION", 101, 114], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["dependence", "OBSERVATION", 138, 148]]], ["SIGN-R1 was exclusively expressed on splenic MZ macrophages 42 and bound directly to C1q or C4 39, 48 .", [["splenic MZ macrophages", "ANATOMY", 37, 59], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 0, 7], ["splenic MZ macrophages 42", "CELL", 37, 62], ["C1q", "GENE_OR_GENE_PRODUCT", 85, 88], ["SIGN", "PROTEIN", 0, 4], ["R1", "DNA", 5, 7], ["splenic MZ macrophages 42", "CELL_LINE", 37, 62], ["C1q", "PROTEIN", 85, 88], ["splenic MZ macrophages", "TEST", 37, 59], ["splenic", "ANATOMY", 37, 44], ["MZ macrophages", "OBSERVATION", 45, 59], ["C4", "ANATOMY_MODIFIER", 92, 94]]], ["Additionally, there is a potential interaction between C1q and C4 49, 50 .", [["C1q", "GENE_OR_GENE_PRODUCT", 55, 58], ["C1q", "PROTEIN", 55, 58], ["C4", "TEST", 63, 65]]], ["Therefore, their exclusive distribution in splenic LRs is expected, and these proteins may be further subdivided into splenic MZ SIGN-R1 + LRs from heterogeneous LRs of various splenic cells 51 .", [["splenic LRs", "ANATOMY", 43, 54], ["splenic MZ", "ANATOMY", 118, 128], ["splenic cells", "ANATOMY", 177, 190], ["MZ", "CHEMICAL", 126, 128], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 43, 54], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 129, 136], ["splenic cells", "CELL", 177, 190], ["R1", "PROTEIN", 134, 136], ["splenic cells", "CELL_TYPE", 177, 190], ["splenic LRs", "TEST", 43, 54], ["splenic MZ SIGN", "TEST", 118, 133], ["distribution", "OBSERVATION_MODIFIER", 27, 39], ["splenic", "ANATOMY", 43, 50], ["LRs", "OBSERVATION", 51, 54], ["splenic", "ANATOMY", 118, 125], ["heterogeneous", "OBSERVATION_MODIFIER", 148, 161], ["various", "ANATOMY_MODIFIER", 169, 176], ["splenic", "ANATOMY", 177, 184], ["cells", "OBSERVATION", 185, 190]]], ["These findings suggested that splenic MZ SIGN-R1 + LRs may provide optimal microenvironmental platforms for reciprocal interactions among SIGN-R1, C1q, and C4, thus preforming a trimolecular complex to rapidly activate the SIGN-R1-mediated classical complement pathway in the spleen.DiscussionBecause SIGN-R1 or C1q directly recognize S. pneumoniae 41,52 , the preformed trimolecular complex of SIGN-R1, C1q, and C4 in splenic MZ SIGN-R1 + LRs could accelerate the generation of a classical pathway C3 convertase (C4bC2a), and the resulting abundant C4b and C4bC2a could sequentially promote fixation of C3 on the cell surface [53] [54] [55] [56] .", [["splenic MZ", "ANATOMY", 30, 40], ["spleen", "ANATOMY", 276, 282], ["splenic MZ", "ANATOMY", 419, 429], ["cell surface", "ANATOMY", 614, 626], ["MZ", "CHEMICAL", 38, 40], ["MZ", "CHEMICAL", 427, 429], ["C4bC2a", "CHEMICAL", 558, 564], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 41, 48], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 138, 145], ["C1q", "GENE_OR_GENE_PRODUCT", 147, 150], ["C4", "GENE_OR_GENE_PRODUCT", 156, 158], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 223, 230], ["spleen", "ORGAN", 276, 282], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 301, 308], ["C1q", "GENE_OR_GENE_PRODUCT", 312, 315], ["S. pneumoniae 41,52", "ORGANISM", 335, 354], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 395, 402], ["C1q", "GENE_OR_GENE_PRODUCT", 404, 407], ["C4", "GENE_OR_GENE_PRODUCT", 413, 415], ["C3 convertase", "GENE_OR_GENE_PRODUCT", 499, 512], ["C4bC2a", "GENE_OR_GENE_PRODUCT", 514, 520], ["C4b", "GENE_OR_GENE_PRODUCT", 550, 553], ["C4bC2a", "GENE_OR_GENE_PRODUCT", 558, 564], ["C3", "GENE_OR_GENE_PRODUCT", 604, 606], ["cell", "CELL", 614, 618], ["R1", "PROTEIN", 46, 48], ["SIGN", "PROTEIN", 138, 142], ["R1", "PROTEIN", 143, 145], ["C1q", "PROTEIN", 147, 150], ["C4", "PROTEIN", 156, 158], ["trimolecular complex", "PROTEIN", 178, 198], ["SIGN", "PROTEIN", 223, 227], ["R1", "PROTEIN", 228, 230], ["SIGN", "PROTEIN", 301, 305], ["R1", "DNA", 306, 308], ["C1q", "PROTEIN", 312, 315], ["trimolecular complex", "PROTEIN", 371, 391], ["SIGN", "PROTEIN", 395, 399], ["R1", "PROTEIN", 400, 402], ["C1q", "PROTEIN", 404, 407], ["C4", "PROTEIN", 413, 415], ["R1", "PROTEIN", 435, 437], ["C3 convertase", "PROTEIN", 499, 512], ["C4bC2a", "PROTEIN", 514, 520], ["C4b", "PROTEIN", 550, 553], ["C4bC2a", "PROTEIN", 558, 564], ["C3", "PROTEIN", 604, 606], ["S. pneumoniae", "SPECIES", 335, 348], ["S. pneumoniae", "SPECIES", 335, 348], ["splenic MZ SIGN", "TEST", 30, 45], ["reciprocal interactions among SIGN-R1, C1q, and C4", "PROBLEM", 108, 158], ["S. pneumoniae", "TEST", 335, 348], ["C1q", "TEST", 404, 407], ["splenic MZ SIGN", "TEST", 419, 434], ["LRs", "PROBLEM", 440, 443], ["the resulting abundant C4b", "PROBLEM", 527, 553], ["the cell surface", "TEST", 610, 626], ["splenic", "ANATOMY", 30, 37], ["MZ", "OBSERVATION", 38, 40], ["C4", "ANATOMY_MODIFIER", 156, 158], ["spleen", "ANATOMY", 276, 282], ["pneumoniae", "OBSERVATION", 338, 348], ["C4", "ANATOMY_MODIFIER", 413, 415], ["splenic", "ANATOMY", 419, 426]]], ["Supporting this possibility, C3, particularly C3\u03b1, was most enriched in splenic LRs, despite having lowest expression in the spleen among examined mouse tissues.", [["splenic LRs", "ANATOMY", 72, 83], ["spleen", "ANATOMY", 125, 131], ["tissues", "ANATOMY", 153, 160], ["C3", "GENE_OR_GENE_PRODUCT", 29, 31], ["C3\u03b1", "GENE_OR_GENE_PRODUCT", 46, 49], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 72, 83], ["spleen", "ORGAN", 125, 131], ["mouse", "ORGANISM", 147, 152], ["tissues", "TISSUE", 153, 160], ["C3", "PROTEIN", 29, 31], ["C3\u03b1", "PROTEIN", 46, 49], ["mouse", "SPECIES", 147, 152], ["mouse", "SPECIES", 147, 152], ["lowest expression in the spleen", "PROBLEM", 100, 131], ["splenic", "ANATOMY", 72, 79], ["lowest expression", "OBSERVATION", 100, 117], ["spleen", "ANATOMY", 125, 131], ["mouse tissues", "OBSERVATION", 147, 160]]], ["Therefore, splenic MZ SIGN-R1 + LRs may be optimized to activate C3, although the C3 distribution was independent of the existence of SIGN-R1, probably due to covalent fixation of C3 fragments on other splenic cells 57 .", [["splenic MZ", "ANATOMY", 11, 21], ["fragments", "ANATOMY", 183, 192], ["splenic cells", "ANATOMY", 202, 215], ["MZ", "CHEMICAL", 19, 21], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 22, 29], ["C3", "GENE_OR_GENE_PRODUCT", 65, 67], ["C3", "GENE_OR_GENE_PRODUCT", 82, 84], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 134, 141], ["C3", "GENE_OR_GENE_PRODUCT", 180, 182], ["splenic cells", "CELL", 202, 215], ["C3", "PROTEIN", 65, 67], ["C3", "PROTEIN", 82, 84], ["SIGN", "PROTEIN", 134, 138], ["R1", "PROTEIN", 139, 141], ["C3 fragments", "PROTEIN", 180, 192], ["splenic cells", "CELL_TYPE", 202, 215], ["splenic MZ SIGN", "TEST", 11, 26], ["LRs", "PROBLEM", 32, 35], ["SIGN-R1", "PROBLEM", 134, 141], ["covalent fixation", "TREATMENT", 159, 176], ["C3 fragments", "PROBLEM", 180, 192], ["splenic", "ANATOMY", 11, 18], ["MZ", "OBSERVATION", 19, 21], ["probably due to", "UNCERTAINTY", 143, 158], ["covalent fixation", "OBSERVATION", 159, 176], ["C3 fragments", "OBSERVATION", 180, 192], ["splenic", "ANATOMY", 202, 209]]], ["Because the complement system should be tightly controlled under physiological conditions to prevent significant damage to self-tissues, enrichment of SIGN-R1, C1q, C4, and C3 in splenic MZ SIGN-R1 + LRs could also precisely regulate complement activation in splenic MZs; indeed, nascent C3b and C4 regulate C1 activation in concert with C3 under normal conditions 58 .DiscussionPneumococcal challenge increased both C1q and C4 and activated C3 only in splenic MZ SIGN-R1 + LRs without the involvement of other complement pathways.", [["self-tissues", "ANATOMY", 123, 135], ["splenic MZ", "ANATOMY", 179, 189], ["splenic MZs", "ANATOMY", 259, 270], ["splenic MZ", "ANATOMY", 453, 463], ["MZ", "CHEMICAL", 187, 189], ["MZ", "CHEMICAL", 461, 463], ["tissues", "TISSUE", 128, 135], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 151, 158], ["C1q", "GENE_OR_GENE_PRODUCT", 160, 163], ["C4", "GENE_OR_GENE_PRODUCT", 165, 167], ["C3", "GENE_OR_GENE_PRODUCT", 173, 175], ["SIGN-R1 + LRs", "GENE_OR_GENE_PRODUCT", 190, 203], ["splenic MZs", "CANCER", 259, 270], ["C3b", "GENE_OR_GENE_PRODUCT", 288, 291], ["C4", "GENE_OR_GENE_PRODUCT", 296, 298], ["C1", "GENE_OR_GENE_PRODUCT", 308, 310], ["C1q", "GENE_OR_GENE_PRODUCT", 417, 420], ["C4", "GENE_OR_GENE_PRODUCT", 425, 427], ["C3", "GENE_OR_GENE_PRODUCT", 442, 444], ["splenic MZ SIGN-R1", "CELL", 453, 471], ["SIGN", "PROTEIN", 151, 155], ["R1", "PROTEIN", 156, 158], ["C1q", "PROTEIN", 160, 163], ["C4", "PROTEIN", 165, 167], ["C3", "PROTEIN", 173, 175], ["splenic MZs", "CELL_TYPE", 259, 270], ["C3b", "PROTEIN", 288, 291], ["C4", "PROTEIN", 296, 298], ["C1", "PROTEIN", 308, 310], ["C3", "PROTEIN", 338, 340], ["C1q", "PROTEIN", 417, 420], ["C4", "PROTEIN", 425, 427], ["C3", "PROTEIN", 442, 444], ["significant damage to self-tissues", "PROBLEM", 101, 135], ["SIGN", "TEST", 151, 155], ["C1q", "TEST", 160, 163], ["splenic MZ SIGN", "TEST", 179, 194], ["splenic MZs", "PROBLEM", 259, 270], ["Pneumococcal challenge", "TEST", 379, 401], ["splenic MZ SIGN", "TEST", 453, 468], ["LRs", "PROBLEM", 474, 477], ["C4", "ANATOMY", 165, 167], ["C3", "ANATOMY", 173, 175], ["splenic", "ANATOMY", 179, 186], ["splenic", "ANATOMY", 259, 266], ["splenic", "ANATOMY", 453, 460]]], ["Therefore, splenic MZ SIGN-R1 + LRs may provide optimal locations for SIGN-R1-mediated C3 activation to accelerate pneumococcal clearance by sequentially enhancing pneumococcal iC3b opsonization and rapid phagocytosis primarily in splenic MZ SIGN-R1 + macrophages.", [["splenic MZ", "ANATOMY", 11, 21], ["splenic MZ SIGN-R1 + macrophages", "ANATOMY", 231, 263], ["MZ", "CHEMICAL", 19, 21], ["MZ", "CHEMICAL", 239, 241], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 22, 29], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 70, 77], ["C3", "GENE_OR_GENE_PRODUCT", 87, 89], ["pneumococcal", "ORGANISM", 115, 127], ["iC3b", "GENE_OR_GENE_PRODUCT", 177, 181], ["splenic MZ SIGN-R1 + macrophages", "CELL", 231, 263], ["SIGN", "PROTEIN", 70, 74], ["C3", "PROTEIN", 87, 89], ["pneumococcal iC3b", "PROTEIN", 164, 181], ["splenic MZ SIGN-R1 + macrophages", "CELL_LINE", 231, 263], ["pneumococcal", "SPECIES", 115, 127], ["pneumococcal", "SPECIES", 164, 176], ["splenic MZ SIGN", "TEST", 11, 26], ["SIGN", "TEST", 70, 74], ["C3 activation", "PROBLEM", 87, 100], ["accelerate pneumococcal clearance", "PROBLEM", 104, 137], ["sequentially enhancing pneumococcal iC3b opsonization", "TEST", 141, 194], ["rapid phagocytosis", "PROBLEM", 199, 217], ["splenic MZ SIGN", "TEST", 231, 246], ["macrophages", "PROBLEM", 252, 263], ["splenic", "ANATOMY", 11, 18], ["MZ", "OBSERVATION", 19, 21], ["pneumococcal", "OBSERVATION", 115, 127], ["pneumococcal", "OBSERVATION_MODIFIER", 164, 176], ["iC3b opsonization", "OBSERVATION", 177, 194], ["rapid phagocytosis", "OBSERVATION", 199, 217], ["splenic", "ANATOMY", 231, 238], ["macrophages", "ANATOMY", 252, 263]]], ["In particular, S. pneumoniae capsules inhibit its recognition by natural IgM, the binding of the serum proteins to subcapsular targets, complement activity, and neutrophil phagocytosis 59, 60 .", [["serum", "ANATOMY", 97, 102], ["subcapsular", "ANATOMY", 115, 126], ["neutrophil", "ANATOMY", 161, 171], ["S. pneumoniae capsules", "ORGANISM", 15, 37], ["IgM", "GENE_OR_GENE_PRODUCT", 73, 76], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["neutrophil", "CELL", 161, 171], ["natural IgM", "PROTEIN", 65, 76], ["serum proteins", "PROTEIN", 97, 111], ["neutrophil", "CELL_TYPE", 161, 171], ["S. pneumoniae", "SPECIES", 15, 28], ["S. pneumoniae", "SPECIES", 15, 28], ["S. pneumoniae capsules", "PROBLEM", 15, 37], ["natural IgM", "TEST", 65, 76], ["the serum proteins", "TEST", 93, 111], ["subcapsular targets", "TEST", 115, 134], ["complement activity", "TEST", 136, 155], ["neutrophil phagocytosis", "TEST", 161, 184], ["pneumoniae", "OBSERVATION", 18, 28], ["natural IgM", "OBSERVATION", 65, 76], ["neutrophil phagocytosis", "OBSERVATION", 161, 184]]], ["However, enrichment of SIGN-R1, C1q, C4, and C3 in splenic MZ SIGN-R1 + LRs could dramatically enhance the simultaneous recognition of pneumococcal CPSs with SIGN-R1 and C1q, thus overcoming impairment of the initial pneumococcal recognition 61 .DiscussionThe human spleen and the classical pathway are integral for protection against infection by S. pneumoniae 39, [62] [63] [64] [65] .Discussion(see figure on previous page) Fig. 7 DC-SIGN in splenic lipid rafts may mediate the classical complement pathway in response to S. pneumoniae challenge by interacting with C1q and C4. a DCEK_DC-SIGN transfectants were incubated with mitomycin C-treated S. pneumoniae type 14 (MitC-Pn14; 1 \u00d7 10 6 , 15 min, 37\u00b0C) and immunostained for DC-SIGN without permeabilization.", [["splenic MZ", "ANATOMY", 51, 61], ["spleen", "ANATOMY", 266, 272], ["splenic lipid rafts", "ANATOMY", 445, 464], ["DC", "ANATOMY", 731, 733], ["MZ", "CHEMICAL", 59, 61], ["infection", "DISEASE", 335, 344], ["mitomycin C", "CHEMICAL", 630, 641], ["mitomycin C", "CHEMICAL", 630, 641], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 23, 30], ["C1q", "GENE_OR_GENE_PRODUCT", 32, 35], ["C4", "GENE_OR_GENE_PRODUCT", 37, 39], ["C3", "GENE_OR_GENE_PRODUCT", 45, 47], ["pneumococcal", "ORGANISM", 135, 147], ["CPSs", "PATHOLOGICAL_FORMATION", 148, 152], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 158, 165], ["C1q", "GENE_OR_GENE_PRODUCT", 170, 173], ["human", "ORGANISM", 260, 265], ["spleen", "ORGAN", 266, 272], ["S. pneumoniae", "ORGANISM", 348, 361], ["39", "ORGANISM", 362, 364], ["[62] [63", "SIMPLE_CHEMICAL", 366, 374], ["S. pneumoniae", "ORGANISM", 525, 538], ["C1q", "GENE_OR_GENE_PRODUCT", 569, 572], ["C4", "GENE_OR_GENE_PRODUCT", 577, 579], ["DCEK_DC-SIGN transfectants", "CELL", 583, 609], ["mitomycin C", "SIMPLE_CHEMICAL", 630, 641], ["S. pneumoniae type 14", "ORGANISM", 650, 671], ["SIGN", "SIMPLE_CHEMICAL", 734, 738], ["SIGN", "PROTEIN", 23, 27], ["R1", "PROTEIN", 28, 30], ["C1q", "PROTEIN", 32, 35], ["C4", "PROTEIN", 37, 39], ["C3", "PROTEIN", 45, 47], ["pneumococcal CPSs", "PROTEIN", 135, 152], ["SIGN", "PROTEIN", 158, 162], ["R1", "PROTEIN", 163, 165], ["C1q", "PROTEIN", 170, 173], ["DC", "CELL_TYPE", 434, 436], ["SIGN", "PROTEIN", 437, 441], ["C1q", "PROTEIN", 569, 572], ["C4", "PROTEIN", 577, 579], ["DCEK_DC-SIGN transfectants", "CELL_LINE", 583, 609], ["DC", "CELL_TYPE", 731, 733], ["SIGN", "PROTEIN", 734, 738], ["human", "SPECIES", 260, 265], ["S. pneumoniae", "SPECIES", 348, 361], ["S. pneumoniae", "SPECIES", 525, 538], ["S. pneumoniae", "SPECIES", 650, 663], ["pneumococcal", "SPECIES", 135, 147], ["pneumococcal", "SPECIES", 217, 229], ["human", "SPECIES", 260, 265], ["S. pneumoniae", "SPECIES", 348, 361], ["S. pneumoniae", "SPECIES", 525, 538], ["S. pneumoniae", "SPECIES", 650, 663], ["SIGN", "TEST", 23, 27], ["C1q", "TEST", 32, 35], ["splenic MZ SIGN", "TEST", 51, 66], ["pneumococcal CPSs", "PROBLEM", 135, 152], ["SIGN-R1 and C1q", "PROBLEM", 158, 173], ["the initial pneumococcal recognition", "TEST", 205, 241], ["infection", "PROBLEM", 335, 344], ["S. pneumoniae", "TEST", 348, 361], ["splenic lipid rafts", "TREATMENT", 445, 464], ["S. pneumoniae challenge", "PROBLEM", 525, 548], ["a DCEK_DC-SIGN transfectants", "TREATMENT", 581, 609], ["mitomycin C", "TREATMENT", 630, 641], ["S. pneumoniae type", "TEST", 650, 668], ["MitC", "TEST", 673, 677], ["permeabilization", "PROBLEM", 747, 763], ["R1", "ANATOMY_MODIFIER", 28, 30], ["C4", "ANATOMY_MODIFIER", 37, 39], ["C3", "ANATOMY_MODIFIER", 45, 47], ["splenic", "ANATOMY", 51, 58], ["MZ", "ANATOMY_MODIFIER", 59, 61], ["pneumococcal CPSs", "OBSERVATION", 135, 152], ["pneumococcal", "OBSERVATION_MODIFIER", 217, 229], ["spleen", "ANATOMY", 266, 272], ["splenic", "ANATOMY", 445, 452], ["lipid rafts", "OBSERVATION", 453, 464], ["pneumoniae", "OBSERVATION", 528, 538], ["C4", "ANATOMY", 577, 579]]], ["A representative cell is shown in the box. b After DCEK_DC-SIGN transfectants were incubated with MitC-Pn14 (1 \u00d7 10 6 , 1 h, 37\u00b0C), lysates were fractionated with sucrose gradient ultracentrifugation, and fractions of LRs were immunoblotted for DC-SIGN, flotilin-1, or caveolin-1. c DC-SIGN BMT /SIGN-R1 TKO mice were injected intravenously with CFSE-labeled MitC-Pn14 (green; 1 \u00d7 10 8 , 15 min or 1 h), and splenic sections were immunostained for DC-SIGN (red). d As in b, but spleens of DC-SIGN BMT /SIGN-R1 TKO mice were used after intravenous injection of live S. pneumoniae (1 \u00d7 10 8 , 1 h). e (Left) Wild-type or DCEK transfectants were incubated with 5 \u03bcg endotoxin-free ovalbumin (efOVA), human C1q, or 3% sera (NMS, NHS, or C1q-depleted human serum) in TC buffer for 1 h at 37\u00b0C, and lysates were immunoblotted for C1q.", [["cell", "ANATOMY", 17, 21], ["DCEK_DC-SIGN transfectants", "ANATOMY", 51, 77], ["lysates", "ANATOMY", 132, 139], ["DC", "ANATOMY", 245, 247], ["DC", "ANATOMY", 283, 285], ["intravenously", "ANATOMY", 327, 340], ["splenic sections", "ANATOMY", 408, 424], ["DC", "ANATOMY", 448, 450], ["spleens", "ANATOMY", 478, 485], ["DC", "ANATOMY", 489, 491], ["intravenous", "ANATOMY", 535, 546], ["DCEK transfectants", "ANATOMY", 619, 637], ["sera", "ANATOMY", 714, 718], ["serum", "ANATOMY", 752, 757], ["lysates", "ANATOMY", 793, 800], ["MitC-Pn14", "CHEMICAL", 98, 107], ["sucrose", "CHEMICAL", 163, 170], ["CFSE", "CHEMICAL", 346, 350], ["MitC-Pn14", "CHEMICAL", 359, 368], ["endotoxin", "CHEMICAL", 663, 672], ["MitC-Pn14", "CHEMICAL", 98, 107], ["sucrose", "CHEMICAL", 163, 170], ["CFSE", "CHEMICAL", 346, 350], ["cell", "CELL", 17, 21], ["DCEK_DC-SIGN transfectants", "CELL", 51, 77], ["MitC-Pn14", "SIMPLE_CHEMICAL", 98, 107], ["lysates", "ORGANISM_SUBSTANCE", 132, 139], ["sucrose", "SIMPLE_CHEMICAL", 163, 170], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 245, 252], ["flotilin-1", "GENE_OR_GENE_PRODUCT", 254, 264], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 269, 279], ["SIGN-R1 TKO", "ORGANISM", 296, 307], ["mice", "ORGANISM", 308, 312], ["CFSE", "SIMPLE_CHEMICAL", 346, 350], ["MitC-Pn14", "SIMPLE_CHEMICAL", 359, 368], ["splenic sections", "MULTI-TISSUE_STRUCTURE", 408, 424], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 448, 455], ["spleens", "ORGAN", 478, 485], ["DC-SIGN BMT", "ORGANISM", 489, 500], ["SIGN-R1 TKO mice", "ORGANISM", 502, 518], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 535, 546], ["S. pneumoniae", "ORGANISM", 565, 578], ["DCEK transfectants", "CELL", 619, 637], ["endotoxin-free ovalbumin", "SIMPLE_CHEMICAL", 663, 687], ["efOVA", "SIMPLE_CHEMICAL", 689, 694], ["human", "ORGANISM", 697, 702], ["C1q", "GENE_OR_GENE_PRODUCT", 703, 706], ["sera", "ORGANISM_SUBSTANCE", 714, 718], ["NMS", "SIMPLE_CHEMICAL", 720, 723], ["NHS", "SIMPLE_CHEMICAL", 725, 728], ["C1q", "GENE_OR_GENE_PRODUCT", 733, 736], ["human", "ORGANISM", 746, 751], ["serum", "ORGANISM_SUBSTANCE", 752, 757], ["TC", "SIMPLE_CHEMICAL", 762, 764], ["lysates", "ORGANISM_SUBSTANCE", 793, 800], ["C1q", "GENE_OR_GENE_PRODUCT", 824, 827], ["DCEK_DC-SIGN transfectants", "CELL_LINE", 51, 77], ["LRs", "PROTEIN", 218, 221], ["DC", "CELL_TYPE", 245, 247], ["SIGN", "PROTEIN", 248, 252], ["flotilin-1", "PROTEIN", 254, 264], ["caveolin-1", "PROTEIN", 269, 279], ["DC", "CELL_TYPE", 448, 450], ["SIGN", "PROTEIN", 451, 455], ["DC", "CELL_TYPE", 489, 491], ["e (Left) Wild-type or DCEK transfectants", "CELL_LINE", 597, 637], ["human C1q", "PROTEIN", 697, 706], ["C1q", "PROTEIN", 733, 736], ["C1q", "PROTEIN", 824, 827], ["mice", "SPECIES", 308, 312], ["mice", "SPECIES", 514, 518], ["S. pneumoniae", "SPECIES", 565, 578], ["human", "SPECIES", 697, 702], ["human", "SPECIES", 746, 751], ["mice", "SPECIES", 308, 312], ["mice", "SPECIES", 514, 518], ["S. pneumoniae", "SPECIES", 565, 578], ["human", "SPECIES", 697, 702], ["human", "SPECIES", 746, 751], ["DCEK_DC", "TEST", 51, 58], ["SIGN transfectants", "TEST", 59, 77], ["MitC", "TEST", 98, 102], ["lysates", "TEST", 132, 139], ["sucrose gradient ultracentrifugation", "TREATMENT", 163, 199], ["LRs", "TEST", 218, 221], ["DC", "TEST", 245, 247], ["flotilin", "TEST", 254, 262], ["CFSE", "TEST", 346, 350], ["MitC", "TEST", 359, 363], ["splenic sections", "TEST", 408, 424], ["R1 TKO mice", "TREATMENT", 507, 518], ["intravenous injection", "TREATMENT", 535, 556], ["pneumoniae", "PROBLEM", 568, 578], ["DCEK transfectants", "TREATMENT", 619, 637], ["5 \u03bcg endotoxin", "TREATMENT", 658, 672], ["free ovalbumin (efOVA", "TREATMENT", 673, 694], ["human C1q", "TREATMENT", 697, 706], ["C1q", "TREATMENT", 733, 736], ["TC buffer", "TREATMENT", 762, 771], ["lysates", "TEST", 793, 800], ["representative cell", "OBSERVATION", 2, 21], ["splenic", "ANATOMY", 408, 415], ["spleens", "ANATOMY", 478, 485], ["pneumoniae", "OBSERVATION", 568, 578], ["Left", "ANATOMY_MODIFIER", 600, 604]]], ["(Right) Wild-type or DCEK_DC-SIGN transfectants were incubated with 3% NMS for 1 h at 37\u00b0C and immunostained for C1q, followed by microscopic analysis.", [["DCEK_DC-SIGN transfectants", "ANATOMY", 21, 47], ["NMS", "DISEASE", 71, 74], ["DCEK_DC-SIGN transfectants", "CELL", 21, 47], ["C", "GENE_OR_GENE_PRODUCT", 89, 90], ["C1q", "GENE_OR_GENE_PRODUCT", 113, 116], ["Right) Wild-type or DCEK_DC-SIGN transfectants", "CELL_LINE", 1, 47], ["C1q", "PROTEIN", 113, 116], ["SIGN transfectants", "PROBLEM", 29, 47], ["microscopic analysis", "TEST", 130, 150], ["Right", "ANATOMY_MODIFIER", 1, 6]]], ["Representative areas are highlighted from low-power images in Figure S7a . f Wild-type or DCEK transfectants were incubated with 5% NMS for 10 min at 37\u00b0C, immunostained for C4 without permeabilization, and analyzed by FACS. g Empty vector or DC-SIGN-transfected HEK293T cells were incubated without or with MitC-Pn14 (1 \u00d7 10 7 ) in the absence or presence of 5% NHS for 15 min at 37\u00b0C, and cell lysates were immunoblotted for DC-SIGN, C1q, C4, and \u03b2-actin. h As in d, but DC-SIGN BMT /SIGN-R1 TKO mice were used, and splenic fractions were immunoblotted for C1q or C4. i Control, SIGN-R1 TKO , and DC-SIGN BMT /SIGN-R1 TKO mice were injected intravenously with Pn14 (1 \u00d7 10 8 ), and their sera were collected at 0, 15, 30, or 60 min and immunoblotted for C3. j As in c, but control, SIGN-R1 KO, SIGN-R1 TKO , and DC-SIGN BMT /SIGN-R1 TKO mice were intravenously injected for 15 min.", [["DCEK transfectants", "ANATOMY", 90, 108], ["DC", "ANATOMY", 243, 245], ["HEK293T cells", "ANATOMY", 263, 276], ["cell lysates", "ANATOMY", 391, 403], ["DC", "ANATOMY", 427, 429], ["DC", "ANATOMY", 473, 475], ["splenic fractions", "ANATOMY", 518, 535], ["DC", "ANATOMY", 599, 601], ["intravenously", "ANATOMY", 643, 656], ["sera", "ANATOMY", 690, 694], ["DC", "ANATOMY", 814, 816], ["NMS", "DISEASE", 132, 135], ["Pn14", "CHEMICAL", 662, 666], ["MitC-Pn14", "CHEMICAL", 308, 317], ["Pn14", "CHEMICAL", 662, 666], ["DCEK transfectants", "CELL", 90, 108], ["DC-SIGN", "CELL", 243, 250], ["HEK293T cells", "CELL", 263, 276], ["NHS", "SIMPLE_CHEMICAL", 363, 366], ["cell lysates", "ORGANISM_SUBSTANCE", 391, 403], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 427, 434], ["C1q", "GENE_OR_GENE_PRODUCT", 436, 439], ["C4", "GENE_OR_GENE_PRODUCT", 441, 443], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 449, 456], ["SIGN-R1 TKO", "ORGANISM", 486, 497], ["mice", "ORGANISM", 498, 502], ["C1q", "GENE_OR_GENE_PRODUCT", 559, 562], ["C4", "GENE_OR_GENE_PRODUCT", 566, 568], ["SIGN-R1 TKO", "CELL", 581, 592], ["DC-SIGN", "CELL", 599, 606], ["SIGN-R1 TKO", "ORGANISM", 612, 623], ["mice", "ORGANISM", 624, 628], ["sera", "ORGANISM_SUBSTANCE", 690, 694], ["C3", "GENE_OR_GENE_PRODUCT", 756, 758], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 784, 791], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 796, 803], ["DC-SIGN BMT", "ORGANISM", 814, 825], ["SIGN-R1 TKO mice", "ORGANISM", 827, 843], ["Wild-type or DCEK transfectants", "CELL_LINE", 77, 108], ["C4", "PROTEIN", 174, 176], ["DC-SIGN-transfected HEK293T cells", "CELL_LINE", 243, 276], ["DC", "CELL_TYPE", 427, 429], ["SIGN", "PROTEIN", 430, 434], ["C1q", "PROTEIN", 436, 439], ["C4", "PROTEIN", 441, 443], ["\u03b2-actin", "PROTEIN", 449, 456], ["DC", "CELL_TYPE", 473, 475], ["C1q", "PROTEIN", 559, 562], ["C4", "PROTEIN", 566, 568], ["DC", "CELL_TYPE", 599, 601], ["C3", "PROTEIN", 756, 758], ["SIGN", "PROTEIN", 784, 788], ["SIGN-R1 TKO", "CELL_LINE", 796, 807], ["DC", "CELL_TYPE", 814, 816], ["mice", "SPECIES", 498, 502], ["mice", "SPECIES", 624, 628], ["mice", "SPECIES", 839, 843], ["mice", "SPECIES", 498, 502], ["mice", "SPECIES", 624, 628], ["mice", "SPECIES", 839, 843], ["DCEK transfectants", "TREATMENT", 90, 108], ["5% NMS", "TREATMENT", 129, 135], ["permeabilization", "PROBLEM", 185, 201], ["MitC", "TEST", 308, 312], ["cell lysates", "TEST", 391, 403], ["DC", "TEST", 427, 429], ["C1q", "TEST", 436, 439], ["\u03b2-actin", "TREATMENT", 449, 456], ["splenic fractions", "TEST", 518, 535], ["C1q or C4", "PROBLEM", 559, 568], ["Pn14", "TREATMENT", 662, 666], ["their sera", "TEST", 684, 694], ["SIGN", "TEST", 796, 800], ["DC", "TEST", 814, 816], ["low", "OBSERVATION_MODIFIER", 42, 45], ["C4", "ANATOMY", 441, 443], ["splenic", "ANATOMY", 518, 525], ["C4", "ANATOMY_MODIFIER", 566, 568]]], ["Splenic sections were immunostained for C3 (red) and SIGN-R1 (green) or C3 (red) and DC-SIGN (green).", [["Splenic sections", "ANATOMY", 0, 16], ["DC", "ANATOMY", 85, 87], ["Splenic sections", "MULTI-TISSUE_STRUCTURE", 0, 16], ["C3", "GENE_OR_GENE_PRODUCT", 40, 42], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 53, 60], ["green)", "GENE_OR_GENE_PRODUCT", 62, 68], ["C3", "GENE_OR_GENE_PRODUCT", 72, 74], ["DC-SIGN", "SIMPLE_CHEMICAL", 85, 92], ["C3", "PROTEIN", 40, 42], ["red", "PROTEIN", 44, 47], ["SIGN", "PROTEIN", 53, 57], ["R1", "PROTEIN", 58, 60], ["C3", "PROTEIN", 72, 74], ["red", "PROTEIN", 76, 79], ["DC", "CELL_TYPE", 85, 87], ["SIGN", "PROTEIN", 88, 92], ["Splenic sections", "TEST", 0, 16], ["C3", "TEST", 40, 42], ["SIGN", "TEST", 53, 57], ["C3", "ANATOMY", 72, 74]]], ["Representative areas are highlighted from low-power images in Figure S7b . k As in h, but spleens of cadavers were used and immunoblotted for C1q, C4, and C3.", [["spleens", "ANATOMY", 90, 97], ["cadavers", "ANATOMY", 101, 109], ["spleens", "ORGAN", 90, 97], ["cadavers", "ORGAN", 101, 109], ["C1q", "GENE_OR_GENE_PRODUCT", 142, 145], ["C4", "GENE_OR_GENE_PRODUCT", 147, 149], ["C3", "GENE_OR_GENE_PRODUCT", 155, 157], ["C1q", "PROTEIN", 142, 145], ["C4", "PROTEIN", 147, 149], ["C3", "PROTEIN", 155, 157], ["spleens of cadavers", "TREATMENT", 90, 109], ["C1q, C4, and C3", "PROBLEM", 142, 157], ["low", "OBSERVATION_MODIFIER", 42, 45], ["spleens", "ANATOMY", 90, 97], ["C4", "ANATOMY_MODIFIER", 147, 149], ["C3", "ANATOMY_MODIFIER", 155, 157]]], ["Scale bars a, e, 20 \u00b5m; c, 250 \u00b5m; j, 50 \u00b5m In particular, the DC-SIGN-C1q complex could also mediate a classical complement pathway against S. pneumoniae in the spleen, representing a potential protection mechanism in the human spleen 24 .", [["DC", "ANATOMY", 63, 65], ["spleen", "ANATOMY", 162, 168], ["spleen", "ANATOMY", 229, 235], ["C1q", "GENE_OR_GENE_PRODUCT", 71, 74], ["S. pneumoniae", "ORGANISM", 141, 154], ["spleen", "ORGAN", 162, 168], ["human", "ORGANISM", 223, 228], ["spleen", "ORGAN", 229, 235], ["DC", "CELL_TYPE", 63, 65], ["SIGN", "PROTEIN", 66, 70], ["C1q complex", "PROTEIN", 71, 82], ["S. pneumoniae", "SPECIES", 141, 154], ["human", "SPECIES", 223, 228], ["S. pneumoniae", "SPECIES", 141, 154], ["human", "SPECIES", 223, 228], ["the DC", "TEST", 59, 65], ["S. pneumoniae in the spleen", "PROBLEM", 141, 168], ["pneumoniae", "OBSERVATION", 144, 154], ["spleen", "ANATOMY", 162, 168], ["human spleen", "ANATOMY", 223, 235]]], ["Indeed, the replaced DC-SIGN on splenic MZs of DC-SIGN BMT / SIGN-R1 TKO mice completely rescued the pneumococcal capture, the sequential activation and deposition of C3 against S. pneumoniae in splenic MZs, which was likely to be related to the DC-SIGN-induced complex of mouse C1q and C4.", [["DC", "ANATOMY", 21, 23], ["splenic MZs", "ANATOMY", 32, 43], ["DC", "ANATOMY", 47, 49], ["splenic MZs", "ANATOMY", 195, 206], ["DC", "ANATOMY", 246, 248], ["DC-SIGN", "SIMPLE_CHEMICAL", 21, 28], ["splenic MZs", "CELL", 32, 43], ["DC-SIGN", "CELL", 47, 54], ["SIGN-R1 TKO mice", "ORGANISM", 61, 77], ["C3", "GENE_OR_GENE_PRODUCT", 167, 169], ["S. pneumoniae", "ORGANISM", 178, 191], ["splenic MZs", "CANCER", 195, 206], ["SIGN", "GENE_OR_GENE_PRODUCT", 249, 253], ["mouse", "ORGANISM", 273, 278], ["C1q", "GENE_OR_GENE_PRODUCT", 279, 282], ["C4", "GENE_OR_GENE_PRODUCT", 287, 289], ["DC", "CELL_TYPE", 21, 23], ["SIGN", "PROTEIN", 24, 28], ["splenic MZs", "CELL_TYPE", 32, 43], ["DC", "CELL_TYPE", 47, 49], ["C3", "PROTEIN", 167, 169], ["splenic MZs", "CELL_TYPE", 195, 206], ["DC", "CELL_TYPE", 246, 248], ["SIGN", "PROTEIN", 249, 253], ["mouse C1q", "PROTEIN", 273, 282], ["C4", "PROTEIN", 287, 289], ["mice", "SPECIES", 73, 77], ["S. pneumoniae", "SPECIES", 178, 191], ["mouse", "SPECIES", 273, 278], ["mice", "SPECIES", 73, 77], ["pneumococcal", "SPECIES", 101, 113], ["S. pneumoniae", "SPECIES", 178, 191], ["mouse", "SPECIES", 273, 278], ["splenic MZs", "TREATMENT", 32, 43], ["DC", "TEST", 47, 49], ["SIGN", "TEST", 61, 65], ["the pneumococcal capture", "TREATMENT", 97, 121], ["the sequential activation", "TREATMENT", 123, 148], ["deposition of C3", "TREATMENT", 153, 169], ["S. pneumoniae", "PROBLEM", 178, 191], ["splenic MZs", "PROBLEM", 195, 206], ["induced complex of mouse C1q and C4", "PROBLEM", 254, 289], ["splenic", "ANATOMY", 32, 39], ["pneumococcal capture", "OBSERVATION", 101, 121], ["pneumoniae", "OBSERVATION", 181, 191], ["splenic", "ANATOMY", 195, 202], ["mouse C1q", "OBSERVATION", 273, 282], ["C4", "ANATOMY_MODIFIER", 287, 289]]], ["Previous studies have shown that recruitment of DC-SIGN into LRs with binding to viral glycoproteins or the gC1qR 29,31,66 strengthens the possible formation of a tetramolecular complex of glycoproteins/ DC-SIGN/C1q/gC1qR and thus increases binding capacity through the complex 24, 67 .", [["DC", "ANATOMY", 48, 50], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 48, 55], ["gC1qR", "GENE_OR_GENE_PRODUCT", 108, 113], ["C1q", "GENE_OR_GENE_PRODUCT", 212, 215], ["gC1qR", "GENE_OR_GENE_PRODUCT", 216, 221], ["DC", "CELL_TYPE", 48, 50], ["SIGN", "PROTEIN", 51, 55], ["viral glycoproteins", "PROTEIN", 81, 100], ["gC1qR 29,31,66", "PROTEIN", 108, 122], ["tetramolecular complex", "PROTEIN", 163, 185], ["glycoproteins", "PROTEIN", 189, 202], ["DC", "PROTEIN", 204, 206], ["SIGN", "PROTEIN", 207, 211], ["C1q", "PROTEIN", 212, 215], ["gC1qR", "PROTEIN", 216, 221], ["complex 24, 67", "PROTEIN", 270, 284], ["Previous studies", "TEST", 0, 16], ["viral glycoproteins", "TEST", 81, 100], ["the gC1qR", "TEST", 104, 113], ["a tetramolecular complex of glycoproteins", "PROBLEM", 161, 202], ["increases binding capacity", "PROBLEM", 231, 257]]], ["Therefore, similar to SIGN-R1, splenic MZ DC-SIGN + LRs may also provide a favorable microenvironment for the DC-SIGN-mediated classical complement pathway by forming another tetramolecular complex of DC-SIGN, C1q, gC1qR, and C4, finally enhancing sequential C3 activation.DiscussionBecause DC-SIGN is exclusively expressed on human splenic perifollicular zone macrophages 37 , the presence of DC-SIGN in cadaver splenic LRs indicates that DC-SIGN is expressed in LRs from human splenic perifollicular zone macrophages.", [["splenic MZ DC", "ANATOMY", 31, 44], ["DC", "ANATOMY", 110, 112], ["DC", "ANATOMY", 201, 203], ["splenic perifollicular zone macrophages", "ANATOMY", 333, 372], ["DC", "ANATOMY", 394, 396], ["DC", "ANATOMY", 440, 442], ["splenic perifollicular zone macrophages", "ANATOMY", 479, 518], ["MZ", "CHEMICAL", 39, 41], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 22, 29], ["splenic MZ DC", "CELL", 31, 44], ["SIGN", "GENE_OR_GENE_PRODUCT", 45, 49], ["SIGN", "GENE_OR_GENE_PRODUCT", 113, 117], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 201, 208], ["C1q", "GENE_OR_GENE_PRODUCT", 210, 213], ["gC1qR", "GENE_OR_GENE_PRODUCT", 215, 220], ["C4", "GENE_OR_GENE_PRODUCT", 226, 228], ["C3", "GENE_OR_GENE_PRODUCT", 259, 261], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 291, 298], ["human", "ORGANISM", 327, 332], ["splenic perifollicular zone macrophages 37", "CELL", 333, 375], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 394, 401], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 440, 447], ["human", "ORGANISM", 473, 478], ["splenic perifollicular zone macrophages", "CELL", 479, 518], ["SIGN", "PROTEIN", 22, 26], ["splenic MZ DC", "CELL_TYPE", 31, 44], ["SIGN", "PROTEIN", 45, 49], ["DC", "CELL_TYPE", 110, 112], ["SIGN", "PROTEIN", 113, 117], ["tetramolecular complex", "PROTEIN", 175, 197], ["DC", "CELL_TYPE", 201, 203], ["SIGN", "PROTEIN", 204, 208], ["C1q", "PROTEIN", 210, 213], ["gC1qR", "PROTEIN", 215, 220], ["C4", "PROTEIN", 226, 228], ["C3", "PROTEIN", 259, 261], ["DC", "CELL_TYPE", 291, 293], ["SIGN", "PROTEIN", 294, 298], ["human splenic perifollicular zone macrophages 37", "CELL_LINE", 327, 375], ["DC", "CELL_TYPE", 394, 396], ["SIGN", "PROTEIN", 397, 401], ["DC", "CELL_TYPE", 440, 442], ["SIGN", "PROTEIN", 443, 447], ["human splenic perifollicular zone macrophages", "CELL_TYPE", 473, 518], ["human", "SPECIES", 327, 332], ["human", "SPECIES", 473, 478], ["human", "SPECIES", 327, 332], ["human", "SPECIES", 473, 478], ["SIGN", "TEST", 22, 26], ["C1q", "TEST", 210, 213], [", gC1qR, and C4, finally enhancing sequential C3 activation", "PROBLEM", 213, 272], ["splenic", "ANATOMY", 31, 38], ["C4", "ANATOMY", 226, 228], ["C3 activation", "OBSERVATION", 259, 272], ["splenic", "ANATOMY", 333, 340], ["perifollicular", "ANATOMY_MODIFIER", 341, 355], ["splenic", "ANATOMY", 413, 420], ["splenic", "ANATOMY", 479, 486], ["perifollicular", "ANATOMY_MODIFIER", 487, 501], ["zone macrophages", "OBSERVATION", 502, 518]]], ["Also, similar with the previous reports 32,68,69 , complements C1q, C4, and C3b were enriched in human splenic LRs.", [["splenic LRs", "ANATOMY", 103, 114], ["C1q", "GENE_OR_GENE_PRODUCT", 63, 66], ["C4", "GENE_OR_GENE_PRODUCT", 68, 70], ["C3b", "GENE_OR_GENE_PRODUCT", 76, 79], ["human", "ORGANISM", 97, 102], ["splenic LRs", "MULTI-TISSUE_STRUCTURE", 103, 114], ["C1q", "PROTEIN", 63, 66], ["C4", "PROTEIN", 68, 70], ["C3b", "PROTEIN", 76, 79], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["C1q", "TEST", 63, 66], ["splenic", "ANATOMY", 103, 110]]], ["Therefore, these cadaver splenic perifollicular zone DC-SIGN + LRs may also be important for the DC-SIGN-mediated classical complement system against S. pneumoniae, explaining why the spleen and the classical pathway are integral for protection against infections to S. pneumoniae in humans [63] [64] [65] .DiscussionThe importance of LRs has been restricted to their roles in receptor-mediated intracellular events from the plasma membrane, so far.", [["splenic perifollicular zone DC", "ANATOMY", 25, 55], ["DC", "ANATOMY", 97, 99], ["spleen", "ANATOMY", 184, 190], ["intracellular", "ANATOMY", 395, 408], ["plasma membrane", "ANATOMY", 425, 440], ["infections", "DISEASE", 253, 263], ["SIGN", "GENE_OR_GENE_PRODUCT", 56, 60], ["SIGN", "GENE_OR_GENE_PRODUCT", 100, 104], ["S. pneumoniae", "ORGANISM", 150, 163], ["spleen", "ORGAN", 184, 190], ["S. pneumoniae", "ORGANISM", 267, 280], ["humans", "ORGANISM", 284, 290], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 395, 408], ["plasma membrane", "CELLULAR_COMPONENT", 425, 440], ["DC", "CELL_TYPE", 53, 55], ["SIGN", "PROTEIN", 56, 60], ["DC", "CELL_TYPE", 97, 99], ["SIGN", "PROTEIN", 100, 104], ["LRs", "PROTEIN", 335, 338], ["S. pneumoniae", "SPECIES", 150, 163], ["S. pneumoniae", "SPECIES", 267, 280], ["humans", "SPECIES", 284, 290], ["S. pneumoniae", "SPECIES", 150, 163], ["S. pneumoniae", "SPECIES", 267, 280], ["humans", "SPECIES", 284, 290], ["these cadaver splenic perifollicular zone DC", "TEST", 11, 55], ["LRs", "PROBLEM", 63, 66], ["S. pneumoniae", "PROBLEM", 150, 163], ["infections", "PROBLEM", 253, 263], ["the plasma membrane", "TREATMENT", 421, 440], ["splenic", "ANATOMY", 25, 32], ["perifollicular", "ANATOMY_MODIFIER", 33, 47], ["pneumoniae", "OBSERVATION", 153, 163], ["spleen", "ANATOMY", 184, 190]]], ["However, splenic MZ LRs provide bidirectional platforms not only for usual events associated with the intracellular milieu, for example, recognition and phagocytosis of pathogens in vivo, but also unusual events associated with the extracellular milieu, such as the complement system, orchestrating early and complicated host responses to microbial infection.", [["splenic MZ", "ANATOMY", 9, 19], ["intracellular", "ANATOMY", 102, 115], ["extracellular", "ANATOMY", 232, 245], ["MZ", "CHEMICAL", 17, 19], ["infection", "DISEASE", 349, 358], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 115], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 232, 245], ["microbial infection", "PROBLEM", 339, 358], ["splenic", "ANATOMY", 9, 16], ["MZ", "OBSERVATION", 17, 19], ["microbial", "OBSERVATION_MODIFIER", 339, 348], ["infection", "OBSERVATION", 349, 358]]], ["Thus, the spleen could be equipped with the most sensitive system to target various pathogens, such as S. pneumoniae 35, 36 and human immunodeficiency virus-1 37, 38 .", [["spleen", "ANATOMY", 10, 16], ["human immunodeficiency virus", "DISEASE", 128, 156], ["spleen", "ORGAN", 10, 16], ["S. pneumoniae 35", "ORGANISM", 103, 119], ["human immunodeficiency virus-1 37", "ORGANISM", 128, 161], ["S. pneumoniae", "SPECIES", 103, 116], ["human immunodeficiency virus-1", "SPECIES", 128, 158], ["S. pneumoniae", "SPECIES", 103, 116], ["human immunodeficiency virus-1", "SPECIES", 128, 158], ["target various pathogens", "PROBLEM", 69, 93], ["S. pneumoniae", "TEST", 103, 116], ["human immunodeficiency virus", "TEST", 128, 156], ["spleen", "ANATOMY", 10, 16], ["various", "OBSERVATION_MODIFIER", 76, 83], ["pathogens", "OBSERVATION", 84, 93]]], ["These findings can explain how such a small portion of splenic SIGN-R1 + macrophages (<0.05%) helps the spleen to efficiently protect hosts against S. pneumoniae, providing insights into the involvement of LRs in the innate immune system and the roles of DC-SIGN in the human spleen.Bacterial strainsStreptococcus pneumoniae capsular serotype 14 (DCC1490), the unencapsulated S. pneumoniae Tn916 mutant Spn14.H, and Staphylococcus aureus strain (RN4220) were used, all of which were kindly provided by Professor Vincent A. Fischetti of Rockefeller University (New York, USA).Bacterial strainsCell culture DCEK, a mouse L-cell fibroblast line, and human embryonic kidney (HEK293T) cells were cultured in RPMI-1640 medium, and CHO cells were cultured in Dulbecco's modified Eagle's medium, supplemented with 10% fetal bovine serum, 100 U/mL penicillin G, and 100 mg/mL streptomycin.", [["splenic SIGN-R1 + macrophages", "ANATOMY", 55, 84], ["spleen", "ANATOMY", 104, 110], ["DC", "ANATOMY", 255, 257], ["spleen", "ANATOMY", 276, 282], ["Cell", "ANATOMY", 592, 596], ["L-cell fibroblast line", "ANATOMY", 619, 641], ["embryonic kidney (HEK293T) cells", "ANATOMY", 653, 685], ["CHO cells", "ANATOMY", 725, 734], ["fetal bovine serum", "ANATOMY", 810, 828], ["penicillin", "CHEMICAL", 839, 849], ["streptomycin", "CHEMICAL", 867, 879], ["penicillin G", "CHEMICAL", 839, 851], ["streptomycin", "CHEMICAL", 867, 879], ["splenic SIGN-R1 + macrophages", "CELL", 55, 84], ["spleen", "ORGAN", 104, 110], ["S. pneumoniae", "ORGANISM", 148, 161], ["LRs", "GENE_OR_GENE_PRODUCT", 206, 209], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 255, 262], ["human", "ORGANISM", 270, 275], ["spleen", "ORGAN", 276, 282], ["Streptococcus pneumoniae", "ORGANISM", 300, 324], ["capsular serotype 14", "ORGANISM", 325, 345], ["S. pneumoniae", "ORGANISM", 376, 389], ["Tn916", "ORGANISM", 390, 395], ["H", "GENE_OR_GENE_PRODUCT", 409, 410], ["Staphylococcus aureus strain", "ORGANISM", 416, 444], ["Cell", "CELL", 592, 596], ["DCEK", "CELL", 605, 609], ["mouse", "ORGANISM", 613, 618], ["L-cell fibroblast line", "CELL", 619, 641], ["human", "ORGANISM", 647, 652], ["embryonic kidney", "CELL", 653, 669], ["HEK293T) cells", "CELL", 671, 685], ["RPMI-1640", "CELL", 703, 712], ["CHO cells", "CELL", 725, 734], ["bovine", "ORGANISM", 816, 822], ["serum", "ORGANISM_SUBSTANCE", 823, 828], ["penicillin G", "SIMPLE_CHEMICAL", 839, 851], ["streptomycin", "SIMPLE_CHEMICAL", 867, 879], ["splenic SIGN-R1 + macrophages", "CELL_LINE", 55, 84], ["DC", "CELL_TYPE", 255, 257], ["SIGN", "PROTEIN", 258, 262], ["DCEK", "CELL_LINE", 605, 609], ["mouse L-cell fibroblast line", "CELL_LINE", 613, 641], ["human embryonic kidney (HEK293T) cells", "CELL_LINE", 647, 685], ["CHO cells", "CELL_LINE", 725, 734], ["S. pneumoniae", "SPECIES", 148, 161], ["human", "SPECIES", 270, 275], ["Streptococcus pneumoniae", "SPECIES", 300, 324], ["S. pneumoniae", "SPECIES", 376, 389], ["Staphylococcus aureus", "SPECIES", 416, 437], ["mouse", "SPECIES", 613, 618], ["human", "SPECIES", 647, 652], ["bovine", "SPECIES", 816, 822], ["S. pneumoniae", "SPECIES", 148, 161], ["human", "SPECIES", 270, 275], ["Streptococcus pneumoniae", "SPECIES", 300, 324], ["S. pneumoniae", "SPECIES", 376, 389], ["Staphylococcus aureus", "SPECIES", 416, 437], ["mouse", "SPECIES", 613, 618], ["human", "SPECIES", 647, 652], ["bovine", "SPECIES", 816, 822], ["splenic SIGN", "TEST", 55, 67], ["macrophages", "PROBLEM", 73, 84], ["S. pneumoniae", "PROBLEM", 148, 161], ["SIGN in the human spleen", "PROBLEM", 258, 282], ["Bacterial strains", "PROBLEM", 283, 300], ["Streptococcus pneumoniae capsular serotype", "PROBLEM", 300, 342], ["Staphylococcus aureus strain", "PROBLEM", 416, 444], ["Bacterial strains", "PROBLEM", 575, 592], ["Cell culture", "TEST", 592, 604], ["DCEK", "TEST", 605, 609], ["a mouse L-cell fibroblast line", "TEST", 611, 641], ["human embryonic kidney (HEK293T) cells", "TEST", 647, 685], ["RPMI", "TEST", 703, 707], ["CHO cells", "TEST", 725, 734], ["Dulbecco", "TEST", 752, 760], ["10% fetal bovine serum", "TREATMENT", 806, 828], ["penicillin G", "TREATMENT", 839, 851], ["streptomycin", "TREATMENT", 867, 879], ["small", "OBSERVATION_MODIFIER", 38, 43], ["splenic", "ANATOMY", 55, 62], ["SIGN", "OBSERVATION", 63, 67], ["macrophages", "ANATOMY", 73, 84], ["spleen", "ANATOMY", 104, 110], ["pneumoniae", "OBSERVATION", 151, 161], ["human", "ANATOMY_MODIFIER", 270, 275], ["spleen", "ANATOMY", 276, 282], ["strains", "OBSERVATION", 293, 300], ["pneumoniae", "OBSERVATION", 379, 389], ["Staphylococcus aureus strain", "OBSERVATION", 416, 444], ["strains", "OBSERVATION", 585, 592], ["cell", "OBSERVATION", 621, 625], ["fibroblast line", "OBSERVATION", 626, 641], ["embryonic", "ANATOMY_MODIFIER", 653, 662], ["kidney", "ANATOMY", 663, 669]]], ["Stable DCEK transfectants expressing complementary (cDNA) for DC-SIGN or SIGN-R1 (DCEK_DC-SIGNS and DCEK_SIGN-R1 in the figures, respectively) and stable CHO transfectants expressing cDNA for Neo, or SIGN-R1 (CHO_Neo, or CHO_SIGN-R1 in the figures, respectively) were used.In vivo animal studiesFemale C57BL/6 mice (6-10 weeks old, weighing 16-20 g) were purchased (The Jackson Laboratory, Bar Harbor, ME, USA) and housed under specific pathogen-free conditions.", [["DCEK transfectants", "ANATOMY", 7, 25], ["DC", "ANATOMY", 62, 64], ["CHO transfectants", "ANATOMY", 154, 171], ["DCEK transfectants", "CELL", 7, 25], ["DC-SIGN", "GENE_OR_GENE_PRODUCT", 62, 69], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 73, 80], ["DCEK_DC-SIGNS", "GENE_OR_GENE_PRODUCT", 82, 95], ["DCEK_SIGN-R1", "GENE_OR_GENE_PRODUCT", 100, 112], ["CHO transfectants", "CELL", 154, 171], ["Neo", "GENE_OR_GENE_PRODUCT", 192, 195], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 200, 207], ["C57BL/6 mice", "ORGANISM", 302, 314], ["DCEK transfectants", "CELL_LINE", 7, 25], ["cDNA", "DNA", 52, 56], ["DC", "CELL_TYPE", 62, 64], ["SIGN", "DNA", 65, 69], ["SIGN", "DNA", 73, 77], ["R1", "DNA", 78, 80], ["DCEK_DC", "DNA", 82, 89], ["SIGNS", "DNA", 90, 95], ["DCEK_SIGN", "DNA", 100, 109], ["R1", "DNA", 110, 112], ["CHO transfectants", "CELL_LINE", 154, 171], ["cDNA", "DNA", 183, 187], ["Neo", "DNA", 192, 195], ["SIGN", "DNA", 200, 204], ["R1", "DNA", 205, 207], ["CHO_Neo", "DNA", 209, 216], ["CHO_SIGN", "DNA", 221, 229], ["R1", "DNA", 230, 232], ["mice", "SPECIES", 310, 314], ["mice", "SPECIES", 310, 314], ["SIGN", "TEST", 73, 77], ["DCEK_DC", "TEST", 82, 89], ["SIGNS", "TEST", 90, 95], ["DCEK_SIGN", "TEST", 100, 109], ["Neo", "TREATMENT", 192, 195], ["SIGN", "TEST", 200, 204], ["CHO_Neo", "TREATMENT", 209, 216], ["CHO_SIGN", "TREATMENT", 221, 229]]], ["SIGN-R1 (CD209b)-KO mice were kindly provided by the Consortium for Functional Glycomics (http:// www.functionalglycomics.org).", [["SIGN-R1", "GENE_OR_GENE_PRODUCT", 0, 7], ["CD209b", "GENE_OR_GENE_PRODUCT", 9, 15], ["CD209b", "PROTEIN", 9, 15], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["SIGN", "TEST", 0, 4]]], ["DC-SIGN transgenic donor mice were provided by the Rockefeller Gene Targeting Resource Center and identified by PCR using DC-SIGN gene primers forward (5\u2032-CgggATCCgAgTggggTgACA TgAgTgACT-3\u2032) and reverse (5\u2032-ACgCgTCgACAAA AgggggTgAAgTTCTgCTACg-3\u2032).", [["mice", "ORGANISM", 25, 29], ["DC", "CELL_TYPE", 0, 2], ["DC-SIGN gene primers", "DNA", 122, 142], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["SIGN transgenic donor mice", "TREATMENT", 3, 29], ["TgAgTgACT", "TEST", 177, 186], ["TgAAgTTCTgCTACg", "TEST", 227, 242]]], ["For in vivo experiments using animal models, all studies were approved by the Institutional Animal Care and Use Committee of Konkuk University (permit number: KU11107) and performed in strict accordance with the approved guidelines for animal care and animal experimentation.", [["all studies", "TEST", 45, 56], ["animal care", "TREATMENT", 236, 247], ["animal experimentation", "TREATMENT", 252, 274]]], ["Mice were housed in a temperature-controlled room with an automated darkness-light cycle system and had ad libitum access to food and water.", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4]]], ["Mice were challenged with 1 \u00d7 10 8 colonyforming unit of S. pneumoniae suspended in 100 mL of PBS in PBS intravenously.", [["intravenously", "ANATOMY", 105, 118], ["Mice", "ORGANISM", 0, 4], ["S. pneumoniae", "ORGANISM", 57, 70], ["Mice", "SPECIES", 0, 4], ["S. pneumoniae", "SPECIES", 57, 70], ["S. pneumoniae", "SPECIES", 57, 70], ["S. pneumoniae", "PROBLEM", 57, 70], ["PBS in PBS intravenously", "TREATMENT", 94, 118], ["pneumoniae", "OBSERVATION", 60, 70]]], ["Prior to tissue dissection, the mice were sacrificed via euthanasia using an overdose of CO 2 with a flow rate 20% of the cage volume per minute, following AVMA Guidelines for the Euthanasia of Animals.Bacterial growth conditions and fluorescent labelingStreptococcus pneumoniae capsular serotype 14 (DCC1490), the unencapsulated S. pneumoniae Tn916 mutant Spn14.H (mt-Pn14), and Staphylococcus aureus were grown in brain heart infusion broth (DIFCO) to mid-logarithmic phase (18 h, 37\u00b0C) .", [["tissue", "ANATOMY", 9, 15], ["brain heart", "ANATOMY", 416, 427], ["overdose", "DISEASE", 77, 85], ["CO 2", "CHEMICAL", 89, 93], ["tissue", "TISSUE", 9, 15], ["mice", "ORGANISM", 32, 36], ["Streptococcus pneumoniae", "ORGANISM", 254, 278], ["capsular serotype 14", "ORGANISM", 279, 299], ["S. pneumoniae", "ORGANISM", 330, 343], ["Tn916", "ORGANISM", 344, 349], ["mt-Pn14", "GENE_OR_GENE_PRODUCT", 366, 373], ["Staphylococcus aureus", "ORGANISM", 380, 401], ["brain", "ORGAN", 416, 421], ["heart", "ORGAN", 422, 427], ["mice", "SPECIES", 32, 36], ["Streptococcus pneumoniae capsular serotype", "SPECIES", 254, 296], ["S. pneumoniae", "SPECIES", 330, 343], ["Staphylococcus aureus", "SPECIES", 380, 401], ["mice", "SPECIES", 32, 36], ["Streptococcus pneumoniae", "SPECIES", 254, 278], ["S. pneumoniae", "SPECIES", 330, 343], ["Staphylococcus aureus", "SPECIES", 380, 401], ["tissue dissection", "TREATMENT", 9, 26], ["a flow rate", "TEST", 99, 110], ["AVMA Guidelines", "TREATMENT", 156, 171], ["Bacterial growth conditions", "PROBLEM", 202, 229], ["fluorescent labelingStreptococcus pneumoniae capsular serotype", "TEST", 234, 296], ["the unencapsulated S. pneumoniae", "TEST", 311, 343], ["mutant Spn", "TEST", 350, 360], ["Staphylococcus aureus", "PROBLEM", 380, 401], ["tissue", "ANATOMY", 9, 15], ["dissection", "OBSERVATION", 16, 26], ["cage volume", "OBSERVATION", 122, 133], ["Staphylococcus aureus", "OBSERVATION", 380, 401], ["brain heart", "ANATOMY", 416, 427]]], ["Bacteria were inactivated with 50 \u03bcg/mL mitomycin C (Sigma) for 1 h and suspensions of 10 9 bacteria were labeled with PKH26 following the manufacturer's instructions or with 5 mM CFSE (Sigma-Aldrich) for 30 min at 37\u00b0C. The fluorescent bacteria were injected intravenously into mice or incubated with cells.Cellular and tissue immunofluorescence microscopyCells on coverslips or 10 \u03bcm OCT (Tissue-Tek) frozen spleen sections were fixed with 100% acetone (10 min, room temperature) and stained, where indicated, with DAPI (4\u2032,6-diamidino-2-phenylindole) (blue) or FITC-, PE-, AMCA-, or Alexa Fluor-conjugated donkey antichicken IgY, goat anti-hamster IgG, donkey anti-rabbit IgG, goat anti-rat IgG, and streptavidin as secondary reagents (purchased from Abcam, Jackson ImmunoResearch Laboratories, or Molecular Probes).", [["intravenously", "ANATOMY", 260, 273], ["cells", "ANATOMY", 302, 307], ["Cellular", "ANATOMY", 308, 316], ["tissue", "ANATOMY", 321, 327], ["Cells", "ANATOMY", 357, 362], ["coverslips", "ANATOMY", 366, 376], ["spleen sections", "ANATOMY", 410, 425], ["mitomycin C", "CHEMICAL", 40, 51], ["PKH26", "CHEMICAL", 119, 124], ["CFSE", "CHEMICAL", 180, 184], ["acetone", "CHEMICAL", 447, 454], ["DAPI", "CHEMICAL", 517, 521], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 523, 552], ["PE", "CHEMICAL", 571, 573], ["AMCA", "CHEMICAL", 576, 580], ["mitomycin C", "CHEMICAL", 40, 51], ["PKH26", "CHEMICAL", 119, 124], ["CFSE", "CHEMICAL", 180, 184], ["acetone", "CHEMICAL", 447, 454], ["DAPI", "CHEMICAL", 517, 521], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 523, 552], ["FITC", "CHEMICAL", 564, 568], ["AMCA", "CHEMICAL", 576, 580], ["Alexa Fluor", "CHEMICAL", 586, 597], ["Bacteria", "CELL", 0, 8], ["mitomycin C", "SIMPLE_CHEMICAL", 40, 51], ["Sigma", "SIMPLE_CHEMICAL", 53, 58], ["PKH26", "SIMPLE_CHEMICAL", 119, 124], ["CFSE", "SIMPLE_CHEMICAL", 180, 184], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 186, 199], ["mice", "ORGANISM", 279, 283], ["cells", "CELL", 302, 307], ["Cellular", "CELL", 308, 316], ["tissue", "TISSUE", 321, 327], ["Cells", "CELL", 357, 362], ["coverslips", "CELL", 366, 376], ["spleen sections", "MULTI-TISSUE_STRUCTURE", 410, 425], ["acetone", "SIMPLE_CHEMICAL", 447, 454], ["DAPI", "SIMPLE_CHEMICAL", 517, 521], ["4\u2032,6-diamidino-2-phenylindole) (blue)", "SIMPLE_CHEMICAL", 523, 560], ["FITC-, PE-", "SIMPLE_CHEMICAL", 564, 574], ["AMCA", "SIMPLE_CHEMICAL", 576, 580], ["Alexa Fluor", "SIMPLE_CHEMICAL", 586, 597], ["donkey", "ORGANISM", 609, 615], ["antichicken IgY", "SIMPLE_CHEMICAL", 616, 631], ["goat", "ORGANISM", 633, 637], ["anti-hamster IgG", "SIMPLE_CHEMICAL", 638, 654], ["donkey", "ORGANISM", 656, 662], ["goat anti-rat IgG", "GENE_OR_GENE_PRODUCT", 680, 697], ["streptavidin", "SIMPLE_CHEMICAL", 703, 715], ["Abcam", "GENE_OR_GENE_PRODUCT", 754, 759], ["Alexa Fluor-conjugated donkey antichicken IgY", "PROTEIN", 586, 631], ["goat anti-hamster IgG", "PROTEIN", 633, 654], ["donkey anti-rabbit IgG", "PROTEIN", 656, 678], ["goat anti-rat IgG", "PROTEIN", 680, 697], ["streptavidin", "PROTEIN", 703, 715], ["Abcam", "PROTEIN", 754, 759], ["mice", "SPECIES", 279, 283], ["donkey", "SPECIES", 609, 615], ["goat", "SPECIES", 633, 637], ["donkey", "SPECIES", 656, 662], ["anti-rabbit", "SPECIES", 663, 674], ["goat", "SPECIES", 680, 684], ["mice", "SPECIES", 279, 283], ["goat", "SPECIES", 633, 637], ["anti-rabbit", "SPECIES", 663, 674], ["goat", "SPECIES", 680, 684], ["Bacteria", "PROBLEM", 0, 8], ["mitomycin C (Sigma)", "TREATMENT", 40, 59], ["suspensions", "TEST", 72, 83], ["PKH26", "TREATMENT", 119, 124], ["the manufacturer's instructions", "TREATMENT", 135, 166], ["The fluorescent bacteria", "PROBLEM", 221, 245], ["Cellular and tissue immunofluorescence microscopy", "TEST", 308, 357], ["coverslips", "TEST", 366, 376], ["OCT", "TEST", 386, 389], ["100% acetone", "TREATMENT", 442, 454], ["DAPI", "TEST", 517, 521], ["diamidino", "TEST", 528, 537], ["FITC", "TEST", 564, 568], ["PE", "TEST", 571, 573], ["AMCA", "TEST", 576, 580], ["Alexa Fluor", "TEST", 586, 597], ["goat anti-hamster IgG", "TREATMENT", 633, 654], ["donkey anti-rabbit IgG", "TREATMENT", 656, 678], ["goat anti-rat IgG", "TREATMENT", 680, 697], ["streptavidin", "TREATMENT", 703, 715], ["fluorescent bacteria", "OBSERVATION", 225, 245], ["tissue", "ANATOMY", 321, 327], ["spleen", "ANATOMY", 410, 416], ["PE", "OBSERVATION", 571, 573]]], ["Cells and spleen sections were examined for fluorescence with a deconvolution fluorescence BX61-32FDIC microscope (Olympus Corp., Tokyo, Japan).", [["Cells", "ANATOMY", 0, 5], ["spleen sections", "ANATOMY", 10, 25], ["Cells", "CELL", 0, 5], ["spleen sections", "MULTI-TISSUE_STRUCTURE", 10, 25], ["spleen sections", "TEST", 10, 25], ["fluorescence", "TEST", 44, 56], ["a deconvolution fluorescence", "TEST", 62, 90], ["spleen", "ANATOMY", 10, 16]]], ["Images were acquired with a Coolsnap EZ system (Roper Scientific, Inc., AZ, USA).Flow cytometryCells used in FACS analysis were detached with 1 mM EDTA in PBS for 10 min and pre-incubated 10 min with 2.4G2 monoclonal antibody at 4\u00b0C to block Fc receptors.", [["Cells", "ANATOMY", 95, 100], ["EDTA", "CHEMICAL", 147, 151], ["EDTA", "CHEMICAL", 147, 151], ["Cells", "CELL", 95, 100], ["EDTA", "SIMPLE_CHEMICAL", 147, 151], ["Fc receptors", "GENE_OR_GENE_PRODUCT", 242, 254], ["Fc receptors", "PROTEIN", 242, 254], ["Images", "TEST", 0, 6], ["Flow cytometry", "TEST", 81, 95], ["FACS analysis", "TEST", 109, 122], ["1 mM EDTA in PBS", "TREATMENT", 142, 158], ["G2 monoclonal antibody", "TREATMENT", 203, 225]]], ["Cells or S. pneumoniae were incubated with 3-5% mouse or human serum in 200 \u03bcL TC buffer (10 mM Tris-HCl, 140 mM NaCl, 2 mM CaCl 2 , 2 mM MgCl 2 , and 1% bovine serum albumin [BSA]), and complement binding to cells or organisms was detected by immunostaining with respective antibodies for 30 min at 4\u00b0C. Cytometric analysis was performed using a FACScan (Becton Dickinson, San Jose, CA, USA) and CellQuestPro (BD Biosciences).", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 63, 68], ["serum", "ANATOMY", 161, 166], ["cells", "ANATOMY", 209, 214], ["Tris-HCl", "CHEMICAL", 96, 104], ["NaCl", "CHEMICAL", 113, 117], ["Tris-HCl", "CHEMICAL", 96, 104], ["NaCl", "CHEMICAL", 113, 117], ["CaCl 2", "CHEMICAL", 124, 130], ["MgCl 2", "CHEMICAL", 138, 144], ["Cells", "CELL", 0, 5], ["S. pneumoniae", "ORGANISM", 9, 22], ["mouse", "ORGANISM", 48, 53], ["human", "ORGANISM", 57, 62], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["Tris-HCl", "SIMPLE_CHEMICAL", 96, 104], ["MgCl 2", "SIMPLE_CHEMICAL", 138, 144], ["bovine", "ORGANISM", 154, 160], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["albumin", "GENE_OR_GENE_PRODUCT", 167, 174], ["BSA", "SIMPLE_CHEMICAL", 176, 179], ["cells", "CELL", 209, 214], ["antibodies", "PROTEIN", 275, 285], ["S. pneumoniae", "SPECIES", 9, 22], ["mouse", "SPECIES", 48, 53], ["human", "SPECIES", 57, 62], ["bovine", "SPECIES", 154, 160], ["S. pneumoniae", "SPECIES", 9, 22], ["mouse", "SPECIES", 48, 53], ["human", "SPECIES", 57, 62], ["S. pneumoniae", "PROBLEM", 9, 22], ["human serum", "TEST", 57, 68], ["140 mM NaCl", "TREATMENT", 106, 117], ["CaCl", "TEST", 124, 128], ["2 mM MgCl", "TREATMENT", 133, 142], ["1% bovine serum albumin", "TREATMENT", 151, 174], ["complement binding to cells", "PROBLEM", 187, 214], ["organisms", "PROBLEM", 218, 227], ["Cytometric analysis", "TEST", 305, 324], ["a FACScan", "TEST", 345, 354], ["pneumoniae", "OBSERVATION", 12, 22]]], ["Subsequent data analysis was performed with CellQuest-Pro (BD Biosciences).Streptococcus pneumoniae uptake and decomposition analysis in vitro and in vivoCells (1 \u00d7 10 5 ) were incubated with mitomycin C-treated and CFSE-labeled S. pneumoniae (1 \u00d7 10 6 ) for the indicated times at 37\u00b0C, and bacterial binding to cells and cytoplasmic decomposition of capsular polysaccharides of S. pneumoniae were examined with a fluorescence microscope.", [["cells", "ANATOMY", 313, 318], ["cytoplasmic", "ANATOMY", 323, 334], ["mitomycin C", "CHEMICAL", 192, 203], ["CFSE", "CHEMICAL", 216, 220], ["mitomycin C", "CHEMICAL", 192, 203], ["CFSE", "CHEMICAL", 216, 220], ["Streptococcus pneumoniae", "ORGANISM", 75, 99], ["mitomycin C", "SIMPLE_CHEMICAL", 192, 203], ["CFSE", "SIMPLE_CHEMICAL", 216, 220], ["S. pneumoniae", "ORGANISM", 229, 242], ["cells", "CELL", 313, 318], ["cytoplasmic", "ORGANISM_SUBSTANCE", 323, 334], ["capsular polysaccharides", "SIMPLE_CHEMICAL", 352, 376], ["S. pneumoniae", "ORGANISM", 380, 393], ["Streptococcus pneumoniae", "SPECIES", 75, 99], ["S. pneumoniae", "SPECIES", 229, 242], ["S. pneumoniae", "SPECIES", 380, 393], ["Streptococcus pneumoniae", "SPECIES", 75, 99], ["S. pneumoniae", "SPECIES", 229, 242], ["S. pneumoniae", "SPECIES", 380, 393], ["Subsequent data analysis", "TEST", 0, 24], ["Streptococcus pneumoniae uptake", "PROBLEM", 75, 106], ["decomposition analysis", "TEST", 111, 133], ["vivoCells", "TEST", 150, 159], ["mitomycin C", "TREATMENT", 192, 203], ["CFSE", "TEST", 216, 220], ["S. pneumoniae", "PROBLEM", 229, 242], ["bacterial binding to cells", "PROBLEM", 292, 318], ["cytoplasmic decomposition", "TEST", 323, 348], ["capsular polysaccharides", "PROBLEM", 352, 376], ["S. pneumoniae", "PROBLEM", 380, 393], ["a fluorescence microscope", "TEST", 413, 438], ["pneumoniae", "OBSERVATION", 89, 99], ["bacterial binding", "OBSERVATION", 292, 309], ["capsular polysaccharides", "OBSERVATION_MODIFIER", 352, 376], ["pneumoniae", "OBSERVATION", 383, 393]]], ["Mice were intravenously injected with mitomycin C-treated and CFSE-labeled S. pneumoniae (1 \u00d7 10 8 ) for the indicated times 39, 41 , and bacterial binding and decomposition were examined on SIGN-R1 \u2212 or SIGN-R1 + cells of spleen tissues.Quantification of bacterial decomposition ratiosTo quantify the pneumococcal decomposition ratio, the number of pneumococcal-bound or -decomposing cells was counted, and the average percentage of pneumococcal-decomposing cells from the total number of pneumococcal-bound cells was calculated in five areas for each sample from five independent experiments.Cell fractionation and purification of LRs with sucrose gradientsTissues from mice or cells were solubilized in 2 mL of 1% Triton X-100 (Junsei Chemical Co., Ltd.) in MESbuffered saline (MBS, 25 mM MES, pH 6.5, 150 mM NaCl).", [["intravenously", "ANATOMY", 10, 23], ["SIGN-R1 \u2212", "ANATOMY", 191, 200], ["SIGN-R1 + cells", "ANATOMY", 204, 219], ["spleen tissues", "ANATOMY", 223, 237], ["cells", "ANATOMY", 385, 390], ["cells", "ANATOMY", 459, 464], ["cells", "ANATOMY", 509, 514], ["Cell", "ANATOMY", 594, 598], ["Tissues", "ANATOMY", 659, 666], ["cells", "ANATOMY", 680, 685], ["mitomycin C", "CHEMICAL", 38, 49], ["CFSE", "CHEMICAL", 62, 66], ["sucrose", "CHEMICAL", 642, 649], ["Triton X-100", "CHEMICAL", 717, 729], ["NaCl", "CHEMICAL", 812, 816], ["mitomycin C", "CHEMICAL", 38, 49], ["CFSE", "CHEMICAL", 62, 66], ["sucrose", "CHEMICAL", 642, 649], ["Triton X-100", "CHEMICAL", 717, 729], ["NaCl", "CHEMICAL", 812, 816], ["Mice", "ORGANISM", 0, 4], ["mitomycin C", "SIMPLE_CHEMICAL", 38, 49], ["CFSE", "SIMPLE_CHEMICAL", 62, 66], ["S. pneumoniae", "ORGANISM", 75, 88], ["SIGN-R1 \u2212", "CELL", 191, 200], ["SIGN-R1 + cells", "CELL", 204, 219], ["spleen tissues", "TISSUE", 223, 237], ["cells", "CELL", 385, 390], ["cells", "CELL", 459, 464], ["cells", "CELL", 509, 514], ["Cell", "CELL", 594, 598], ["sucrose", "SIMPLE_CHEMICAL", 642, 649], ["Tissues", "TISSUE", 659, 666], ["mice", "ORGANISM", 672, 676], ["cells", "CELL", 680, 685], ["Triton X-100", "SIMPLE_CHEMICAL", 717, 729], ["MESbuffered saline", "SIMPLE_CHEMICAL", 761, 779], ["SIGN-R1 \u2212 or SIGN-R1 + cells", "CELL_LINE", 191, 219], ["pneumococcal-bound cells", "CELL_TYPE", 490, 514], ["Mice", "SPECIES", 0, 4], ["S. pneumoniae", "SPECIES", 75, 88], ["mice", "SPECIES", 672, 676], ["S. pneumoniae", "SPECIES", 75, 88], ["pneumococcal", "SPECIES", 302, 314], ["pneumococcal", "SPECIES", 350, 362], ["pneumococcal", "SPECIES", 434, 446], ["pneumococcal", "SPECIES", 490, 502], ["mice", "SPECIES", 672, 676], ["mitomycin C", "TREATMENT", 38, 49], ["CFSE", "TEST", 62, 66], ["S. pneumoniae", "PROBLEM", 75, 88], ["bacterial binding", "PROBLEM", 138, 155], ["SIGN", "TEST", 191, 195], ["SIGN", "TEST", 204, 208], ["bacterial decomposition ratios", "PROBLEM", 256, 286], ["the pneumococcal decomposition ratio", "TEST", 298, 334], ["pneumococcal-bound", "PROBLEM", 350, 368], ["decomposing cells", "PROBLEM", 373, 390], ["pneumococcal-decomposing cells", "PROBLEM", 434, 464], ["pneumococcal-bound cells", "TREATMENT", 490, 514], ["Cell fractionation", "TREATMENT", 594, 612], ["sucrose gradients", "TREATMENT", 642, 659], ["1% Triton", "TREATMENT", 714, 723], ["MESbuffered saline (MBS", "TREATMENT", 761, 784], ["pH", "TEST", 797, 799], ["pneumoniae", "OBSERVATION", 78, 88], ["bacterial binding", "OBSERVATION", 138, 155], ["spleen tissues", "ANATOMY", 223, 237], ["bacterial decomposition", "OBSERVATION", 256, 279], ["pneumococcal", "OBSERVATION_MODIFIER", 302, 314], ["pneumococcal", "OBSERVATION_MODIFIER", 350, 362], ["pneumococcal", "OBSERVATION_MODIFIER", 434, 446], ["decomposing cells", "OBSERVATION", 447, 464], ["total", "OBSERVATION_MODIFIER", 474, 479], ["number", "OBSERVATION_MODIFIER", 480, 486], ["pneumococcal", "OBSERVATION_MODIFIER", 490, 502], ["bound cells", "OBSERVATION", 503, 514]]], ["After homogenizing with 10 up-and-down strokes of a tight-fitting Dounce homogenizer, the tissue or cellular extracts were adjusted to 4 mL with sucrose concentrations of 45% or 40%, respectively, and overlaid with 4 mL of 30% sucrose and 4 mL of 5% sucrose in MBS.", [["tissue", "ANATOMY", 90, 96], ["cellular extracts", "ANATOMY", 100, 117], ["strokes", "DISEASE", 39, 46], ["sucrose", "CHEMICAL", 145, 152], ["sucrose", "CHEMICAL", 227, 234], ["sucrose", "CHEMICAL", 250, 257], ["sucrose", "CHEMICAL", 145, 152], ["sucrose", "CHEMICAL", 227, 234], ["sucrose", "CHEMICAL", 250, 257], ["tissue", "TISSUE", 90, 96], ["cellular extracts", "ORGANISM_SUBSTANCE", 100, 117], ["sucrose", "SIMPLE_CHEMICAL", 145, 152], ["sucrose", "SIMPLE_CHEMICAL", 227, 234], ["sucrose", "SIMPLE_CHEMICAL", 250, 257], ["a tight-fitting Dounce homogenizer", "TREATMENT", 50, 84], ["cellular extracts", "TREATMENT", 100, 117], ["sucrose concentrations", "TREATMENT", 145, 167], ["30% sucrose", "TREATMENT", 223, 234], ["5% sucrose in MBS", "TREATMENT", 247, 264]]], ["The sucrose gradient was formed by centrifugation at 200,000 \u00d7 g for 18-20 h at 4\u00b0C using a Beckman SW41ti rotor.", [["sucrose", "CHEMICAL", 4, 11], ["sucrose", "CHEMICAL", 4, 11], ["sucrose", "SIMPLE_CHEMICAL", 4, 11], ["The sucrose gradient", "TREATMENT", 0, 20], ["a Beckman SW41ti rotor", "TREATMENT", 90, 112]]], ["After centrifugation, the sucrose gradients were fractionated into 12 fractions without pelleting, and an opaque buoyant band corresponding to the LRs was collected at the interface between the 30% and 5% sucrose gradients.", [["sucrose", "CHEMICAL", 26, 33], ["sucrose", "CHEMICAL", 205, 212], ["sucrose", "CHEMICAL", 26, 33], ["sucrose", "CHEMICAL", 205, 212], ["sucrose", "SIMPLE_CHEMICAL", 26, 33], ["sucrose", "SIMPLE_CHEMICAL", 205, 212], ["centrifugation", "TREATMENT", 6, 20], ["the sucrose gradients", "TREATMENT", 22, 43], ["an opaque buoyant band", "TREATMENT", 103, 125], ["the LRs", "TEST", 143, 150], ["5% sucrose gradients", "TREATMENT", 202, 222]]], ["The same quantity of proteins from each fraction was used for immunoblotting analysis.Plasmids and transfectionClone pMX DC-SIGN was a gift from Dr. Chae Gyu Park (Rockefeller University).", [["DC", "ANATOMY", 121, 123], ["Clone pMX DC", "CELL_LINE", 111, 123], ["immunoblotting analysis", "TEST", 62, 85], ["Plasmids", "TREATMENT", 86, 94], ["quantity", "OBSERVATION_MODIFIER", 9, 17], ["transfection", "OBSERVATION", 99, 111]]], ["This clone c DC-SIGN expression was monitored by immunoblotting analysis using anti-DC-SIGN antibodies.", [["DC", "ANATOMY", 13, 15], ["clone", "CELL", 5, 10], ["SIGN", "GENE_OR_GENE_PRODUCT", 16, 20], ["anti-DC-SIGN antibodies", "GENE_OR_GENE_PRODUCT", 79, 102], ["clone c DC", "CELL_LINE", 5, 15], ["SIGN", "PROTEIN", 16, 20], ["anti-DC-SIGN antibodies", "PROTEIN", 79, 102], ["immunoblotting analysis", "TEST", 49, 72]]], ["DCEK transfectants were transiently transfected with plasmids encoding dynamin II K44A (dominant-negative dynamin with a point mutation in the nucleotide-binding site, a gift from Professor Seung-Jae Lee, Seoul National University College of Medicine, Seoul, Korea) or with an empty pcDNA3 vector for 48 h, using Lipofectamine Plus reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's specifications.SIGN-R1 TKO mouse generationSIGN-R1 TKO or isotype control mice were generated by intravenous injection of 100 \u03bcg 22D1 antibody or isotype hamster IgG for 48 h.", [["DCEK transfectants", "ANATOMY", 0, 18], ["plasmids", "ANATOMY", 53, 61], ["intravenous", "ANATOMY", 519, 530], ["nucleotide", "CHEMICAL", 143, 153], ["nucleotide", "CHEMICAL", 143, 153], ["DCEK transfectants", "CELL", 0, 18], ["dynamin II K44A", "GENE_OR_GENE_PRODUCT", 71, 86], ["dynamin", "GENE_OR_GENE_PRODUCT", 106, 113], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 283, 289], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 437, 444], ["mouse", "ORGANISM", 449, 454], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 465, 472], ["mice", "ORGANISM", 496, 500], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 519, 530], ["DCEK transfectants", "CELL_LINE", 0, 18], ["plasmids", "DNA", 53, 61], ["dynamin II K44A", "PROTEIN", 71, 86], ["dominant-negative dynamin", "PROTEIN", 88, 113], ["nucleotide-binding site", "DNA", 143, 166], ["100 \u03bcg 22D1 antibody", "PROTEIN", 544, 564], ["isotype hamster IgG", "PROTEIN", 568, 587], ["mouse", "SPECIES", 449, 454], ["mice", "SPECIES", 496, 500], ["hamster", "SPECIES", 576, 583], ["mouse", "SPECIES", 449, 454], ["mice", "SPECIES", 496, 500], ["hamster", "SPECIES", 576, 583], ["DCEK transfectants", "TREATMENT", 0, 18], ["a point mutation", "PROBLEM", 119, 135], ["an empty pcDNA3 vector", "TREATMENT", 274, 296], ["Lipofectamine", "TREATMENT", 313, 326], ["reagent (Invitrogen Life Technologies", "TREATMENT", 332, 369], ["isotype control mice", "TREATMENT", 480, 500], ["intravenous injection", "TREATMENT", 519, 540], ["isotype hamster IgG", "TREATMENT", 568, 587], ["R1 TKO", "OBSERVATION", 442, 448], ["mouse generation", "OBSERVATION", 449, 465]]], ["The 22D1 antibody selectively and transiently depleted the surface SIGN-R1 molecule, but not SIGN-R1 + macrophages in the splenic MZ, permitting analysis of its function in vivo, as in a previous report 70 .Complement C3-depleted miceControl mice were obtained by intraperitoneally injecting 60 U/kg of cobra venom factor one day prior to the experimental challenge.", [["surface", "ANATOMY", 59, 66], ["SIGN-R1 + macrophages", "ANATOMY", 93, 114], ["splenic MZ", "ANATOMY", 122, 132], ["intraperitoneally", "ANATOMY", 264, 281], ["MZ", "CHEMICAL", 130, 132], ["22D1", "GENE_OR_GENE_PRODUCT", 4, 8], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 67, 74], ["SIGN-R1", "GENE_OR_GENE_PRODUCT", 93, 100], ["splenic MZ", "MULTI-TISSUE_STRUCTURE", 122, 132], ["Complement C3", "GENE_OR_GENE_PRODUCT", 207, 220], ["miceControl", "ORGANISM", 230, 241], ["mice", "ORGANISM", 242, 246], ["cobra", "ORGANISM", 303, 308], ["venom", "ORGANISM_SUBSTANCE", 309, 314], ["22D1 antibody", "PROTEIN", 4, 17], ["surface SIGN-R1 molecule", "PROTEIN", 59, 83], ["SIGN", "PROTEIN", 93, 97], ["R1", "PROTEIN", 98, 100], ["macrophages", "CELL_TYPE", 103, 114], ["splenic MZ", "CELL_TYPE", 122, 132], ["Complement C3", "PROTEIN", 207, 220], ["cobra venom factor", "PROTEIN", 303, 321], ["mice", "SPECIES", 242, 246], ["mice", "SPECIES", 242, 246], ["The 22D1 antibody", "TEST", 0, 17], ["the surface SIGN", "TEST", 55, 71], ["SIGN", "TEST", 93, 97], ["macrophages", "PROBLEM", 103, 114], ["Complement C3-depleted miceControl mice", "TREATMENT", 207, 246], ["cobra venom factor", "TREATMENT", 303, 321], ["the experimental challenge", "TREATMENT", 339, 365], ["depleted", "OBSERVATION", 46, 54], ["surface", "OBSERVATION_MODIFIER", 59, 66], ["R1 molecule", "OBSERVATION", 72, 83], ["macrophages", "OBSERVATION", 103, 114], ["splenic", "ANATOMY", 122, 129], ["MZ", "ANATOMY_MODIFIER", 130, 132]]], ["C3 depletion was confirmed by Western blot analysis for C3 by using sera.Mouse infection studiesMitomycin C-treated fluorescent bacteria (1 \u00d7 10 8 ) were intravenously administered to mice for the indicated times.", [["sera", "ANATOMY", 68, 72], ["infection", "DISEASE", 79, 88], ["Mitomycin C", "CHEMICAL", 96, 107], ["Mitomycin C", "CHEMICAL", 96, 107], ["C3", "GENE_OR_GENE_PRODUCT", 0, 2], ["C3", "GENE_OR_GENE_PRODUCT", 56, 58], ["sera", "ORGANISM_SUBSTANCE", 68, 72], ["Mouse", "ORGANISM", 73, 78], ["Mitomycin C", "SIMPLE_CHEMICAL", 96, 107], ["mice", "ORGANISM", 184, 188], ["C3", "PROTEIN", 0, 2], ["C3", "PROTEIN", 56, 58], ["Mouse", "SPECIES", 73, 78], ["mice", "SPECIES", 184, 188], ["Mouse", "SPECIES", 73, 78], ["mice", "SPECIES", 184, 188], ["C3 depletion", "PROBLEM", 0, 12], ["blot analysis", "TEST", 38, 51], ["Mouse infection", "PROBLEM", 73, 88], ["Mitomycin C-treated fluorescent bacteria", "TREATMENT", 96, 136], ["depletion", "OBSERVATION", 3, 12], ["infection", "OBSERVATION", 79, 88]]], ["Mice were sacrificed, and spleen sections were examined by deconvolution fluorescence microscopy.Assay for in vivo and in vitro C3 processingTo quantify C3 processing in tissues in vivo, 1 \u00d7 10 8 S. pneumoniae were injected intravenously, and tissue lysates were collected at the indicated times, separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotted with polyclonal antimouse C3 antibodies.", [["spleen sections", "ANATOMY", 26, 41], ["tissues", "ANATOMY", 170, 177], ["intravenously", "ANATOMY", 224, 237], ["tissue lysates", "ANATOMY", 243, 257], ["sodium dodecyl sulfate", "CHEMICAL", 310, 332], ["sodium dodecyl sulfate", "CHEMICAL", 310, 332], ["polyacrylamide", "CHEMICAL", 333, 347], ["Mice", "ORGANISM", 0, 4], ["spleen sections", "MULTI-TISSUE_STRUCTURE", 26, 41], ["C3", "GENE_OR_GENE_PRODUCT", 153, 155], ["tissues", "TISSUE", 170, 177], ["S. pneumoniae", "ORGANISM", 196, 209], ["tissue lysates", "ORGANISM_SUBSTANCE", 243, 257], ["sodium dodecyl sulfate polyacrylamide", "SIMPLE_CHEMICAL", 310, 347], ["antimouse C3 antibodies", "GENE_OR_GENE_PRODUCT", 414, 437], ["C3", "PROTEIN", 153, 155], ["polyclonal antimouse C3 antibodies", "PROTEIN", 403, 437], ["Mice", "SPECIES", 0, 4], ["S. pneumoniae", "SPECIES", 196, 209], ["Mice", "SPECIES", 0, 4], ["S. pneumoniae", "SPECIES", 196, 209], ["deconvolution fluorescence microscopy", "TEST", 59, 96], ["Assay", "TEST", 97, 102], ["pneumoniae", "PROBLEM", 199, 209], ["tissue lysates", "TEST", 243, 257], ["sodium dodecyl sulfate polyacrylamide gel electrophoresis", "TREATMENT", 310, 367], ["polyclonal antimouse C3 antibodies", "TREATMENT", 403, 437], ["spleen", "ANATOMY", 26, 32], ["tissues", "ANATOMY", 170, 177], ["pneumoniae", "OBSERVATION", 199, 209]]], ["For in vitro C3 processing, 1 \u00d7 10 8 S. pneumoniae were incubated with 5% NHS in TC buffer (140 mM NaCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 10 mM Tris, pH 7.5, supplemented with 1% BSA) for 30 min at 37\u00b0C. The bacteria were washed, mixed, and boiled with 20 \u00b5L of 2\u00d7 SDS sample buffer.", [["NaCl", "CHEMICAL", 99, 103], ["CaCl", "CHEMICAL", 110, 114], ["NaCl", "CHEMICAL", 99, 103], ["CaCl 2", "CHEMICAL", 110, 116], ["MgCl 2", "CHEMICAL", 124, 130], ["Tris", "CHEMICAL", 139, 143], ["S. pneumoniae", "ORGANISM", 37, 50], ["NHS", "SIMPLE_CHEMICAL", 74, 77], ["TC", "SIMPLE_CHEMICAL", 81, 83], ["BSA", "SIMPLE_CHEMICAL", 174, 177], ["S. pneumoniae", "SPECIES", 37, 50], ["S. pneumoniae", "SPECIES", 37, 50], ["vitro C3 processing", "TEST", 7, 26], ["pneumoniae", "PROBLEM", 40, 50], ["5% NHS in TC buffer", "TREATMENT", 71, 90], ["NaCl", "TEST", 99, 103], ["2 mM CaCl", "TREATMENT", 105, 114], ["2 mM MgCl", "TREATMENT", 119, 128], ["pH", "TEST", 145, 147], ["The bacteria", "PROBLEM", 199, 211], ["pneumoniae", "OBSERVATION", 40, 50], ["bacteria", "OBSERVATION", 203, 211]]], ["Bacterial lysates were separated by SDS-PAGE and immunoblotted with polyclonal antimouse C3 antibodies.", [["lysates", "ANATOMY", 10, 17], ["lysates", "ORGANISM_SUBSTANCE", 10, 17], ["antimouse C3 antibodies", "GENE_OR_GENE_PRODUCT", 79, 102], ["polyclonal antimouse C3 antibodies", "PROTEIN", 68, 102], ["Bacterial lysates", "PROBLEM", 0, 17], ["SDS", "TEST", 36, 39], ["polyclonal antimouse C3 antibodies", "TREATMENT", 68, 102]]], ["These antibodies detected the components of native C3, \u03b1C3, and \u03b2C3, as well as the fragments of \u03b1C3 (molecular weights in humans: 113 kDa for \u03b1C3, 104 kDa of \u03b1C3\u2032, 63 kDa and 41 kDa for iC3b fragments, and 75 kDa for \u03b2C3; molecular weights in rats: 120 kDa for \u03b1C3, 70 kDa and 43 kDa for iC3b fragments, and 65 kDa for \u03b2C3) that are generated during C3 processing by C3 convertases by immunoblotting analysis.", [["C3", "GENE_OR_GENE_PRODUCT", 51, 53], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 55, 58], ["\u03b2C3", "GENE_OR_GENE_PRODUCT", 64, 67], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 97, 100], ["humans", "ORGANISM", 123, 129], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 143, 146], ["\u03b1C3\u2032", "GENE_OR_GENE_PRODUCT", 159, 163], ["iC3b", "GENE_OR_GENE_PRODUCT", 187, 191], ["\u03b2C3", "GENE_OR_GENE_PRODUCT", 218, 221], ["rats", "ORGANISM", 244, 248], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 262, 265], ["iC3b", "GENE_OR_GENE_PRODUCT", 289, 293], ["\u03b2C3", "GENE_OR_GENE_PRODUCT", 320, 323], ["C3", "GENE_OR_GENE_PRODUCT", 351, 353], ["C3 convertases", "GENE_OR_GENE_PRODUCT", 368, 382], ["antibodies", "PROTEIN", 6, 16], ["C3", "PROTEIN", 51, 53], ["\u03b1C3", "PROTEIN", 55, 58], ["\u03b2C3", "PROTEIN", 64, 67], ["\u03b1C3", "PROTEIN", 97, 100], ["\u03b1C3", "PROTEIN", 143, 146], ["\u03b1C3\u2032", "PROTEIN", 159, 163], ["63 kDa", "PROTEIN", 165, 171], ["41 kDa", "PROTEIN", 176, 182], ["iC3b fragments", "PROTEIN", 187, 201], ["75 kDa", "PROTEIN", 207, 213], ["\u03b2C3", "PROTEIN", 218, 221], ["\u03b1C3", "PROTEIN", 262, 265], ["70 kDa", "PROTEIN", 267, 273], ["43 kDa", "PROTEIN", 278, 284], ["iC3b fragments", "PROTEIN", 289, 303], ["65 kDa", "PROTEIN", 309, 315], ["\u03b2C3", "PROTEIN", 320, 323], ["C3", "PROTEIN", 351, 353], ["C3 convertases", "PROTEIN", 368, 382], ["humans", "SPECIES", 123, 129], ["rats", "SPECIES", 244, 248], ["humans", "SPECIES", 123, 129], ["These antibodies", "TEST", 0, 16], ["native C3, \u03b1C3, and \u03b2C3", "PROBLEM", 44, 67], ["C3", "TEST", 144, 146], ["kDa", "TEST", 152, 155], ["C3\u2032", "TEST", 160, 163], ["kDa", "TEST", 168, 171], ["kDa", "TEST", 179, 182], ["iC3b fragments", "TEST", 187, 201], ["kDa", "TEST", 210, 213], ["C3", "TEST", 219, 221], ["molecular weights", "TEST", 223, 240], ["C3", "TEST", 263, 265], ["iC3b fragments", "PROBLEM", 289, 303], ["kDa for \u03b2C3)", "TEST", 312, 324], ["immunoblotting analysis", "TEST", 386, 409], ["native", "ANATOMY_MODIFIER", 44, 50], ["C3", "ANATOMY_MODIFIER", 51, 53], ["C3", "ANATOMY_MODIFIER", 56, 58], ["C3", "ANATOMY_MODIFIER", 65, 67], ["fragments", "OBSERVATION", 84, 93]]], ["In the steady state, \u03b1C3 and \u03b2C3 are predominant, with a few larger iC3b.", [["\u03b1C3", "GENE_OR_GENE_PRODUCT", 21, 24], ["\u03b2C3", "GENE_OR_GENE_PRODUCT", 29, 32], ["iC3b", "GENE_OR_GENE_PRODUCT", 68, 72], ["\u03b1C3", "PROTEIN", 21, 24], ["\u03b2C3", "PROTEIN", 29, 32], ["iC3b", "PROTEIN", 68, 72], ["C3", "ANATOMY_MODIFIER", 30, 32], ["predominant", "OBSERVATION_MODIFIER", 37, 48], ["few", "OBSERVATION_MODIFIER", 57, 60], ["larger", "OBSERVATION_MODIFIER", 61, 67], ["iC3b", "OBSERVATION", 68, 72]]], ["With activation, \u03b1C3 and larger iC3b are rapidly processed into smaller fragments, including 43 kDa iC3b, but not \u03b2C3, which serves as a loading control for the immunoblotting analysis, resulting in loss of most of the detectable \u03b1C3 as well as larger iC3b, but accumulation of the smaller iC3b in C3 activation in immunoblotting analysis 70 .Western blot analysis and immunodetectionTissues, cells, and bacteria were lysed in RIPA buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.0/1% Nonidet P-40/0.5% sodium deoxycholate/0.1% SDS) supplemented with 0.2% protease inhibitor cocktail (Sigma), and lysed samples were mixed with an equal volume of 2\u00d7 SDS sample buffer containing 2-mercaptoethanol and boiled at 95\u00b0C for 5 min (100\u00b0C for 10 min).", [["fragments", "ANATOMY", 72, 81], ["Tissues", "ANATOMY", 384, 391], ["cells", "ANATOMY", 393, 398], ["samples", "ANATOMY", 597, 604], ["NaCl", "CHEMICAL", 447, 451], ["Tris-HCl", "CHEMICAL", 459, 467], ["Nonidet P-40", "CHEMICAL", 479, 491], ["sodium deoxycholate", "CHEMICAL", 497, 516], ["2-mercaptoethanol", "CHEMICAL", 672, 689], ["NaCl", "CHEMICAL", 447, 451], ["Tris-HCl", "CHEMICAL", 459, 467], ["sodium deoxycholate", "CHEMICAL", 497, 516], ["2-mercaptoethanol", "CHEMICAL", 672, 689], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 17, 20], ["iC3b", "GENE_OR_GENE_PRODUCT", 32, 36], ["iC3b", "GENE_OR_GENE_PRODUCT", 100, 104], ["\u03b2C3", "GENE_OR_GENE_PRODUCT", 114, 117], ["\u03b1C3", "GENE_OR_GENE_PRODUCT", 230, 233], ["iC3b", "GENE_OR_GENE_PRODUCT", 252, 256], ["iC3b", "GENE_OR_GENE_PRODUCT", 290, 294], ["C3", "GENE_OR_GENE_PRODUCT", 298, 300], ["cells", "CELL", 393, 398], ["Tris-HCl", "SIMPLE_CHEMICAL", 459, 467], ["Nonidet P-40", "SIMPLE_CHEMICAL", 479, 491], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 497, 516], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 672, 689], ["\u03b1C3", "PROTEIN", 17, 20], ["iC3b", "PROTEIN", 32, 36], ["43 kDa iC3b", "PROTEIN", 93, 104], ["\u03b2C3", "PROTEIN", 114, 117], ["\u03b1C3", "PROTEIN", 230, 233], ["iC3b", "PROTEIN", 252, 256], ["iC3b", "PROTEIN", 290, 294], ["C3", "PROTEIN", 298, 300], ["\u03b1C3 and larger iC3b", "TREATMENT", 17, 36], ["smaller fragments", "PROBLEM", 64, 81], ["43 kDa iC3b", "TEST", 93, 104], ["a loading control", "TREATMENT", 135, 152], ["the immunoblotting analysis", "TEST", 157, 184], ["larger iC3b", "PROBLEM", 245, 256], ["immunoblotting analysis", "TEST", 315, 338], ["Western blot analysis", "TEST", 343, 364], ["immunodetectionTissues", "TEST", 369, 391], ["cells", "TEST", 393, 398], ["bacteria", "PROBLEM", 404, 412], ["NaCl", "TEST", 447, 451], ["Tris", "TEST", 459, 463], ["HCl", "TEST", 464, 467], ["pH", "TEST", 469, 471], ["P", "TEST", 487, 488], ["sodium deoxycholate", "TREATMENT", 497, 516], ["0.2% protease inhibitor cocktail", "TREATMENT", 545, 577], ["SDS sample buffer", "TREATMENT", 643, 660], ["mercaptoethanol", "TREATMENT", 674, 689], ["larger", "OBSERVATION_MODIFIER", 25, 31], ["iC3b", "OBSERVATION", 32, 36], ["smaller", "OBSERVATION_MODIFIER", 64, 71], ["fragments", "OBSERVATION", 72, 81], ["larger", "OBSERVATION_MODIFIER", 245, 251], ["iC3b", "OBSERVATION", 252, 256], ["smaller", "OBSERVATION_MODIFIER", 282, 289], ["iC3b", "OBSERVATION", 290, 294], ["C3 activation", "OBSERVATION", 298, 311]]], ["Diluted sera (1:50) or fractions of LRs were mixed with 2\u00d7 or 5\u00d7 SDS sample buffer with 2-mercaptoethanol and boiled at 95\u00b0C for 10 min (100\u00b0C for 10 min).", [["sera", "ANATOMY", 8, 12], ["2-mercaptoethanol", "CHEMICAL", 88, 105], ["2-mercaptoethanol", "CHEMICAL", 88, 105], ["sera", "ORGANISM_SUBSTANCE", 8, 12], ["2-mercaptoethanol", "SIMPLE_CHEMICAL", 88, 105], ["mercaptoethanol", "TREATMENT", 90, 105]]], ["The samples were separated by SDS-PAGE on 4-15% gradient gels and transferred to polyvinylidene difluoride membranes, followed by incubation with antibodies.", [["samples", "ANATOMY", 4, 11], ["membranes", "ANATOMY", 107, 116], ["polyvinylidene", "CHEMICAL", 81, 95], ["difluoride", "CHEMICAL", 96, 106], ["membranes", "CELLULAR_COMPONENT", 107, 116], ["antibodies", "PROTEIN", 146, 156], ["The samples", "TEST", 0, 11], ["SDS", "TEST", 30, 33], ["15% gradient gels", "TREATMENT", 44, 61], ["polyvinylidene difluoride membranes", "TREATMENT", 81, 116]]], ["Antibody-reactive bands on the blots were visualized with peroxidase-labeled secondary antibodies, followed by treatment with West-ZOL plus (Intron) or Immobilon (Millipore).Human cadaver spleen studiesHuman cadaveric spleens were donated from the Department of Anatomy, School of Medicine, Konkuk University (Seoul, Korea).Software used in this studyFluorescent images were analyzed with the MetaMorph software (Universal Imaging).", [["spleen", "ANATOMY", 188, 194], ["spleens", "ANATOMY", 218, 225], ["ZOL", "CHEMICAL", 131, 134], ["ZOL", "CHEMICAL", 131, 134], ["peroxidase", "SIMPLE_CHEMICAL", 58, 68], ["ZOL", "SIMPLE_CHEMICAL", 131, 134], ["Human", "ORGANISM", 174, 179], ["spleen", "ORGAN", 188, 194], ["Human", "ORGANISM", 202, 207], ["spleens", "ORGAN", 218, 225], ["peroxidase", "PROTEIN", 58, 68], ["secondary antibodies", "PROTEIN", 77, 97], ["Human", "SPECIES", 174, 179], ["Human", "SPECIES", 202, 207], ["Human", "SPECIES", 174, 179], ["Antibody", "TEST", 0, 8], ["reactive bands", "PROBLEM", 9, 23], ["the blots", "TEST", 27, 36], ["peroxidase", "TEST", 58, 68], ["secondary antibodies", "PROBLEM", 77, 97], ["West-ZOL plus (Intron)", "TREATMENT", 126, 148], ["Immobilon (Millipore", "TREATMENT", 152, 172], ["Human cadaver spleen studiesHuman cadaveric spleens", "TREATMENT", 174, 225], ["this study", "TEST", 341, 351], ["Fluorescent images", "TEST", 351, 369], ["Universal Imaging", "TEST", 413, 430], ["reactive bands", "OBSERVATION", 9, 23], ["spleen", "ANATOMY", 188, 194]]], ["Immunoblotting signals were detected using LAS-4200 (Fuji Film).Statistical analysesThe number of cells binding to bacteria and the number of cells decomposing bacteria were counted.", [["cells", "ANATOMY", 98, 103], ["cells", "ANATOMY", 142, 147], ["LAS-4200", "CHEMICAL", 43, 51], ["LAS-4200", "CHEMICAL", 43, 51], ["cells", "CELL", 98, 103], ["cells", "CELL", 142, 147], ["Immunoblotting signals", "TEST", 0, 22], ["Fuji Film", "TEST", 53, 62], ["Statistical analyses", "TEST", 64, 84], ["cells binding", "PROBLEM", 98, 111], ["bacteria", "PROBLEM", 115, 123], ["cells decomposing bacteria", "PROBLEM", 142, 168], ["bacteria", "OBSERVATION_MODIFIER", 115, 123], ["bacteria", "OBSERVATION_MODIFIER", 160, 168]]], ["The average percentage of pneumococcal decomposition of the total pneumococcal binding to cells was calculated in five areas of each sample from three independent experiments and shown in the indicated graphs.", [["cells", "ANATOMY", 90, 95], ["cells", "CELL", 90, 95], ["pneumococcal", "SPECIES", 26, 38], ["pneumococcal", "SPECIES", 66, 78], ["pneumococcal decomposition", "TREATMENT", 26, 52], ["the total pneumococcal binding to cells", "PROBLEM", 56, 95], ["average", "OBSERVATION_MODIFIER", 4, 11], ["percentage", "OBSERVATION_MODIFIER", 12, 22], ["pneumococcal decomposition", "OBSERVATION", 26, 52], ["total", "OBSERVATION_MODIFIER", 60, 65], ["pneumococcal binding to cells", "OBSERVATION", 66, 95]]], ["Statistical significance between groups were determined by two-way analysis of variance, followed by Tukey's post hoc tests and unpaired Student's t tests with a two-tailed test. p Value < 0.05 was taken to indicate statistical significance (not significant, ns; p < 0.001) Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [["hoc tests", "TEST", 114, 123], ["Student's t tests", "TEST", 137, 154], ["a two-tailed test", "TEST", 160, 177], ["p Value", "TEST", 179, 186]]]], "e8392d9561be82ded77c6e5d75f321d752776424": [["IntroductionCoronaviruses (CoVs), members of the Coronaviridae family and sub family Coronavirinae within the order Nidovirales, are enveloped viruses with a positive-sense RNA genome of 27-31 kb [1] .", [["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 49, 62], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 116, 127], ["CoVs", "PROTEIN", 27, 31], ["Coronaviridae family", "PROTEIN", 49, 69], ["positive-sense RNA genome", "DNA", 158, 183], ["Nidovirales", "TREATMENT", 116, 127]]], ["Based on genetic and serological analyses, CoVs are divided into three genera [2] alpha-and beta-and gamma-coronaviruses.IntroductionAlpha-and beta-coronaviruses have been isolated from mammals, while gamma-coronaviruses genera is formed by Avian infectious bronchitis virus (IBV), together with the genetically closely related Turkey coronavirus [3, 4, 5, 6] , Pheasant coronavirus [7] , and recently identified coronaviruses from several species of wild birds [8, 9] , a beluga whale [10] and an Asian Leopard cat [11] .IntroductionDue to their high mutation and recombination rate during replication, CoVs are able to generate extensive genotypic variation, which facilitates adaptation to new host species [12] .", [["Avian infectious bronchitis virus", "DISEASE", 241, 274], ["CoVs", "GENE_OR_GENE_PRODUCT", 43, 47], ["beta", "GENE_OR_GENE_PRODUCT", 92, 96], ["gamma-coronaviruses", "GENE_OR_GENE_PRODUCT", 101, 120], ["Alpha", "GENE_OR_GENE_PRODUCT", 133, 138], ["beta-coronaviruses", "GENE_OR_GENE_PRODUCT", 143, 161], ["gamma-coronaviruses", "GENE_OR_GENE_PRODUCT", 201, 220], ["Avian infectious bronchitis virus", "ORGANISM", 241, 274], ["IBV", "ORGANISM", 276, 279], ["Turkey coronavirus", "ORGANISM", 328, 346], ["Pheasant coronavirus", "ORGANISM", 362, 382], ["coronaviruses", "ORGANISM", 413, 426], ["CoVs", "GENE_OR_GENE_PRODUCT", 604, 608], ["CoVs", "DNA", 43, 47], ["beta", "PROTEIN", 92, 96], ["gamma-coronaviruses", "PROTEIN", 101, 120], ["Alpha-and beta-coronaviruses", "PROTEIN", 133, 161], ["CoVs", "DNA", 604, 608], ["Avian infectious bronchitis virus", "SPECIES", 241, 274], ["Pheasant coronavirus", "SPECIES", 362, 382], ["cat", "SPECIES", 512, 515], ["Avian infectious bronchitis virus", "SPECIES", 241, 274], ["IBV", "SPECIES", 276, 279], ["Turkey coronavirus", "SPECIES", 328, 346], ["Pheasant coronavirus", "SPECIES", 362, 382], ["Asian Leopard cat", "SPECIES", 498, 515], ["genetic and serological analyses", "TEST", 9, 41], ["CoVs", "TEST", 43, 47], ["genera", "TEST", 71, 77], ["alpha", "TEST", 82, 87], ["beta", "TEST", 92, 96], ["IntroductionAlpha", "TEST", 121, 138], ["beta-coronaviruses", "TREATMENT", 143, 161], ["Avian infectious bronchitis virus", "PROBLEM", 241, 274], ["Pheasant coronavirus", "PROBLEM", 362, 382], ["coronaviruses", "PROBLEM", 413, 426], ["a beluga whale", "TEST", 471, 485], ["IntroductionDue", "TREATMENT", 522, 537], ["their high mutation", "PROBLEM", 541, 560], ["recombination rate during replication", "TREATMENT", 565, 602], ["CoVs", "PROBLEM", 604, 608], ["coronaviruses", "OBSERVATION", 413, 426]]], ["In animals, CoVs generally cause respiratory or intestinal infections, but they have also been associated with a wide spectrum of other clinical symptoms, including hepatic, renal, reproductive and neurological diseases [13] .", [["respiratory", "ANATOMY", 33, 44], ["intestinal", "ANATOMY", 48, 58], ["hepatic", "ANATOMY", 165, 172], ["renal", "ANATOMY", 174, 179], ["neurological", "ANATOMY", 198, 210], ["respiratory or intestinal infections", "DISEASE", 33, 69], ["hepatic, renal, reproductive and neurological diseases", "DISEASE", 165, 219], ["CoVs", "GENE_OR_GENE_PRODUCT", 12, 16], ["intestinal", "ORGAN", 48, 58], ["hepatic", "MULTI-TISSUE_STRUCTURE", 165, 172], ["renal", "ORGAN", 174, 179], ["CoVs", "PROBLEM", 12, 16], ["respiratory or intestinal infections", "PROBLEM", 33, 69], ["a wide spectrum of other clinical symptoms", "PROBLEM", 111, 153], ["hepatic, renal, reproductive and neurological diseases", "PROBLEM", 165, 219], ["intestinal", "ANATOMY", 48, 58], ["infections", "OBSERVATION", 59, 69], ["hepatic", "ANATOMY", 165, 172], ["renal", "ANATOMY", 174, 179]]], ["The only exception is the notorious feline infectious peritonitis virus (FIPV), which causes a sporadic but fatal generalized disease in Felidae [14] .IntroductionBeyond their causal role in the common cold, human coronaviruses (HCoVs) received relatively little attention as human pathogens until the emergence of the severe acute respiratory syndrome (SARS) epidemic in 2003 [15] .", [["feline infectious peritonitis", "DISEASE", 36, 65], ["acute respiratory syndrome", "DISEASE", 326, 352], ["SARS", "DISEASE", 354, 358], ["feline infectious peritonitis virus", "ORGANISM", 36, 71], ["human", "ORGANISM", 208, 213], ["coronaviruses", "ORGANISM", 214, 227], ["HCoVs", "CANCER", 229, 234], ["human", "ORGANISM", 276, 281], ["feline infectious peritonitis virus", "SPECIES", 36, 71], ["human", "SPECIES", 208, 213], ["human", "SPECIES", 276, 281], ["feline infectious peritonitis virus", "SPECIES", 36, 71], ["FIPV", "SPECIES", 73, 77], ["human coronaviruses", "SPECIES", 208, 227], ["human", "SPECIES", 276, 281], ["the notorious feline infectious peritonitis virus", "PROBLEM", 22, 71], ["a sporadic but fatal generalized disease in Felidae", "PROBLEM", 93, 144], ["human coronaviruses (HCoVs)", "TREATMENT", 208, 235], ["human pathogens", "PROBLEM", 276, 291], ["the severe acute respiratory syndrome", "PROBLEM", 315, 352], ["notorious feline", "OBSERVATION_MODIFIER", 26, 42], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["peritonitis", "OBSERVATION", 54, 65], ["sporadic", "OBSERVATION_MODIFIER", 95, 103], ["fatal", "OBSERVATION_MODIFIER", 108, 113], ["generalized", "OBSERVATION_MODIFIER", 114, 125], ["disease", "OBSERVATION", 126, 133], ["common cold", "ANATOMY", 195, 206], ["severe", "OBSERVATION_MODIFIER", 319, 325], ["acute", "OBSERVATION_MODIFIER", 326, 331], ["respiratory syndrome", "OBSERVATION", 332, 352]]], ["The identification of SARS-CoV, with its pandemic potential, provided new impetus to CoV research; since then, many previously unidentified CoVs have been discovered in humans and animals [16, 17] .", [["SARS", "DISEASE", 22, 26], ["SARS-CoV", "ORGANISM", 22, 30], ["CoV", "ORGANISM", 85, 88], ["CoVs", "GENE_OR_GENE_PRODUCT", 140, 144], ["humans", "ORGANISM", 169, 175], ["CoVs", "DNA", 140, 144], ["humans", "SPECIES", 169, 175], ["SARS-CoV", "SPECIES", 22, 30], ["humans", "SPECIES", 169, 175], ["SARS", "PROBLEM", 22, 26], ["CoV", "PROBLEM", 27, 30], ["many previously unidentified CoVs", "PROBLEM", 111, 144], ["SARS", "OBSERVATION", 22, 26], ["CoVs", "OBSERVATION", 140, 144]]], ["Because evidence based on molecular genetic data showed that the causative agent of SARS most likely originated from recombination events between mammalian-like and avian-like parental viruses present in wild animal species [18] , CoVs are considered not only as pathogens of veterinary importance but also as a threat to mankind.", [["SARS", "DISEASE", 84, 88], ["avian-like parental viruses", "ORGANISM", 165, 192], ["CoVs", "GENE_OR_GENE_PRODUCT", 231, 235], ["molecular genetic data", "TEST", 26, 48], ["SARS", "PROBLEM", 84, 88], ["recombination events", "PROBLEM", 117, 137], ["parental viruses", "PROBLEM", 176, 192], ["CoVs", "PROBLEM", 231, 235], ["viruses", "OBSERVATION", 185, 192]]], ["Therefore, surveillance for possible animal reservoirs of CoVs has gained importance in the research community.IntroductionWild bird species are reservoirs for a number of emerging viruses.", [["CoVs", "CHEMICAL", 58, 62], ["CoVs", "GENE_OR_GENE_PRODUCT", 58, 62], ["surveillance", "TEST", 11, 23], ["animal reservoirs of CoVs", "PROBLEM", 37, 62], ["bird species", "OBSERVATION", 128, 140], ["viruses", "OBSERVATION", 181, 188]]], ["The most well-known among them is avian influenza A virus [19] .", [["avian influenza A virus", "DISEASE", 34, 57], ["avian", "ORGANISM", 34, 39], ["influenza A virus", "ORGANISM", 40, 57], ["avian influenza A virus", "SPECIES", 34, 57], ["avian influenza A virus", "PROBLEM", 34, 57]]], ["Wild bird species may also harbour other respiratory and enteric viruses, including CoVs.", [["respiratory", "ANATOMY", 41, 52], ["respiratory and enteric viruses", "DISEASE", 41, 72], ["CoVs", "GENE_OR_GENE_PRODUCT", 84, 88], ["Wild bird species", "PROBLEM", 0, 17], ["CoVs", "PROBLEM", 84, 88], ["bird species", "OBSERVATION", 5, 17], ["enteric", "ANATOMY", 57, 64], ["viruses", "OBSERVATION", 65, 72]]], ["IBV is a gamma-coronavirus that is responsible for severe economic losses in the poultry industry [20] .", [["IBV", "ORGANISM", 0, 3], ["IBV", "SPECIES", 0, 3], ["IBV", "PROBLEM", 0, 3], ["severe economic losses", "PROBLEM", 51, 73], ["responsible for", "UNCERTAINTY", 35, 50], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["economic", "OBSERVATION_MODIFIER", 58, 66], ["losses", "OBSERVATION", 67, 73]]], ["This global virus causes an acute and highly contagious respiratory disease in chickens (Gallus gallus) of all ages and diminishes egg production in hens [21] .", [["respiratory", "ANATOMY", 56, 67], ["egg", "ANATOMY", 131, 134], ["respiratory disease", "DISEASE", 56, 75], ["chickens", "ORGANISM", 79, 87], ["Gallus gallus", "ORGANISM", 89, 102], ["egg", "ORGANISM_SUBDIVISION", 131, 134], ["chickens", "SPECIES", 79, 87], ["Gallus gallus", "SPECIES", 89, 102], ["chickens", "SPECIES", 79, 87], ["Gallus gallus", "SPECIES", 89, 102], ["This global virus", "PROBLEM", 0, 17], ["an acute and highly contagious respiratory disease in chickens (Gallus gallus", "PROBLEM", 25, 102], ["diminishes egg production", "PROBLEM", 120, 145], ["virus", "OBSERVATION", 12, 17], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["highly", "OBSERVATION_MODIFIER", 38, 44], ["contagious", "OBSERVATION_MODIFIER", 45, 55], ["respiratory disease", "OBSERVATION", 56, 75], ["Gallus gallus", "ANATOMY", 89, 102], ["diminishes", "OBSERVATION_MODIFIER", 120, 130], ["egg", "OBSERVATION_MODIFIER", 131, 134]]], ["A number of IBV strains cause severe nephritis, with mortality reaching up to 30% [20] .", [["nephritis", "DISEASE", 37, 46], ["IBV", "ORGANISM", 12, 15], ["IBV", "SPECIES", 12, 15], ["IBV strains", "PROBLEM", 12, 23], ["severe nephritis", "PROBLEM", 30, 46], ["IBV strains", "OBSERVATION", 12, 23], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["nephritis", "OBSERVATION", 37, 46]]], ["Disease control is based mostly on vaccination, but the virus constant antigenic changes sometimes result in incomplete protection [22] .", [["Disease control", "PROBLEM", 0, 15], ["vaccination", "TREATMENT", 35, 46], ["the virus constant antigenic changes", "PROBLEM", 52, 88]]], ["Although chickens are the primary natural host of IBV, several research groups have recently found IBV-like viruses and new CoVs in other bird species [13, 23] .", [["chickens", "ORGANISM", 9, 17], ["IBV", "ORGANISM", 50, 53], ["IBV-like viruses", "ORGANISM", 99, 115], ["CoVs", "GENE_OR_GENE_PRODUCT", 124, 128], ["chickens", "SPECIES", 9, 17], ["chickens", "SPECIES", 9, 17], ["IBV", "SPECIES", 50, 53], ["IBV", "SPECIES", 99, 102], ["IBV", "PROBLEM", 50, 53], ["IBV", "PROBLEM", 99, 102], ["like viruses", "PROBLEM", 103, 115], ["new CoVs in other bird species", "PROBLEM", 120, 150], ["IBV", "OBSERVATION", 99, 102], ["viruses", "OBSERVATION", 108, 115], ["new", "OBSERVATION_MODIFIER", 120, 123], ["CoVs", "OBSERVATION_MODIFIER", 124, 128]]], ["Furthermore, new CoVs that are genetically distinct from IBV have been identified in different bird families [9] and in beluga whales [10] .", [["CoVs", "GENE_OR_GENE_PRODUCT", 17, 21], ["IBV", "ORGANISM", 57, 60], ["CoVs", "PROTEIN", 17, 21], ["IBV", "SPECIES", 57, 60], ["new CoVs", "PROBLEM", 13, 21], ["IBV", "PROBLEM", 57, 60], ["new", "OBSERVATION_MODIFIER", 13, 16], ["CoVs", "OBSERVATION", 17, 21]]], ["Our investigations showed the presence of gamma-CoVs in wild mallards (Anas platyrhynchos), indicating that wild ducks may spread and harbour CoVs [24] .", [["gamma-CoVs", "CHEMICAL", 42, 52], ["gamma-CoVs", "GENE_OR_GENE_PRODUCT", 42, 52], ["mallards", "ORGANISM", 61, 69], ["Anas platyrhynchos", "ORGANISM", 71, 89], ["ducks", "ORGANISM", 113, 118], ["gamma-CoVs", "PROTEIN", 42, 52], ["mallards", "SPECIES", 61, 69], ["Anas platyrhynchos", "SPECIES", 71, 89], ["ducks", "SPECIES", 113, 118], ["wild mallards", "SPECIES", 56, 69], ["Anas platyrhynchos", "SPECIES", 71, 89], ["Our investigations", "TEST", 0, 18], ["gamma-CoVs", "PROBLEM", 42, 52], ["wild ducks", "PROBLEM", 108, 118], ["wild mallards", "OBSERVATION", 56, 69]]], ["These data emphasize that the geographic distribution, host range and genetic diversity of avian CoVs are much greater than was previously thought, a finding that could impact both animal and human health.IntroductionIn the present study, we performed surveillance and molecular epidemiological studies on CoV infections in wild birds from the Beringia area (between Siberia and Alaska) for the following reasons: (1) to study the genetic diversity of avian viruses with a special emphasis on new CoV subgroups; (2) to characterise the distribution of CoVs in an area where the Arctic meets the Pacific to better understand how the viruses may emerge and spread globally; (3) to study the phylogenetic aspects of CoVs in wildlife reservoirs.Prevalence of coronaviral nucleic acid in wild birdsSamples originating from 26 bird species were tested for CoVs polymerase (RdRp) gene by RT-PCR, and 64 of the 1,002 faecal and cloacal samples were positive (6.4%).", [["Samples", "ANATOMY", 793, 800], ["faecal", "ANATOMY", 909, 915], ["cloacal samples", "ANATOMY", 920, 935], ["CoV infections", "DISEASE", 306, 320], ["nucleic acid", "CHEMICAL", 767, 779], ["avian", "ORGANISM", 91, 96], ["CoVs", "GENE_OR_GENE_PRODUCT", 97, 101], ["human", "ORGANISM", 192, 197], ["CoV", "ORGANISM", 306, 309], ["avian viruses", "ORGANISM", 452, 465], ["CoV", "ORGANISM", 497, 500], ["CoVs", "GENE_OR_GENE_PRODUCT", 552, 556], ["CoVs", "GENE_OR_GENE_PRODUCT", 713, 717], ["coronaviral nucleic acid", "SIMPLE_CHEMICAL", 755, 779], ["birds", "ORGANISM", 788, 793], ["CoVs polymerase", "GENE_OR_GENE_PRODUCT", 850, 865], ["RdRp", "GENE_OR_GENE_PRODUCT", 867, 871], ["faecal", "ORGANISM_SUBSTANCE", 909, 915], ["cloacal samples", "CANCER", 920, 935], ["CoVs polymerase (RdRp) gene", "DNA", 850, 877], ["human", "SPECIES", 192, 197], ["human", "SPECIES", 192, 197], ["genetic diversity of avian CoVs", "PROBLEM", 70, 101], ["the present study", "TEST", 220, 237], ["surveillance", "TEST", 252, 264], ["molecular epidemiological studies", "TEST", 269, 302], ["CoV infections", "PROBLEM", 306, 320], ["the Beringia area", "PROBLEM", 340, 357], ["avian viruses", "PROBLEM", 452, 465], ["new CoV subgroups", "TREATMENT", 493, 510], ["CoVs", "PROBLEM", 552, 556], ["the viruses", "PROBLEM", 628, 639], ["coronaviral nucleic acid", "TREATMENT", 755, 779], ["Samples", "TEST", 793, 800], ["bird species", "TEST", 821, 833], ["CoVs polymerase", "TEST", 850, 865], ["RdRp", "TEST", 867, 871], ["RT-PCR", "TEST", 881, 887], ["cloacal samples", "TEST", 920, 935], ["avian CoVs", "OBSERVATION", 91, 101], ["avian viruses", "OBSERVATION", 452, 465], ["CoVs", "OBSERVATION", 552, 556]]], ["These groups were geese (5 species, n = 233), waders (9 species, n = 130), gulls (6 species, n = 322), ducks (1 species, n = 122), auks (2 species, n = 128) and seabirds (3 species, n = 67) ( Table 1) .", [["ducks", "ORGANISM", 103, 108], ["ducks", "SPECIES", 103, 108], ["waders (9 species", "PROBLEM", 46, 63], ["gulls (6 species", "TEST", 75, 91], ["ducks", "TEST", 103, 108], ["auks", "TEST", 131, 135], ["seabirds", "TEST", 161, 169]]], ["Gamma- coronaviruses were found in all the 18 CoV positive bird species, and there was a significant difference in PCR-prevalence between bird groups (x 2 = 36, 43, df = 5, p,0.001).", [["Gamma- coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 20], ["CoV", "ORGANISM", 46, 49], ["Gamma- coronaviruses", "PROBLEM", 0, 20], ["18 CoV positive bird species", "PROBLEM", 43, 71], ["PCR", "TEST", 115, 118], ["df", "TEST", 165, 167], ["p,", "TEST", 173, 175], ["coronaviruses", "OBSERVATION", 7, 20], ["bird species", "OBSERVATION", 59, 71], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["difference", "OBSERVATION_MODIFIER", 101, 111]]], ["Wader species were most frequently noted as CoV-positive (17.1%), followed by ducks (11.5%), geese (8.2%), gulls (3.1%) and seabirds (1.5%), while auks had the lowest prevalence (0.8%).", [["CoV", "ORGANISM", 44, 47], ["ducks", "ORGANISM", 78, 83], ["ducks", "SPECIES", 78, 83], ["Wader species", "PROBLEM", 0, 13], ["CoV", "TEST", 44, 47], ["ducks", "TEST", 78, 83], ["geese", "TEST", 93, 98], ["gulls", "TEST", 107, 112], ["seabirds", "TEST", 124, 132]]], ["In contrast, none of the 101 examined tufted puffins were CoV positive.", [["puffins", "GENE_OR_GENE_PRODUCT", 45, 52], ["CoV", "ORGANISM", 58, 61], ["CoV positive", "PROBLEM", 58, 70]]], ["Furthermore, there was notable variation in the proportion of PCR-positive samples between areas: Point Barrow, Kolyushin Commander-and Wrangel Islands, Petropavlovsk-Kamchatskiy.", [["samples", "ANATOMY", 75, 82], ["notable variation", "PROBLEM", 23, 40], ["PCR", "TEST", 62, 65], ["notable", "OBSERVATION_MODIFIER", 23, 30], ["variation", "OBSERVATION_MODIFIER", 31, 40]]], ["The lowest rates were observed on Commander (2.3%) and Wrangel Islands (3.5%); Petropavlovsk-Kamchatskiy was at the mid-point (8.2%), and the highest rates were detected at Point Barrow (11%) and Kolyushin (27.5%) (x 2 = 81.51, df = 4, p,0.001) ( Table 2) .", [["The lowest rates", "TEST", 0, 16], ["Commander", "TEST", 34, 43], ["Wrangel Islands", "TEST", 55, 70], ["Petropavlovsk", "TEST", 79, 92], ["Kamchatskiy", "TEST", 93, 104], ["the highest rates", "TEST", 138, 155], ["Kolyushin", "TEST", 196, 205]]], ["However, the sampled avifauna also differed among sites (x 2 = 1754.7, df = 20, p,0.001); while ducks were only sampled at Point Barrow, the majority of waders and geese were sampled from the tundra at Kolyushin and Wrangel Island ( Table 3) .Phylogenetic analysesPhylogenetic analyses of amplified CoV polymerase (RdRp) gene fragments showed that the detected viruses belonged to gamma-coronaviruses.", [["ducks", "ORGANISM", 96, 101], ["CoV polymerase", "GENE_OR_GENE_PRODUCT", 299, 313], ["amplified CoV polymerase (RdRp) gene fragments", "DNA", 289, 335], ["ducks", "SPECIES", 96, 101], ["df", "TEST", 71, 73], ["p,", "TEST", 80, 82], ["Phylogenetic analyses", "TEST", 243, 264], ["Phylogenetic analyses", "TEST", 264, 285], ["amplified CoV polymerase (RdRp) gene fragments", "PROBLEM", 289, 335], ["the detected viruses", "PROBLEM", 348, 368], ["CoV polymerase", "OBSERVATION_MODIFIER", 299, 313]]], ["Trees constructed using the neighbourjoining, maximum parsimony and maximum likelihood methods all showed similar topologies ( Figure 1 and data not shown).", [["the neighbourjoining", "TREATMENT", 24, 44]]], ["All of the viruses found in this study belonged to gamma-coronaviruses and were most closely related to IBV strains (nucleotide distances ranged between 17.9-24.2%).", [["nucleotide", "CHEMICAL", 117, 127], ["gamma-coronaviruses", "CANCER", 51, 70], ["IBV", "ORGANISM", 104, 107], ["IBV", "SPECIES", 104, 107], ["the viruses", "PROBLEM", 7, 18], ["this study", "TEST", 28, 38], ["IBV strains", "PROBLEM", 104, 115], ["nucleotide distances", "TEST", 117, 137], ["viruses", "OBSERVATION", 11, 18]]], ["Within the gammacoronaviruses branch, two clusters were identified.", [["gammacoronaviruses branch", "ANATOMY", 11, 36], ["gammacoronaviruses branch", "DNA", 11, 36], ["gammacoronaviruses", "ANATOMY", 11, 29], ["branch", "ANATOMY_MODIFIER", 30, 36], ["two", "OBSERVATION_MODIFIER", 38, 41], ["clusters", "OBSERVATION_MODIFIER", 42, 50]]], ["Cluster A contained eight Alaskan and one Russian virus, and the withingroup distance ranged between 0.8-16%.", [["Russian virus", "SPECIES", 42, 55], ["the withingroup distance", "TEST", 61, 85]]], ["The Russian Brent goose viruses formed cluster B with a within-group distance of 0.9-3.5%.", [["Brent goose viruses", "ORGANISM", 12, 31], ["Russian Brent goose viruses", "SPECIES", 4, 31]]], ["The mean distance between the two clusters was 19.1%.", [["mean", "OBSERVATION_MODIFIER", 4, 8], ["two", "OBSERVATION_MODIFIER", 30, 33], ["clusters", "OBSERVATION_MODIFIER", 34, 42]]], ["The trees also revealed clustering of strains based on geographic location and host species.", [["strains", "PROBLEM", 38, 45], ["host species", "PROBLEM", 79, 91], ["host species", "OBSERVATION", 79, 91]]], ["The Alaskan and Russian CoVs formed distinct clusters in the majority of the trees.", [["CoVs", "GENE_OR_GENE_PRODUCT", 24, 28], ["distinct", "OBSERVATION_MODIFIER", 36, 44], ["clusters", "OBSERVATION_MODIFIER", 45, 53]]], ["However, the trees also revealed diversity among CoV strains originating from the same geographic area.", [["CoV", "ORGANISM", 49, 52], ["diversity among CoV strains", "PROBLEM", 33, 60], ["diversity", "OBSERVATION_MODIFIER", 33, 42], ["CoV strains", "OBSERVATION", 49, 60], ["geographic", "OBSERVATION_MODIFIER", 87, 97], ["area", "OBSERVATION_MODIFIER", 98, 102]]], ["The goose and duck viruses clustered separately, but CoVs of other origins showed more extended genetic diversity.DiscussionIn the present study, gamma-coronaviruses were detected in 6.4% of the examined wild bird samples, with some variation between geographically separated populations.", [["samples", "ANATOMY", 214, 221], ["goose", "ORGANISM", 4, 9], ["duck viruses", "ORGANISM", 14, 26], ["CoVs", "GENE_OR_GENE_PRODUCT", 53, 57], ["bird", "ORGANISM", 209, 213], ["samples", "CANCER", 214, 221], ["goose", "SPECIES", 4, 9], ["duck", "SPECIES", 14, 18], ["duck viruses", "SPECIES", 14, 26], ["The goose and duck viruses", "PROBLEM", 0, 26], ["the present study", "TEST", 127, 144], ["coronaviruses", "PROBLEM", 152, 165], ["goose", "OBSERVATION_MODIFIER", 4, 9], ["duck viruses", "OBSERVATION", 14, 26], ["genetic diversity", "OBSERVATION", 96, 113], ["geographically", "OBSERVATION_MODIFIER", 251, 265], ["separated", "OBSERVATION_MODIFIER", 266, 275], ["populations", "OBSERVATION_MODIFIER", 276, 287]]], ["An example of a major difference between hosts within CoV phylogenies is the gamma-coronaviruses, which contains both avian CoVs and CoVs isolated from beluga and Asian leopard cats.", [["CoV", "ORGANISM", 54, 57], ["gamma-coronaviruses", "ORGANISM", 77, 96], ["avian", "ORGANISM", 118, 123], ["CoVs", "GENE_OR_GENE_PRODUCT", 124, 128], ["CoVs", "GENE_OR_GENE_PRODUCT", 133, 137], ["leopard cats", "ORGANISM", 169, 181], ["gamma-coronaviruses", "PROTEIN", 77, 96], ["avian", "SPECIES", 118, 123], ["cats", "SPECIES", 177, 181], ["Asian leopard", "SPECIES", 163, 176], ["a major difference between hosts within CoV phylogenies", "PROBLEM", 14, 69], ["the gamma-coronaviruses", "PROBLEM", 73, 96], ["CoVs", "PROBLEM", 133, 137], ["gamma-coronaviruses", "OBSERVATION", 77, 96], ["both", "OBSERVATION_MODIFIER", 113, 117], ["avian CoVs", "OBSERVATION", 118, 128]]], ["Beluga lives in the arctic waters around the sampling sites of this investigation.", [["this investigation", "TEST", 63, 81]]], ["This might indicate a degree of bird-mammalian CoV exchange.", [["CoV", "ORGANISM", 47, 50], ["bird-mammalian CoV exchange", "TREATMENT", 32, 59], ["bird", "OBSERVATION", 32, 36], ["mammalian CoV exchange", "OBSERVATION", 37, 59]]], ["Taken together, the data show that there is circulation of genetically divergent avian CoVs among the wild bird population in the Beringia region.DiscussionAlthough the number of samples analyzed in this study was limited, it can be assumed that the genetic variation of CoVs among wild birds is much higher than previously thought.", [["samples", "ANATOMY", 179, 186], ["avian", "ORGANISM", 81, 86], ["CoVs", "GENE_OR_GENE_PRODUCT", 87, 91], ["samples", "CANCER", 179, 186], ["CoVs", "GENE_OR_GENE_PRODUCT", 271, 275], ["avian", "SPECIES", 81, 86], ["the data", "TEST", 16, 24], ["this study", "TEST", 199, 209], ["CoVs", "PROBLEM", 271, 275], ["wild", "OBSERVATION_MODIFIER", 102, 106], ["bird", "OBSERVATION_MODIFIER", 107, 111], ["population", "OBSERVATION_MODIFIER", 112, 122], ["Beringia", "ANATOMY", 130, 138], ["region", "ANATOMY_MODIFIER", 139, 145]]], ["The detection of coronaviruses related to the gamma-coronaviruses in geographically distinct areas, such as Russia and Alaska, indicate that CoVs are widespread among birds associated with water environments, and this may have implications for poultry health.", [["coronaviruses", "ORGANISM", 17, 30], ["gamma-coronaviruses", "GENE_OR_GENE_PRODUCT", 46, 65], ["CoVs", "GENE_OR_GENE_PRODUCT", 141, 145], ["birds", "ORGANISM", 167, 172], ["coronaviruses", "PROBLEM", 17, 30], ["the gamma-coronaviruses", "PROBLEM", 42, 65], ["CoVs", "PROBLEM", 141, 145], ["coronaviruses", "OBSERVATION", 17, 30], ["gamma-coronaviruses", "OBSERVATION", 46, 65], ["geographically", "OBSERVATION_MODIFIER", 69, 83], ["distinct", "OBSERVATION_MODIFIER", 84, 92], ["areas", "OBSERVATION", 93, 98]]], ["Our results show that gamma-coronaviruses are much more widespread among birds than was previously suspected.", [["gamma-coronaviruses", "GENE_OR_GENE_PRODUCT", 22, 41], ["birds", "ORGANISM", 73, 78], ["much more", "OBSERVATION_MODIFIER", 46, 55], ["widespread", "OBSERVATION_MODIFIER", 56, 66]]], ["Most of the birds sampled in this study are migratory and leave Beringia when conditions deteriorate in the autumn.", [["birds", "ORGANISM", 12, 17], ["this study", "TEST", 29, 39], ["migratory", "OBSERVATION_MODIFIER", 44, 53]]], ["Some birds, such as the gulls and auks, remain at fairly northern latitudes, while the ducks, geese and waders migrate either to Asia, North America or even South America.", [["birds", "ORGANISM", 5, 10], ["ducks", "ORGANISM", 87, 92], ["ducks", "SPECIES", 87, 92]]], ["The Beringia area has been proposed to be an important gateway between Eurasia and North America for influenza A virus, where the meeting of birds and viruses from different hemispheres can allow disease transmission to occur [25] .", [["hemispheres", "ANATOMY", 174, 185], ["influenza A virus", "DISEASE", 101, 118], ["influenza A virus", "ORGANISM", 101, 118], ["birds", "ORGANISM", 141, 146], ["hemispheres", "MULTI-TISSUE_STRUCTURE", 174, 185], ["influenza A virus", "SPECIES", 101, 118], ["influenza A virus", "SPECIES", 101, 118], ["The Beringia area", "PROBLEM", 0, 17], ["influenza A virus", "PROBLEM", 101, 118]]], ["From this and other studies, it is reasonable to assume that a great variety of hitherto undetected CoVs exist in wild bird species.", [["CoVs", "GENE_OR_GENE_PRODUCT", 100, 104], ["CoVs", "PROTEIN", 100, 104], ["other studies", "TEST", 14, 27], ["hitherto undetected CoVs", "PROBLEM", 80, 104], ["bird species", "OBSERVATION", 119, 131]]], ["Previous studies that examined the host range and genetic diversity of CoVs [23, 26, 27] have revealed that CoVs in wild birds are present mainly in wildfowl (Anseriformes) and waders (Charadriiformes).", [["CoVs", "GENE_OR_GENE_PRODUCT", 108, 112], ["wild birds", "ORGANISM", 116, 126], ["CoVs", "PROTEIN", 108, 112], ["Previous studies", "TEST", 0, 16], ["CoVs", "TEST", 71, 75], ["CoVs", "PROBLEM", 108, 112], ["CoVs", "OBSERVATION", 108, 112], ["wild birds", "OBSERVATION", 116, 126]]], ["Our results corroborate these findings and indicate that CoVs are common among birds in the Beringia region.", [["CoVs", "GENE_OR_GENE_PRODUCT", 57, 61], ["CoVs", "PROTEIN", 57, 61], ["CoVs", "PROBLEM", 57, 61], ["CoVs", "OBSERVATION", 57, 61]]], ["Intensified surveillance of wild birds is an important means of assessing the relative prevalence of IBV strain variants, and this knowledge would aid risk assessments and risk management of these viruses.", [["IBV", "ORGANISM", 101, 104], ["IBV", "SPECIES", 101, 104], ["IBV strain variants", "PROBLEM", 101, 120], ["risk assessments", "TEST", 151, 167], ["risk management", "TREATMENT", 172, 187], ["these viruses", "PROBLEM", 191, 204], ["wild birds", "OBSERVATION", 28, 38], ["viruses", "OBSERVATION", 197, 204]]], ["Wild bird surveillance that includes virus isolation may also be a tool for obtaining strains of avian CoV that can be used for vaccine development and diagnostics, as some of these sequences are indeed similar to outbreak strains of IBV.DiscussionThe CoVs detected in this study were genetically diverse within the examined genomic region.", [["avian CoV", "ORGANISM", 97, 106], ["IBV", "ORGANISM", 234, 237], ["CoVs", "GENE_OR_GENE_PRODUCT", 252, 256], ["CoVs", "DNA", 252, 256], ["genomic region", "DNA", 325, 339], ["avian CoV", "SPECIES", 97, 106], ["avian CoV", "SPECIES", 97, 106], ["IBV", "SPECIES", 234, 237], ["virus isolation", "TREATMENT", 37, 52], ["avian CoV", "TREATMENT", 97, 106], ["vaccine development", "TREATMENT", 128, 147], ["diagnostics", "TEST", 152, 163], ["IBV", "PROBLEM", 234, 237], ["The CoVs", "PROBLEM", 248, 256], ["this study", "TEST", 269, 279]]], ["All the viruses were phylogenetically close to various IBV strains, and all belonged to gammacoronavirusa.", [["IBV", "ORGANISM", 55, 58], ["IBV", "SPECIES", 55, 58], ["All the viruses", "PROBLEM", 0, 15], ["various IBV strains", "PROBLEM", 47, 66], ["viruses", "OBSERVATION", 8, 15]]], ["An important question is whether these viruses originated from IBV [26, 27] of domesticated birds, or whether wild birds were the original reservoirs and IBV emerged from the wildlife.", [["IBV", "ORGANISM", 63, 66], ["birds", "ORGANISM", 92, 97], ["birds", "ORGANISM", 115, 120], ["IBV", "ORGANISM", 154, 157], ["IBV", "SPECIES", 63, 66], ["IBV", "SPECIES", 154, 157], ["these viruses", "PROBLEM", 33, 46], ["IBV", "PROBLEM", 63, 66], ["IBV", "TREATMENT", 154, 157], ["viruses", "OBSERVATION", 39, 46]]], ["Some support for the latter notion comes from the three gamma-coronavirusa Russian Brent goose CoVs that showed a considerable phylogenetic distance from IBV and were more closely related to goose coronavirus [8] .", [["goose", "ORGANISM", 89, 94], ["CoVs", "ORGANISM", 95, 99], ["IBV", "ORGANISM", 154, 157], ["goose coronavirus", "ORGANISM", 191, 208], ["goose", "SPECIES", 89, 94], ["goose coronavirus", "SPECIES", 191, 208], ["Russian Brent goose", "SPECIES", 75, 94], ["IBV", "SPECIES", 154, 157], ["goose coronavirus", "SPECIES", 191, 208], ["Some support", "TREATMENT", 0, 12], ["Brent goose CoVs", "PROBLEM", 83, 99], ["IBV", "PROBLEM", 154, 157], ["goose coronavirus", "PROBLEM", 191, 208]]], ["Since avian coronaviruses get their diversity primarily from hypervariable regions residing in the spike gene, highly detailed genetic characterization of this genomic region including metagenomic methods will provide information regarding the phylogenetic relationship between different gamma-coronaviruses.DiscussionTaken together, this study provides insight into the genetic diversity of avian CoVs including its wildlife animal reservoirs.", [["avian coronaviruses", "ORGANISM", 6, 25], ["avian", "ORGANISM", 392, 397], ["CoVs", "GENE_OR_GENE_PRODUCT", 398, 402], ["hypervariable regions", "DNA", 61, 82], ["spike gene", "DNA", 99, 109], ["genomic region", "DNA", 160, 174], ["avian coronaviruses", "PROBLEM", 6, 25], ["hypervariable regions", "PROBLEM", 61, 82], ["this genomic region", "PROBLEM", 155, 174], ["metagenomic methods", "TREATMENT", 185, 204], ["this study", "TEST", 334, 344], ["avian CoVs", "OBSERVATION", 392, 402]]], ["The majority of the human emerging infectious diseases of the past few decades, including AIDS, Ebola fever, avian influenza and severe acute respiratory syndrome (SARS), resulted from interspecies transmission of zoonotic RNA viruses [28, 29, 30, 31] .", [["infectious diseases", "DISEASE", 35, 54], ["AIDS", "DISEASE", 90, 94], ["Ebola fever", "DISEASE", 96, 107], ["avian influenza", "DISEASE", 109, 124], ["acute respiratory syndrome", "DISEASE", 136, 162], ["SARS", "DISEASE", 164, 168], ["zoonotic RNA viruses", "DISEASE", 214, 234], ["human", "ORGANISM", 20, 25], ["Ebola fever", "ORGANISM", 96, 107], ["avian influenza", "ORGANISM", 109, 124], ["human", "SPECIES", 20, 25], ["Ebola fever", "SPECIES", 96, 107], ["avian influenza", "SPECIES", 109, 124], ["human", "SPECIES", 20, 25], ["AIDS", "PROBLEM", 90, 94], ["Ebola fever", "PROBLEM", 96, 107], ["avian influenza", "PROBLEM", 109, 124], ["severe acute respiratory syndrome", "PROBLEM", 129, 162], ["SARS", "PROBLEM", 164, 168], ["zoonotic RNA viruses", "PROBLEM", 214, 234], ["infectious", "OBSERVATION", 35, 45], ["Ebola", "OBSERVATION_MODIFIER", 96, 101], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["acute", "OBSERVATION_MODIFIER", 136, 141], ["respiratory syndrome", "OBSERVATION", 142, 162], ["zoonotic RNA viruses", "OBSERVATION", 214, 234]]], ["Adaptation of a non-human CoV to a human host occurred with both SARS-CoV and OC43-CoV; both are examples of a penetration of the animal-human species barrier.", [["non-human CoV", "ORGANISM", 16, 29], ["human", "ORGANISM", 35, 40], ["SARS-CoV", "ORGANISM", 65, 73], ["OC43-CoV", "ORGANISM", 78, 86], ["human", "ORGANISM", 137, 142], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 137, 142], ["non-human CoV", "SPECIES", 16, 29], ["human", "SPECIES", 35, 40], ["SARS-CoV", "SPECIES", 65, 73], ["OC43-CoV", "SPECIES", 78, 86], ["human", "SPECIES", 137, 142], ["the animal-human species barrier", "TREATMENT", 126, 158]]], ["It is likely that they were enzootic in an unknown animal species before suddenly emerging as a virulent human virus.", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human virus", "SPECIES", 105, 116], ["enzootic", "PROBLEM", 28, 36], ["a virulent human virus", "PROBLEM", 94, 116], ["is likely", "UNCERTAINTY", 3, 12], ["enzootic", "OBSERVATION_MODIFIER", 28, 36]]], ["Before establishing the ecology of the emergence of these human viral pathogens and reconstructing their evolutionary pathways, it is necessary to identify closely related CoVs in wild animal hosts [32] .", [["human", "ORGANISM", 58, 63], ["CoVs", "GENE_OR_GENE_PRODUCT", 172, 176], ["CoVs", "DNA", 172, 176], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["these human viral pathogens", "PROBLEM", 52, 79]]], ["Examining the prevalence and effects of CoV infections in wild birds will increase our knowledge about CoV interactions with their hosts and may suggest as yet unexploited avenues for combating CoV infections.", [["CoV infections", "DISEASE", 40, 54], ["CoV infections", "DISEASE", 194, 208], ["CoV", "ORGANISM", 40, 43], ["CoV", "ORGANISM", 103, 106], ["CoV", "ORGANISM", 194, 197], ["CoV", "SPECIES", 194, 197], ["CoV infections", "PROBLEM", 40, 54], ["combating CoV infections", "PROBLEM", 184, 208], ["CoV", "OBSERVATION_MODIFIER", 40, 43], ["infections", "OBSERVATION", 44, 54]]], ["There is a clear need for a better understanding of CoV ecology, and this will require more data through better surveillance of wild birds and more research on the behaviour of these viruses in wild bird populations.Ethical StatementAll animals were handled in strict accordance with good animal practice as defined by the Laboratory Animal of Swedish Board of Agriculture, and all animal work was approved by the Russian Academy of Medical Sciences and Russian Authorities.SamplingIn total, 1,002 samples were collected from five geographic areas within the Bering Strait: Point Barrow, Kolyushin, Wrangel Island, Commander Island and Petropavlovsk-Kamchatskiy ( Figure 2 ).", [["samples", "ANATOMY", 498, 505], ["CoV", "ORGANISM", 52, 55], ["wild birds", "PROBLEM", 128, 138], ["these viruses", "PROBLEM", 177, 190], ["Sampling", "TEST", 474, 482], ["clear", "OBSERVATION", 11, 16], ["viruses", "OBSERVATION", 183, 190]]], ["These samples represented 26 different bird species, three bird orders and six bird families ( Table 4 ).", [["samples", "ANATOMY", 6, 13], ["These samples", "TEST", 0, 13], ["26 different", "OBSERVATION_MODIFIER", 26, 38], ["bird species", "OBSERVATION", 39, 51]]], ["The samples were collected either with a sterile cotton swab from the cloacae of trapped birds (shorebirds) or from fresh faecal samples on the ground (northern pintails Anas acuta).", [["samples", "ANATOMY", 4, 11], ["samples", "ANATOMY", 129, 136], ["birds", "ORGANISM", 89, 94], ["faecal samples", "ORGANISM_SUBSTANCE", 122, 136], ["ground", "ORGANISM_SUBDIVISION", 144, 150], ["Anas acuta", "SPECIES", 170, 180], ["cotton", "SPECIES", 49, 55], ["Anas acuta", "SPECIES", 170, 180], ["The samples", "TEST", 0, 11], ["a sterile cotton swab", "TREATMENT", 39, 60], ["fresh faecal samples", "TEST", 116, 136]]], ["For faecal sample collection, we made sure that the flock to be sampled contained only northern pintails by watching them with a telescope, and only fresh droppings were sampled.", [["faecal sample", "ANATOMY", 4, 17], ["faecal sample collection", "PROBLEM", 4, 28], ["the flock", "TREATMENT", 48, 57], ["a telescope", "TREATMENT", 127, 138]]], ["Each sample was immediately stored in Hank's balanced salt solution (HBSS) [34] and maintained at 280uC until the samples reached the laboratory.Detection of coronavirus by RT-PCRVirions were lysed by mixing a 150-ml sample with 450 ml TRIzol (Invitrogen, Carlsbad, CA, USA).", [["sample", "ANATOMY", 5, 11], ["samples", "ANATOMY", 114, 121], ["coronavirus", "ORGANISM", 158, 169], ["RT-PCRVirions", "ORGANISM", 173, 186], ["Hank's balanced salt solution", "TREATMENT", 38, 67], ["coronavirus", "PROBLEM", 158, 169], ["TRIzol", "TREATMENT", 236, 242]]], ["Nucleic acid was subsequently separated by the addition of 160 ml chloroform to yield an excess of 300 ml water phase suitable for RNA purification.", [["Nucleic acid", "CHEMICAL", 0, 12], ["chloroform", "CHEMICAL", 66, 76], ["Nucleic acid", "SIMPLE_CHEMICAL", 0, 12], ["Nucleic acid", "TREATMENT", 0, 12], ["RNA purification", "TREATMENT", 131, 147]]], ["Viral RNA was extracted using the MagAttract Viral RNA M48 extraction kit in combination with the M48 Biorobot (both supplied by Qiagen, Hilden, Germany).", [["Viral", "ORGANISM", 0, 5], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["the MagAttract Viral RNA M48 extraction kit", "TREATMENT", 30, 73], ["the M48 Biorobot", "TREATMENT", 94, 110]]], ["The CoV screening was performed by amplifying a 179-nt stretch of the CoV RdRp gene using our previously published one-step pan-CoV RT-PCR method [24] .", [["CoV", "GENE_OR_GENE_PRODUCT", 70, 73], ["179-nt stretch", "DNA", 48, 62], ["CoV RdRp gene", "DNA", 70, 83], ["CoV RdRp", "SPECIES", 70, 78], ["The CoV screening", "TEST", 0, 17], ["the CoV RdRp gene", "TREATMENT", 66, 83]]], ["Standard precautions were taken to avoid PCR contamination, and no false-positive result was observed in water controls.", [["Standard precautions", "TREATMENT", 0, 20], ["PCR contamination", "PROBLEM", 41, 58], ["false-positive result", "PROBLEM", 67, 88]]], ["The PCR products were gelpurified using a QIAquick gel extraction kit (QIAgen, Hilden, Germany).", [["The PCR products", "TREATMENT", 0, 16], ["a QIAquick gel extraction kit", "TREATMENT", 40, 69]]], ["Both strands of the PCR products were sequenced using the fluorescent dye terminator method with an ABI PRISMH Big Dye TM Terminator Cycle Sequencing v3.1 Ready Reaction kit (Perkin Elmer, Waltham, MA, USA) on an ABI PRISMH 310 genetic analyzer according to the manufacturer's recommendations (Applied Biosystems).Statistical analysisWe used chi-square tests to determine the between-site effects and the effect of bird group on the proportion of positive individuals.", [["PCR products", "DNA", 20, 32], ["the PCR products", "TREATMENT", 16, 32], ["the fluorescent dye terminator method", "TREATMENT", 54, 91], ["an ABI", "TEST", 97, 103], ["Sequencing", "TEST", 139, 149], ["an ABI", "TEST", 210, 216], ["genetic analyzer", "TEST", 228, 244], ["chi-square tests", "TEST", 342, 358], ["positive individuals", "PROBLEM", 447, 467], ["strands", "OBSERVATION_MODIFIER", 5, 12], ["positive individuals", "OBSERVATION", 447, 467]]], ["A value of P,0.001 was considered statistically significant.Sequence and phylogenetic analysisSequences were assembled and edited using the BioEdit v.7.0.7.", [["BioEdit v.7.0.7", "DNA", 140, 155], ["A value", "TEST", 0, 7], ["phylogenetic analysisSequences", "TEST", 73, 103], ["the BioEdit", "TEST", 136, 147], ["significant", "OBSERVATION_MODIFIER", 48, 59]]], ["The neighbour-joining algorithm was implemented with the Kimura-2 parameter model using a transition-to-translation ratio of 2.0.", [["translation ratio", "TEST", 104, 121]]], ["Other models were tested that showed similar topologies.", [["Other models", "TEST", 0, 12]]], ["Maximum likelihood phylogenetic trees were generated using the PHYLIP version 3.68 software [38] .", [["phylogenetic trees", "OBSERVATION", 19, 37]]], ["The sequences were deposited in GenBank under the following accession numbers: GU396668-GU396690.", [["GU396668-GU396690", "CHEMICAL", 79, 96]]]], "892eacdebd1c97059d208029ca82998bdf1c9bfd": [["IntroductionFeline infectious peritonitis (FIP) is a highly fatal and immune-mediated pyogranulomatous disease that occurs in both domestic and wild felidae.", [["pyogranulomatous", "ANATOMY", 86, 102], ["felidae", "ANATOMY", 149, 156], ["infectious peritonitis", "DISEASE", 19, 41], ["FIP", "DISEASE", 43, 46], ["pyogranulomatous disease", "DISEASE", 86, 110], ["felidae", "CANCER", 149, 156], ["IntroductionFeline infectious peritonitis", "PROBLEM", 0, 41], ["immune-mediated pyogranulomatous disease", "PROBLEM", 70, 110], ["infectious", "OBSERVATION_MODIFIER", 19, 29], ["peritonitis", "OBSERVATION", 30, 41], ["FIP", "OBSERVATION_MODIFIER", 43, 46], ["highly", "OBSERVATION_MODIFIER", 53, 59], ["fatal", "OBSERVATION_MODIFIER", 60, 65], ["pyogranulomatous disease", "OBSERVATION", 86, 110], ["wild felidae", "OBSERVATION", 144, 156]]], ["The disease is caused by feline coronavirus (FCoV).", [["feline coronavirus", "DISEASE", 25, 43], ["feline coronavirus", "ORGANISM", 25, 43], ["FCoV", "CANCER", 45, 49], ["feline coronavirus", "SPECIES", 25, 43], ["feline coronavirus", "SPECIES", 25, 43], ["FCoV", "SPECIES", 45, 49], ["The disease", "PROBLEM", 0, 11], ["feline coronavirus", "PROBLEM", 25, 43], ["disease", "OBSERVATION", 4, 11], ["feline coronavirus", "OBSERVATION", 25, 43]]], ["FCoV is a member of the family Coronaviridae, genus Coronavirus which is a group of enveloped and positive-stranded RNA viruses.", [["FCoV", "CHEMICAL", 0, 4], ["FCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 31, 44], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 52, 63], ["FCoV", "PROTEIN", 0, 4], ["the family Coronaviridae", "TREATMENT", 20, 44], ["genus Coronavirus", "PROBLEM", 46, 63], ["stranded RNA viruses", "PROBLEM", 107, 127], ["genus Coronavirus", "ANATOMY", 46, 63], ["stranded RNA viruses", "OBSERVATION", 107, 127]]], ["Antigenically and genetically, coronaviruses are currently grouped into at least four groups.", [["coronaviruses", "ORGANISM", 31, 44], ["coronaviruses", "PROBLEM", 31, 44], ["coronaviruses", "OBSERVATION", 31, 44]]], ["FCoV belongs to group I coronavirus which includes canine coronavirus (CCoV), transmissible gastroenteritis virus (TGEV), porcine respiratory coronavirus and human coronavirus 229E (Wege et al., 1982) .IntroductionTwo pathotypes of FCoVs are also known: one is feline enteric coronavirus (FECV) which causes from asymptomatic infection to severe enteritis and another is feline infectious peritonitis virus (FIPV) that causes www.elsevier.com/locate/vetmic Veterinary Microbiology 124 (2007) [348] [349] [350] [351] [352] fatal immune-mediated disease FIP (Pedersen, 1987; Pedersen et al., 1981) .", [["FCoV", "CHEMICAL", 0, 4], ["canine coronavirus (CCoV)", "DISEASE", 51, 76], ["transmissible gastroenteritis virus", "DISEASE", 78, 113], ["porcine respiratory coronavirus", "DISEASE", 122, 153], ["FCoVs", "DISEASE", 232, 237], ["feline enteric coronavirus", "DISEASE", 261, 287], ["infection", "DISEASE", 326, 335], ["enteritis", "DISEASE", 346, 355], ["feline infectious peritonitis", "DISEASE", 371, 400], ["FIP", "DISEASE", 552, 555], ["FCoV", "GENE_OR_GENE_PRODUCT", 0, 4], ["group I coronavirus", "ORGANISM", 16, 35], ["canine coronavirus", "ORGANISM", 51, 69], ["CCoV", "ORGANISM", 71, 75], ["transmissible gastroenteritis virus", "ORGANISM", 78, 113], ["TGEV", "ORGANISM", 115, 119], ["porcine respiratory coronavirus", "ORGANISM", 122, 153], ["human", "ORGANISM", 158, 163], ["coronavirus 229E", "ORGANISM", 164, 180], ["FCoVs", "GENE_OR_GENE_PRODUCT", 232, 237], ["feline enteric coronavirus", "ORGANISM", 261, 287], ["FECV", "ORGANISM", 289, 293], ["feline infectious peritonitis virus", "ORGANISM", 371, 406], ["FCoV", "PROTEIN", 0, 4], ["coronavirus", "SPECIES", 24, 35], ["canine coronavirus", "SPECIES", 51, 69], ["transmissible gastroenteritis virus", "SPECIES", 78, 113], ["TGEV", "SPECIES", 115, 119], ["porcine respiratory coronavirus", "SPECIES", 122, 153], ["human", "SPECIES", 158, 163], ["coronavirus", "SPECIES", 164, 175], ["feline enteric coronavirus", "SPECIES", 261, 287], ["feline", "SPECIES", 371, 377], ["I coronavirus", "SPECIES", 22, 35], ["canine coronavirus", "SPECIES", 51, 69], ["CCoV", "SPECIES", 71, 75], ["transmissible gastroenteritis virus", "SPECIES", 78, 113], ["TGEV", "SPECIES", 115, 119], ["porcine respiratory coronavirus", "SPECIES", 122, 153], ["human coronavirus", "SPECIES", 158, 175], ["feline enteric coronavirus", "SPECIES", 261, 287], ["FECV", "SPECIES", 289, 293], ["feline infectious peritonitis virus", "SPECIES", 371, 406], ["FIPV", "SPECIES", 408, 412], ["FCoV", "PROBLEM", 0, 4], ["group I coronavirus", "PROBLEM", 16, 35], ["canine coronavirus (CCoV", "PROBLEM", 51, 75], ["transmissible gastroenteritis virus", "PROBLEM", 78, 113], ["porcine respiratory coronavirus", "PROBLEM", 122, 153], ["human coronavirus", "TEST", 158, 175], ["feline enteric coronavirus (FECV)", "PROBLEM", 261, 294], ["asymptomatic infection", "PROBLEM", 313, 335], ["severe enteritis", "PROBLEM", 339, 355], ["feline infectious peritonitis virus", "PROBLEM", 371, 406], ["fatal immune", "TEST", 522, 534], ["mediated disease FIP", "PROBLEM", 535, 555], ["canine coronavirus", "ANATOMY", 51, 69], ["gastroenteritis virus", "OBSERVATION", 92, 113], ["respiratory coronavirus", "OBSERVATION", 130, 153], ["coronavirus", "OBSERVATION", 276, 287], ["asymptomatic", "OBSERVATION_MODIFIER", 313, 325], ["infection", "OBSERVATION", 326, 335], ["severe", "OBSERVATION_MODIFIER", 339, 345], ["enteritis", "OBSERVATION", 346, 355], ["infectious", "OBSERVATION_MODIFIER", 378, 388], ["peritonitis", "OBSERVATION", 389, 400]]], ["It was demonstrated that FIPV arises inside of cats by mutation from infected FECV (Vennema et al., 1998) .", [["FIPV", "CHEMICAL", 25, 29], ["FIPV", "SIMPLE_CHEMICAL", 25, 29], ["cats", "ORGANISM", 47, 51], ["FIPV", "PROTEIN", 25, 29], ["FECV", "SPECIES", 78, 82], ["FIPV", "PROBLEM", 25, 29], ["FIPV", "OBSERVATION", 25, 29]]], ["However, it is difficult to distinguish between FECV and FIPV by in vitro serological and genetical methods Fiscus and Teramoto, 1987; Pedersen et al., 1984) .IntroductionBoth FECV and FIPV are divided into two types I and II, based on their neutralization reactivity with spike (S) protein-specific mAbs (Fiscus and Teramoto, 1987; Hohdatsu et al., 1991b Hohdatsu et al., , 1992 and sequence analysis of the S protein gene (Motokawa et al., 1995 (Motokawa et al., , 1996 .", [["FIPV", "SIMPLE_CHEMICAL", 185, 189], ["FECV", "PROTEIN", 176, 180], ["FIPV", "DNA", 185, 189], ["spike (S) protein", "PROTEIN", 273, 290], ["mAbs", "PROTEIN", 300, 304], ["S protein gene", "DNA", 409, 423], ["FIPV", "TREATMENT", 57, 61], ["FIPV", "PROBLEM", 185, 189], ["their neutralization reactivity", "TEST", 236, 267], ["sequence analysis", "TEST", 384, 401], ["FIPV", "OBSERVATION", 185, 189]]], ["While FCoV type I grows poorly in cell culture, type II can grow well in many different cell lines .", [["cell culture", "ANATOMY", 34, 46], ["cell lines", "ANATOMY", 88, 98], ["FCoV type I", "GENE_OR_GENE_PRODUCT", 6, 17], ["cell", "CELL", 34, 38], ["cell lines", "CELL", 88, 98], ["FCoV type I", "PROTEIN", 6, 17], ["cell lines", "CELL_LINE", 88, 98], ["poorly in cell culture", "PROBLEM", 24, 46], ["different cell lines", "OBSERVATION", 78, 98]]], ["Furthermore, type II FCoV shows close antigenic and genetic relationship to CCoV and TGEV, suggesting that FCoV type II arose from double recombination between FCoV type I and CCoV (Herrewegh et al., 1998) FCoV type II strains are more frequently utilized than type I strains for in vitro experiments because of higher efficient growth.", [["type II FCoV", "GENE_OR_GENE_PRODUCT", 13, 25], ["CCoV", "GENE_OR_GENE_PRODUCT", 76, 80], ["TGEV", "ORGANISM", 85, 89], ["FCoV type II", "ORGANISM", 107, 119], ["FCoV type I", "GENE_OR_GENE_PRODUCT", 160, 171], ["FCoV type II strains", "ORGANISM", 206, 226], ["type II FCoV", "PROTEIN", 13, 25], ["FCoV type II", "PROTEIN", 107, 119], ["CCoV", "SPECIES", 76, 80], ["TGEV", "SPECIES", 85, 89], ["type II FCoV", "PROBLEM", 13, 25], ["TGEV", "PROBLEM", 85, 89], ["FCoV type II", "PROBLEM", 107, 119], ["double recombination", "TREATMENT", 131, 151], ["FCoV type II strains", "PROBLEM", 206, 226], ["type I strains", "PROBLEM", 261, 275], ["vitro experiments", "TREATMENT", 283, 300], ["higher efficient growth", "PROBLEM", 312, 335], ["FCoV", "OBSERVATION", 107, 111]]], ["For serological survey of FCoV infection, antibody has been detected by indirect fluorescent antibody assay (IFA) or enzyme-linked immunosorbent assay (ELISA) using FCoV (Pedersen, 1976; Scott, 1979; Horzinek and Osterhaus, 1979; Ishida et al., 1987) .", [["FCoV infection", "DISEASE", 26, 40], ["FCoV", "ORGANISM", 26, 30], ["FCoV", "SPECIES", 26, 30], ["serological survey", "TEST", 4, 22], ["FCoV infection", "PROBLEM", 26, 40], ["antibody", "TEST", 42, 50], ["indirect fluorescent antibody assay", "TEST", 72, 107], ["IFA", "TEST", 109, 112], ["enzyme", "TEST", 117, 123], ["immunosorbent assay", "TEST", 131, 150], ["FCoV infection", "OBSERVATION", 26, 40]]], ["Alternatively CCoV or TGEV are also used as a target antigen because of serological close relations to FCoV.", [["CCoV", "GENE_OR_GENE_PRODUCT", 14, 18], ["TGEV", "ORGANISM", 22, 26], ["FCoV", "GENE_OR_GENE_PRODUCT", 103, 107], ["CCoV", "PROTEIN", 14, 18], ["FCoV", "PROTEIN", 103, 107], ["TGEV", "SPECIES", 22, 26], ["CCoV", "SPECIES", 14, 18], ["TGEV", "SPECIES", 22, 26], ["TGEV", "PROBLEM", 22, 26], ["a target antigen", "TEST", 44, 60]]], ["However, discrimination ability (specificity) of these methods using heterologous antigens seems to be low since they detect also cross-reactive antibodies between types I and II, such as antibody to nucleocapsid (N) protein.IntroductionIn this study, we developed a plaque-reduction neutralization test (PRNT) to serologically distinguish FCoV type I and II infections in cats, and we applied it for field cases.Cell culturesFeline whole fetus cells (fcwf-4 cells), which are fetal feline lung cells having characteristics of macrophages (Jacobse-Geels and Horzinek, 1983) were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS), 100 U/ml penicillin and 100 mg/ml streptomycin.", [["plaque", "ANATOMY", 267, 273], ["Cell cultures", "ANATOMY", 413, 426], ["whole fetus cells", "ANATOMY", 433, 450], ["fcwf-4 cells", "ANATOMY", 452, 464], ["fetal", "ANATOMY", 477, 482], ["lung cells", "ANATOMY", 490, 500], ["macrophages", "ANATOMY", 527, 538], ["fetal calf serum", "ANATOMY", 645, 661], ["FCoV type I and II infections", "DISEASE", 340, 369], ["penicillin", "CHEMICAL", 678, 688], ["streptomycin", "CHEMICAL", 703, 715], ["penicillin", "CHEMICAL", 678, 688], ["streptomycin", "CHEMICAL", 703, 715], ["antibody to nucleocapsid (N) protein", "GENE_OR_GENE_PRODUCT", 188, 224], ["cats", "ORGANISM", 373, 377], ["Cell cultures", "CELL", 413, 426], ["Feline", "ORGANISM", 426, 432], ["fetus cells", "CELL", 439, 450], ["fcwf-4 cells", "CELL", 452, 464], ["feline", "ORGANISM", 483, 489], ["lung cells", "CELL", 490, 500], ["macrophages", "CELL", 527, 538], ["Jacobse-Geels", "CELL", 540, 553], ["fetal calf", "ORGANISM_SUBSTANCE", 645, 655], ["serum", "ORGANISM_SUBSTANCE", 656, 661], ["FCS", "ORGANISM_SUBSTANCE", 663, 666], ["penicillin", "SIMPLE_CHEMICAL", 678, 688], ["streptomycin", "SIMPLE_CHEMICAL", 703, 715], ["heterologous antigens", "PROTEIN", 69, 90], ["cross-reactive antibodies", "PROTEIN", 130, 155], ["I and II", "PROTEIN", 170, 178], ["nucleocapsid (N) protein", "PROTEIN", 200, 224], ["Feline whole fetus cells", "CELL_TYPE", 426, 450], ["fcwf-4 cells", "CELL_LINE", 452, 464], ["fetal feline lung cells", "CELL_TYPE", 477, 500], ["macrophages", "CELL_TYPE", 527, 538], ["cats", "SPECIES", 373, 377], ["feline", "SPECIES", 483, 489], ["calf", "SPECIES", 651, 655], ["FCoV type I", "SPECIES", 340, 351], ["these methods", "TEST", 49, 62], ["heterologous antigens", "TEST", 69, 90], ["cross-reactive antibodies between types I and II", "PROBLEM", 130, 178], ["this study", "TEST", 240, 250], ["a plaque-reduction neutralization test", "TREATMENT", 265, 303], ["FCoV type I", "PROBLEM", 340, 351], ["II infections in cats", "PROBLEM", 356, 377], ["Cell cultures", "TEST", 413, 426], ["Feline whole fetus cells", "PROBLEM", 426, 450], ["fcwf", "TEST", 452, 456], ["fetal feline lung cells", "PROBLEM", 477, 500], ["macrophages", "PROBLEM", 527, 538], ["penicillin", "TREATMENT", 678, 688], ["streptomycin", "TREATMENT", 703, 715], ["plaque", "OBSERVATION", 267, 273], ["infections", "OBSERVATION", 359, 369], ["fetus cells", "OBSERVATION", 439, 450], ["lung", "ANATOMY", 490, 494], ["macrophages", "OBSERVATION", 527, 538]]], ["The cells were maintained in a humidified 5% CO 2 incubator at 37 8C.VirusesFIPV type I strains C3663 and Yayoi and FIPV type II strains KUK-H/L and M91-267 were used in this study.", [["cells", "ANATOMY", 4, 9], ["M91-267", "CHEMICAL", 149, 156], ["CO 2", "CHEMICAL", 45, 49], ["cells", "CELL", 4, 9], ["FIPV type II", "ORGANISM", 116, 128], ["KUK-H/L", "CELL", 137, 144], ["M91-267", "CELL", 149, 156], ["a humidified 5% CO 2 incubator", "TREATMENT", 29, 59], ["type I strains", "PROBLEM", 81, 95], ["Yayoi", "TEST", 106, 111], ["KUK", "TEST", 137, 140], ["M91", "TEST", 149, 152], ["this study", "TEST", 170, 180]]], ["KUK-H strain was isolated from the spleen sample of effusive form FIP case in 1987 by using CRFK cells, and KUK-H/L was plaque-purified from the KUK-H strain (Mochizuki et al., 1997) .", [["spleen sample", "ANATOMY", 35, 48], ["CRFK cells", "ANATOMY", 92, 102], ["plaque", "ANATOMY", 120, 126], ["KUK-H", "CHEMICAL", 0, 5], ["FIP", "DISEASE", 66, 69], ["KUK-H", "GENE_OR_GENE_PRODUCT", 0, 5], ["spleen", "ORGAN", 35, 41], ["CRFK cells", "CELL", 92, 102], ["KUK-H/L", "GENE_OR_GENE_PRODUCT", 108, 115], ["CRFK cells", "CELL_LINE", 92, 102], ["KUK", "PROTEIN", 108, 111], ["KUK", "TEST", 0, 3], ["H strain", "PROBLEM", 4, 12], ["the spleen sample", "TEST", 31, 48], ["KUK", "TEST", 108, 111], ["plaque", "PROBLEM", 120, 126], ["spleen", "ANATOMY", 35, 41], ["plaque", "OBSERVATION", 120, 126]]], ["M91-267 strain was isolated from the spleen sample taken at the postmortem examination of effusive form FIP case in 1991 (Mochizuki et al., 1997) .", [["spleen sample", "ANATOMY", 37, 50], ["M91-267", "CHEMICAL", 0, 7], ["FIP", "DISEASE", 104, 107], ["M91-267 strain", "CELL", 0, 14], ["spleen", "ORGAN", 37, 43], ["M91-267 strain", "SPECIES", 0, 14], ["M91", "TEST", 0, 3], ["strain", "PROBLEM", 8, 14], ["the spleen sample", "TEST", 33, 50], ["the postmortem examination", "TEST", 60, 86], ["spleen", "ANATOMY", 37, 43]]], ["These two strains were classified into type II by using FCoV type-specific mAbs, kindly provided by Dr. T. Hohdatsu (Hohdatsu et al., 1991a, b) .", [["FCoV type-specific mAbs", "PROTEIN", 56, 79], ["FCoV type-specific mAbs", "TREATMENT", 56, 79]]], ["C3663 strain was isolated from a cat with an effusive form of FIP in 1994 and used as a reference FCoV type I (Mochizuki et al., 1997) .", [["C3663", "CHEMICAL", 0, 5], ["FIP", "DISEASE", 62, 65], ["cat", "ORGANISM", 33, 36], ["strain", "PROBLEM", 6, 12], ["FIP", "PROBLEM", 62, 65], ["FIP", "OBSERVATION", 62, 65]]], ["In addition, it was genetically confirmed that C3663 belongs to type I FCoVand M91-267 and KUK-H/L do to type II (manuscript in preparation).", [["C3663", "CHEMICAL", 47, 52], ["C3663", "SIMPLE_CHEMICAL", 47, 52], ["KUK-H", "GENE_OR_GENE_PRODUCT", 91, 96], ["M91", "TEST", 79, 82], ["KUK", "TEST", 91, 94]]], ["Yayoi strain was isolated from liver homogenate from non-effusive form of FIP by serial passage in suckling mouse brain and then in fcwf-4 cells and have been used as Japanese prototype strain of FCoV type I (Hayashi et al., 1981) .", [["liver homogenate", "ANATOMY", 31, 47], ["brain", "ANATOMY", 114, 119], ["fcwf-4 cells", "ANATOMY", 132, 144], ["Yayoi strain", "ORGANISM", 0, 12], ["liver", "ORGAN", 31, 36], ["homogenate", "ORGANISM_SUBSTANCE", 37, 47], ["FIP", "ORGANISM", 74, 77], ["mouse", "ORGANISM", 108, 113], ["brain", "ORGAN", 114, 119], ["fcwf-4 cells", "CELL", 132, 144], ["fcwf-4 cells", "CELL_LINE", 132, 144], ["mouse", "SPECIES", 108, 113], ["mouse", "SPECIES", 108, 113], ["FCoV type I", "SPECIES", 196, 207], ["Yayoi strain", "PROBLEM", 0, 12], ["FIP", "PROBLEM", 74, 77], ["suckling mouse brain", "PROBLEM", 99, 119], ["liver", "ANATOMY", 31, 36], ["FIP", "OBSERVATION", 74, 77], ["brain", "ANATOMY", 114, 119]]], ["C3663, KUK-H/L and M91-267 strains were used in subsequent experiments within 10 passages in fcwf-4 cells.", [["fcwf-4 cells", "ANATOMY", 93, 105], ["KUK-H/L", "CELL", 7, 14], ["fcwf-4 cells", "CELL", 93, 105], ["fcwf-4 cells", "CELL_LINE", 93, 105], ["KUK", "TEST", 7, 10], ["M91", "TEST", 19, 22], ["strains", "PROBLEM", 27, 34]]], ["Although the passage history of Yayoi strain is unknown, it was propagated less than three times in our laboratory.Cat seraFour sera (Nos.1-4) were collected from cats clinically diagnosed as FIP and serologically identified as type I infection by indirect immunofluorescent assay using unfixed fcwf-4 cells infected with FCoV type I or II.", [["sera", "ANATOMY", 128, 132], ["fcwf-4 cells", "ANATOMY", 295, 307], ["FIP", "DISEASE", 192, 195], ["type I infection", "DISEASE", 228, 244], ["Yayoi strain", "ORGANISM", 32, 44], ["sera", "ORGANISM_SUBSTANCE", 128, 132], ["Nos.1-4", "CELL", 134, 141], ["cats", "ORGANISM", 163, 167], ["fcwf-4 cells", "CELL", 295, 307], ["FCoV type I", "GENE_OR_GENE_PRODUCT", 322, 333], ["FCoV type I or II", "PROTEIN", 322, 339], ["cats", "SPECIES", 163, 167], ["FCoV type I", "SPECIES", 322, 333], ["Yayoi strain", "PROBLEM", 32, 44], ["Cat seraFour sera", "TEST", 115, 132], ["FIP", "PROBLEM", 192, 195], ["type I infection", "PROBLEM", 228, 244], ["indirect immunofluorescent assay", "TEST", 248, 280], ["unfixed fcwf", "TEST", 287, 299]]], ["On the other hand, we could not obtain any sera from naturally FCoV type II infected cats.", [["sera", "ANATOMY", 43, 47], ["sera", "ORGANISM_SUBSTANCE", 43, 47], ["FCoV type II", "ORGANISM", 63, 75], ["cats", "ORGANISM", 85, 89], ["cats", "SPECIES", 85, 89], ["any sera", "PROBLEM", 39, 47]]], ["Therefore, two sera collected from cats experimentally infected with M91-267 or KUK-H/L were used in this study (Mochizuki et al., 1997) .Cat seraTo evaluate the seroprevalence of FCoV types I and II in Japan, sera were collected from 79 cats, which visited to one veterinary hospital in 2004 and 2005.", [["sera", "ANATOMY", 15, 19], ["sera", "ANATOMY", 210, 214], ["M91-267", "CHEMICAL", 69, 76], ["sera", "ORGANISM_SUBSTANCE", 15, 19], ["cats", "ORGANISM", 35, 39], ["KUK-H/L", "CELL", 80, 87], ["sera", "ORGANISM_SUBSTANCE", 210, 214], ["cats", "ORGANISM", 238, 242], ["cats", "SPECIES", 35, 39], ["cats", "SPECIES", 238, 242], ["M91-267", "SPECIES", 69, 76], ["FCoV", "SPECIES", 180, 184], ["two sera", "TEST", 11, 19], ["M91", "TEST", 69, 72], ["KUK", "TEST", 80, 83], ["this study", "TEST", 101, 111]]], ["Two of them were clinically and serologically diagnosed as FIP in the hospital.Plaque-reduction neutralization test (PRNT)Serological test was performed by PRNT using serum samples inactivated by heating at 56 8C for 30 min.", [["Plaque", "ANATOMY", 79, 85], ["serum samples", "ANATOMY", 167, 180], ["FIP", "DISEASE", 59, 62], ["PRNT", "SIMPLE_CHEMICAL", 156, 160], ["serum samples", "ORGANISM_SUBSTANCE", 167, 180], ["PRNT", "PROTEIN", 156, 160], ["Plaque-reduction neutralization test", "TEST", 79, 115], ["Serological test", "TEST", 122, 138], ["serum samples", "TEST", 167, 180]]], ["The sera diluted with DMEM containing 2% FCS and each virus diluted to approximately 2 \u00c2 10 3 PFU/ml with DMEM containing 2% FCS were equally mixed and incubated at 37 8C for 1 h.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["FCS", "ORGANISM_SUBSTANCE", 41, 44], ["FCS", "ORGANISM_SUBSTANCE", 125, 128], ["DMEM", "TREATMENT", 22, 26], ["2% FCS", "TREATMENT", 38, 44], ["each virus", "PROBLEM", 49, 59], ["DMEM", "TREATMENT", 106, 110], ["2% FCS", "TREATMENT", 122, 128]]], ["Then 50 ml of the mixture was inoculated onto fcwf-4 cells monolayer in 24-well plate (SUMITOMO BAKELITE, Japan).", [["fcwf-4 cells monolayer", "ANATOMY", 46, 68], ["fcwf-4", "CHEMICAL", 46, 52], ["fcwf-4 cells monolayer", "CELL", 46, 68], ["the mixture", "TREATMENT", 14, 25], ["fcwf-4 cells monolayer", "TREATMENT", 46, 68]]], ["After absorption at 37 8C 1 h, the inoculum was removed and 0.8% agarose (SeaPlaque 1 Agarose, TaKaRa, Japan) in growth medium was overlaid.", [["agarose", "SIMPLE_CHEMICAL", 65, 72], ["the inoculum", "TREATMENT", 31, 43], ["0.8% agarose (SeaPlaque 1 Agarose", "TREATMENT", 60, 93], ["TaKaRa", "TREATMENT", 95, 101]]], ["The infected cells were incubated at 37 8C until cytopathic effect (CPE) appeared, fixed with phosphate-buffered formalin and stained with crystal violet.", [["cells", "ANATOMY", 13, 18], ["phosphate", "CHEMICAL", 94, 103], ["phosphate", "CHEMICAL", 94, 103], ["formalin", "CHEMICAL", 113, 121], ["cells", "CELL", 13, 18], ["phosphate-buffered formalin", "SIMPLE_CHEMICAL", 94, 121], ["infected cells", "CELL_TYPE", 4, 18], ["The infected cells", "PROBLEM", 0, 18], ["cytopathic effect", "PROBLEM", 49, 66], ["CPE", "TEST", 68, 71], ["phosphate", "TEST", 94, 103], ["crystal violet", "PROBLEM", 139, 153], ["infected cells", "OBSERVATION", 4, 18], ["crystal violet", "OBSERVATION", 139, 153]]], ["When the number of plaques was less than 75% of those in control wells, the diluted sera were judged to be positive.", [["plaques", "ANATOMY", 19, 26], ["sera", "ANATOMY", 84, 88], ["plaques", "PATHOLOGICAL_FORMATION", 19, 26], ["sera", "ORGANISM_SUBSTANCE", 84, 88], ["plaques", "PROBLEM", 19, 26], ["the diluted sera", "TEST", 72, 88], ["plaques", "OBSERVATION", 19, 26], ["positive", "OBSERVATION", 107, 115]]], ["For screening of cat sera, all sera finally diluted to 1:10 were examined for PRNT.", [["sera", "ANATOMY", 21, 25], ["sera", "ANATOMY", 31, 35], ["cat", "ORGANISM", 17, 20], ["sera", "ORGANISM_SUBSTANCE", 21, 25], ["sera", "ORGANISM_SUBSTANCE", 31, 35], ["PRNT", "GENE_OR_GENE_PRODUCT", 78, 82], ["PRNT", "PROTEIN", 78, 82], ["cat", "SPECIES", 17, 20], ["cat", "SPECIES", 17, 20], ["screening of cat sera", "TEST", 4, 25], ["all sera", "TEST", 27, 35], ["PRNT", "PROBLEM", 78, 82]]], ["The positive sera were further diluted to 1:33, 1:100, 1:333, 1:1000, 1:3333, and 1:10000 to determine virus-neutralizing titers.", [["sera", "ANATOMY", 13, 17], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["The positive sera", "TEST", 0, 17], ["virus", "PROBLEM", 103, 108], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["neutralizing titers", "OBSERVATION", 109, 128]]], ["The titers were expressed as the highest serum dilution showing 75% plaque reduction or more.Development of virus neutralization (VN) testTo determine the antigenic relationship between FCoV types I and II, serum samples from cats experimentally infected with FIPV type II M91-267 or KUK-H/L and naturally infected with FIPV type I were examined by PRNT.", [["serum", "ANATOMY", 41, 46], ["plaque", "ANATOMY", 68, 74], ["serum samples", "ANATOMY", 207, 220], ["plaque reduction", "DISEASE", 68, 84], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["plaque", "PATHOLOGICAL_FORMATION", 68, 74], ["FCoV types I", "GENE_OR_GENE_PRODUCT", 186, 198], ["serum samples", "ORGANISM_SUBSTANCE", 207, 220], ["cats", "ORGANISM", 226, 230], ["FIPV type II M91-267", "ORGANISM", 260, 280], ["KUK-H/L", "ORGANISM", 284, 291], ["FIPV type I", "GENE_OR_GENE_PRODUCT", 320, 331], ["PRNT", "PROTEIN", 349, 353], ["cats", "SPECIES", 226, 230], ["FIPV type II M91-267", "SPECIES", 260, 280], ["FIPV type I", "SPECIES", 320, 331], ["the highest serum dilution", "TEST", 29, 55], ["75% plaque reduction", "PROBLEM", 64, 84], ["virus neutralization", "PROBLEM", 108, 128], ["serum samples", "TEST", 207, 220], ["cats", "TEST", 226, 230], ["KUK", "TEST", 284, 287], ["plaque", "OBSERVATION", 68, 74], ["virus neutralization", "OBSERVATION", 108, 128], ["infected", "OBSERVATION", 306, 314]]], ["Four sera from FIPV type I infected cats showed VN titers to C3663 and Yayoi ranging from 1:1000 to 1:16000, and those to M91-267 and KUK-H/L ranging from <1:10 to 1:40 (Table 1) .", [["sera", "ANATOMY", 5, 9], ["sera", "ORGANISM_SUBSTANCE", 5, 9], ["FIPV type I", "ORGANISM", 15, 26], ["cats", "ORGANISM", 36, 40], ["VN", "GENE_OR_GENE_PRODUCT", 48, 50], ["cats", "SPECIES", 36, 40], ["FIPV type I", "SPECIES", 15, 26], ["Four sera", "TEST", 0, 9], ["VN titers", "TEST", 48, 57], ["Yayoi", "TEST", 71, 76], ["M91", "TEST", 122, 125], ["KUK", "TEST", 134, 137]]], ["Sera collected from the experimentally FIPV type II infected cats had higher VN titers to type II ranging from 1:4000 to 1:128000 and lower VN titers to type I ranging from 1:80 to 1:1280 (Table 1) .", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["FIPV type II", "ORGANISM", 39, 51], ["cats", "ORGANISM", 61, 65], ["VN", "GENE_OR_GENE_PRODUCT", 77, 79], ["VN", "PROTEIN", 77, 79], ["VN", "PROTEIN", 140, 142], ["cats", "SPECIES", 61, 65], ["Sera", "TEST", 0, 4], ["the experimentally FIPV type II infected cats", "PROBLEM", 20, 65], ["higher VN titers", "PROBLEM", 70, 86]]], ["These results indicated that FCoV-infected cat sera had significantly higher VN titers to homologous type, but not to heterologous type.", [["sera", "ANATOMY", 47, 51], ["FCoV", "CHEMICAL", 29, 33], ["FCoV", "GENE_OR_GENE_PRODUCT", 29, 33], ["cat", "ORGANISM", 43, 46], ["sera", "ORGANISM_SUBSTANCE", 47, 51], ["VN", "GENE_OR_GENE_PRODUCT", 77, 79], ["FCoV", "PROTEIN", 29, 33], ["VN", "PROTEIN", 77, 79], ["cat", "SPECIES", 43, 46], ["cat", "SPECIES", 43, 46], ["FCoV", "TEST", 29, 33], ["infected cat sera", "TEST", 34, 51], ["significantly higher VN titers", "PROBLEM", 56, 86], ["FCoV", "OBSERVATION", 29, 33]]], ["Therefore, this PRNT using both types of FCoV must be able to distinguish serologically between FCoV type I and II infections.Prevalence of FCoV types in JapanA total of 79 cat sera collected in Japan were examined for the prevalence of antibodies to FCoV types I and II by PRNT using C3663 and M91-267 strains.", [["sera", "ANATOMY", 177, 181], ["infections", "DISEASE", 115, 125], ["FCoV", "GENE_OR_GENE_PRODUCT", 41, 45], ["cat", "ORGANISM", 173, 176], ["sera", "ORGANISM_SUBSTANCE", 177, 181], ["M91-267 strains", "CELL", 295, 310], ["PRNT", "PROTEIN", 16, 20], ["antibodies", "PROTEIN", 237, 247], ["cat", "SPECIES", 173, 176], ["FCoV type I", "SPECIES", 96, 107], ["cat", "SPECIES", 173, 176], ["FCoV", "SPECIES", 251, 255], ["M91-267", "SPECIES", 295, 302], ["this PRNT", "TREATMENT", 11, 20], ["FCoV", "TREATMENT", 41, 45], ["II infections", "PROBLEM", 112, 125], ["FCoV types", "TREATMENT", 140, 150], ["cat sera", "TEST", 173, 181], ["antibodies", "PROBLEM", 237, 247], ["PRNT", "TEST", 274, 278], ["M91", "TEST", 295, 298], ["FCoV", "OBSERVATION", 41, 45], ["infections", "OBSERVATION", 115, 125], ["FCoV types", "OBSERVATION", 140, 150]]], ["The result showed that 50 (63.3%) cats were seropositive to FCoV (Fig. 1 ).", [["cats", "ORGANISM", 34, 38], ["cats", "SPECIES", 34, 38], ["FCoV", "SPECIES", 60, 64]]], ["Among these seropositive samples, 49 (98%) possessed significantly higher titers against type I, and only one (2%) did against type II.", [["samples", "ANATOMY", 25, 32], ["samples", "CANCER", 25, 32], ["type I", "SPECIES", 89, 95], ["these seropositive samples", "TEST", 6, 32]]], ["Although three samples had VN titers of 1:33 to type II, two of them had higher VN titers to type I (1:3333).", [["samples", "ANATOMY", 15, 22], ["VN", "PROTEIN", 80, 82], ["VN titers", "TEST", 27, 36], ["higher", "OBSERVATION_MODIFIER", 73, 79], ["VN titers", "OBSERVATION", 80, 89]]], ["Since one sample did not have VN titer to type I, it was regarded as positive for type II.", [["VN", "GENE_OR_GENE_PRODUCT", 30, 32], ["VN", "PROTEIN", 30, 32], ["type II", "PROBLEM", 82, 89]]], ["All two samples from FIP cases had the highest VN titers to type I (1:10000), meanwhile, these were negative (<1:10) to type II.DiscussionIn this study, we distinguished types of FCoV which had infected cats by VN test.", [["samples", "ANATOMY", 8, 15], ["FIP", "DISEASE", 21, 24], ["FIP", "ORGANISM", 21, 24], ["FCoV", "CANCER", 179, 183], ["cats", "ORGANISM", 203, 207], ["VN", "PROTEIN", 47, 49], ["cats", "SPECIES", 203, 207], ["FIP cases", "TEST", 21, 30], ["this study", "TEST", 141, 151], ["FCoV", "PROBLEM", 179, 183], ["VN test", "TEST", 211, 218], ["FCoV", "OBSERVATION", 179, 183]]], ["At first, we determined cross-reactivities of the known sera from FIP cats (Table 1 ).", [["sera", "ANATOMY", 56, 60], ["sera", "ORGANISM_SUBSTANCE", 56, 60], ["cats", "SPECIES", 70, 74]]], ["VN titers difference between homologous type was five-fold or less, and to heterologous type was 25-fold or more, indicating that the present PRNT can clearly differentiate FCoV types.", [["VN", "GENE_OR_GENE_PRODUCT", 0, 2], ["FCoV", "CANCER", 173, 177], ["VN", "PROTEIN", 0, 2], ["PRNT", "PROTEIN", 142, 146], ["VN titers", "TEST", 0, 9], ["the present PRNT", "PROBLEM", 130, 146], ["FCoV types", "OBSERVATION", 173, 183]]], ["It is known that a major difference between types I and II is located in S protein responsible for eliciting VN antibodies (Fiscus and Teramoto, 1987; De Groot et al., 1989; Corapi et al., 1992) .DiscussionUsing the PRNT, we examined the recent status of FCoV seroprevalence in field cats.", [["FCoV", "CHEMICAL", 255, 259], ["VN antibodies", "GENE_OR_GENE_PRODUCT", 109, 122], ["FCoV", "GENE_OR_GENE_PRODUCT", 255, 259], ["cats", "ORGANISM", 284, 288], ["S protein", "PROTEIN", 73, 82], ["VN antibodies", "PROTEIN", 109, 122], ["cats", "SPECIES", 284, 288]]], ["More than 60% of the cats were found to be FCoV seropositive and this was similar to the positive rate described in other countries (Pedersen et al., 1981; Loeffler et al., 1978; Kummrow et al., 2005; Bell et al., 2006) .", [["cats", "ORGANISM", 21, 25], ["FCoV", "CANCER", 43, 47], ["cats", "SPECIES", 21, 25], ["FCoV seropositive", "PROBLEM", 43, 60], ["FCoV", "OBSERVATION", 43, 47]]], ["In Japan, Hohdatsu et al. (1992) first described that 21.3% of chronically diseased cats and 13.4% of non-diseased cats had antibodies to FCoV by IFA to detect FCoV infection.", [["infection", "DISEASE", 165, 174], ["cats", "ORGANISM", 84, 88], ["cats", "ORGANISM", 115, 119], ["FCoV", "GENE_OR_GENE_PRODUCT", 138, 142], ["IFA", "SIMPLE_CHEMICAL", 146, 149], ["FCoV", "GENE_OR_GENE_PRODUCT", 160, 164], ["antibodies", "PROTEIN", 124, 134], ["FCoV", "PROTEIN", 138, 142], ["cats", "SPECIES", 84, 88], ["cats", "SPECIES", 115, 119], ["FCoV", "SPECIES", 138, 142], ["FCoV", "SPECIES", 160, 164], ["chronically diseased cats", "PROBLEM", 63, 88], ["non-diseased cats", "PROBLEM", 102, 119], ["antibodies to FCoV", "PROBLEM", 124, 142], ["IFA", "TEST", 146, 149], ["FCoV infection", "PROBLEM", 160, 174], ["FCoV infection", "OBSERVATION", 160, 174]]], ["The seroprevalence rate obtained in the present study is about three times higher than that in the previous report.", [["The seroprevalence rate", "TEST", 0, 23]]], ["Since different methods and samples were used for epidemiology, it is impossible to directly compare the prevalence of FCoV in Japan.", [["FCoV", "DISEASE", 119, 123], ["FCoV", "SPECIES", 119, 123], ["FCoV", "PROBLEM", 119, 123], ["FCoV", "OBSERVATION", 119, 123]]], ["However, most probable explanation for this discrepancy is that FCoV has been widespreading among Japanese cat population during the last decade.DiscussionPrevious studies conducted in several countries including Japan have revealed that 69-91% of seropositive cats were suspected to be type I infection (Hohdatsu et al., 1992; Vennema, 1999; Kummrow et al., 2005) .", [["FCoV", "CHEMICAL", 64, 68], ["type I infection", "DISEASE", 287, 303], ["FCoV", "GENE_OR_GENE_PRODUCT", 64, 68], ["cat", "ORGANISM", 107, 110], ["cats", "ORGANISM", 261, 265], ["cat", "SPECIES", 107, 110], ["cats", "SPECIES", 261, 265], ["this discrepancy", "PROBLEM", 39, 55], ["FCoV", "PROBLEM", 64, 68], ["DiscussionPrevious studies", "TEST", 145, 171], ["seropositive cats", "PROBLEM", 248, 265], ["type I infection", "PROBLEM", 287, 303], ["most probable explanation for", "UNCERTAINTY", 9, 38], ["FCoV", "OBSERVATION", 64, 68], ["infection", "OBSERVATION", 294, 303]]], ["In the present study, it was found that 49 cats (98%) possessed type I specific antibodies and only one cat (2%) to type II.", [["cats", "ORGANISM", 43, 47], ["cat", "ORGANISM", 104, 107], ["type I specific antibodies", "PROTEIN", 64, 90], ["cats", "SPECIES", 43, 47], ["cats", "TEST", 43, 47], ["type I specific antibodies", "PROBLEM", 64, 90]]], ["The prevalence of type I infection revealed here was significantly higher than the previous report (80.4% in chronically diseased cats) by competitive ELISA (Hohdatsu et al., 1992) .", [["type I infection", "DISEASE", 18, 34], ["cats", "ORGANISM", 130, 134], ["cats", "SPECIES", 130, 134], ["type I infection", "PROBLEM", 18, 34], ["type I", "OBSERVATION_MODIFIER", 18, 24], ["infection", "OBSERVATION", 25, 34]]], ["Although this and the previous report (Hohdatsu et al., 1992) were different in methods and samples, it might suggest that type II FCoV infection has been decreasing in Japanese domestic cats in recent years.DiscussionIn conclusion, our newly established VN test can specifically detect and distinguish between types of FCoV infection.", [["infection", "DISEASE", 136, 145], ["FCoV infection", "DISEASE", 320, 334], ["type II FCoV", "GENE_OR_GENE_PRODUCT", 123, 135], ["cats", "ORGANISM", 187, 191], ["FCoV", "CANCER", 320, 324], ["VN", "PROTEIN", 255, 257], ["cats", "SPECIES", 187, 191], ["FCoV", "SPECIES", 320, 324], ["type II FCoV infection", "PROBLEM", 123, 145], ["VN test", "TEST", 255, 262], ["FCoV infection", "PROBLEM", 320, 334], ["type II", "OBSERVATION_MODIFIER", 123, 130], ["FCoV", "OBSERVATION_MODIFIER", 131, 135], ["infection", "OBSERVATION", 136, 145], ["decreasing", "OBSERVATION_MODIFIER", 155, 165], ["FCoV", "OBSERVATION_MODIFIER", 320, 324], ["infection", "OBSERVATION", 325, 334]]], ["In addition, FCoV type I, but not type II, has widely spread among cats population in Japan.", [["FCoV type I", "GENE_OR_GENE_PRODUCT", 13, 24], ["type II", "GENE_OR_GENE_PRODUCT", 34, 41], ["cats", "ORGANISM", 67, 71], ["FCoV type I", "PROTEIN", 13, 24], ["cats", "SPECIES", 67, 71], ["FCoV type I", "SPECIES", 13, 24], ["FCoV type I", "PROBLEM", 13, 24], ["FCoV", "OBSERVATION", 13, 17], ["widely", "OBSERVATION_MODIFIER", 47, 53], ["spread", "OBSERVATION_MODIFIER", 54, 60]]]], "PMC7384783": [["IntroductionIn January 2020, an outbreak of COVID-19 began in Wuhan, China, and this disease spread rapidly to more than 200 countries.1 COVID-19 is caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has a very high transmissibility.2, 3 Restricting public mobility is a crucial public health tool to control respiratory infectious diseases.", [["COVID-19", "CHEMICAL", 44, 52], ["COVID-19", "CHEMICAL", 137, 145], ["coronavirus", "DISEASE", 167, 178], ["acute respiratory syndrome coronavirus", "DISEASE", 195, 233], ["respiratory infectious diseases", "DISEASE", 365, 396], ["coronavirus", "ORGANISM", 167, 178], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 188, 235], ["SARS-CoV-2", "ORGANISM", 237, 247], ["coronavirus", "SPECIES", 167, 178], ["severe acute respiratory syndrome coronavirus", "SPECIES", 188, 233], ["SARS-CoV-2", "SPECIES", 237, 247], ["COVID", "TEST", 44, 49], ["this disease", "PROBLEM", 80, 92], ["a novel coronavirus", "PROBLEM", 159, 178], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 188, 233], ["SARS-CoV", "TEST", 237, 245], ["respiratory infectious diseases", "PROBLEM", 365, 396], ["disease", "OBSERVATION", 85, 92], ["coronavirus", "OBSERVATION", 167, 178], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["respiratory syndrome", "OBSERVATION", 201, 221], ["very", "OBSERVATION_MODIFIER", 262, 266], ["high transmissibility", "OBSERVATION", 267, 288], ["respiratory", "ANATOMY", 365, 376], ["infectious", "OBSERVATION", 377, 387]]], ["Such restrictions include physical distancing and community containment measures for reducing public transport use and public gatherings, school closures, and working from home where possible.", [["community containment measures", "TREATMENT", 50, 80]]], ["Previous studies investigating influenza epidemics provided evidence for the small effects of these measures.", [["influenza epidemics", "DISEASE", 31, 50], ["Previous studies", "TEST", 0, 16], ["influenza epidemics", "PROBLEM", 31, 50], ["these measures", "TREATMENT", 94, 108], ["small", "OBSERVATION_MODIFIER", 77, 82]]], ["For example, mobility restrictions were estimated to only reduce the peak number of individuals infected with H1N1 virus in local transmission by 10% and delay the peak incidence by 2 days.4 However, this scarcity of evidence is probably because such studies only captured information on some subpopulations, such as school children or people at work, not the whole population.5, 6", [["H1N1", "DISEASE", 110, 114], ["H1N1 virus", "ORGANISM", 110, 120], ["children", "ORGANISM", 324, 332], ["people", "ORGANISM", 336, 342], ["children", "SPECIES", 324, 332], ["people", "SPECIES", 336, 342], ["H1N1 virus", "SPECIES", 110, 120], ["H1N1 virus", "PROBLEM", 110, 120], ["probably because", "UNCERTAINTY", 229, 245]]]], "82aec91aec3367c18a7736eeb3e4a76839042b89": [["IntroductionRespiratory disease in swine, as with other species, is generally considered a multifactorial problem caused by a combination of viral and bacterial infectious agents, as well as adverse environmental conditions. www.elsevier.com/locate/vetmic Available online at www.sciencedirect.com Veterinary Microbiology 128 (2008) [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] The list of infectious agents that cause respiratory disease in swine is extensive and includes both viral agents, such as porcine reproductive and respiratory syndrome virus (PRRSV), swine influenza virus (SIV) and porcine respiratory coronavirus (PRCV); and bacterial agents, such as Mycoplasma hyopneumoniae, Bordetella bronchiseptica, Pasteurella multocida and Actinobacillus pleuropneumoniae.", [["respiratory", "ANATOMY", 434, 445], ["IntroductionRespiratory disease", "DISEASE", 0, 31], ["[39] [40] [41] [42] [43] [44] [45] [46", "CHEMICAL", 348, 386], ["respiratory disease", "DISEASE", 434, 453], ["porcine reproductive and respiratory syndrome virus", "DISEASE", 516, 567], ["swine influenza virus", "DISEASE", 577, 598], ["porcine respiratory coronavirus", "DISEASE", 609, 640], ["Mycoplasma hyopneumoniae", "DISEASE", 679, 703], ["Bordetella bronchiseptica", "DISEASE", 705, 730], ["swine", "ORGANISM", 35, 40], ["[36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47]", "SIMPLE_CHEMICAL", 333, 392], ["swine", "ORGANISM", 457, 462], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 516, 567], ["PRRSV", "ORGANISM", 569, 574], ["swine influenza virus", "ORGANISM", 577, 598], ["SIV", "ORGANISM", 600, 603], ["porcine respiratory coronavirus", "ORGANISM", 609, 640], ["PRCV", "CANCER", 642, 646], ["Mycoplasma hyopneumoniae", "ORGANISM", 679, 703], ["Bordetella bronchiseptica", "ORGANISM", 705, 730], ["Pasteurella multocida", "ORGANISM", 732, 753], ["Actinobacillus pleuropneumoniae", "ORGANISM", 758, 789], ["swine", "SPECIES", 35, 40], ["swine", "SPECIES", 457, 462], ["porcine", "SPECIES", 516, 523], ["PRRSV", "SPECIES", 569, 574], ["swine influenza virus", "SPECIES", 577, 598], ["porcine respiratory coronavirus", "SPECIES", 609, 640], ["Mycoplasma hyopneumoniae", "SPECIES", 679, 703], ["Bordetella bronchiseptica", "SPECIES", 705, 730], ["Pasteurella multocida", "SPECIES", 732, 753], ["Actinobacillus pleuropneumoniae", "SPECIES", 758, 789], ["swine", "SPECIES", 35, 40], ["swine", "SPECIES", 457, 462], ["PRRSV", "SPECIES", 569, 574], ["swine influenza virus", "SPECIES", 577, 598], ["SIV", "SPECIES", 600, 603], ["porcine respiratory coronavirus", "SPECIES", 609, 640], ["PRCV", "SPECIES", 642, 646], ["Mycoplasma hyopneumoniae", "SPECIES", 679, 703], ["Bordetella bronchiseptica", "SPECIES", 705, 730], ["Pasteurella multocida", "SPECIES", 732, 753], ["Actinobacillus pleuropneumoniae", "SPECIES", 758, 789], ["IntroductionRespiratory disease", "PROBLEM", 0, 31], ["a multifactorial problem", "PROBLEM", 89, 113], ["viral and bacterial infectious agents", "PROBLEM", 141, 178], ["adverse environmental conditions", "PROBLEM", 191, 223], ["infectious agents", "TREATMENT", 405, 422], ["respiratory disease", "PROBLEM", 434, 453], ["viral agents", "TREATMENT", 494, 506], ["porcine reproductive", "PROBLEM", 516, 536], ["respiratory syndrome virus", "PROBLEM", 541, 567], ["PRRSV", "PROBLEM", 569, 574], ["swine influenza virus", "PROBLEM", 577, 598], ["porcine respiratory coronavirus (PRCV)", "TREATMENT", 609, 647], ["bacterial agents", "TREATMENT", 653, 669], ["Mycoplasma hyopneumoniae", "PROBLEM", 679, 703], ["Bordetella bronchiseptica", "PROBLEM", 705, 730], ["Pasteurella multocida", "PROBLEM", 732, 753], ["Actinobacillus pleuropneumoniae", "PROBLEM", 758, 789], ["disease", "OBSERVATION", 24, 31], ["viral", "OBSERVATION", 141, 146], ["bacterial", "OBSERVATION_MODIFIER", 151, 160], ["infectious", "OBSERVATION", 161, 171], ["infectious", "OBSERVATION", 405, 415], ["respiratory disease", "OBSERVATION", 434, 453], ["viral agents", "OBSERVATION", 494, 506], ["respiratory syndrome", "OBSERVATION", 541, 561], ["respiratory coronavirus", "OBSERVATION", 617, 640], ["bacterial agents", "OBSERVATION", 653, 669], ["Mycoplasma hyopneumoniae", "OBSERVATION", 679, 703], ["Actinobacillus pleuropneumoniae", "OBSERVATION", 758, 789]]], ["Although any one of these pathogens can potentially cause disease on its own, more serious and chronic respiratory disease results, and more economic losses are incurred, when infection with multiple pathogens occurs.", [["respiratory", "ANATOMY", 103, 114], ["respiratory disease", "DISEASE", 103, 122], ["infection", "DISEASE", 176, 185], ["these pathogens", "PROBLEM", 20, 35], ["disease", "PROBLEM", 58, 65], ["chronic respiratory disease results", "PROBLEM", 95, 130], ["infection", "PROBLEM", 176, 185], ["multiple pathogens", "PROBLEM", 191, 209], ["pathogens", "OBSERVATION", 26, 35], ["serious", "OBSERVATION_MODIFIER", 83, 90], ["chronic", "OBSERVATION_MODIFIER", 95, 102], ["respiratory disease", "OBSERVATION", 103, 122], ["multiple", "OBSERVATION_MODIFIER", 191, 199], ["pathogens", "OBSERVATION", 200, 209]]], ["Although the multifactorial nature of respiratory disease is well accepted, the specific mechanisms by which respiratory pathogens interact with each other or the host to cause more severe disease are poorly understood.IntroductionCoronaviruses are enveloped, single-stranded, RNA viruses which cause respiratory and enteric disease in animals, including the common cold and severe acute respiratory syndrome (SARS) in humans.", [["respiratory", "ANATOMY", 38, 49], ["respiratory", "ANATOMY", 109, 120], ["respiratory", "ANATOMY", 301, 312], ["respiratory disease", "DISEASE", 38, 57], ["respiratory and enteric disease", "DISEASE", 301, 332], ["acute respiratory syndrome", "DISEASE", 382, 408], ["SARS", "DISEASE", 410, 414], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 231, 244], ["humans", "ORGANISM", 419, 425], ["humans", "SPECIES", 419, 425], ["humans", "SPECIES", 419, 425], ["respiratory disease", "PROBLEM", 38, 57], ["more severe disease", "PROBLEM", 177, 196], ["IntroductionCoronaviruses", "PROBLEM", 219, 244], ["RNA viruses", "PROBLEM", 277, 288], ["respiratory and enteric disease in animals", "PROBLEM", 301, 343], ["the common cold and severe acute respiratory syndrome", "PROBLEM", 355, 408], ["multifactorial", "OBSERVATION_MODIFIER", 13, 27], ["respiratory disease", "OBSERVATION", 38, 57], ["severe", "OBSERVATION_MODIFIER", 182, 188], ["disease", "OBSERVATION", 189, 196], ["enteric disease", "OBSERVATION", 317, 332], ["common cold", "ANATOMY", 359, 370], ["severe", "OBSERVATION_MODIFIER", 375, 381], ["acute", "OBSERVATION_MODIFIER", 382, 387], ["respiratory syndrome", "OBSERVATION", 388, 408]]], ["Porcine respiratory coronavirus is a naturally occurring deletion mutant of transmissible gastroenteritis virus (TGE), an enteric coronavirus of swine (Rasschaert et al., 1990; Britton et al., 1991; Wesley et al., 1991) .", [["respiratory coronavirus", "DISEASE", 8, 31], ["transmissible gastroenteritis", "DISEASE", 76, 105], ["TGE", "DISEASE", 113, 116], ["enteric coronavirus of swine", "DISEASE", 122, 150], ["Porcine respiratory coronavirus", "ORGANISM", 0, 31], ["transmissible gastroenteritis virus", "ORGANISM", 76, 111], ["TGE", "CANCER", 113, 116], ["enteric coronavirus", "ORGANISM", 122, 141], ["swine", "ORGANISM", 145, 150], ["Porcine respiratory coronavirus", "SPECIES", 0, 31], ["transmissible gastroenteritis virus", "SPECIES", 76, 111], ["coronavirus", "SPECIES", 130, 141], ["swine", "SPECIES", 145, 150], ["Porcine respiratory coronavirus", "SPECIES", 0, 31], ["transmissible gastroenteritis virus", "SPECIES", 76, 111], ["TGE", "SPECIES", 113, 116], ["swine", "SPECIES", 145, 150], ["Porcine respiratory coronavirus", "PROBLEM", 0, 31], ["transmissible gastroenteritis virus", "PROBLEM", 76, 111], ["respiratory coronavirus", "OBSERVATION", 8, 31], ["transmissible", "OBSERVATION_MODIFIER", 76, 89], ["gastroenteritis virus", "OBSERVATION", 90, 111], ["enteric coronavirus", "ANATOMY", 122, 141]]], ["A deletion in the spike gene of TGE has altered the tropism of PRCV from primarily enteric to primarily respiratory in nature.", [["respiratory", "ANATOMY", 104, 115], ["TGE", "CHEMICAL", 32, 35], ["TGE", "GENE_OR_GENE_PRODUCT", 32, 35], ["PRCV", "CANCER", 63, 67], ["spike gene", "DNA", 18, 28], ["TGE", "DNA", 32, 35], ["PRCV", "SPECIES", 63, 67], ["A deletion", "PROBLEM", 0, 10], ["the tropism of PRCV", "PROBLEM", 48, 67], ["deletion", "OBSERVATION", 2, 10], ["tropism", "OBSERVATION", 52, 59]]], ["Although experimentally PRCV has been shown to cause bronchointersitial pneumonia, the clinical relevance of this virus has been debated, since many farms seroconvert without overt clinical signs of disease.", [["PRCV", "CHEMICAL", 24, 28], ["pneumonia", "DISEASE", 72, 81], ["PRCV", "CANCER", 24, 28], ["PRCV", "PROTEIN", 24, 28], ["PRCV", "SPECIES", 24, 28], ["bronchointersitial pneumonia", "PROBLEM", 53, 81], ["this virus", "PROBLEM", 109, 119], ["overt clinical signs of disease", "PROBLEM", 175, 206], ["bronchointersitial", "OBSERVATION_MODIFIER", 53, 71], ["pneumonia", "OBSERVATION", 72, 81], ["disease", "OBSERVATION", 199, 206]]], ["What role, if any, PRCV plays in multifactorial respiratory disease is still being investigated.", [["respiratory", "ANATOMY", 48, 59], ["PRCV", "CHEMICAL", 19, 23], ["respiratory disease", "DISEASE", 48, 67], ["PRCV", "GENE_OR_GENE_PRODUCT", 19, 23], ["multifactorial respiratory disease", "PROBLEM", 33, 67], ["multifactorial", "OBSERVATION_MODIFIER", 33, 47], ["respiratory disease", "OBSERVATION", 48, 67]]], ["Prior work has shown that exposure to PRCV decreases replication of SIV, in vivo, and mixed results have been reported with coinfections of PRCV and PRRSV (Van Reeth and Pensaert, 1994; .", [["PRCV", "CHEMICAL", 38, 42], ["PRCV", "CHEMICAL", 38, 42], ["PRCV", "ORGANISM", 38, 42], ["SIV", "ORGANISM", 68, 71], ["PRCV", "ORGANISM", 140, 144], ["PRRSV", "ORGANISM", 149, 154], ["PRRSV", "SPECIES", 149, 154], ["PRCV", "SPECIES", 38, 42], ["SIV", "SPECIES", 68, 71], ["PRCV", "SPECIES", 140, 144], ["PRRSV", "SPECIES", 149, 154], ["PRCV", "TREATMENT", 38, 42]]], ["However, experimental exposure of pigs to bacterial lipopolysaccharide (LPS) following PRCV infection led to more severe respiratory disease and increased tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-1 levels than exposure to either LPS or PRCValone .", [["respiratory", "ANATOMY", 121, 132], ["lipopolysaccharide", "CHEMICAL", 52, 70], ["LPS", "CHEMICAL", 72, 75], ["PRCV", "CHEMICAL", 87, 91], ["infection", "DISEASE", 92, 101], ["respiratory disease", "DISEASE", 121, 140], ["tumor", "DISEASE", 155, 160], ["necrosis", "DISEASE", 161, 169], ["LPS", "CHEMICAL", 249, 252], ["PRCValone", "CHEMICAL", 256, 265], ["PRCValone", "CHEMICAL", 256, 265], ["pigs", "ORGANISM", 34, 38], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 52, 70], ["LPS", "SIMPLE_CHEMICAL", 72, 75], ["tumor necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 155, 182], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 184, 193], ["interleukin (IL)-1", "GENE_OR_GENE_PRODUCT", 199, 217], ["LPS", "SIMPLE_CHEMICAL", 249, 252], ["PRCValone", "SIMPLE_CHEMICAL", 256, 265], ["tumor necrosis factor-alpha", "PROTEIN", 155, 182], ["TNF", "PROTEIN", 184, 187], ["pigs", "SPECIES", 34, 38], ["pigs", "SPECIES", 34, 38], ["PRCV", "SPECIES", 87, 91], ["pigs to bacterial lipopolysaccharide (LPS", "TREATMENT", 34, 75], ["PRCV infection", "PROBLEM", 87, 101], ["more severe respiratory disease", "PROBLEM", 109, 140], ["increased tumor necrosis factor", "PROBLEM", 145, 176], ["alpha (TNF", "TEST", 177, 187], ["interleukin (IL)", "TEST", 199, 215], ["LPS", "TREATMENT", 249, 252], ["PRCValone", "TREATMENT", 256, 265], ["infection", "OBSERVATION", 92, 101], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["respiratory disease", "OBSERVATION", 121, 140], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["tumor", "OBSERVATION", 155, 160], ["necrosis", "OBSERVATION_MODIFIER", 161, 169]]], ["Thus, infection with PRCV and gramnegative bacteria may result in a more severe disease.IntroductionThe species belonging to the genus Bordetella are closely related gram-negative bacteria which cause respiratory disease in animals.", [["respiratory", "ANATOMY", 201, 212], ["infection", "DISEASE", 6, 15], ["respiratory disease", "DISEASE", 201, 220], ["genus Bordetella", "ORGANISM", 129, 145], ["PRCV", "SPECIES", 21, 25], ["infection", "PROBLEM", 6, 15], ["PRCV", "PROBLEM", 21, 25], ["gramnegative bacteria", "PROBLEM", 30, 51], ["a more severe disease", "PROBLEM", 66, 87], ["the genus Bordetella", "TEST", 125, 145], ["gram", "TEST", 166, 170], ["negative bacteria", "PROBLEM", 171, 188], ["respiratory disease in animals", "PROBLEM", 201, 231], ["infection", "OBSERVATION", 6, 15], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disease", "OBSERVATION", 80, 87], ["negative bacteria", "OBSERVATION", 171, 188], ["respiratory disease", "OBSERVATION", 201, 220]]], ["Bordetella pertussis is the obligatory human pathogen that causes whooping cough, and B. bronchiseptica is the more promiscuous pathogen that is the etiologic agent of respiratory disease in a number of animals including swine.", [["respiratory", "ANATOMY", 168, 179], ["Bordetella pertussis", "DISEASE", 0, 20], ["whooping cough", "DISEASE", 66, 80], ["B. bronchiseptica", "DISEASE", 86, 103], ["respiratory disease", "DISEASE", 168, 187], ["Bordetella pertussis", "ORGANISM", 0, 20], ["human", "ORGANISM", 39, 44], ["B. bronchiseptica", "ORGANISM", 86, 103], ["swine", "ORGANISM", 221, 226], ["Bordetella pertussis", "SPECIES", 0, 20], ["human", "SPECIES", 39, 44], ["B. bronchiseptica", "SPECIES", 86, 103], ["swine", "SPECIES", 221, 226], ["Bordetella pertussis", "SPECIES", 0, 20], ["human", "SPECIES", 39, 44], ["B. bronchiseptica", "SPECIES", 86, 103], ["swine", "SPECIES", 221, 226], ["Bordetella pertussis", "PROBLEM", 0, 20], ["the obligatory human pathogen", "PROBLEM", 24, 53], ["whooping cough", "PROBLEM", 66, 80], ["B. bronchiseptica", "PROBLEM", 86, 103], ["the more promiscuous pathogen", "PROBLEM", 107, 136], ["respiratory disease", "PROBLEM", 168, 187], ["more promiscuous", "OBSERVATION_MODIFIER", 111, 127], ["pathogen", "OBSERVATION", 128, 136], ["respiratory disease", "OBSERVATION", 168, 187]]], ["Although B. bronchiseptica can cause pneumonia in neonatal pigs and rhinitis and bronchitis in older swine on its own, its role in multifactorial disease is also under investigation.", [["B. bronchiseptica", "DISEASE", 9, 26], ["pneumonia", "DISEASE", 37, 46], ["neonatal pigs and rhinitis", "DISEASE", 50, 76], ["bronchitis", "DISEASE", 81, 91], ["B. bronchiseptica", "ORGANISM", 9, 26], ["pigs", "ORGANISM", 59, 63], ["B. bronchiseptica", "SPECIES", 9, 26], ["pigs", "SPECIES", 59, 63], ["swine", "SPECIES", 101, 106], ["B. bronchiseptica", "SPECIES", 9, 26], ["pigs", "SPECIES", 59, 63], ["swine", "SPECIES", 101, 106], ["B. bronchiseptica", "PROBLEM", 9, 26], ["pneumonia", "PROBLEM", 37, 46], ["neonatal pigs", "PROBLEM", 50, 63], ["rhinitis", "PROBLEM", 68, 76], ["bronchitis", "PROBLEM", 81, 91], ["multifactorial disease", "PROBLEM", 131, 153], ["bronchiseptica", "OBSERVATION", 12, 26], ["can cause", "UNCERTAINTY", 27, 36], ["pneumonia", "OBSERVATION", 37, 46], ["neonatal pigs", "ANATOMY", 50, 63], ["rhinitis", "OBSERVATION", 68, 76], ["bronchitis", "OBSERVATION", 81, 91], ["multifactorial", "OBSERVATION_MODIFIER", 131, 145], ["disease", "OBSERVATION", 146, 153]]], ["Prior infection with B. bronchiseptica in swine has led to increased colonization and more severe disease with other bacterial agents such as P. multocida, Streptococcus suis and Haemophilus parasuis (Chanter et al., 1989; Vecht et al., 1992; Brockmeier et al., 2001; Brockmeier, 2004) , and coinfection of B. bronchiseptica with PRRSV in swine exacerbated clinical disease and induced B bronchiseptica pneumonia (Brockmeier et al., 2000) .IntroductionThe innate immune response of the lung is not only important for initial protection from infectious agents and stimulation of the adaptive immune response, but the nature of the innate response can dictate the character of the pathology observed and the outcome of infection.", [["lung", "ANATOMY", 486, 490], ["infection", "DISEASE", 6, 15], ["P. multocida", "DISEASE", 142, 154], ["Streptococcus suis", "DISEASE", 156, 174], ["Haemophilus parasuis", "DISEASE", 179, 199], ["B. bronchiseptica", "DISEASE", 307, 324], ["B bronchiseptica pneumonia", "DISEASE", 386, 412], ["infection", "DISEASE", 717, 726], ["B. bronchiseptica", "ORGANISM", 21, 38], ["swine", "ORGANISM", 42, 47], ["P. multocida", "ORGANISM", 142, 154], ["Streptococcus suis", "ORGANISM", 156, 174], ["Haemophilus parasuis", "ORGANISM", 179, 199], ["B. bronchiseptica", "ORGANISM", 307, 324], ["PRRSV", "ORGANISM", 330, 335], ["swine", "ORGANISM", 339, 344], ["B bronchiseptica", "ORGANISM", 386, 402], ["lung", "ORGAN", 486, 490], ["B. bronchiseptica", "SPECIES", 21, 38], ["swine", "SPECIES", 42, 47], ["P. multocida", "SPECIES", 142, 154], ["Streptococcus suis", "SPECIES", 156, 174], ["Haemophilus parasuis", "SPECIES", 179, 199], ["B. bronchiseptica", "SPECIES", 307, 324], ["PRRSV", "SPECIES", 330, 335], ["swine", "SPECIES", 339, 344], ["B bronchiseptica", "SPECIES", 386, 402], ["B. bronchiseptica", "SPECIES", 21, 38], ["swine", "SPECIES", 42, 47], ["P. multocida", "SPECIES", 142, 154], ["Streptococcus suis", "SPECIES", 156, 174], ["Haemophilus parasuis", "SPECIES", 179, 199], ["B. bronchiseptica", "SPECIES", 307, 324], ["PRRSV", "SPECIES", 330, 335], ["swine", "SPECIES", 339, 344], ["B bronchiseptica", "SPECIES", 386, 402], ["Prior infection", "PROBLEM", 0, 15], ["B. bronchiseptica", "PROBLEM", 21, 38], ["increased colonization", "PROBLEM", 59, 81], ["more severe disease", "PROBLEM", 86, 105], ["other bacterial agents", "TREATMENT", 111, 133], ["P. multocida", "PROBLEM", 142, 154], ["Streptococcus suis", "PROBLEM", 156, 174], ["Haemophilus parasuis", "PROBLEM", 179, 199], ["bronchiseptica", "PROBLEM", 310, 324], ["PRRSV", "PROBLEM", 330, 335], ["clinical disease", "PROBLEM", 357, 373], ["induced B bronchiseptica pneumonia", "PROBLEM", 378, 412], ["infectious agents", "TREATMENT", 541, 558], ["stimulation", "TREATMENT", 563, 574], ["the pathology", "PROBLEM", 675, 688], ["infection", "PROBLEM", 717, 726], ["infection", "OBSERVATION", 6, 15], ["bronchiseptica", "OBSERVATION", 24, 38], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["colonization", "OBSERVATION", 69, 81], ["more severe", "OBSERVATION_MODIFIER", 86, 97], ["disease", "OBSERVATION", 98, 105], ["bronchiseptica", "OBSERVATION_MODIFIER", 388, 402], ["pneumonia", "OBSERVATION", 403, 412], ["lung", "ANATOMY", 486, 490], ["not only", "UNCERTAINTY", 494, 502], ["infectious", "OBSERVATION", 541, 551], ["infection", "OBSERVATION", 717, 726]]], ["Proinflammatory cytokines, such as TNFalpha, IL-1 and IL-6, as well as the chemokines IL-8 and monocyte chemotactic protein-1 (MCP-1) are often produced after recognition of pathogen associated molecular patterns for early host protection and recruitment of effector cells.", [["effector cells", "ANATOMY", 258, 272], ["TNFalpha", "GENE_OR_GENE_PRODUCT", 35, 43], ["IL-1", "GENE_OR_GENE_PRODUCT", 45, 49], ["IL-6", "GENE_OR_GENE_PRODUCT", 54, 58], ["IL-8", "GENE_OR_GENE_PRODUCT", 86, 90], ["monocyte chemotactic protein-1", "GENE_OR_GENE_PRODUCT", 95, 125], ["MCP-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["cells", "CELL", 267, 272], ["Proinflammatory cytokines", "PROTEIN", 0, 25], ["TNFalpha", "PROTEIN", 35, 43], ["IL-6", "PROTEIN", 54, 58], ["chemokines", "PROTEIN", 75, 85], ["IL-8", "PROTEIN", 86, 90], ["monocyte chemotactic protein-1 (MCP-1", "PROTEIN", 95, 132], ["effector cells", "CELL_TYPE", 258, 272], ["Proinflammatory cytokines", "TEST", 0, 25], ["TNFalpha", "TEST", 35, 43], ["IL", "TEST", 45, 47], ["IL", "TEST", 54, 56], ["the chemokines IL", "TEST", 71, 88], ["monocyte chemotactic protein", "TEST", 95, 123], ["MCP", "TEST", 127, 130], ["pathogen associated molecular patterns", "PROBLEM", 174, 212], ["early host protection", "TREATMENT", 217, 238], ["recruitment of effector cells", "TREATMENT", 243, 272], ["cytokines", "OBSERVATION", 16, 25], ["TNFalpha", "ANATOMY", 35, 43], ["effector cells", "OBSERVATION", 258, 272]]], ["Exposure to multiple infectious agents may result in distinct cytokine patterns and thus alter the severity of disease compared to that observed during infection with individual agents.", [["infection", "DISEASE", 152, 161], ["cytokine", "PROTEIN", 62, 70], ["multiple infectious agents", "TREATMENT", 12, 38], ["distinct cytokine patterns", "PROBLEM", 53, 79], ["disease", "PROBLEM", 111, 118], ["individual agents", "TREATMENT", 167, 184], ["multiple", "OBSERVATION_MODIFIER", 12, 20], ["infectious", "OBSERVATION", 21, 31], ["distinct", "OBSERVATION_MODIFIER", 53, 61], ["cytokine patterns", "OBSERVATION", 62, 79], ["disease", "OBSERVATION", 111, 118], ["infection", "OBSERVATION", 152, 161]]], ["In this report we determine whether coinfection with PRCV and B. bronchiseptica leads to increased severity of respiratory disease, and if so, whether or not the local proinflammatory cytokine response helps to elucidate the mechanism of this interaction.", [["respiratory", "ANATOMY", 111, 122], ["coinfection", "DISEASE", 36, 47], ["PRCV", "CHEMICAL", 53, 57], ["B. bronchiseptica", "DISEASE", 62, 79], ["respiratory disease", "DISEASE", 111, 130], ["PRCV", "GENE_OR_GENE_PRODUCT", 53, 57], ["B. bronchiseptica", "ORGANISM", 62, 79], ["proinflammatory cytokine", "PROTEIN", 168, 192], ["B. bronchiseptica", "SPECIES", 62, 79], ["PRCV", "SPECIES", 53, 57], ["B. bronchiseptica", "SPECIES", 62, 79], ["coinfection", "PROBLEM", 36, 47], ["PRCV", "TREATMENT", 53, 57], ["B. bronchiseptica", "PROBLEM", 62, 79], ["respiratory disease", "PROBLEM", 111, 130], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["severity", "OBSERVATION_MODIFIER", 99, 107], ["respiratory disease", "OBSERVATION", 111, 130]]], ["The data reported here demonstrates that coinfection results in a proinflammatory response that is different from each individual infection, and this proinflammatory response likely contributes to the differences in disease pathology observed during infection with PRCV and B. bronchiseptica.PRCV and B. bronchiseptica inoculaThe PRCV isolate used was isolated from a pig on a farm in Iowa that was experiencing respiratory disease.", [["respiratory", "ANATOMY", 412, 423], ["coinfection", "DISEASE", 41, 52], ["infection", "DISEASE", 130, 139], ["infection", "DISEASE", 250, 259], ["PRCV", "CHEMICAL", 330, 334], ["respiratory disease", "DISEASE", 412, 431], ["B. bronchiseptica", "ORGANISM", 274, 291], ["B. bronchiseptica", "ORGANISM", 301, 318], ["PRCV", "ORGANISM", 330, 334], ["pig", "ORGANISM", 368, 371], ["B. bronchiseptica", "SPECIES", 274, 291], ["B. bronchiseptica", "SPECIES", 301, 318], ["pig", "SPECIES", 368, 371], ["PRCV", "SPECIES", 265, 269], ["B. bronchiseptica", "SPECIES", 274, 291], ["PRCV", "SPECIES", 292, 296], ["B. bronchiseptica inocula", "SPECIES", 301, 326], ["PRCV", "SPECIES", 330, 334], ["pig", "SPECIES", 368, 371], ["The data", "TEST", 0, 8], ["coinfection", "PROBLEM", 41, 52], ["a proinflammatory response", "PROBLEM", 64, 90], ["each individual infection", "PROBLEM", 114, 139], ["disease pathology", "PROBLEM", 216, 233], ["infection", "PROBLEM", 250, 259], ["PRCV", "TREATMENT", 265, 269], ["B. bronchiseptica", "PROBLEM", 274, 291], ["PRCV", "TREATMENT", 292, 296], ["The PRCV isolate", "TREATMENT", 326, 342], ["respiratory disease", "PROBLEM", 412, 431], ["coinfection", "OBSERVATION", 41, 52], ["proinflammatory response", "OBSERVATION", 66, 90], ["different", "OBSERVATION_MODIFIER", 99, 108], ["infection", "OBSERVATION", 130, 139], ["bronchiseptica", "OBSERVATION", 277, 291], ["bronchiseptica inocula", "OBSERVATION", 304, 326], ["respiratory disease", "OBSERVATION", 412, 431]]], ["This isolate of PRCV has a 648-nucleotide deletion after base 99 of the spike gene compared to the Purdue strain of TGE (data not shown).", [["PRCV", "CHEMICAL", 16, 20], ["PRCV", "CANCER", 16, 20], ["TGE", "CANCER", 116, 119], ["PRCV", "DNA", 16, 20], ["648-nucleotide deletion", "DNA", 27, 50], ["base 99", "DNA", 57, 64], ["spike gene", "DNA", 72, 82], ["PRCV", "SPECIES", 16, 20], ["PRCV", "TEST", 16, 20], ["nucleotide deletion", "PROBLEM", 31, 50]]], ["PRCV was isolated on swine testicular (ST) cells, passaged two times and frozen at \u00c080 8C.", [["testicular (ST) cells", "ANATOMY", 27, 48], ["swine", "ORGANISM", 21, 26], ["testicular (ST) cells", "CELL", 27, 48], ["PRCV", "PROTEIN", 0, 4], ["swine testicular (ST) cells", "CELL_TYPE", 21, 48], ["swine", "SPECIES", 21, 26], ["PRCV", "SPECIES", 0, 4], ["swine", "SPECIES", 21, 26], ["swine testicular (ST) cells", "TREATMENT", 21, 48]]], ["Pigs were inoculated intranasally with 4 ml (2 ml/nostril) of cell culture medium containing 10 6 median cell culture infectious dose (CCID 50 )/ml of PRCV.", [["intranasally", "ANATOMY", 21, 33], ["cell", "ANATOMY", 62, 66], ["cell", "ANATOMY", 105, 109], ["Pigs", "ORGANISM", 0, 4], ["cell", "CELL", 62, 66], ["cell", "CELL", 105, 109], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["PRCV", "SPECIES", 151, 155], ["Pigs", "TREATMENT", 0, 4], ["cell culture medium", "TREATMENT", 62, 81], ["PRCV", "TREATMENT", 151, 155]]], ["Sham inoculum was prepared from uninfected ST cells.PRCV and B. bronchiseptica inoculaB. bronchiseptica strain KM22 is a virulent phase I swine isolate cultured from a herd with atrophic rhinitis.", [["ST cells", "ANATOMY", 43, 51], ["KM22", "CHEMICAL", 111, 115], ["atrophic rhinitis", "DISEASE", 178, 195], ["ST cells", "CELL", 43, 51], ["PRCV", "GENE_OR_GENE_PRODUCT", 52, 56], ["B. bronchiseptica inoculaB", "ORGANISM", 61, 87], ["bronchiseptica strain KM22", "ORGANISM", 89, 115], ["swine", "ORGANISM", 138, 143], ["uninfected ST cells", "CELL_TYPE", 32, 51], ["B. bronchiseptica", "SPECIES", 61, 78], ["bronchiseptica", "SPECIES", 89, 103], ["swine", "SPECIES", 138, 143], ["PRCV", "SPECIES", 52, 56], ["B. bronchiseptica", "SPECIES", 61, 78], ["swine", "SPECIES", 138, 143], ["Sham inoculum", "PROBLEM", 0, 13], ["PRCV", "TREATMENT", 52, 56], ["B. bronchiseptica inoculaB", "PROBLEM", 61, 87], ["bronchiseptica strain", "PROBLEM", 89, 110], ["atrophic rhinitis", "PROBLEM", 178, 195], ["inoculum", "OBSERVATION", 5, 13], ["uninfected ST cells", "OBSERVATION", 32, 51], ["bronchiseptica inoculaB", "OBSERVATION", 64, 87], ["virulent phase", "OBSERVATION_MODIFIER", 121, 135], ["atrophic", "OBSERVATION_MODIFIER", 178, 186], ["rhinitis", "OBSERVATION", 187, 195]]], ["To prepare the inoculum, B. bronchiseptica was cultured on Bordet-Gengou agar supplemented with 10% sheep's blood at 37 8C for 40 h and suspended in phosphate buffered saline (PBS).", [["blood", "ANATOMY", 108, 113], ["phosphate", "CHEMICAL", 149, 158], ["phosphate", "CHEMICAL", 149, 158], ["B. bronchiseptica", "ORGANISM", 25, 42], ["sheep", "ORGANISM", 100, 105], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 149, 174], ["B. bronchiseptica", "SPECIES", 25, 42], ["sheep", "SPECIES", 100, 105], ["B. bronchiseptica", "SPECIES", 25, 42], ["sheep", "SPECIES", 100, 105], ["the inoculum", "TREATMENT", 11, 23], ["Gengou agar", "TREATMENT", 66, 77], ["10% sheep's blood", "TREATMENT", 96, 113], ["phosphate buffered saline (PBS", "TREATMENT", 149, 179]]], ["Pigs were inoculated intranasally with 1 ml of PBS (0.5 ml/nostril) containing 10 6 colony forming units (CFU)/ml of B. bronchiseptica.Experimental designTwo experiments were performed.", [["intranasally", "ANATOMY", 21, 33], ["Pigs", "ORGANISM", 0, 4], ["B. bronchiseptica", "ORGANISM", 117, 134], ["Pigs", "SPECIES", 0, 4], ["B. bronchiseptica", "SPECIES", 117, 134], ["Pigs", "SPECIES", 0, 4], ["B. bronchiseptica", "SPECIES", 117, 134], ["Pigs", "TREATMENT", 0, 4], ["PBS", "TREATMENT", 47, 50], ["B. bronchiseptica", "PROBLEM", 117, 134], ["Experimental designTwo experiments", "TEST", 135, 169], ["bronchiseptica", "OBSERVATION", 120, 134]]], ["At 3 weeks of age, 40 pigs (experiment 1) and 48 pigs (experiment 2) were transferred from herds (a different herd in each experiment), which were negative for antibody to PRCV, PRRSVand SIV, to an animal isolation facility at the National Animal Disease Center.", [["pigs", "ORGANISM", 22, 26], ["pigs", "ORGANISM", 49, 53], ["PRCV", "ORGANISM", 172, 176], ["PRRSVand SIV", "ORGANISM", 178, 190], ["pigs", "SPECIES", 22, 26], ["pigs", "SPECIES", 49, 53], ["pigs", "SPECIES", 22, 26], ["pigs", "SPECIES", 49, 53], ["PRCV", "SPECIES", 172, 176], ["PRRSVand SIV", "SPECIES", 178, 190], ["antibody to PRCV", "PROBLEM", 160, 176]]], ["No medications or vaccinations were given to the piglets.", [["piglets", "ORGANISM", 49, 56], ["piglets", "SPECIES", 49, 56], ["medications", "TREATMENT", 3, 14], ["vaccinations", "TREATMENT", 18, 30]]], ["Nasal swabs were obtained from all pigs before the start of the experiment, and neither B. bronchiseptica nor PRCV was isolated.", [["Nasal swabs", "ANATOMY", 0, 11], ["Nasal swabs", "ORGANISM_SUBSTANCE", 0, 11], ["pigs", "ORGANISM", 35, 39], ["B. bronchiseptica", "ORGANISM", 88, 105], ["PRCV", "ORGANISM", 110, 114], ["pigs", "SPECIES", 35, 39], ["B. bronchiseptica", "SPECIES", 88, 105], ["pigs", "SPECIES", 35, 39], ["B. bronchiseptica", "SPECIES", 88, 105], ["PRCV", "SPECIES", 110, 114], ["Nasal swabs", "TEST", 0, 11], ["neither B. bronchiseptica", "PROBLEM", 80, 105], ["bronchiseptica", "OBSERVATION", 91, 105]]], ["The pigs were randomly divided into 4 groups with 10 pigs/group (experiment 1) and 12 pigs/ group (experiment 2).", [["pigs", "ORGANISM", 4, 8], ["pigs", "ORGANISM", 53, 57], ["pigs", "ORGANISM", 86, 90], ["pigs", "SPECIES", 4, 8], ["pigs", "SPECIES", 53, 57], ["pigs", "SPECIES", 86, 90], ["pigs", "SPECIES", 4, 8], ["The pigs", "TREATMENT", 0, 8], ["10 pigs/group (experiment", "TREATMENT", 50, 75]]], ["After 1 week of acclimation, on day 0 of the experiment, the pigs in group 1 were intranasally inoculated with sham PBS and cell culture medium from uninfected ST cells, pigs in group 2 were inoculated intranasally with B. bronchiseptica and sham cell culture medium, the pigs in group 3 were intranasally inoculated with sham PBS and PRCV, the pigs in group 4 were inoculated with PRCV followed by B. bronchiseptica.", [["cell", "ANATOMY", 124, 128], ["ST cells", "ANATOMY", 160, 168], ["intranasally", "ANATOMY", 202, 214], ["cell", "ANATOMY", 247, 251], ["PRCV", "CHEMICAL", 382, 386], ["pigs", "ORGANISM", 61, 65], ["cell", "CELL", 124, 128], ["ST cells", "CELL", 160, 168], ["pigs", "ORGANISM", 170, 174], ["B. bronchiseptica", "ORGANISM", 220, 237], ["sham cell", "CELL", 242, 251], ["pigs", "ORGANISM", 272, 276], ["pigs", "ORGANISM", 345, 349], ["B. bronchiseptica", "ORGANISM", 399, 416], ["uninfected ST cells", "CELL_TYPE", 149, 168], ["pigs", "SPECIES", 61, 65], ["pigs", "SPECIES", 170, 174], ["B. bronchiseptica", "SPECIES", 220, 237], ["pigs", "SPECIES", 272, 276], ["pigs", "SPECIES", 345, 349], ["B. bronchiseptica", "SPECIES", 399, 416], ["pigs", "SPECIES", 61, 65], ["B. bronchiseptica", "SPECIES", 220, 237], ["PRCV", "SPECIES", 335, 339], ["PRCV", "SPECIES", 382, 386], ["B. bronchiseptica", "SPECIES", 399, 416], ["the pigs in group 1", "TREATMENT", 57, 76], ["sham PBS", "TREATMENT", 111, 119], ["cell culture medium", "TEST", 124, 143], ["uninfected ST cells", "PROBLEM", 149, 168], ["pigs in group 2", "TREATMENT", 170, 185], ["B. bronchiseptica", "PROBLEM", 220, 237], ["sham cell culture medium", "TEST", 242, 266], ["the pigs in group 3", "TREATMENT", 268, 287], ["sham PBS", "TREATMENT", 322, 330], ["PRCV", "TREATMENT", 335, 339], ["the pigs in group 4", "TREATMENT", 341, 360], ["PRCV", "TREATMENT", 382, 386], ["B. bronchiseptica", "PROBLEM", 399, 416], ["sham cell", "OBSERVATION", 242, 251], ["bronchiseptica", "OBSERVATION", 402, 416]]], ["In experiment 1, 5 pigs from each group were euthanized on days 4 and 10 of the experiment.", [["pigs", "ORGANISM", 19, 23], ["pigs", "SPECIES", 19, 23], ["pigs", "SPECIES", 19, 23]]], ["In experiment 2, 4 pigs from each group were euthanized on days 1, 4 and 10 of the experiment.Pathological evaluationAt necropsy, an estimate of gross lung involvement was assigned based on the percentage of each lung lobe affected and the percentage of total lung volume each lobe represented.", [["lung", "ANATOMY", 151, 155], ["lung lobe", "ANATOMY", 213, 222], ["lung", "ANATOMY", 260, 264], ["pigs", "ORGANISM", 19, 23], ["lung", "ORGAN", 151, 155], ["lung lobe", "MULTI-TISSUE_STRUCTURE", 213, 222], ["lung", "ORGAN", 260, 264], ["pigs", "SPECIES", 19, 23], ["pigs", "SPECIES", 19, 23], ["Pathological evaluation", "TEST", 94, 117], ["gross lung involvement", "PROBLEM", 145, 167], ["gross", "OBSERVATION_MODIFIER", 145, 150], ["lung", "ANATOMY", 151, 155], ["involvement", "OBSERVATION", 156, 167], ["lung", "ANATOMY", 213, 217], ["lobe", "ANATOMY_MODIFIER", 218, 222], ["percentage", "OBSERVATION_MODIFIER", 240, 250], ["total", "OBSERVATION_MODIFIER", 254, 259], ["lung", "ANATOMY", 260, 264], ["volume", "OBSERVATION", 265, 271], ["lobe", "ANATOMY_MODIFIER", 277, 281]]], ["Percentage of total lung volume of each lobe was estimated as 5% for the left cranial, 6% for the left middle, 29% for the left caudal, 11% for the right cranial, 10% for the right middle, 34% for the right caudal and 5% for the intermediate lung lobes (Christensen and Mousing, 1992) .Pathological evaluationSections from the lung were taken for microscopic evaluation.", [["lung", "ANATOMY", 20, 24], ["lobe", "ANATOMY", 40, 44], ["left cranial", "ANATOMY", 73, 85], ["left middle", "ANATOMY", 98, 109], ["left caudal", "ANATOMY", 123, 134], ["right cranial", "ANATOMY", 148, 161], ["right middle", "ANATOMY", 175, 187], ["right caudal", "ANATOMY", 201, 213], ["lung lobes", "ANATOMY", 242, 252], ["lung", "ANATOMY", 327, 331], ["lung", "ORGAN", 20, 24], ["lobe", "ORGAN", 40, 44], ["cranial", "ORGAN", 78, 85], ["caudal", "ORGAN", 128, 134], ["cranial", "ORGAN", 154, 161], ["caudal", "ORGAN", 207, 213], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 242, 252], ["lung", "ORGAN", 327, 331], ["total lung volume", "TEST", 14, 31], ["Pathological evaluationSections from the lung", "TEST", 286, 331], ["microscopic evaluation", "TEST", 347, 369], ["total", "OBSERVATION_MODIFIER", 14, 19], ["lung", "ANATOMY", 20, 24], ["volume", "ANATOMY_MODIFIER", 25, 31], ["lobe", "ANATOMY_MODIFIER", 40, 44], ["left", "ANATOMY_MODIFIER", 73, 77], ["cranial", "ANATOMY", 78, 85], ["left", "ANATOMY_MODIFIER", 98, 102], ["middle", "ANATOMY_MODIFIER", 103, 109], ["left", "ANATOMY_MODIFIER", 123, 127], ["caudal", "ANATOMY_MODIFIER", 128, 134], ["right", "ANATOMY_MODIFIER", 148, 153], ["cranial", "ANATOMY_MODIFIER", 154, 161], ["right", "ANATOMY_MODIFIER", 175, 180], ["middle", "ANATOMY_MODIFIER", 181, 187], ["right", "ANATOMY_MODIFIER", 201, 206], ["caudal", "ANATOMY_MODIFIER", 207, 213], ["lung", "ANATOMY", 242, 246], ["lobes", "ANATOMY_MODIFIER", 247, 252], ["lung", "ANATOMY", 327, 331]]], ["All tissues were fixed in 10% neutral buffered formalin for 24 h and then placed in 90% ethanol.", [["tissues", "ANATOMY", 4, 11], ["formalin", "CHEMICAL", 47, 55], ["ethanol", "CHEMICAL", 88, 95], ["formalin", "CHEMICAL", 47, 55], ["ethanol", "CHEMICAL", 88, 95], ["tissues", "TISSUE", 4, 11], ["formalin", "SIMPLE_CHEMICAL", 47, 55], ["ethanol", "SIMPLE_CHEMICAL", 88, 95], ["tissues", "ANATOMY", 4, 11], ["fixed", "OBSERVATION_MODIFIER", 17, 22]]], ["All sections were routinely processed and embedded in paraffin, sectioned and stained with hematoxylin and eosin.Virus and bacterial isolationA sample of nasal turbinate, trachea and lung from each pig was weighed and ground individually in PBS to make a 10% weight to volume suspension.", [["sections", "ANATOMY", 4, 12], ["sample", "ANATOMY", 144, 150], ["nasal turbinate", "ANATOMY", 154, 169], ["trachea", "ANATOMY", 171, 178], ["lung", "ANATOMY", 183, 187], ["paraffin", "CHEMICAL", 54, 62], ["hematoxylin", "CHEMICAL", 91, 102], ["eosin", "CHEMICAL", 107, 112], ["hematoxylin", "SIMPLE_CHEMICAL", 91, 102], ["eosin", "SIMPLE_CHEMICAL", 107, 112], ["Virus", "ORGANISM", 113, 118], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 154, 169], ["trachea", "MULTI-TISSUE_STRUCTURE", 171, 178], ["lung", "ORGAN", 183, 187], ["pig", "ORGANISM", 198, 201], ["pig", "SPECIES", 198, 201], ["pig", "SPECIES", 198, 201], ["hematoxylin", "TREATMENT", 91, 102], ["Virus", "PROBLEM", 113, 118], ["bacterial isolationA sample", "TEST", 123, 150], ["nasal turbinate", "TREATMENT", 154, 169], ["a 10% weight to volume suspension", "TREATMENT", 253, 286], ["bacterial isolationA", "OBSERVATION", 123, 143], ["nasal turbinate", "ANATOMY", 154, 169], ["trachea", "ANATOMY", 171, 178], ["lung", "ANATOMY", 183, 187]]], ["The number of CFU of B. bronchiseptica/g of tissue was determined by plating serial 10-fold dilutions of homogenates on duplicate selective blood agar plates containing 20 mg/ml penicillin, 10 mg/ml amphotericin B, 10 mg/ml streptomycin and 10 mg/ ml spectinomycin.", [["tissue", "ANATOMY", 44, 50], ["homogenates", "ANATOMY", 105, 116], ["blood", "ANATOMY", 140, 145], ["penicillin", "CHEMICAL", 178, 188], ["amphotericin B", "CHEMICAL", 199, 213], ["streptomycin", "CHEMICAL", 224, 236], ["spectinomycin", "CHEMICAL", 251, 264], ["penicillin", "CHEMICAL", 178, 188], ["amphotericin B", "CHEMICAL", 199, 213], ["streptomycin", "CHEMICAL", 224, 236], ["spectinomycin", "CHEMICAL", 251, 264], ["B. bronchiseptica", "ORGANISM", 21, 38], ["tissue", "TISSUE", 44, 50], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["penicillin", "SIMPLE_CHEMICAL", 178, 188], ["amphotericin B", "SIMPLE_CHEMICAL", 199, 213], ["streptomycin", "SIMPLE_CHEMICAL", 224, 236], ["spectinomycin", "SIMPLE_CHEMICAL", 251, 264], ["B. bronchiseptica", "SPECIES", 21, 38], ["B. bronchiseptica", "SPECIES", 21, 38], ["B. bronchiseptica/g of tissue", "PROBLEM", 21, 50], ["duplicate selective blood agar plates", "TREATMENT", 120, 157], ["penicillin", "TREATMENT", 178, 188], ["amphotericin B", "TREATMENT", 199, 213], ["streptomycin", "TREATMENT", 224, 236], ["spectinomycin", "TREATMENT", 251, 264]]], ["In both experiments, fluid from bronchoalveolar lavage (BALF) was obtained for virus isolation, and in addition, nasal swabs collected in 1 ml of PBS, and samples of ground turbinate, ground trachea and ground lung were obtained from the second experiment for virus isolation and frozen at \u00c080 8C.", [["bronchoalveolar lavage", "ANATOMY", 32, 54], ["BALF", "ANATOMY", 56, 60], ["nasal swabs", "ANATOMY", 113, 124], ["samples", "ANATOMY", 155, 162], ["turbinate", "ANATOMY", 173, 182], ["trachea", "ANATOMY", 191, 198], ["ground lung", "ANATOMY", 203, 214], ["fluid", "ORGANISM_SUBSTANCE", 21, 26], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 32, 54], ["BALF", "ORGANISM_SUBSTANCE", 56, 60], ["ground turbinate", "MULTI-TISSUE_STRUCTURE", 166, 182], ["ground trachea", "MULTI-TISSUE_STRUCTURE", 184, 198], ["lung", "ORGAN", 210, 214], ["fluid from bronchoalveolar lavage (BALF)", "TEST", 21, 61], ["virus isolation", "TREATMENT", 79, 94], ["nasal swabs", "TEST", 113, 124], ["PBS", "TEST", 146, 149], ["samples of ground turbinate, ground trachea and ground lung", "TEST", 155, 214], ["virus isolation", "TREATMENT", 260, 275], ["fluid", "OBSERVATION_MODIFIER", 21, 26], ["bronchoalveolar lavage", "OBSERVATION", 32, 54], ["nasal", "ANATOMY", 113, 118], ["ground turbinate", "ANATOMY", 166, 182], ["ground", "ANATOMY_MODIFIER", 184, 190], ["trachea", "ANATOMY", 191, 198], ["ground", "ANATOMY_MODIFIER", 203, 209], ["lung", "ANATOMY", 210, 214]]], ["Isolation of PRCV was performed by inoculation of 100 ml of sample onto a monolayer of ST cells in a 24-well plate.", [["sample", "ANATOMY", 60, 66], ["monolayer", "ANATOMY", 74, 83], ["ST cells", "ANATOMY", 87, 95], ["PRCV", "CANCER", 13, 17], ["monolayer", "CELL", 74, 83], ["ST cells", "CELL", 87, 95], ["ST cells", "CELL_TYPE", 87, 95], ["PRCV", "SPECIES", 13, 17], ["Isolation of PRCV", "TREATMENT", 0, 17], ["a monolayer of ST cells", "TREATMENT", 72, 95]]], ["The cells were examined for cytopathic effect for 1 week.Alveolar macrophage isolationThe lungs were filled with 200 ml of sterile PBS, gently massaged, and following aspiration, approximately 100 ml of the PBS was recovered.", [["cells", "ANATOMY", 4, 9], ["Alveolar macrophage", "ANATOMY", 57, 76], ["lungs", "ANATOMY", 90, 95], ["cells", "CELL", 4, 9], ["Alveolar macrophage", "CELL", 57, 76], ["lungs", "ORGAN", 90, 95], ["cytopathic effect", "PROBLEM", 28, 45], ["Alveolar macrophage isolation", "TREATMENT", 57, 86], ["sterile PBS", "TREATMENT", 123, 134], ["aspiration", "TEST", 167, 177], ["the PBS", "TEST", 203, 210], ["macrophage isolation", "OBSERVATION", 66, 86], ["lungs", "ANATOMY", 90, 95], ["filled", "OBSERVATION", 101, 107], ["aspiration", "OBSERVATION", 167, 177]]], ["This BALF was centrifuged at 450 \u00c2 g for 15 min and alveolar macrophages (AM) were isolated by plastic adherence.", [["BALF", "ANATOMY", 5, 9], ["alveolar macrophages", "ANATOMY", 52, 72], ["AM", "ANATOMY", 74, 76], ["BALF", "ORGANISM_SUBSTANCE", 5, 9], ["alveolar macrophages", "CELL", 52, 72], ["AM", "CELL", 74, 76], ["alveolar macrophages", "CELL_TYPE", 52, 72], ["AM", "CELL_TYPE", 74, 76], ["This BALF", "TEST", 0, 9], ["alveolar macrophages", "ANATOMY", 52, 72]]], ["BALF cells were cultured in flat-bottom, 6-well plates for 2-h in cell culture media [RPMI 1640, 2 mM L-glutamine, 1\u00c2 antibiotic/antimycotic (all from Invitrogen), 25 mM HEPES, 100 mg/ml Gentamicin and 5% swine sera].", [["BALF cells", "ANATOMY", 0, 10], ["cell", "ANATOMY", 66, 70], ["sera", "ANATOMY", 211, 215], ["L-glutamine", "CHEMICAL", 102, 113], ["Gentamicin", "CHEMICAL", 187, 197], ["L-glutamine", "CHEMICAL", 102, 113], ["HEPES", "CHEMICAL", 170, 175], ["Gentamicin", "CHEMICAL", 187, 197], ["BALF cells", "CELL", 0, 10], ["cell", "CELL", 66, 70], ["L-glutamine", "SIMPLE_CHEMICAL", 102, 113], ["Gentamicin", "SIMPLE_CHEMICAL", 187, 197], ["swine", "ORGANISM", 205, 210], ["sera", "ORGANISM_SUBSTANCE", 211, 215], ["BALF cells", "CELL_TYPE", 0, 10], ["swine", "SPECIES", 205, 210], ["swine", "SPECIES", 205, 210], ["BALF cells", "TEST", 0, 10], ["RPMI", "TEST", 86, 90], ["2 mM L-glutamine", "TREATMENT", 97, 113], ["antibiotic", "TREATMENT", 118, 128], ["antimycotic", "TREATMENT", 129, 140], ["Invitrogen", "TREATMENT", 151, 161], ["25 mM HEPES", "TREATMENT", 164, 175], ["Gentamicin", "TREATMENT", 187, 197]]], ["After 2-h the non-adherent cells were washed away.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["non-adherent cells", "CELL_TYPE", 14, 32], ["the non-adherent cells", "TREATMENT", 10, 32], ["non-adherent cells", "OBSERVATION", 14, 32]]], ["The adherent cell population was collected in RLT buffer and stored at \u00c080 8C for later RNA isolation.Cytokine gene expressionRNA was isolated from cells collected in RLT buffer (Qiagen RNeasy Mini kit).", [["cell", "ANATOMY", 13, 17], ["cells", "ANATOMY", 148, 153], ["cell population", "CELL", 13, 28], ["Cytokine", "GENE_OR_GENE_PRODUCT", 102, 110], ["cells", "CELL", 148, 153], ["adherent cell population", "CELL_LINE", 4, 28], ["Cytokine gene expressionRNA", "DNA", 102, 129], ["The adherent cell population", "TREATMENT", 0, 28], ["later RNA isolation", "TREATMENT", 82, 101], ["Cytokine gene expressionRNA", "PROBLEM", 102, 129], ["adherent", "OBSERVATION_MODIFIER", 4, 12], ["cell population", "OBSERVATION", 13, 28]]], ["Reverse-transcription for cDNA synthesis was done using random primers and SuperScript II Reverse Transcriptase according to the manufacturer's recommendations (Invitrogen).", [["SuperScript II Reverse Transcriptase", "PROTEIN", 75, 111], ["cDNA synthesis", "PROBLEM", 26, 40], ["random primers", "TREATMENT", 56, 70], ["SuperScript II Reverse Transcriptase", "TREATMENT", 75, 111]]], ["SYBR green based real-time PCR was carried out for various mRNA targets according to manufacturer's recommendations (SYBR Green Master Mix, Applied Biosystems).", [["SYBR green", "CHEMICAL", 0, 10], ["SYBR green", "TEST", 0, 10], ["PCR", "TEST", 27, 30], ["various mRNA targets", "TREATMENT", 51, 71]]], ["Briefly, mRNA, SYBR Green Master Mix and primers (final concentration 600 nM) were mixed in a 20 ml reaction and cycled as follows: 95 8C for 15 min, 95 8C for 15 s followed by 50 8C for 1 min (45 cycles) and a final dissociation step.", [["mRNA", "RNA", 9, 13]]], ["Levels of mRNA were calculated using the 2 \u00c0DDCt method, which expresses mRNA from the cells of infected pigs relative to the sham infected pigs after normalizing to beta-actin (Livak and Schmittgen, 2001) .", [["cells", "ANATOMY", 87, 92], ["cells", "CELL", 87, 92], ["pigs", "ORGANISM", 105, 109], ["pigs", "ORGANISM", 140, 144], ["beta-actin", "GENE_OR_GENE_PRODUCT", 166, 176], ["mRNA", "RNA", 10, 14], ["mRNA", "RNA", 73, 77], ["beta-actin", "PROTEIN", 166, 176], ["pigs", "SPECIES", 105, 109], ["pigs", "SPECIES", 140, 144], ["pigs", "SPECIES", 105, 109], ["pigs", "SPECIES", 140, 144], ["mRNA", "TEST", 10, 14], ["the 2 \u00c0DDCt method", "TREATMENT", 37, 55], ["infected pigs", "PROBLEM", 96, 109], ["infected pigs", "OBSERVATION", 96, 109]]], ["Primers are listed in Table 1 , and PCR products were less than 100 base pairs in size.", [["PCR products", "DNA", 36, 48], ["PCR products", "TEST", 36, 48], ["size", "OBSERVATION_MODIFIER", 82, 86]]], ["Primers were generated using Primer Express, purchased from Integrated DNA Technologies (IDT), and primer pair efficiency confirmed using the method described by Livak and Schmittgen (2001) .StatisticsStatistical analysis was done using Student's t-test assuming unequal variance and a significance level of p 0.05, comparing the mean percentage of lung affected between single and dual infected groups, the number of CFU's of B. bronchiseptica isolated from different tissues between single and dual infected groups, and the fold change in cytokine message expression between single and dual infected groups.Macroscopic and microscopic analysis of lesionsClinical signs were generally mild in all infected groups, and consisted of sneezing, coughing, lethargy and pigs that were quicker to fatigue.", [["lung", "ANATOMY", 349, 353], ["tissues", "ANATOMY", 469, 476], ["lesions", "ANATOMY", 649, 656], ["sneezing", "DISEASE", 732, 740], ["coughing", "DISEASE", 742, 750], ["lethargy", "DISEASE", 752, 760], ["fatigue", "DISEASE", 791, 798], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["lung", "ORGAN", 349, 353], ["B. bronchiseptica", "ORGANISM", 427, 444], ["tissues", "TISSUE", 469, 476], ["lesions", "PATHOLOGICAL_FORMATION", 649, 656], ["pigs", "ORGANISM", 765, 769], ["Primer Express", "DNA", 29, 43], ["cytokine", "PROTEIN", 541, 549], ["B. bronchiseptica", "SPECIES", 427, 444], ["pigs", "SPECIES", 765, 769], ["B. bronchiseptica", "SPECIES", 427, 444], ["pigs", "SPECIES", 765, 769], ["primer pair efficiency", "PROBLEM", 99, 121], ["the method", "TREATMENT", 138, 148], ["StatisticsStatistical analysis", "TEST", 191, 221], ["Student's t-test", "TEST", 237, 253], ["unequal variance", "PROBLEM", 263, 279], ["single and dual infected groups", "PROBLEM", 371, 402], ["B. bronchiseptica", "PROBLEM", 427, 444], ["single and dual infected groups", "TREATMENT", 485, 516], ["the fold change", "PROBLEM", 522, 537], ["single and dual infected groups", "TREATMENT", 577, 608], ["Macroscopic and microscopic analysis", "TEST", 609, 645], ["lesions", "PROBLEM", 649, 656], ["Clinical signs", "PROBLEM", 656, 670], ["generally mild in all infected groups", "PROBLEM", 676, 713], ["sneezing", "PROBLEM", 732, 740], ["coughing", "PROBLEM", 742, 750], ["lethargy", "PROBLEM", 752, 760], ["pigs", "PROBLEM", 765, 769], ["fatigue", "PROBLEM", 791, 798], ["lung", "ANATOMY", 349, 353], ["affected", "OBSERVATION", 354, 362], ["dual", "OBSERVATION_MODIFIER", 382, 386], ["infected", "OBSERVATION", 387, 395], ["bronchiseptica", "OBSERVATION", 430, 444], ["different tissues", "OBSERVATION_MODIFIER", 459, 476], ["dual", "OBSERVATION_MODIFIER", 496, 500], ["infected", "OBSERVATION", 501, 509], ["fold", "OBSERVATION_MODIFIER", 526, 530], ["change", "OBSERVATION_MODIFIER", 531, 537], ["cytokine message expression", "OBSERVATION", 541, 568], ["infected", "OBSERVATION", 593, 601], ["lesions", "OBSERVATION", 649, 656], ["mild", "OBSERVATION_MODIFIER", 686, 690], ["infected", "OBSERVATION", 698, 706], ["sneezing", "OBSERVATION", 732, 740]]], ["There was a general impression that coinfected pigs were slightly more affected since clinical signs were recorded earlier and there were more of the above mentioned signs recorded for this group in both experiments.Macroscopic and microscopic analysis of lesionsThe number of pigs/group with macroscopic lesions of pneumonia, and the mean percentage of lung affected by pneumonia for each group, for both experiments is summarized in Table 2 .", [["lesions", "ANATOMY", 256, 263], ["lesions", "ANATOMY", 305, 312], ["lung", "ANATOMY", 354, 358], ["pneumonia", "DISEASE", 316, 325], ["pneumonia", "DISEASE", 371, 380], ["pigs", "ORGANISM", 47, 51], ["lesions", "PATHOLOGICAL_FORMATION", 256, 263], ["pigs", "ORGANISM", 277, 281], ["lesions", "PATHOLOGICAL_FORMATION", 305, 312], ["lung", "ORGAN", 354, 358], ["pigs", "SPECIES", 47, 51], ["pigs", "SPECIES", 277, 281], ["pigs", "SPECIES", 47, 51], ["coinfected pigs", "PROBLEM", 36, 51], ["clinical signs", "TEST", 86, 100], ["Macroscopic and microscopic analysis", "TEST", 216, 252], ["lesions", "PROBLEM", 256, 263], ["pigs/group", "TREATMENT", 277, 287], ["macroscopic lesions", "PROBLEM", 293, 312], ["pneumonia", "PROBLEM", 316, 325], ["pneumonia", "PROBLEM", 371, 380], ["lesions", "OBSERVATION", 256, 263], ["lesions", "OBSERVATION", 305, 312], ["pneumonia", "OBSERVATION", 316, 325], ["mean", "OBSERVATION_MODIFIER", 335, 339], ["percentage", "OBSERVATION_MODIFIER", 340, 350], ["lung", "ANATOMY", 354, 358], ["pneumonia", "OBSERVATION", 371, 380]]], ["Gross pneumonic lesions, irrespective of agent given, were characterized by bilateral, multifocal red consolidation which tended to have a more cranial-ventral distribution ( Fig. 1 ).", [["Gross pneumonic lesions", "ANATOMY", 0, 23], ["cranial", "ANATOMY", 144, 151], ["ventral", "ANATOMY", 152, 159], ["Gross pneumonic lesions", "PATHOLOGICAL_FORMATION", 0, 23], ["Gross pneumonic lesions", "PROBLEM", 0, 23], ["agent", "TREATMENT", 41, 46], ["bilateral, multifocal red consolidation", "PROBLEM", 76, 115], ["pneumonic", "OBSERVATION_MODIFIER", 6, 15], ["lesions", "OBSERVATION", 16, 23], ["bilateral", "ANATOMY_MODIFIER", 76, 85], ["multifocal", "OBSERVATION_MODIFIER", 87, 97], ["red", "OBSERVATION_MODIFIER", 98, 101], ["consolidation", "OBSERVATION", 102, 115], ["more", "OBSERVATION_MODIFIER", 139, 143], ["cranial", "ANATOMY_MODIFIER", 144, 151], ["ventral", "ANATOMY_MODIFIER", 152, 159], ["distribution", "OBSERVATION_MODIFIER", 160, 172]]], ["In the first experiment, the mean percentage of lung involvement was greatest for the group infected with both PRCV and B. bronchiseptica as compared to either agent alone.", [["lung", "ANATOMY", 48, 52], ["lung", "ORGAN", 48, 52], ["PRCV", "ORGANISM", 111, 115], ["B. bronchiseptica", "ORGANISM", 120, 137], ["B. bronchiseptica", "SPECIES", 120, 137], ["PRCV", "SPECIES", 111, 115], ["B. bronchiseptica", "SPECIES", 120, 137], ["lung involvement", "PROBLEM", 48, 64], ["both PRCV", "TREATMENT", 106, 115], ["B. bronchiseptica", "PROBLEM", 120, 137], ["lung", "ANATOMY", 48, 52], ["involvement", "OBSERVATION", 53, 64], ["bronchiseptica", "OBSERVATION", 123, 137]]], ["This difference was greatest and statistically significant 10 days after challenge, when the mean percentage of lung involvement was 19% for the coinfected group, but only 1.4 and 5.5% for the groups infected with B. bronchiseptica or PRCV, respectively.", [["lung", "ANATOMY", 112, 116], ["coinfected", "DISEASE", 145, 155], ["lung", "ORGAN", 112, 116], ["B. bronchiseptica", "ORGANISM", 214, 231], ["B. bronchiseptica", "SPECIES", 214, 231], ["B. bronchiseptica", "SPECIES", 214, 231], ["PRCV", "SPECIES", 235, 239], ["lung involvement", "PROBLEM", 112, 128], ["greatest", "OBSERVATION_MODIFIER", 20, 28], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["lung", "ANATOMY", 112, 116], ["involvement", "OBSERVATION", 117, 128], ["bronchiseptica", "OBSERVATION", 217, 231]]], ["The mean percentage of lung affected was greater at 10 days than 4 days after challenge for all infected groups.", [["lung", "ANATOMY", 23, 27], ["lung", "ORGAN", 23, 27], ["all infected groups", "PROBLEM", 92, 111], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["percentage", "OBSERVATION_MODIFIER", 9, 19], ["lung", "ANATOMY", 23, 27], ["affected", "OBSERVATION", 28, 36], ["greater", "OBSERVATION_MODIFIER", 41, 48], ["infected", "OBSERVATION", 96, 104]]], ["Most pigs in all groups had gross evidence of ascarid migration in the liver.Macroscopic and microscopic analysis of lesionsTTGAATTCGAGTCTGCCCTGT CCCAGGAAGACGGGCTTT NCBI accession numbers used to derive primers. a Royaee et al. (2004) .Macroscopic and microscopic analysis of lesionsGross lesions for the second experiment were similar in character to the first experiment.", [["ascarid", "ANATOMY", 46, 53], ["liver", "ANATOMY", 71, 76], ["lesions", "ANATOMY", 117, 124], ["lesions", "ANATOMY", 276, 283], ["Gross lesions", "ANATOMY", 283, 296], ["pigs", "ORGANISM", 5, 9], ["liver", "ORGAN", 71, 76], ["lesions", "PATHOLOGICAL_FORMATION", 117, 124], ["lesions", "PATHOLOGICAL_FORMATION", 276, 283], ["Gross lesions", "CANCER", 283, 296], ["pigs", "SPECIES", 5, 9], ["ascarid migration in the liver", "PROBLEM", 46, 76], ["Macroscopic and microscopic analysis", "TEST", 77, 113], ["lesions", "PROBLEM", 117, 124], ["Macroscopic and microscopic analysis", "TEST", 236, 272], ["lesions", "PROBLEM", 276, 283], ["Gross lesions", "PROBLEM", 283, 296], ["evidence of", "UNCERTAINTY", 34, 45], ["ascarid migration", "OBSERVATION", 46, 63], ["liver", "ANATOMY", 71, 76], ["lesions", "OBSERVATION", 117, 124], ["lesions", "OBSERVATION", 276, 283], ["lesions", "OBSERVATION", 289, 296]]], ["The mean percentage of lung involvement for the coinfected group was again greater than the single agent infected groups at days 1 and 10 post-infection, but at day 4 the mean percentage of lung involvement was greatest for the group infected with PRCV alone.", [["lung", "ANATOMY", 23, 27], ["lung", "ANATOMY", 190, 194], ["coinfected", "DISEASE", 48, 58], ["infection", "DISEASE", 143, 152], ["PRCV", "CHEMICAL", 248, 252], ["PRCV", "CHEMICAL", 248, 252], ["lung", "ORGAN", 23, 27], ["lung", "ORGAN", 190, 194], ["PRCV", "SPECIES", 248, 252], ["lung involvement", "PROBLEM", 23, 39], ["the coinfected group", "PROBLEM", 44, 64], ["infection", "PROBLEM", 143, 152], ["lung involvement", "PROBLEM", 190, 206], ["PRCV", "TREATMENT", 248, 252], ["mean", "OBSERVATION_MODIFIER", 4, 8], ["percentage", "OBSERVATION_MODIFIER", 9, 19], ["lung", "ANATOMY", 23, 27], ["involvement", "OBSERVATION", 28, 39], ["infected", "OBSERVATION", 105, 113], ["infection", "OBSERVATION", 143, 152], ["lung", "ANATOMY", 190, 194], ["involvement", "OBSERVATION", 195, 206]]], ["All 12 pigs in the coinfected group had pneumonic lesions, whereas only 7 pigs in the PRCV group and 3 pigs in the B. bronchiseptica group had gross lesions; the largest difference being at the 1-day time point.", [["pneumonic lesions", "ANATOMY", 40, 57], ["PRCV", "ANATOMY", 86, 90], ["gross lesions", "ANATOMY", 143, 156], ["coinfected", "DISEASE", 19, 29], ["pneumonic lesions", "DISEASE", 40, 57], ["PRCV", "CHEMICAL", 86, 90], ["pigs", "ORGANISM", 7, 11], ["pneumonic lesions", "PATHOLOGICAL_FORMATION", 40, 57], ["pigs", "ORGANISM", 74, 78], ["PRCV", "CANCER", 86, 90], ["pigs", "ORGANISM", 103, 107], ["B. bronchiseptica", "ORGANISM", 115, 132], ["gross lesions", "PATHOLOGICAL_FORMATION", 143, 156], ["pigs", "SPECIES", 7, 11], ["pigs", "SPECIES", 74, 78], ["pigs", "SPECIES", 103, 107], ["B. bronchiseptica group", "SPECIES", 115, 138], ["pigs", "SPECIES", 7, 11], ["pigs", "SPECIES", 74, 78], ["pigs", "SPECIES", 103, 107], ["B. bronchiseptica", "SPECIES", 115, 132], ["pneumonic lesions", "PROBLEM", 40, 57], ["gross lesions", "PROBLEM", 143, 156], ["coinfected", "OBSERVATION_MODIFIER", 19, 29], ["pneumonic", "OBSERVATION_MODIFIER", 40, 49], ["lesions", "OBSERVATION", 50, 57], ["gross", "OBSERVATION_MODIFIER", 143, 148], ["lesions", "OBSERVATION", 149, 156], ["largest", "OBSERVATION_MODIFIER", 162, 169], ["difference", "OBSERVATION_MODIFIER", 170, 180]]], ["Again, lesions were more severe, in general, at 10 days postinfection, except for the group of pigs infected with PRCV alone, in which lesions peaked at 4 days postinfection.Macroscopic and microscopic analysis of lesionsIn experiment 1, not all pigs infected with B. bronchiseptica alone had microscopic lesions.", [["lesions", "ANATOMY", 7, 14], ["lesions", "ANATOMY", 135, 142], ["lesions", "ANATOMY", 214, 221], ["lesions", "ANATOMY", 305, 312], ["PRCV", "CHEMICAL", 114, 118], ["lesions", "PATHOLOGICAL_FORMATION", 7, 14], ["pigs", "ORGANISM", 95, 99], ["lesions", "PATHOLOGICAL_FORMATION", 135, 142], ["lesions", "PATHOLOGICAL_FORMATION", 214, 221], ["pigs", "ORGANISM", 246, 250], ["B. bronchiseptica", "ORGANISM", 265, 282], ["lesions", "PATHOLOGICAL_FORMATION", 305, 312], ["pigs", "SPECIES", 95, 99], ["pigs", "SPECIES", 246, 250], ["B. bronchiseptica", "SPECIES", 265, 282], ["pigs", "SPECIES", 95, 99], ["PRCV", "SPECIES", 114, 118], ["pigs", "SPECIES", 246, 250], ["B. bronchiseptica", "SPECIES", 265, 282], ["lesions", "PROBLEM", 7, 14], ["PRCV", "TREATMENT", 114, 118], ["Macroscopic and microscopic analysis", "TEST", 174, 210], ["lesions", "PROBLEM", 214, 221], ["B. bronchiseptica", "PROBLEM", 265, 282], ["microscopic lesions", "PROBLEM", 293, 312], ["lesions", "OBSERVATION", 7, 14], ["more severe", "OBSERVATION_MODIFIER", 20, 31], ["lesions", "OBSERVATION", 135, 142], ["lesions", "OBSERVATION", 214, 221], ["lesions", "OBSERVATION", 305, 312]]], ["However, in the pigs with microscopic lesions, the lesions consisted of mild multifocal areas of interstitial thickening of the alveoli with mononuclear cells and occasional focal accumulations of neutrophils in the bronchi and alveoli (Fig. 2) .", [["lesions", "ANATOMY", 38, 45], ["lesions", "ANATOMY", 51, 58], ["interstitial", "ANATOMY", 97, 109], ["alveoli", "ANATOMY", 128, 135], ["mononuclear cells", "ANATOMY", 141, 158], ["neutrophils", "ANATOMY", 197, 208], ["bronchi", "ANATOMY", 216, 223], ["alveoli", "ANATOMY", 228, 235], ["pigs", "ORGANISM", 16, 20], ["lesions", "PATHOLOGICAL_FORMATION", 38, 45], ["lesions", "PATHOLOGICAL_FORMATION", 51, 58], ["alveoli", "MULTI-TISSUE_STRUCTURE", 128, 135], ["mononuclear cells", "CELL", 141, 158], ["neutrophils", "CELL", 197, 208], ["bronchi", "MULTI-TISSUE_STRUCTURE", 216, 223], ["alveoli", "MULTI-TISSUE_STRUCTURE", 228, 235], ["mononuclear cells", "CELL_TYPE", 141, 158], ["neutrophils", "CELL_TYPE", 197, 208], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["microscopic lesions", "PROBLEM", 26, 45], ["the lesions", "PROBLEM", 47, 58], ["interstitial thickening of the alveoli", "PROBLEM", 97, 135], ["mononuclear cells", "PROBLEM", 141, 158], ["occasional focal accumulations of neutrophils in the bronchi", "PROBLEM", 163, 223], ["microscopic", "OBSERVATION_MODIFIER", 26, 37], ["lesions", "OBSERVATION", 38, 45], ["lesions", "OBSERVATION", 51, 58], ["mild", "OBSERVATION_MODIFIER", 72, 76], ["multifocal", "OBSERVATION_MODIFIER", 77, 87], ["areas", "OBSERVATION_MODIFIER", 88, 93], ["interstitial", "ANATOMY_MODIFIER", 97, 109], ["thickening", "OBSERVATION", 110, 120], ["alveoli", "ANATOMY", 128, 135], ["mononuclear cells", "OBSERVATION", 141, 158], ["occasional", "OBSERVATION_MODIFIER", 163, 173], ["focal", "OBSERVATION_MODIFIER", 174, 179], ["accumulations of neutrophils", "OBSERVATION", 180, 208], ["bronchi", "ANATOMY", 216, 223], ["alveoli", "ANATOMY_MODIFIER", 228, 235]]], ["Microscopic lesions of the lung of pigs infected with PRCV alone typically consisted of multifocal areas of moderate to severe interstitial thickening of alveoli with mononuclear cells and lymphocytic perivascular and peribronchiolar infiltrates.", [["lesions", "ANATOMY", 12, 19], ["lung", "ANATOMY", 27, 31], ["interstitial", "ANATOMY", 127, 139], ["alveoli", "ANATOMY", 154, 161], ["mononuclear cells", "ANATOMY", 167, 184], ["lymphocytic perivascular", "ANATOMY", 189, 213], ["peribronchiolar infiltrates", "ANATOMY", 218, 245], ["Microscopic lesions", "PATHOLOGICAL_FORMATION", 0, 19], ["lung", "ORGAN", 27, 31], ["pigs", "ORGANISM", 35, 39], ["alveoli", "CELL", 154, 161], ["mononuclear cells", "CELL", 167, 184], ["lymphocytic perivascular", "PATHOLOGICAL_FORMATION", 189, 213], ["peribronchiolar infiltrates", "PATHOLOGICAL_FORMATION", 218, 245], ["mononuclear cells", "CELL_TYPE", 167, 184], ["pigs", "SPECIES", 35, 39], ["pigs", "SPECIES", 35, 39], ["PRCV", "SPECIES", 54, 58], ["Microscopic lesions of the lung of pigs infected", "PROBLEM", 0, 48], ["moderate to severe interstitial thickening of alveoli", "PROBLEM", 108, 161], ["mononuclear cells", "PROBLEM", 167, 184], ["lymphocytic perivascular and peribronchiolar infiltrates", "PROBLEM", 189, 245], ["lesions", "OBSERVATION", 12, 19], ["lung", "ANATOMY", 27, 31], ["multifocal", "OBSERVATION_MODIFIER", 88, 98], ["moderate", "OBSERVATION_MODIFIER", 108, 116], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["interstitial", "ANATOMY_MODIFIER", 127, 139], ["thickening", "OBSERVATION", 140, 150], ["alveoli", "ANATOMY_MODIFIER", 154, 161], ["mononuclear cells", "OBSERVATION", 167, 184], ["lymphocytic", "OBSERVATION_MODIFIER", 189, 200], ["perivascular", "ANATOMY_MODIFIER", 201, 213], ["peribronchiolar", "ANATOMY_MODIFIER", 218, 233], ["infiltrates", "OBSERVATION", 234, 245]]], ["These changes tended to be more pronounced on day 10 after challenge as compared to day 4, but at day 4 there were mild infiltrates of neutrophils in some of the airways that were not present on day 10 (Fig. 2) .", [["neutrophils", "ANATOMY", 135, 146], ["airways", "ANATOMY", 162, 169], ["neutrophils", "CELL", 135, 146], ["airways", "MULTI-TISSUE_STRUCTURE", 162, 169], ["neutrophils", "CELL_TYPE", 135, 146], ["mild infiltrates of neutrophils", "PROBLEM", 115, 146], ["more pronounced", "OBSERVATION_MODIFIER", 27, 42], ["mild", "OBSERVATION_MODIFIER", 115, 119], ["infiltrates", "OBSERVATION", 120, 131], ["neutrophils", "OBSERVATION", 135, 146], ["airways", "ANATOMY", 162, 169]]], ["Microscopic lesions in coinfected pigs included changes seen in pigs infected with single agents but also included additional changes and tended to be more severe than pigs infected with either agent alone.", [["lesions", "ANATOMY", 12, 19], ["Microscopic lesions", "PATHOLOGICAL_FORMATION", 0, 19], ["pigs", "ORGANISM", 34, 38], ["pigs", "ORGANISM", 64, 68], ["pigs", "ORGANISM", 168, 172], ["pigs", "SPECIES", 34, 38], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 168, 172], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 168, 172], ["Microscopic lesions", "PROBLEM", 0, 19], ["coinfected pigs", "TREATMENT", 23, 38], ["single agents", "TREATMENT", 83, 96], ["lesions", "OBSERVATION", 12, 19], ["coinfected pigs", "OBSERVATION", 23, 38], ["more severe", "OBSERVATION_MODIFIER", 151, 162]]], ["Typical microscopic lesions of the lung of pigs infected with both PRCV and B. bronchiseptica consisted of multifocal areas of moderate to severe interstitial thickening of the alveoli with mononuclear cells, lymphocytic perivascular and peribronchiolar cuffing, intra-alveolar epithelial cell necrosis with type II pneumocyte hyperplasia, and syncycial cell formation.", [["lesions", "ANATOMY", 20, 27], ["lung", "ANATOMY", 35, 39], ["interstitial", "ANATOMY", 146, 158], ["alveoli", "ANATOMY", 177, 184], ["mononuclear cells", "ANATOMY", 190, 207], ["lymphocytic perivascular", "ANATOMY", 209, 233], ["peribronchiolar", "ANATOMY", 238, 253], ["intra-alveolar epithelial cell", "ANATOMY", 263, 293], ["syncycial cell", "ANATOMY", 344, 358], ["B. bronchiseptica", "DISEASE", 76, 93], ["necrosis", "DISEASE", 294, 302], ["hyperplasia", "DISEASE", 327, 338], ["lesions", "PATHOLOGICAL_FORMATION", 20, 27], ["lung", "ORGAN", 35, 39], ["pigs", "ORGANISM", 43, 47], ["B. bronchiseptica", "ORGANISM", 76, 93], ["alveoli", "MULTI-TISSUE_STRUCTURE", 177, 184], ["mononuclear cells", "CELL", 190, 207], ["lymphocytic perivascular", "TISSUE", 209, 233], ["intra-alveolar epithelial cell", "CELL", 263, 293], ["syncycial cell", "CELL", 344, 358], ["mononuclear cells", "CELL_TYPE", 190, 207], ["pigs", "SPECIES", 43, 47], ["B. bronchiseptica", "SPECIES", 76, 93], ["pigs", "SPECIES", 43, 47], ["PRCV", "SPECIES", 67, 71], ["B. bronchiseptica", "SPECIES", 76, 93], ["Typical microscopic lesions of the lung of pigs infected", "PROBLEM", 0, 56], ["both PRCV", "TREATMENT", 62, 71], ["B. bronchiseptica", "PROBLEM", 76, 93], ["moderate to severe interstitial thickening of the alveoli", "PROBLEM", 127, 184], ["mononuclear cells", "PROBLEM", 190, 207], ["lymphocytic perivascular and peribronchiolar cuffing", "PROBLEM", 209, 261], ["intra-alveolar epithelial cell necrosis", "PROBLEM", 263, 302], ["type II pneumocyte hyperplasia", "PROBLEM", 308, 338], ["syncycial cell formation", "PROBLEM", 344, 368], ["microscopic", "OBSERVATION_MODIFIER", 8, 19], ["lesions", "OBSERVATION", 20, 27], ["lung", "ANATOMY", 35, 39], ["bronchiseptica", "OBSERVATION", 79, 93], ["multifocal", "OBSERVATION_MODIFIER", 107, 117], ["moderate", "OBSERVATION_MODIFIER", 127, 135], ["severe", "OBSERVATION_MODIFIER", 139, 145], ["interstitial", "ANATOMY_MODIFIER", 146, 158], ["thickening", "OBSERVATION", 159, 169], ["alveoli", "ANATOMY", 177, 184], ["mononuclear cells", "OBSERVATION", 190, 207], ["lymphocytic", "OBSERVATION_MODIFIER", 209, 220], ["perivascular", "ANATOMY_MODIFIER", 221, 233], ["peribronchiolar cuffing", "OBSERVATION", 238, 261], ["intra-alveolar", "ANATOMY_MODIFIER", 263, 277], ["epithelial cell necrosis", "OBSERVATION", 278, 302], ["type II", "OBSERVATION_MODIFIER", 308, 315], ["pneumocyte hyperplasia", "OBSERVATION", 316, 338], ["syncycial cell formation", "OBSERVATION", 344, 368]]], ["Intra-alveolar aggregates of neutrophils, macrophages, epithelial cells and necrotic debris were also present in coinfected pigs, as well as, accumulations of neutrophils in the bronchi and bronchioles, terminal bronchiolar epithelial cell necrosis and flattening, interlobular edema and occasional hemorrhage (Fig. 2) .", [["Intra-alveolar aggregates", "ANATOMY", 0, 25], ["neutrophils", "ANATOMY", 29, 40], ["macrophages", "ANATOMY", 42, 53], ["epithelial cells", "ANATOMY", 55, 71], ["necrotic debris", "ANATOMY", 76, 91], ["neutrophils", "ANATOMY", 159, 170], ["bronchi", "ANATOMY", 178, 185], ["bronchioles", "ANATOMY", 190, 201], ["bronchiolar epithelial cell", "ANATOMY", 212, 239], ["interlobular edema", "ANATOMY", 265, 283], ["necrosis", "DISEASE", 240, 248], ["interlobular edema", "DISEASE", 265, 283], ["hemorrhage", "DISEASE", 299, 309], ["neutrophils", "CELL", 29, 40], ["macrophages", "CELL", 42, 53], ["epithelial cells", "CELL", 55, 71], ["necrotic debris", "TISSUE", 76, 91], ["pigs", "ORGANISM", 124, 128], ["neutrophils", "CELL", 159, 170], ["bronchi", "MULTI-TISSUE_STRUCTURE", 178, 185], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 190, 201], ["bronchiolar epithelial cell", "CELL", 212, 239], ["interlobular edema", "PATHOLOGICAL_FORMATION", 265, 283], ["neutrophils", "CELL_TYPE", 29, 40], ["macrophages", "CELL_TYPE", 42, 53], ["epithelial cells", "CELL_TYPE", 55, 71], ["neutrophils", "CELL_TYPE", 159, 170], ["pigs", "SPECIES", 124, 128], ["pigs", "SPECIES", 124, 128], ["Intra-alveolar aggregates of neutrophils", "PROBLEM", 0, 40], ["macrophages", "PROBLEM", 42, 53], ["epithelial cells", "PROBLEM", 55, 71], ["necrotic debris", "PROBLEM", 76, 91], ["accumulations of neutrophils in the bronchi and bronchioles", "PROBLEM", 142, 201], ["terminal bronchiolar epithelial cell necrosis", "PROBLEM", 203, 248], ["flattening", "PROBLEM", 253, 263], ["interlobular edema", "PROBLEM", 265, 283], ["occasional hemorrhage", "PROBLEM", 288, 309], ["aggregates", "OBSERVATION", 15, 25], ["neutrophils", "ANATOMY", 29, 40], ["macrophages", "OBSERVATION_MODIFIER", 42, 53], ["epithelial cells", "OBSERVATION", 55, 71], ["necrotic", "OBSERVATION_MODIFIER", 76, 84], ["debris", "OBSERVATION", 85, 91], ["coinfected pigs", "OBSERVATION", 113, 128], ["accumulations", "OBSERVATION_MODIFIER", 142, 155], ["neutrophils", "OBSERVATION", 159, 170], ["bronchi", "ANATOMY", 178, 185], ["bronchioles", "ANATOMY", 190, 201], ["terminal", "OBSERVATION_MODIFIER", 203, 211], ["bronchiolar", "ANATOMY_MODIFIER", 212, 223], ["epithelial cell necrosis", "OBSERVATION", 224, 248], ["flattening", "OBSERVATION_MODIFIER", 253, 263], ["interlobular", "ANATOMY_MODIFIER", 265, 277], ["edema", "OBSERVATION", 278, 283], ["occasional", "OBSERVATION_MODIFIER", 288, 298], ["hemorrhage", "OBSERVATION", 299, 309], ["Fig", "OBSERVATION_MODIFIER", 311, 314]]], ["Again, these changes tended to be more pronounced on day 10 postinfection.", [["more pronounced", "OBSERVATION_MODIFIER", 34, 49]]], ["Three of the control animals had mild microscopic lesions consisting of peribronchial and perivascular infiltrates of lymphocytes, macrophages and eosinophils.", [["lesions", "ANATOMY", 50, 57], ["peribronchial", "ANATOMY", 72, 85], ["perivascular infiltrates", "ANATOMY", 90, 114], ["lymphocytes", "ANATOMY", 118, 129], ["macrophages", "ANATOMY", 131, 142], ["eosinophils", "ANATOMY", 147, 158], ["animals", "ORGANISM", 21, 28], ["lesions", "PATHOLOGICAL_FORMATION", 50, 57], ["peribronchial", "PATHOLOGICAL_FORMATION", 72, 85], ["lymphocytes", "CELL", 118, 129], ["macrophages", "CELL", 131, 142], ["eosinophils", "CELL", 147, 158], ["lymphocytes", "CELL_TYPE", 118, 129], ["macrophages", "CELL_TYPE", 131, 142], ["eosinophils", "CELL_TYPE", 147, 158], ["mild microscopic lesions", "PROBLEM", 33, 57], ["peribronchial and perivascular infiltrates of lymphocytes", "PROBLEM", 72, 129], ["macrophages", "PROBLEM", 131, 142], ["eosinophils", "TEST", 147, 158], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["microscopic", "OBSERVATION_MODIFIER", 38, 49], ["lesions", "OBSERVATION", 50, 57], ["peribronchial", "ANATOMY", 72, 85], ["perivascular", "ANATOMY_MODIFIER", 90, 102], ["infiltrates", "OBSERVATION", 103, 114], ["lymphocytes", "ANATOMY", 118, 129], ["macrophages", "OBSERVATION_MODIFIER", 131, 142], ["eosinophils", "OBSERVATION_MODIFIER", 147, 158]]], ["Bronchoalveolar lavage was tested by PCR for the presence of Mycoplasma, and none was detected (data not shown).", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["Bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 0, 22], ["Bronchoalveolar lavage", "TEST", 0, 22], ["PCR", "TEST", 37, 40], ["Mycoplasma", "PROBLEM", 61, 71], ["lavage", "OBSERVATION", 16, 22], ["Mycoplasma", "OBSERVATION", 61, 71]]], ["The microscopic lesions seen in the second experiment were similar to the first experiment at days 4 and 10 post-infection except that there were fewer epithelial cell changes seen.", [["lesions", "ANATOMY", 16, 23], ["epithelial cell", "ANATOMY", 152, 167], ["infection", "DISEASE", 113, 122], ["lesions", "PATHOLOGICAL_FORMATION", 16, 23], ["epithelial cell", "CELL", 152, 167], ["The microscopic lesions", "PROBLEM", 0, 23], ["infection", "PROBLEM", 113, 122], ["fewer epithelial cell changes", "PROBLEM", 146, 175], ["microscopic", "OBSERVATION_MODIFIER", 4, 15], ["lesions", "OBSERVATION", 16, 23], ["infection", "OBSERVATION", 113, 122], ["fewer", "OBSERVATION_MODIFIER", 146, 151], ["epithelial cell changes", "OBSERVATION", 152, 175]]], ["At day 1 postinfection, the lung of 1 pig infected with PRCV and all the coinfected pigs had interstitial thickening, alveoli containing macrophages, neutrophils and fibrin, and mild peribronchiolar and perivascular lymphocytic infiltrates.B. bronchiseptica and PRCV isolationB. bronchiseptica was isolated from the turbinate and/or trachea of all pigs from both experiments that were challenged with the bacterium in numbers that were similar between the two groups (Table 3 ).", [["lung", "ANATOMY", 28, 32], ["interstitial", "ANATOMY", 93, 105], ["alveoli", "ANATOMY", 118, 125], ["macrophages", "ANATOMY", 137, 148], ["neutrophils", "ANATOMY", 150, 161], ["fibrin", "ANATOMY", 166, 172], ["peribronchiolar", "ANATOMY", 183, 198], ["perivascular lymphocytic infiltrates", "ANATOMY", 203, 239], ["turbinate", "ANATOMY", 316, 325], ["trachea", "ANATOMY", 333, 340], ["lung", "ORGAN", 28, 32], ["pig", "ORGANISM", 38, 41], ["PRCV", "CANCER", 56, 60], ["pigs", "ORGANISM", 84, 88], ["alveoli", "MULTI-TISSUE_STRUCTURE", 118, 125], ["macrophages", "CELL", 137, 148], ["neutrophils", "CELL", 150, 161], ["fibrin", "GENE_OR_GENE_PRODUCT", 166, 172], ["perivascular lymphocytic infiltrates", "PATHOLOGICAL_FORMATION", 203, 239], ["B. bronchiseptica", "ORGANISM", 240, 257], ["PRCV", "ORGANISM", 262, 266], ["bronchiseptica", "ORGANISM", 279, 293], ["turbinate", "ORGAN", 316, 325], ["trachea", "ORGAN", 333, 340], ["pigs", "ORGANISM", 348, 352], ["macrophages", "CELL_TYPE", 137, 148], ["neutrophils", "CELL_TYPE", 150, 161], ["fibrin", "PROTEIN", 166, 172], ["pig", "SPECIES", 38, 41], ["pigs", "SPECIES", 84, 88], ["B. bronchiseptica", "SPECIES", 240, 257], ["bronchiseptica", "SPECIES", 279, 293], ["pigs", "SPECIES", 348, 352], ["pig", "SPECIES", 38, 41], ["PRCV", "SPECIES", 56, 60], ["pigs", "SPECIES", 84, 88], ["B. bronchiseptica", "SPECIES", 240, 257], ["PRCV", "SPECIES", 262, 266], ["bronchiseptica", "SPECIES", 279, 293], ["pigs", "SPECIES", 348, 352], ["PRCV", "TREATMENT", 56, 60], ["interstitial thickening", "PROBLEM", 93, 116], ["alveoli containing macrophages", "PROBLEM", 118, 148], ["neutrophils", "TEST", 150, 161], ["fibrin", "PROBLEM", 166, 172], ["mild peribronchiolar and perivascular lymphocytic infiltrates", "PROBLEM", 178, 239], ["bronchiseptica", "PROBLEM", 243, 257], ["PRCV isolationB", "TREATMENT", 262, 277], ["bronchiseptica", "PROBLEM", 279, 293], ["the bacterium in numbers", "PROBLEM", 401, 425], ["postinfection", "OBSERVATION", 9, 22], ["lung", "ANATOMY", 28, 32], ["coinfected", "OBSERVATION_MODIFIER", 73, 83], ["interstitial", "ANATOMY_MODIFIER", 93, 105], ["thickening", "OBSERVATION", 106, 116], ["alveoli", "ANATOMY_MODIFIER", 118, 125], ["macrophages", "OBSERVATION_MODIFIER", 137, 148], ["neutrophils", "OBSERVATION_MODIFIER", 150, 161], ["fibrin", "OBSERVATION_MODIFIER", 166, 172], ["mild", "OBSERVATION_MODIFIER", 178, 182], ["peribronchiolar", "ANATOMY_MODIFIER", 183, 198], ["perivascular", "ANATOMY_MODIFIER", 203, 215], ["lymphocytic infiltrates", "OBSERVATION", 216, 239], ["bronchiseptica", "OBSERVATION", 243, 257], ["turbinate", "ANATOMY", 316, 325], ["trachea", "ANATOMY", 333, 340], ["all pigs", "ANATOMY", 344, 352], ["bacterium", "OBSERVATION_MODIFIER", 405, 414]]], ["In the first experiment, B. bronchiseptica was isolated from the lung of 8 of 10 challenged with the bacteria alone and 6 of 10 coinfected pigs (Table 3 ) and in similar numbers.", [["lung", "ANATOMY", 65, 69], ["B. bronchiseptica", "ORGANISM", 25, 42], ["lung", "ORGAN", 65, 69], ["pigs", "ORGANISM", 139, 143], ["B. bronchiseptica", "SPECIES", 25, 42], ["pigs", "SPECIES", 139, 143], ["B. bronchiseptica", "SPECIES", 25, 42], ["pigs", "SPECIES", 139, 143], ["B. bronchiseptica", "PROBLEM", 25, 42], ["the bacteria", "PROBLEM", 97, 109], ["bronchiseptica", "OBSERVATION", 28, 42], ["lung", "ANATOMY", 65, 69]]], ["B. bronchiseptica was isolated from the lung of more coinfected pigs than single infected pigs in the second experiment.", [["lung", "ANATOMY", 40, 44], ["B. bronchiseptica", "ORGANISM", 0, 17], ["lung", "ORGAN", 40, 44], ["pigs", "ORGANISM", 64, 68], ["pigs", "ORGANISM", 90, 94], ["B. bronchiseptica", "SPECIES", 0, 17], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 90, 94], ["B. bronchiseptica", "SPECIES", 0, 17], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 90, 94], ["B. bronchiseptica", "PROBLEM", 0, 17], ["bronchiseptica", "OBSERVATION", 3, 17], ["lung", "ANATOMY", 40, 44], ["more", "OBSERVATION_MODIFIER", 48, 52], ["coinfected", "OBSERVATION_MODIFIER", 53, 63], ["pigs", "OBSERVATION_MODIFIER", 64, 68], ["infected", "OBSERVATION_MODIFIER", 81, 89], ["pigs", "OBSERVATION", 90, 94]]], ["Eight of 12 coinfected pigs had B. bronchiseptica in their lungs, whereas only 3 of 12 pigs challenged with B. bronchiseptica alone did (Table 3) .", [["lungs", "ANATOMY", 59, 64], ["pigs", "ORGANISM", 23, 27], ["B. bronchiseptica", "ORGANISM", 32, 49], ["lungs", "ORGAN", 59, 64], ["pigs", "ORGANISM", 87, 91], ["B. bronchiseptica", "ORGANISM", 108, 125], ["pigs", "SPECIES", 23, 27], ["B. bronchiseptica", "SPECIES", 32, 49], ["pigs", "SPECIES", 87, 91], ["B. bronchiseptica", "SPECIES", 108, 125], ["pigs", "SPECIES", 23, 27], ["B. bronchiseptica", "SPECIES", 32, 49], ["pigs", "SPECIES", 87, 91], ["B. bronchiseptica", "SPECIES", 108, 125], ["B. bronchiseptica in their lungs", "PROBLEM", 32, 64], ["bronchiseptica", "OBSERVATION", 35, 49], ["lungs", "ANATOMY", 59, 64]]], ["In the first experiment, PRCV was isolated from the BALF on day 4 post-infection from 9 of 10 pigs given the virus, but the virus had been cleared from all pigs euthanized on day 10 (Table 4) .", [["BALF", "ANATOMY", 52, 56], ["infection", "DISEASE", 71, 80], ["PRCV", "ORGANISM", 25, 29], ["BALF", "ORGANISM_SUBSTANCE", 52, 56], ["pigs", "ORGANISM", 94, 98], ["pigs", "ORGANISM", 156, 160], ["PRCV", "PROTEIN", 25, 29], ["pigs", "SPECIES", 94, 98], ["pigs", "SPECIES", 156, 160], ["PRCV", "SPECIES", 25, 29], ["pigs", "SPECIES", 94, 98], ["pigs", "SPECIES", 156, 160], ["infection", "PROBLEM", 71, 80], ["the virus", "PROBLEM", 105, 114], ["the virus", "PROBLEM", 120, 129], ["infection", "OBSERVATION", 71, 80]]], ["PRCV was isolated from the BALF or lung of more coinfected pigs than single infected pigs in the second experiment.", [["BALF", "ANATOMY", 27, 31], ["lung", "ANATOMY", 35, 39], ["PRCV", "GENE_OR_GENE_PRODUCT", 0, 4], ["BALF", "ORGANISM_SUBSTANCE", 27, 31], ["lung", "ORGAN", 35, 39], ["pigs", "ORGANISM", 59, 63], ["pigs", "ORGANISM", 85, 89], ["PRCV", "PROTEIN", 0, 4], ["pigs", "SPECIES", 59, 63], ["pigs", "SPECIES", 85, 89], ["PRCV", "SPECIES", 0, 4], ["pigs", "SPECIES", 59, 63], ["pigs", "SPECIES", 85, 89], ["BALF", "ANATOMY", 27, 31], ["lung", "ANATOMY", 35, 39], ["more", "OBSERVATION_MODIFIER", 43, 47], ["coinfected", "OBSERVATION", 48, 58], ["infected", "OBSERVATION_MODIFIER", 76, 84], ["pigs", "OBSERVATION", 85, 89]]], ["Seven of 12 coinfected pigs had PRCV in their lung or BALF, whereas only 2 of 12 pigs that were challenged with PRCV alone did (Table 4) .", [["lung", "ANATOMY", 46, 50], ["BALF", "ANATOMY", 54, 58], ["PRCV", "CHEMICAL", 112, 116], ["PRCV", "CHEMICAL", 112, 116], ["pigs", "ORGANISM", 23, 27], ["lung", "ORGAN", 46, 50], ["BALF", "ORGANISM_SUBSTANCE", 54, 58], ["pigs", "ORGANISM", 81, 85], ["pigs", "SPECIES", 23, 27], ["pigs", "SPECIES", 81, 85], ["pigs", "SPECIES", 23, 27], ["PRCV", "SPECIES", 32, 36], ["pigs", "SPECIES", 81, 85], ["PRCV", "SPECIES", 112, 116], ["PRCV", "TREATMENT", 32, 36], ["PRCV", "TREATMENT", 112, 116], ["coinfected", "OBSERVATION", 12, 22], ["lung", "ANATOMY", 46, 50], ["BALF", "ANATOMY", 54, 58]]], ["PRCV was isolated from the nasal swab, turbinate or trachea of all pigs challenged with the virus that were euthanized on days 1 and 4 post-infection, indicating that all pigs were indeed successfully infected (Table 4) .", [["nasal swab", "ANATOMY", 27, 37], ["turbinate", "ANATOMY", 39, 48], ["trachea", "ANATOMY", 52, 59], ["infection", "DISEASE", 140, 149], ["PRCV", "GENE_OR_GENE_PRODUCT", 0, 4], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 27, 37], ["turbinate", "ORGAN", 39, 48], ["trachea", "ORGAN", 52, 59], ["pigs", "ORGANISM", 67, 71], ["pigs", "ORGANISM", 171, 175], ["PRCV", "PROTEIN", 0, 4], ["pigs", "SPECIES", 67, 71], ["pigs", "SPECIES", 171, 175], ["PRCV", "SPECIES", 0, 4], ["pigs", "SPECIES", 67, 71], ["pigs", "SPECIES", 171, 175], ["the nasal swab", "TEST", 23, 37], ["turbinate", "PROBLEM", 39, 48], ["all pigs", "TREATMENT", 63, 71], ["the virus", "PROBLEM", 88, 97], ["infection", "PROBLEM", 140, 149], ["nasal swab", "ANATOMY", 27, 37], ["turbinate", "ANATOMY", 39, 48], ["trachea", "ANATOMY", 52, 59], ["infection", "OBSERVATION", 140, 149]]], ["Again, the virus was largely cleared by day 10 post-infection, as PRCV was not detected in any of the samples tested except the BALF from 1 coinfected pig.Cytokine gene expressionCytokine production after infection likely plays a role in pathological changes observed during infection.", [["samples", "ANATOMY", 102, 109], ["BALF", "ANATOMY", 128, 132], ["infection", "DISEASE", 52, 61], ["infection", "DISEASE", 205, 214], ["infection", "DISEASE", 275, 284], ["BALF", "ORGANISM_SUBSTANCE", 128, 132], ["pig", "ORGANISM", 151, 154], ["Cytokine", "GENE_OR_GENE_PRODUCT", 155, 163], ["pig", "SPECIES", 151, 154], ["PRCV", "SPECIES", 66, 70], ["pig", "SPECIES", 151, 154], ["the virus", "PROBLEM", 7, 16], ["infection", "PROBLEM", 52, 61], ["PRCV", "TEST", 66, 70], ["the samples", "TEST", 98, 109], ["the BALF", "TEST", 124, 132], ["Cytokine gene expressionCytokine production", "PROBLEM", 155, 198], ["infection", "PROBLEM", 205, 214], ["pathological changes", "PROBLEM", 238, 258], ["infection", "PROBLEM", 275, 284], ["virus", "OBSERVATION", 11, 16], ["cleared", "OBSERVATION_MODIFIER", 29, 36], ["infection", "OBSERVATION", 52, 61], ["infection", "OBSERVATION", 275, 284]]], ["Alveolar macrophages reside in the airway space of the lungs and are one of the first cells encountered during respiratory disease.", [["Alveolar macrophages", "ANATOMY", 0, 20], ["airway space", "ANATOMY", 35, 47], ["lungs", "ANATOMY", 55, 60], ["cells", "ANATOMY", 86, 91], ["respiratory", "ANATOMY", 111, 122], ["respiratory disease", "DISEASE", 111, 130], ["Alveolar macrophages", "CELL", 0, 20], ["airway space", "MULTI-TISSUE_STRUCTURE", 35, 47], ["lungs", "ORGAN", 55, 60], ["cells", "CELL", 86, 91], ["Alveolar macrophages", "CELL_TYPE", 0, 20], ["Alveolar macrophages", "PROBLEM", 0, 20], ["respiratory disease", "PROBLEM", 111, 130], ["macrophages", "OBSERVATION", 9, 20], ["airway", "ANATOMY", 35, 41], ["space", "ANATOMY_MODIFIER", 42, 47], ["lungs", "ANATOMY", 55, 60], ["respiratory disease", "OBSERVATION", 111, 130]]], ["Thus, during the second experiment we investigated changes in cytokine and chemokine mRNA levels in AM isolated from infected pigs.", [["AM", "ANATOMY", 100, 102], ["AM", "CELL", 100, 102], ["pigs", "ORGANISM", 126, 130], ["cytokine", "PROTEIN", 62, 70], ["chemokine mRNA", "RNA", 75, 89], ["pigs", "SPECIES", 126, 130], ["pigs", "SPECIES", 126, 130], ["changes in cytokine and chemokine mRNA levels", "PROBLEM", 51, 96], ["infected pigs", "OBSERVATION", 117, 130]]], ["Fig. 3 summarizes changes in mRNA levels of proinflammatory cytokines of infected pigs relative to sham treated.", [["pigs", "ORGANISM", 82, 86], ["proinflammatory cytokines", "PROTEIN", 44, 69], ["pigs", "SPECIES", 82, 86], ["pigs", "SPECIES", 82, 86], ["mRNA levels", "TEST", 29, 40], ["proinflammatory cytokines", "TREATMENT", 44, 69], ["infected pigs", "TREATMENT", 73, 86], ["proinflammatory cytokines", "OBSERVATION", 44, 69], ["infected", "OBSERVATION", 73, 81]]], ["In general, pigs challenged with B. bronchiseptica alone had increased mRNA levels of all the proinflammatory cytokines genes measured (TNF-alpha, IL-6, MCP-1, IL-8 and IL-1beta) at day 1 post-infection, with the majority of pigs responding with 4-fold or greater increases in transcript.", [["infection", "DISEASE", 193, 202], ["pigs", "ORGANISM", 12, 16], ["B. bronchiseptica", "ORGANISM", 33, 50], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 136, 145], ["IL-6", "GENE_OR_GENE_PRODUCT", 147, 151], ["MCP-1", "GENE_OR_GENE_PRODUCT", 153, 158], ["IL-8", "GENE_OR_GENE_PRODUCT", 160, 164], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 169, 177], ["pigs", "ORGANISM", 225, 229], ["proinflammatory cytokines genes", "DNA", 94, 125], ["TNF", "PROTEIN", 136, 139], ["MCP", "PROTEIN", 153, 156], ["IL-1beta", "PROTEIN", 169, 177], ["pigs", "SPECIES", 12, 16], ["B. bronchiseptica", "SPECIES", 33, 50], ["pigs", "SPECIES", 225, 229], ["pigs", "SPECIES", 12, 16], ["B. bronchiseptica", "SPECIES", 33, 50], ["pigs", "SPECIES", 225, 229], ["B. bronchiseptica", "PROBLEM", 33, 50], ["increased mRNA levels", "PROBLEM", 61, 82], ["the proinflammatory cytokines genes", "TEST", 90, 125], ["TNF", "TEST", 136, 139], ["alpha", "TEST", 140, 145], ["IL", "TEST", 147, 149], ["MCP", "TEST", 153, 156], ["IL", "TEST", 160, 162], ["IL-1beta", "TREATMENT", 169, 177], ["infection", "PROBLEM", 193, 202], ["infection", "OBSERVATION", 193, 202], ["greater", "OBSERVATION_MODIFIER", 256, 263], ["increases", "OBSERVATION_MODIFIER", 264, 273]]], ["B. bronchiseptica was not isolated from the lung of any of these pigs nor did any of the pigs have lesions either macroscopically or microscopically.", [["lung", "ANATOMY", 44, 48], ["lesions", "ANATOMY", 99, 106], ["B. bronchiseptica", "ORGANISM", 0, 17], ["lung", "ORGAN", 44, 48], ["pigs", "ORGANISM", 65, 69], ["pigs", "ORGANISM", 89, 93], ["lesions", "CANCER", 99, 106], ["B. bronchiseptica", "SPECIES", 0, 17], ["pigs", "SPECIES", 65, 69], ["pigs", "SPECIES", 89, 93], ["B. bronchiseptica", "SPECIES", 0, 17], ["pigs", "SPECIES", 65, 69], ["pigs", "SPECIES", 89, 93], ["B. bronchiseptica", "PROBLEM", 0, 17], ["lesions", "PROBLEM", 99, 106], ["bronchiseptica", "OBSERVATION", 3, 17], ["lung", "ANATOMY", 44, 48], ["lesions", "OBSERVATION", 99, 106]]], ["By day 4 postinfection, cytokine mRNA levels in alveolar macrophages collected from pigs infected with B. bronchiseptica alone were near or below levels observed in uninfected animals.", [["alveolar macrophages", "ANATOMY", 48, 68], ["alveolar macrophages", "CELL", 48, 68], ["pigs", "ORGANISM", 84, 88], ["B. bronchiseptica", "ORGANISM", 103, 120], ["cytokine mRNA", "RNA", 24, 37], ["alveolar macrophages", "CELL_TYPE", 48, 68], ["pigs", "SPECIES", 84, 88], ["B. bronchiseptica", "SPECIES", 103, 120], ["pigs", "SPECIES", 84, 88], ["B. bronchiseptica", "SPECIES", 103, 120], ["cytokine mRNA levels", "TEST", 24, 44], ["alveolar macrophages", "PROBLEM", 48, 68], ["B. bronchiseptica", "PROBLEM", 103, 120], ["alveolar macrophages", "ANATOMY", 48, 68], ["uninfected animals", "OBSERVATION", 165, 183]]], ["Fifty percent or more of the pigs had a greater than 2-fold reduction in transcript detected for IL-6, MCP-1, IL-8 and IL-1beta.", [["pigs", "ORGANISM", 29, 33], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["MCP-1", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-8", "GENE_OR_GENE_PRODUCT", 110, 114], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 119, 127], ["IL-6", "PROTEIN", 97, 101], ["MCP", "PROTEIN", 103, 106], ["IL-8", "PROTEIN", 110, 114], ["IL-1beta", "PROTEIN", 119, 127], ["pigs", "SPECIES", 29, 33], ["pigs", "SPECIES", 29, 33], ["IL", "TEST", 97, 99], ["MCP", "TEST", 103, 106], ["IL", "TEST", 110, 112], ["greater", "OBSERVATION_MODIFIER", 40, 47]]], ["The cytokine mRNA levels in B. bronchiseptica infected pigs were essentially equal to sham infected pigs by 10 days post-infection with one exception.", [["B. bronchiseptica", "ORGANISM", 28, 45], ["pigs", "ORGANISM", 55, 59], ["pigs", "ORGANISM", 100, 104], ["cytokine mRNA", "RNA", 4, 17], ["B. bronchiseptica infected pigs", "SPECIES", 28, 59], ["pigs", "SPECIES", 100, 104], ["B. bronchiseptica", "SPECIES", 28, 45], ["pigs", "SPECIES", 55, 59], ["pigs", "SPECIES", 100, 104], ["The cytokine mRNA levels", "TEST", 0, 24], ["B. bronchiseptica infected pigs", "PROBLEM", 28, 59], ["bronchiseptica", "OBSERVATION_MODIFIER", 31, 45], ["infected", "OBSERVATION", 46, 54]]], ["One pig infected with B. bronchiseptica alone, which had lung lesions involving a significant portion of the lung (see Fig. 1a ), had a 2-fold or greater increase in transcription of TNF-alpha, IL-6 and MCP-1.Cytokine gene expressionWith the exception of MCP-1, mRNA levels of the cytokines examined on day 1 post-infection in animals infected with PRCV alone were the same as sham infected pigs (IL-6) or were 2-fold or more below levels examined for sham infected pigs (TNF-alpha, IL-8 and IL-1beta).", [["lung lesions", "ANATOMY", 57, 69], ["lung", "ANATOMY", 109, 113], ["lung lesions", "DISEASE", 57, 69], ["infection", "DISEASE", 314, 323], ["PRCV", "CHEMICAL", 349, 353], ["pig", "ORGANISM", 4, 7], ["B. bronchiseptica", "ORGANISM", 22, 39], ["lung lesions", "PATHOLOGICAL_FORMATION", 57, 69], ["lung", "ORGAN", 109, 113], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 183, 192], ["IL-6", "GENE_OR_GENE_PRODUCT", 194, 198], ["MCP-1", "GENE_OR_GENE_PRODUCT", 203, 208], ["Cytokine", "GENE_OR_GENE_PRODUCT", 209, 217], ["MCP-1", "GENE_OR_GENE_PRODUCT", 255, 260], ["animals", "ORGANISM", 327, 334], ["pigs", "ORGANISM", 391, 395], ["IL-6", "GENE_OR_GENE_PRODUCT", 397, 401], ["pigs", "ORGANISM", 466, 470], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 472, 481], ["IL-8", "GENE_OR_GENE_PRODUCT", 483, 487], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 492, 500], ["TNF-alpha, IL-6", "PROTEIN", 183, 198], ["MCP-1", "PROTEIN", 203, 208], ["Cytokine gene", "DNA", 209, 222], ["MCP", "PROTEIN", 255, 258], ["cytokines", "PROTEIN", 281, 290], ["TNF-alpha, IL-8", "PROTEIN", 472, 487], ["IL-1beta", "PROTEIN", 492, 500], ["pig", "SPECIES", 4, 7], ["B. bronchiseptica", "SPECIES", 22, 39], ["pigs", "SPECIES", 391, 395], ["pigs", "SPECIES", 466, 470], ["pig", "SPECIES", 4, 7], ["B. bronchiseptica", "SPECIES", 22, 39], ["PRCV", "SPECIES", 349, 353], ["pigs", "SPECIES", 391, 395], ["pigs", "SPECIES", 466, 470], ["B. bronchiseptica", "PROBLEM", 22, 39], ["lung lesions", "PROBLEM", 57, 69], ["a 2-fold", "PROBLEM", 134, 142], ["TNF", "TEST", 183, 186], ["alpha", "TEST", 187, 192], ["IL", "TEST", 194, 196], ["MCP", "TEST", 203, 206], ["MCP", "TEST", 255, 258], ["mRNA levels", "TEST", 262, 273], ["the cytokines", "TEST", 277, 290], ["infection", "PROBLEM", 314, 323], ["PRCV", "TREATMENT", 349, 353], ["sham infected pigs", "PROBLEM", 452, 470], ["TNF", "TEST", 472, 475], ["alpha", "TEST", 476, 481], ["IL", "TEST", 483, 485], ["infected", "OBSERVATION_MODIFIER", 8, 16], ["bronchiseptica", "OBSERVATION", 25, 39], ["lung", "ANATOMY", 57, 61], ["lesions", "OBSERVATION", 62, 69], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["portion", "ANATOMY_MODIFIER", 94, 101], ["lung", "ANATOMY", 109, 113], ["greater", "OBSERVATION_MODIFIER", 146, 153], ["increase", "OBSERVATION_MODIFIER", 154, 162], ["TNF", "ANATOMY", 183, 186], ["infection", "OBSERVATION", 314, 323]]], ["The one pig that had increased MCP-1 transcript levels (13-fold) in this group at this time was the pig with the microscopic lesions described above on day 1.", [["lesions", "ANATOMY", 125, 132], ["pig", "ORGANISM", 8, 11], ["MCP-1", "GENE_OR_GENE_PRODUCT", 31, 36], ["pig", "ORGANISM", 100, 103], ["lesions", "PATHOLOGICAL_FORMATION", 125, 132], ["MCP", "PROTEIN", 31, 34], ["pig", "SPECIES", 8, 11], ["pig", "SPECIES", 8, 11], ["pig", "SPECIES", 100, 103], ["increased MCP", "PROBLEM", 21, 34], ["transcript levels", "TEST", 37, 54], ["the microscopic lesions", "PROBLEM", 109, 132], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["MCP", "OBSERVATION_MODIFIER", 31, 34], ["microscopic", "OBSERVATION_MODIFIER", 113, 124], ["lesions", "OBSERVATION", 125, 132]]], ["This trend continued in the pigs infected with PRCV alone, as mRNA levels of IL-6, MCP-1, IL-8 and IL-1beta were at or below the levels measured in sham treated animals on day 4.", [["PRCV", "CHEMICAL", 47, 51], ["PRCV", "CHEMICAL", 47, 51], ["pigs", "ORGANISM", 28, 32], ["PRCV", "SIMPLE_CHEMICAL", 47, 51], ["IL-6", "GENE_OR_GENE_PRODUCT", 77, 81], ["MCP-1", "GENE_OR_GENE_PRODUCT", 83, 88], ["IL-8", "GENE_OR_GENE_PRODUCT", 90, 94], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 99, 107], ["IL-6", "PROTEIN", 77, 81], ["MCP", "PROTEIN", 83, 86], ["IL-8", "PROTEIN", 90, 94], ["IL-1beta", "PROTEIN", 99, 107], ["pigs", "SPECIES", 28, 32], ["pigs", "SPECIES", 28, 32], ["PRCV", "SPECIES", 47, 51], ["mRNA levels", "TEST", 62, 73], ["IL", "TEST", 77, 79], ["MCP", "TEST", 83, 86], ["IL", "TEST", 90, 92], ["IL-1beta", "TREATMENT", 99, 107]]], ["MCP-1 mRNA levels in PRCV infected pigs showed marked elevation on day 10 post-infection with an average 12-fold increase.", [["PRCV", "ANATOMY", 21, 25], ["infection", "DISEASE", 79, 88], ["MCP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["pigs", "ORGANISM", 35, 39], ["MCP", "PROTEIN", 0, 3], ["pigs", "SPECIES", 35, 39], ["PRCV", "SPECIES", 21, 25], ["pigs", "SPECIES", 35, 39], ["MCP", "TEST", 0, 3], ["mRNA levels", "TEST", 6, 17], ["PRCV infected pigs", "TEST", 21, 39], ["marked elevation", "PROBLEM", 47, 63], ["infection", "PROBLEM", 79, 88], ["marked", "OBSERVATION_MODIFIER", 47, 53], ["elevation", "OBSERVATION_MODIFIER", 54, 63], ["infection", "OBSERVATION", 79, 88], ["-fold", "OBSERVATION_MODIFIER", 107, 112], ["increase", "OBSERVATION_MODIFIER", 113, 121]]], ["The level of MCP-1 was negatively correlated (R = \u00c00.904) with the percentage of lung macroscopically affected with lesions.", [["lung", "ANATOMY", 81, 85], ["lesions", "ANATOMY", 116, 123], ["MCP-1", "GENE_OR_GENE_PRODUCT", 13, 18], ["lung", "ORGAN", 81, 85], ["lesions", "PATHOLOGICAL_FORMATION", 116, 123], ["MCP", "PROTEIN", 13, 16], ["MCP", "TEST", 13, 16], ["lesions", "PROBLEM", 116, 123], ["lung", "ANATOMY", 81, 85], ["macroscopically", "OBSERVATION", 86, 101], ["lesions", "OBSERVATION", 116, 123]]], ["Three of the pigs at this time point had increases in MCP-1 transcript of 12-to 20-fold and had gross lesions affecting 0-3% of their lung, while the pig with 14% affected lung had no increase in MCP-1 transcript compared to sham treated pigs.", [["gross lesions", "ANATOMY", 96, 109], ["lung", "ANATOMY", 134, 138], ["lung", "ANATOMY", 172, 176], ["pigs", "ORGANISM", 13, 17], ["MCP-1", "GENE_OR_GENE_PRODUCT", 54, 59], ["lesions", "PATHOLOGICAL_FORMATION", 102, 109], ["lung", "ORGAN", 134, 138], ["pig", "ORGANISM", 150, 153], ["lung", "ORGAN", 172, 176], ["MCP-1", "GENE_OR_GENE_PRODUCT", 196, 201], ["pigs", "ORGANISM", 238, 242], ["MCP", "PROTEIN", 54, 57], ["MCP", "PROTEIN", 196, 199], ["pigs", "SPECIES", 13, 17], ["pig", "SPECIES", 150, 153], ["pigs", "SPECIES", 238, 242], ["pig", "SPECIES", 150, 153], ["pigs", "SPECIES", 238, 242], ["MCP", "TEST", 54, 57], ["gross lesions", "PROBLEM", 96, 109], ["MCP", "TEST", 196, 199], ["increases", "OBSERVATION_MODIFIER", 41, 50], ["gross", "OBSERVATION_MODIFIER", 96, 101], ["lesions", "OBSERVATION", 102, 109], ["lung", "ANATOMY", 134, 138], ["lung", "ANATOMY", 172, 176], ["no", "UNCERTAINTY", 181, 183], ["increase", "OBSERVATION_MODIFIER", 184, 192]]], ["TNF-alpha, IL-6, IL-8 and IL-1beta mRNA levels remained at levels observed in control animals in this group 10 days post-infection.", [["TNF-alpha", "GENE_OR_GENE_PRODUCT", 0, 9], ["IL-6", "GENE_OR_GENE_PRODUCT", 11, 15], ["IL-8", "GENE_OR_GENE_PRODUCT", 17, 21], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 26, 34], ["TNF", "PROTEIN", 0, 3], ["TNF", "TEST", 0, 3], ["alpha", "TEST", 4, 9], ["IL", "TEST", 11, 13], ["IL", "TEST", 17, 19], ["IL-1beta mRNA levels", "TEST", 26, 46], ["alpha", "ANATOMY", 4, 9]]], ["Cytokine changes observed on day 1 post-infection in coinfected pigs were similar to those observed in pigs infected with B. bronchiseptica alone.", [["infection", "DISEASE", 40, 49], ["pigs", "ORGANISM", 64, 68], ["pigs", "ORGANISM", 103, 107], ["B. bronchiseptica", "ORGANISM", 122, 139], ["Cytokine", "PROTEIN", 0, 8], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 103, 107], ["B. bronchiseptica", "SPECIES", 122, 139], ["pigs", "SPECIES", 64, 68], ["pigs", "SPECIES", 103, 107], ["B. bronchiseptica", "SPECIES", 122, 139], ["Cytokine changes", "PROBLEM", 0, 16], ["infection", "PROBLEM", 40, 49], ["coinfected pigs", "TREATMENT", 53, 68], ["infection", "OBSERVATION", 40, 49]]], ["Coinfected pigs exhibited at least a 2-fold increase in mRNA levels of TNF-alpha and IL-8, a 5-fold increase of IL-6 and IL-1beta, and nearly 15-fold increase of MCP-1.", [["pigs", "ORGANISM", 11, 15], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 71, 80], ["IL-8", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 121, 129], ["MCP-1", "GENE_OR_GENE_PRODUCT", 162, 167], ["TNF", "PROTEIN", 71, 74], ["IL-6", "PROTEIN", 112, 116], ["IL-1beta", "PROTEIN", 121, 129], ["MCP", "PROTEIN", 162, 165], ["pigs", "SPECIES", 11, 15], ["Coinfected pigs", "TREATMENT", 0, 15], ["a 2-fold increase", "PROBLEM", 35, 52], ["mRNA levels", "TEST", 56, 67], ["TNF", "TEST", 71, 74], ["alpha", "TEST", 75, 80], ["IL", "TEST", 85, 87], ["IL", "TEST", 112, 114], ["MCP", "TEST", 162, 165], ["TNF", "ANATOMY", 71, 74], ["15-fold", "OBSERVATION_MODIFIER", 142, 149]]], ["Although the increase in mRNA levels were similar to that of pigs infected with B. bronchiseptica alone, the mRNA levels of TNF-alpha, IL-8, IL-6 and IL-1beta were significantly greater in coinfected pigs when compared to PRCV infected pigs.", [["pigs", "ORGANISM", 61, 65], ["B. bronchiseptica", "ORGANISM", 80, 97], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 124, 133], ["IL-8", "GENE_OR_GENE_PRODUCT", 135, 139], ["IL-6", "GENE_OR_GENE_PRODUCT", 141, 145], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 150, 158], ["pigs", "ORGANISM", 200, 204], ["pigs", "ORGANISM", 236, 240], ["TNF", "PROTEIN", 124, 127], ["IL-1beta", "PROTEIN", 150, 158], ["pigs", "SPECIES", 61, 65], ["B. bronchiseptica", "SPECIES", 80, 97], ["pigs", "SPECIES", 200, 204], ["pigs", "SPECIES", 236, 240], ["pigs", "SPECIES", 61, 65], ["B. bronchiseptica", "SPECIES", 80, 97], ["pigs", "SPECIES", 200, 204], ["PRCV", "SPECIES", 222, 226], ["pigs", "SPECIES", 236, 240], ["the increase in mRNA levels", "PROBLEM", 9, 36], ["B. bronchiseptica", "TREATMENT", 80, 97], ["the mRNA levels", "TEST", 105, 120], ["TNF", "TEST", 124, 127], ["alpha", "TEST", 128, 133], ["IL", "TEST", 135, 137], ["IL", "TEST", 141, 143], ["IL-1beta", "TREATMENT", 150, 158], ["increase", "OBSERVATION_MODIFIER", 13, 21], ["infected", "OBSERVATION", 227, 235]]], ["While none of the AM collected from pigs receiving PRCV or B. bronchiseptica alone showed an increase in MCP-1 mRNA levels 4 days post-infection, 3 of the 4 pigs in the coinfected group had a 55-fold or greater increase of MCP-1 mRNA, which made the coinfected group's mRNA levels of this cytokine statistically greater than for either of the single infected groups.", [["PRCV", "CHEMICAL", 51, 55], ["coinfected", "DISEASE", 169, 179], ["AM", "CELL", 18, 20], ["pigs", "ORGANISM", 36, 40], ["B. bronchiseptica", "ORGANISM", 59, 76], ["MCP-1", "GENE_OR_GENE_PRODUCT", 105, 110], ["pigs", "ORGANISM", 157, 161], ["MCP-1", "GENE_OR_GENE_PRODUCT", 223, 228], ["MCP", "PROTEIN", 105, 108], ["MCP-1 mRNA", "RNA", 223, 233], ["cytokine", "PROTEIN", 289, 297], ["pigs", "SPECIES", 36, 40], ["B. bronchiseptica", "SPECIES", 59, 76], ["pigs", "SPECIES", 157, 161], ["pigs", "SPECIES", 36, 40], ["PRCV", "SPECIES", 51, 55], ["B. bronchiseptica", "SPECIES", 59, 76], ["pigs", "SPECIES", 157, 161], ["PRCV", "TREATMENT", 51, 55], ["B. bronchiseptica", "PROBLEM", 59, 76], ["an increase in MCP", "PROBLEM", 90, 108], ["MCP", "TEST", 223, 226], ["this cytokine", "PROBLEM", 284, 297], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["MCP", "OBSERVATION_MODIFIER", 105, 108], ["greater", "OBSERVATION_MODIFIER", 203, 210], ["increase", "OBSERVATION_MODIFIER", 211, 219], ["infected", "OBSERVATION", 350, 358]]], ["These three pigs had the largest percentage of lung affected by macroscopic lesions, more severe microscopic lesions, and both B. bronchiseptica and PRCV were isolated from the lung, while the one pig that did not have an increase in MCP-1 transcript had the fewest lesions and no B. bronchiseptica or PRCV isolated from its lungs.", [["lung", "ANATOMY", 47, 51], ["lesions", "ANATOMY", 76, 83], ["lesions", "ANATOMY", 109, 116], ["PRCV", "ANATOMY", 149, 153], ["lung", "ANATOMY", 177, 181], ["lesions", "ANATOMY", 266, 273], ["lungs", "ANATOMY", 325, 330], ["pigs", "ORGANISM", 12, 16], ["lung", "ORGAN", 47, 51], ["macroscopic lesions", "PATHOLOGICAL_FORMATION", 64, 83], ["lesions", "PATHOLOGICAL_FORMATION", 109, 116], ["B. bronchiseptica", "ORGANISM", 127, 144], ["PRCV", "CANCER", 149, 153], ["lung", "ORGAN", 177, 181], ["pig", "ORGANISM", 197, 200], ["MCP-1", "GENE_OR_GENE_PRODUCT", 234, 239], ["lesions", "PATHOLOGICAL_FORMATION", 266, 273], ["B. bronchiseptica", "ORGANISM", 281, 298], ["PRCV", "ORGANISM", 302, 306], ["lungs", "ORGAN", 325, 330], ["MCP", "PROTEIN", 234, 237], ["pigs", "SPECIES", 12, 16], ["B. bronchiseptica", "SPECIES", 127, 144], ["pig", "SPECIES", 197, 200], ["B. bronchiseptica", "SPECIES", 281, 298], ["B. bronchiseptica", "SPECIES", 127, 144], ["PRCV", "SPECIES", 149, 153], ["pig", "SPECIES", 197, 200], ["B. bronchiseptica", "SPECIES", 281, 298], ["PRCV", "SPECIES", 302, 306], ["macroscopic lesions", "PROBLEM", 64, 83], ["more severe microscopic lesions", "PROBLEM", 85, 116], ["B. bronchiseptica and PRCV", "PROBLEM", 127, 153], ["MCP", "TEST", 234, 237], ["the fewest lesions", "PROBLEM", 255, 273], ["B. bronchiseptica", "PROBLEM", 281, 298], ["PRCV", "PROBLEM", 302, 306], ["largest", "OBSERVATION_MODIFIER", 25, 32], ["percentage", "OBSERVATION_MODIFIER", 33, 43], ["lung", "ANATOMY", 47, 51], ["macroscopic", "OBSERVATION_MODIFIER", 64, 75], ["lesions", "OBSERVATION", 76, 83], ["more", "OBSERVATION_MODIFIER", 85, 89], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["microscopic", "OBSERVATION_MODIFIER", 97, 108], ["lesions", "OBSERVATION", 109, 116], ["bronchiseptica", "OBSERVATION", 130, 144], ["lung", "ANATOMY", 177, 181], ["increase", "OBSERVATION_MODIFIER", 222, 230], ["MCP", "OBSERVATION_MODIFIER", 234, 237], ["fewest", "OBSERVATION_MODIFIER", 259, 265], ["lesions", "OBSERVATION", 266, 273], ["no", "UNCERTAINTY", 278, 280], ["bronchiseptica", "OBSERVATION", 284, 298], ["lungs", "ANATOMY", 325, 330]]], ["At 10 days post-infection, the majority of coinfected pigs had increased mRNA levels for all the proinflammatory cytokines tested except TNF-alpha, for which all 4 pigs had a greater than 2-fold reduction of mRNA.", [["pigs", "ORGANISM", 54, 58], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 137, 146], ["pigs", "ORGANISM", 164, 168], ["proinflammatory cytokines", "PROTEIN", 97, 122], ["TNF-alpha", "PROTEIN", 137, 146], ["mRNA", "RNA", 208, 212], ["pigs", "SPECIES", 54, 58], ["pigs", "SPECIES", 164, 168], ["pigs", "SPECIES", 54, 58], ["pigs", "SPECIES", 164, 168], ["coinfected pigs", "TREATMENT", 43, 58], ["increased mRNA levels", "PROBLEM", 63, 84], ["the proinflammatory cytokines", "TEST", 93, 122], ["TNF", "TEST", 137, 140]]], ["The coinfected group had significantly less TNF-alpha transcript and significantly more MCP-1 transcript, than the group infected with B. bronchi- septica alone.", [["TNF-alpha", "GENE_OR_GENE_PRODUCT", 44, 53], ["MCP-1", "GENE_OR_GENE_PRODUCT", 88, 93], ["B. bronchi- septica", "ORGANISM", 135, 154], ["TNF-alpha transcript", "RNA", 44, 64], ["MCP", "PROTEIN", 88, 91], ["B. bronchi- septica", "SPECIES", 135, 154], ["B. bronchi- septica", "SPECIES", 135, 154], ["MCP", "TEST", 88, 91], ["coinfected", "OBSERVATION", 4, 14], ["alpha transcript", "OBSERVATION_MODIFIER", 48, 64], ["bronchi", "ANATOMY", 138, 145]]], ["The coinfected group had close to significantly greater (0.5 p 0.1) IL-6, MCP-1, IL-8 and IL-1beta transcripts, than the group infected with PRCV alone.", [["PRCV", "CHEMICAL", 141, 145], ["PRCV", "CHEMICAL", 141, 145], ["IL-6", "GENE_OR_GENE_PRODUCT", 68, 72], ["MCP-1", "GENE_OR_GENE_PRODUCT", 74, 79], ["IL-8", "GENE_OR_GENE_PRODUCT", 81, 85], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 90, 98], ["PRCV", "SIMPLE_CHEMICAL", 141, 145], ["PRCV", "SPECIES", 141, 145], ["IL", "TEST", 68, 70], ["MCP", "TEST", 74, 77], ["IL", "TEST", 81, 83], ["IL-1beta transcripts", "TREATMENT", 90, 110], ["PRCV", "TREATMENT", 141, 145], ["coinfected", "OBSERVATION", 4, 14]]], ["Overall, at 10 days post-infection more coinfected pigs responded with at least a 2-fold increase of any cytokine compared to pigs infected with a single pathogen.", [["pigs", "ORGANISM", 51, 55], ["pigs", "ORGANISM", 126, 130], ["cytokine", "PROTEIN", 105, 113], ["pigs", "SPECIES", 51, 55], ["pigs", "SPECIES", 126, 130], ["pigs", "SPECIES", 51, 55], ["pigs", "SPECIES", 126, 130], ["any cytokine", "TREATMENT", 101, 113], ["a single pathogen", "PROBLEM", 145, 162]]], ["For all timepoints, coinfected pigs exhibited enhanced mRNA levels of proinflammatory cytokines 60% of the time as compared to 23% for pigs infected with B. bronchiseptica alone and 13% for pigs infected with PRCV alone.", [["PRCV", "CHEMICAL", 209, 213], ["pigs", "ORGANISM", 31, 35], ["pigs", "ORGANISM", 135, 139], ["B. bronchiseptica", "ORGANISM", 154, 171], ["pigs", "ORGANISM", 190, 194], ["proinflammatory cytokines", "PROTEIN", 70, 95], ["pigs", "SPECIES", 31, 35], ["pigs", "SPECIES", 135, 139], ["B. bronchiseptica", "SPECIES", 154, 171], ["pigs", "SPECIES", 190, 194], ["pigs", "SPECIES", 31, 35], ["pigs", "SPECIES", 135, 139], ["B. bronchiseptica", "SPECIES", 154, 171], ["pigs", "SPECIES", 190, 194], ["PRCV", "SPECIES", 209, 213], ["coinfected pigs", "TREATMENT", 20, 35], ["proinflammatory cytokines", "TEST", 70, 95], ["B. bronchiseptica", "TREATMENT", 154, 171], ["PRCV", "TREATMENT", 209, 213], ["proinflammatory", "OBSERVATION_MODIFIER", 70, 85]]], ["With the exception of TNF-alpha at 10 days post-infection, coinfected pigs also had no apparent down regulation of examined cytokines.DiscussionBecause of its unique role in gas exchange and constant exposure to the environment, the respiratory tract is one of the most common sights for pathogen entry.", [["respiratory tract", "ANATOMY", 233, 250], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 22, 31], ["pigs", "ORGANISM", 70, 74], ["respiratory tract", "ORGANISM_SUBDIVISION", 233, 250], ["TNF-alpha", "PROTEIN", 22, 31], ["cytokines", "PROTEIN", 124, 133], ["pigs", "SPECIES", 70, 74], ["pigs", "SPECIES", 70, 74], ["TNF", "PROBLEM", 22, 25], ["gas exchange", "TREATMENT", 174, 186], ["the respiratory tract", "PROBLEM", 229, 250], ["TNF", "OBSERVATION", 22, 25], ["no apparent", "UNCERTAINTY", 84, 95], ["gas exchange", "OBSERVATION", 174, 186], ["respiratory tract", "ANATOMY", 233, 250]]], ["Although any pathogen by itself may cause disease, it is not uncommon for multiple agents to be involved in respiratory disease.", [["respiratory", "ANATOMY", 108, 119], ["respiratory disease", "DISEASE", 108, 127], ["disease", "PROBLEM", 42, 49], ["respiratory disease", "PROBLEM", 108, 127], ["respiratory disease", "OBSERVATION", 108, 127]]], ["Interactions among multiple pathogens often appear to generate a more severe or chronic outcome than is observed with the individual pathogens by themselves, but little is known about the specific interactions.", [["multiple pathogens", "PROBLEM", 19, 37], ["chronic", "OBSERVATION_MODIFIER", 80, 87]]], ["In both experiments performed in this study, coinfection with PRCV and B. bronchiseptica resulted in a higher percentage of the lung, on average, affected by pneumonia and an increased severity of microscopic lesions of pneumonia as compared to pigs infected with either pathogen by itself.", [["lung", "ANATOMY", 128, 132], ["lesions", "ANATOMY", 209, 216], ["coinfection", "DISEASE", 45, 56], ["pneumonia", "DISEASE", 158, 167], ["pneumonia", "DISEASE", 220, 229], ["PRCV", "ORGANISM", 62, 66], ["B. bronchiseptica", "ORGANISM", 71, 88], ["lung", "ORGAN", 128, 132], ["microscopic lesions", "PATHOLOGICAL_FORMATION", 197, 216], ["pigs", "ORGANISM", 245, 249], ["B. bronchiseptica", "SPECIES", 71, 88], ["pigs", "SPECIES", 245, 249], ["PRCV", "SPECIES", 62, 66], ["B. bronchiseptica", "SPECIES", 71, 88], ["pigs", "SPECIES", 245, 249], ["this study", "TEST", 33, 43], ["coinfection", "PROBLEM", 45, 56], ["PRCV", "TREATMENT", 62, 66], ["B. bronchiseptica", "PROBLEM", 71, 88], ["pneumonia", "PROBLEM", 158, 167], ["microscopic lesions", "PROBLEM", 197, 216], ["pneumonia", "PROBLEM", 220, 229], ["higher", "OBSERVATION_MODIFIER", 103, 109], ["percentage", "OBSERVATION_MODIFIER", 110, 120], ["lung", "ANATOMY", 128, 132], ["pneumonia", "OBSERVATION", 158, 167], ["increased", "OBSERVATION_MODIFIER", 175, 184], ["severity", "OBSERVATION_MODIFIER", 185, 193], ["microscopic", "OBSERVATION_MODIFIER", 197, 208], ["lesions", "OBSERVATION", 209, 216], ["pneumonia", "OBSERVATION", 220, 229], ["pathogen", "OBSERVATION", 271, 279]]], ["The increased severity of gross and microscopic lesions at day 1 post-infection indicate that lesions developed earlier in coinfected pigs than in pigs infected with either agent alone.", [["gross", "ANATOMY", 26, 31], ["lesions", "ANATOMY", 48, 55], ["lesions", "ANATOMY", 94, 101], ["infection", "DISEASE", 70, 79], ["lesions", "PATHOLOGICAL_FORMATION", 48, 55], ["lesions", "PATHOLOGICAL_FORMATION", 94, 101], ["pigs", "ORGANISM", 134, 138], ["pigs", "ORGANISM", 147, 151], ["pigs", "SPECIES", 134, 138], ["pigs", "SPECIES", 147, 151], ["pigs", "SPECIES", 134, 138], ["pigs", "SPECIES", 147, 151], ["The increased severity of gross and microscopic lesions", "PROBLEM", 0, 55], ["infection", "PROBLEM", 70, 79], ["lesions", "PROBLEM", 94, 101], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["severity", "OBSERVATION_MODIFIER", 14, 22], ["gross", "OBSERVATION_MODIFIER", 26, 31], ["microscopic", "OBSERVATION_MODIFIER", 36, 47], ["lesions", "OBSERVATION", 48, 55], ["infection", "OBSERVATION", 70, 79], ["lesions", "OBSERVATION", 94, 101]]], ["In addition, the increased severity of lesions in coinfected pigs at day 10 post-infection, a time when lesions should be resolving, suggests there was also a delay in resolution of the lesions compared to pigs infected with virus or bacteria alone.", [["lesions", "ANATOMY", 39, 46], ["lesions", "ANATOMY", 104, 111], ["lesions", "ANATOMY", 186, 193], ["infection", "DISEASE", 81, 90], ["lesions", "PATHOLOGICAL_FORMATION", 39, 46], ["pigs", "ORGANISM", 61, 65], ["lesions", "PATHOLOGICAL_FORMATION", 104, 111], ["lesions", "PATHOLOGICAL_FORMATION", 186, 193], ["pigs", "ORGANISM", 206, 210], ["pigs", "SPECIES", 61, 65], ["pigs", "SPECIES", 206, 210], ["pigs", "SPECIES", 61, 65], ["pigs", "SPECIES", 206, 210], ["the increased severity of lesions", "PROBLEM", 13, 46], ["coinfected pigs", "TREATMENT", 50, 65], ["infection", "PROBLEM", 81, 90], ["lesions", "PROBLEM", 104, 111], ["the lesions", "PROBLEM", 182, 193], ["virus", "PROBLEM", 225, 230], ["bacteria", "PROBLEM", 234, 242], ["increased", "OBSERVATION_MODIFIER", 17, 26], ["severity", "OBSERVATION_MODIFIER", 27, 35], ["lesions", "OBSERVATION", 39, 46], ["coinfected", "OBSERVATION_MODIFIER", 50, 60], ["pigs", "OBSERVATION_MODIFIER", 61, 65], ["infection", "OBSERVATION", 81, 90], ["lesions", "OBSERVATION", 104, 111], ["resolution", "OBSERVATION_MODIFIER", 168, 178], ["lesions", "OBSERVATION", 186, 193]]], ["It is unlikely that lesions observed in coinfected animals were solely an additive effect, since the percentage of lung affected in the coinfected group was greater than the combined effect of the single infected groups.", [["lesions", "ANATOMY", 20, 27], ["lung", "ANATOMY", 115, 119], ["coinfected", "DISEASE", 136, 146], ["lesions", "PATHOLOGICAL_FORMATION", 20, 27], ["lung", "ORGAN", 115, 119], ["lesions", "PROBLEM", 20, 27], ["the single infected groups", "PROBLEM", 193, 219], ["unlikely", "UNCERTAINTY", 6, 14], ["lesions", "OBSERVATION", 20, 27], ["lung", "ANATOMY", 115, 119], ["affected", "OBSERVATION", 120, 128], ["coinfected", "OBSERVATION", 136, 146], ["infected", "OBSERVATION", 204, 212]]], ["Furthermore, microscopic lesions in coinfected pigs were not just a combination of those induced by PRCV or B. bronchiseptica alone, as new lesions not observed in pigs infected with either pathogen alone were observed.DiscussionThe isolation of both B. bronchiseptica and PRCV from the lungs of coinfected pigs was greater, as compared to singly infected pigs, in the second experiment.", [["lesions", "ANATOMY", 25, 32], ["lesions", "ANATOMY", 140, 147], ["lungs", "ANATOMY", 287, 292], ["PRCV", "CHEMICAL", 100, 104], ["lesions", "PATHOLOGICAL_FORMATION", 25, 32], ["pigs", "ORGANISM", 47, 51], ["PRCV", "SIMPLE_CHEMICAL", 100, 104], ["B. bronchiseptica", "ORGANISM", 108, 125], ["lesions", "PATHOLOGICAL_FORMATION", 140, 147], ["pigs", "ORGANISM", 164, 168], ["B. bronchiseptica", "ORGANISM", 251, 268], ["PRCV", "ORGANISM", 273, 277], ["lungs", "ORGAN", 287, 292], ["pigs", "ORGANISM", 307, 311], ["pigs", "ORGANISM", 356, 360], ["pigs", "SPECIES", 47, 51], ["B. bronchiseptica", "SPECIES", 108, 125], ["pigs", "SPECIES", 164, 168], ["B. bronchiseptica", "SPECIES", 251, 268], ["pigs", "SPECIES", 307, 311], ["pigs", "SPECIES", 356, 360], ["pigs", "SPECIES", 47, 51], ["PRCV", "SPECIES", 100, 104], ["B. bronchiseptica", "SPECIES", 108, 125], ["pigs", "SPECIES", 164, 168], ["B. bronchiseptica", "SPECIES", 251, 268], ["PRCV", "SPECIES", 273, 277], ["pigs", "SPECIES", 307, 311], ["pigs", "SPECIES", 356, 360], ["microscopic lesions in coinfected pigs", "PROBLEM", 13, 51], ["B. bronchiseptica", "PROBLEM", 108, 125], ["new lesions", "PROBLEM", 136, 147], ["pathogen", "PROBLEM", 190, 198], ["both B. bronchiseptica", "PROBLEM", 246, 268], ["PRCV", "TREATMENT", 273, 277], ["coinfected pigs", "PROBLEM", 296, 311], ["microscopic", "OBSERVATION_MODIFIER", 13, 24], ["lesions", "OBSERVATION", 25, 32], ["coinfected pigs", "OBSERVATION", 36, 51], ["new", "OBSERVATION_MODIFIER", 136, 139], ["lesions", "OBSERVATION", 140, 147], ["bronchiseptica", "OBSERVATION", 254, 268], ["lungs", "ANATOMY", 287, 292], ["coinfected", "OBSERVATION", 296, 306], ["greater", "OBSERVATION_MODIFIER", 316, 323], ["infected", "OBSERVATION_MODIFIER", 347, 355], ["pigs", "OBSERVATION", 356, 360]]], ["These results may help explain the increased severity of lesions seen in coinfected pigs.", [["lesions", "ANATOMY", 57, 64], ["lesions", "PATHOLOGICAL_FORMATION", 57, 64], ["pigs", "ORGANISM", 84, 88], ["pigs", "SPECIES", 84, 88], ["pigs", "SPECIES", 84, 88], ["the increased severity of lesions", "PROBLEM", 31, 64], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["severity", "OBSERVATION_MODIFIER", 45, 53], ["lesions", "OBSERVATION", 57, 64], ["coinfected pigs", "OBSERVATION", 73, 88]]], ["This was not the case in the first experiment, where the isolation rate was roughly the same for both single and dual infected pigs.", [["pigs", "ORGANISM", 127, 131], ["pigs", "SPECIES", 127, 131], ["pigs", "SPECIES", 127, 131], ["the isolation rate", "TEST", 53, 71], ["dual infected pigs", "TREATMENT", 113, 131], ["infected pigs", "OBSERVATION", 118, 131]]], ["However, there were only minor, if any, gross or microscopic lesions that accompanied the isolation of B. bronchiseptica from the pigs infected with bacteria alone in the first experiment.", [["lesions", "ANATOMY", 61, 68], ["lesions", "PATHOLOGICAL_FORMATION", 61, 68], ["B. bronchiseptica", "ORGANISM", 103, 120], ["pigs", "ORGANISM", 130, 134], ["B. bronchiseptica", "SPECIES", 103, 120], ["pigs", "SPECIES", 130, 134], ["B. bronchiseptica", "SPECIES", 103, 120], ["pigs", "SPECIES", 130, 134], ["any, gross or microscopic lesions", "PROBLEM", 35, 68], ["B. bronchiseptica", "PROBLEM", 103, 120], ["bacteria", "PROBLEM", 149, 157], ["minor", "OBSERVATION_MODIFIER", 25, 30], ["gross", "OBSERVATION_MODIFIER", 40, 45], ["microscopic", "OBSERVATION_MODIFIER", 49, 60], ["lesions", "OBSERVATION", 61, 68], ["bronchiseptica", "OBSERVATION", 106, 120], ["bacteria", "OBSERVATION_MODIFIER", 149, 157]]], ["Although isolation of B. bronchiseptica from the turbinates and trachea is common in the age of pig used for these experiments, isolation from the lung in pigs challenged with B. bronchiseptica alone is not typical of prior experiments with this isolate (Brockmeier et al., 2000) .DiscussionThere was evidence of ascarid infection and migration through the liver and lung of the pigs in the first experiment.", [["turbinates", "ANATOMY", 49, 59], ["trachea", "ANATOMY", 64, 71], ["lung", "ANATOMY", 147, 151], ["liver", "ANATOMY", 357, 362], ["lung", "ANATOMY", 367, 371], ["infection", "DISEASE", 321, 330], ["B. bronchiseptica", "ORGANISM", 22, 39], ["turbinates", "ORGAN", 49, 59], ["trachea", "ORGAN", 64, 71], ["pig", "ORGANISM", 96, 99], ["lung", "ORGAN", 147, 151], ["pigs", "ORGANISM", 155, 159], ["B. bronchiseptica", "ORGANISM", 176, 193], ["liver", "ORGAN", 357, 362], ["lung", "ORGAN", 367, 371], ["pigs", "ORGANISM", 379, 383], ["B. bronchiseptica", "SPECIES", 22, 39], ["pig", "SPECIES", 96, 99], ["pigs", "SPECIES", 155, 159], ["B. bronchiseptica", "SPECIES", 176, 193], ["pigs", "SPECIES", 379, 383], ["B. bronchiseptica", "SPECIES", 22, 39], ["pig", "SPECIES", 96, 99], ["pigs", "SPECIES", 155, 159], ["B. bronchiseptica", "SPECIES", 176, 193], ["B. bronchiseptica from the turbinates", "PROBLEM", 22, 59], ["these experiments", "TREATMENT", 109, 126], ["isolation", "TREATMENT", 128, 137], ["ascarid infection", "PROBLEM", 313, 330], ["bronchiseptica", "OBSERVATION", 25, 39], ["turbinates", "ANATOMY", 49, 59], ["trachea", "ANATOMY", 64, 71], ["common", "OBSERVATION_MODIFIER", 75, 81], ["lung", "ANATOMY", 147, 151], ["evidence of", "UNCERTAINTY", 301, 312], ["ascarid", "OBSERVATION_MODIFIER", 313, 320], ["infection", "OBSERVATION", 321, 330], ["migration", "OBSERVATION_MODIFIER", 335, 344], ["liver", "ANATOMY", 357, 362], ["lung", "ANATOMY", 367, 371], ["pigs", "OBSERVATION_MODIFIER", 379, 383]]], ["Previous studies have indicated that parasitic infections can alter the response to bacterial and viral infections.", [["parasitic infections", "DISEASE", 37, 57], ["bacterial and viral infections", "DISEASE", 84, 114], ["Previous studies", "TEST", 0, 16], ["parasitic infections", "PROBLEM", 37, 57], ["bacterial and viral infections", "PROBLEM", 84, 114], ["parasitic", "OBSERVATION_MODIFIER", 37, 46], ["infections", "OBSERVATION", 47, 57], ["bacterial", "OBSERVATION_MODIFIER", 84, 93], ["viral", "OBSERVATION_MODIFIER", 98, 103], ["infections", "OBSERVATION", 104, 114]]], ["For example, aerosol exposure to P. multocida in mice with migrating Ascaris suum larvae developed more severe pneumonia than Ascaris free mice (Tjornehoj et al., 1992) , and coinfection with Schistosoma mansoni and vaccinia virus resulted in a decreased antiviral Th1 response and delayed viral clearance in mice (Actor et al., 1993) .", [["pneumonia", "DISEASE", 111, 120], ["coinfection", "DISEASE", 175, 186], ["Schistosoma mansoni", "DISEASE", 192, 211], ["P. multocida", "ORGANISM", 33, 45], ["mice", "ORGANISM", 49, 53], ["Ascaris suum", "ORGANISM", 69, 81], ["larvae", "ORGANISM", 82, 88], ["Ascaris free mice", "ORGANISM", 126, 143], ["Schistosoma mansoni", "ORGANISM", 192, 211], ["vaccinia virus", "ORGANISM", 216, 230], ["mice", "ORGANISM", 309, 313], ["P. multocida", "SPECIES", 33, 45], ["mice", "SPECIES", 49, 53], ["Ascaris suum", "SPECIES", 69, 81], ["mice", "SPECIES", 139, 143], ["Schistosoma mansoni", "SPECIES", 192, 211], ["vaccinia virus", "SPECIES", 216, 230], ["mice", "SPECIES", 309, 313], ["P. multocida", "SPECIES", 33, 45], ["mice", "SPECIES", 49, 53], ["Ascaris suum", "SPECIES", 69, 81], ["mice", "SPECIES", 139, 143], ["Schistosoma mansoni", "SPECIES", 192, 211], ["vaccinia virus", "SPECIES", 216, 230], ["mice", "SPECIES", 309, 313], ["aerosol exposure", "TREATMENT", 13, 29], ["multocida", "PROBLEM", 36, 45], ["migrating Ascaris suum larvae", "PROBLEM", 59, 88], ["more severe pneumonia", "PROBLEM", 99, 120], ["coinfection", "PROBLEM", 175, 186], ["Schistosoma mansoni", "PROBLEM", 192, 211], ["vaccinia virus", "PROBLEM", 216, 230], ["a decreased antiviral Th1 response", "PROBLEM", 243, 277], ["delayed viral clearance", "PROBLEM", 282, 305], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["pneumonia", "OBSERVATION", 111, 120], ["coinfection", "OBSERVATION", 175, 186], ["Schistosoma mansoni", "OBSERVATION", 192, 211], ["decreased", "OBSERVATION_MODIFIER", 245, 254], ["antiviral Th1", "OBSERVATION", 255, 268]]], ["A. suum, the probable cause of the lesions seen in the pigs in the first experiment, has also been shown to skew the adaptive immune response to a Th2 type response (Dawson et al., 2005) .", [["lesions", "ANATOMY", 35, 42], ["A. suum", "ORGANISM", 0, 7], ["lesions", "PATHOLOGICAL_FORMATION", 35, 42], ["pigs", "ORGANISM", 55, 59], ["A. suum", "SPECIES", 0, 7], ["pigs", "SPECIES", 55, 59], ["A. suum", "SPECIES", 0, 7], ["the lesions", "PROBLEM", 31, 42], ["probable cause", "UNCERTAINTY", 13, 27], ["lesions", "OBSERVATION", 35, 42]]], ["Thus, the increased isolation of B. bronchiseptica and PRCV, the appearance of mild microscopic lesions in control pigs, and the increased severity of microscopic lesions in coinfected pigs that were all seen in the first experiment as compared to the second, may be attributed to the resolving ascarid migration that was evident in these pigs.", [["lesions", "ANATOMY", 96, 103], ["lesions", "ANATOMY", 163, 170], ["B. bronchiseptica", "ORGANISM", 33, 50], ["PRCV", "CANCER", 55, 59], ["lesions", "PATHOLOGICAL_FORMATION", 96, 103], ["pigs", "ORGANISM", 115, 119], ["microscopic lesions", "PATHOLOGICAL_FORMATION", 151, 170], ["pigs", "ORGANISM", 185, 189], ["pigs", "ORGANISM", 339, 343], ["B. bronchiseptica", "SPECIES", 33, 50], ["pigs", "SPECIES", 115, 119], ["pigs", "SPECIES", 185, 189], ["pigs", "SPECIES", 339, 343], ["B. bronchiseptica", "SPECIES", 33, 50], ["PRCV", "SPECIES", 55, 59], ["pigs", "SPECIES", 115, 119], ["pigs", "SPECIES", 185, 189], ["B. bronchiseptica and PRCV", "PROBLEM", 33, 59], ["mild microscopic lesions in control pigs", "PROBLEM", 79, 119], ["microscopic lesions", "PROBLEM", 151, 170], ["coinfected pigs", "PROBLEM", 174, 189], ["the resolving ascarid migration", "PROBLEM", 281, 312], ["increased", "OBSERVATION_MODIFIER", 10, 19], ["isolation", "OBSERVATION_MODIFIER", 20, 29], ["bronchiseptica", "OBSERVATION_MODIFIER", 36, 50], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["microscopic", "OBSERVATION_MODIFIER", 84, 95], ["lesions", "OBSERVATION", 96, 103], ["increased", "OBSERVATION_MODIFIER", 129, 138], ["severity", "OBSERVATION_MODIFIER", 139, 147], ["microscopic", "OBSERVATION_MODIFIER", 151, 162], ["lesions", "OBSERVATION", 163, 170], ["coinfected pigs", "OBSERVATION", 174, 189], ["may be attributed to", "UNCERTAINTY", 260, 280], ["resolving", "OBSERVATION_MODIFIER", 285, 294], ["ascarid", "OBSERVATION_MODIFIER", 295, 302], ["migration", "OBSERVATION", 303, 312]]], ["These results illustrate the difficulties in reproducing the effects of experimental combined infections in out bred conventionally raised animals such as pigs.DiscussionAlveolar macrophages are first-responders during pulmonary disease and take action against invading pathogens through the production of proinflammatory cytokines and chemokines.", [["Alveolar macrophages", "ANATOMY", 170, 190], ["pulmonary", "ANATOMY", 219, 228], ["infections", "DISEASE", 94, 104], ["pulmonary disease", "DISEASE", 219, 236], ["pigs", "ORGANISM", 155, 159], ["Alveolar macrophages", "CELL", 170, 190], ["pulmonary", "ORGAN", 219, 228], ["Alveolar macrophages", "CELL_TYPE", 170, 190], ["proinflammatory cytokines", "PROTEIN", 306, 331], ["chemokines", "PROTEIN", 336, 346], ["pigs", "SPECIES", 155, 159], ["pigs", "SPECIES", 155, 159], ["experimental combined infections", "PROBLEM", 72, 104], ["Alveolar macrophages", "PROBLEM", 170, 190], ["pulmonary disease", "PROBLEM", 219, 236], ["invading pathogens", "PROBLEM", 261, 279], ["proinflammatory cytokines", "TREATMENT", 306, 331], ["chemokines", "TREATMENT", 336, 346], ["infections", "OBSERVATION", 94, 104], ["Alveolar macrophages", "OBSERVATION", 170, 190], ["pulmonary", "ANATOMY", 219, 228], ["disease", "OBSERVATION", 229, 236], ["proinflammatory cytokines", "OBSERVATION", 306, 331]]], ["In addition, alveolar macrophages can recruit effector cells to the site of infection and act as antigen-presenting cells.", [["alveolar macrophages", "ANATOMY", 13, 33], ["effector cells", "ANATOMY", 46, 60], ["site", "ANATOMY", 68, 72], ["cells", "ANATOMY", 116, 121], ["infection", "DISEASE", 76, 85], ["alveolar macrophages", "CELL", 13, 33], ["effector cells", "CELL", 46, 60], ["cells", "CELL", 116, 121], ["alveolar macrophages", "CELL_TYPE", 13, 33], ["effector cells", "CELL_TYPE", 46, 60], ["antigen-presenting cells", "CELL_TYPE", 97, 121], ["alveolar macrophages", "PROBLEM", 13, 33], ["effector cells", "PROBLEM", 46, 60], ["infection", "PROBLEM", 76, 85], ["alveolar macrophages", "OBSERVATION", 13, 33], ["effector cells", "OBSERVATION", 46, 60], ["infection", "OBSERVATION", 76, 85]]], ["As well as pathogen burden, another explanation for the increased disease severity observed in coinfected pigs may be, in part, the result of enhanced proinflammatory cytokine expression in alveolar macrophages.", [["alveolar macrophages", "ANATOMY", 190, 210], ["pigs", "ORGANISM", 106, 110], ["alveolar macrophages", "CELL", 190, 210], ["proinflammatory cytokine", "PROTEIN", 151, 175], ["alveolar macrophages", "CELL_TYPE", 190, 210], ["pigs", "SPECIES", 106, 110], ["pigs", "SPECIES", 106, 110], ["pathogen burden", "PROBLEM", 11, 26], ["the increased disease severity", "PROBLEM", 52, 82], ["enhanced proinflammatory cytokine expression in alveolar macrophages", "PROBLEM", 142, 210], ["pathogen", "OBSERVATION_MODIFIER", 11, 19], ["burden", "OBSERVATION", 20, 26], ["increased", "OBSERVATION_MODIFIER", 56, 65], ["disease", "OBSERVATION", 66, 73], ["proinflammatory cytokine expression", "OBSERVATION", 151, 186], ["alveolar macrophages", "OBSERVATION", 190, 210]]], ["Although cytokines were only examined at the transcriptional level, and enhanced transcription does not assure the cytokines are secreted and functional, an increase in transcription of at least one proinflammatory cytokine was detected in 100% of the coinfected pigs at each of the various time points, whereas only 50% of the pigs from each of the groups infected with a single agent responded.", [["pigs", "ORGANISM", 263, 267], ["pigs", "ORGANISM", 328, 332], ["cytokines", "PROTEIN", 9, 18], ["cytokines", "PROTEIN", 115, 124], ["proinflammatory cytokine", "PROTEIN", 199, 223], ["pigs", "SPECIES", 263, 267], ["pigs", "SPECIES", 328, 332], ["pigs", "SPECIES", 263, 267], ["pigs", "SPECIES", 328, 332], ["cytokines", "PROBLEM", 9, 18], ["a single agent", "TREATMENT", 371, 385], ["increase", "OBSERVATION_MODIFIER", 157, 165], ["proinflammatory", "OBSERVATION_MODIFIER", 199, 214], ["coinfected", "OBSERVATION", 252, 262], ["infected", "OBSERVATION", 357, 365]]], ["Quantitatively, IL-6 and MCP-1 showed the largest transcriptional changes in coinfected pigs when compared to pigs infected with either agent alone.DiscussionIn general, pigs infected with B. bronchiseptica alone had an increase of mRNA of all cytokines tested at day 1 post-infection, even though no lesions were seen nor was bacteria recovered from the samples of lung tested.", [["lesions", "ANATOMY", 301, 308], ["samples", "ANATOMY", 355, 362], ["lung", "ANATOMY", 366, 370], ["infection", "DISEASE", 275, 284], ["IL-6", "GENE_OR_GENE_PRODUCT", 16, 20], ["MCP-1", "GENE_OR_GENE_PRODUCT", 25, 30], ["pigs", "ORGANISM", 88, 92], ["pigs", "ORGANISM", 110, 114], ["pigs", "ORGANISM", 170, 174], ["B. bronchiseptica", "ORGANISM", 189, 206], ["lesions", "PATHOLOGICAL_FORMATION", 301, 308], ["lung", "ORGAN", 366, 370], ["IL-6", "PROTEIN", 16, 20], ["MCP-1", "PROTEIN", 25, 30], ["mRNA", "RNA", 232, 236], ["cytokines", "PROTEIN", 244, 253], ["pigs", "SPECIES", 88, 92], ["pigs", "SPECIES", 110, 114], ["pigs", "SPECIES", 170, 174], ["B. bronchiseptica", "SPECIES", 189, 206], ["pigs", "SPECIES", 88, 92], ["pigs", "SPECIES", 110, 114], ["pigs", "SPECIES", 170, 174], ["B. bronchiseptica", "SPECIES", 189, 206], ["Quantitatively", "TEST", 0, 14], ["IL", "TEST", 16, 18], ["MCP", "TEST", 25, 28], ["the largest transcriptional changes", "PROBLEM", 38, 73], ["coinfected pigs", "TREATMENT", 77, 92], ["B. bronchiseptica", "TREATMENT", 189, 206], ["all cytokines", "TEST", 240, 253], ["infection", "PROBLEM", 275, 284], ["lesions", "PROBLEM", 301, 308], ["bacteria", "PROBLEM", 327, 335], ["largest", "OBSERVATION_MODIFIER", 42, 49], ["transcriptional changes", "OBSERVATION", 50, 73], ["coinfected pigs", "OBSERVATION", 77, 92], ["increase", "OBSERVATION_MODIFIER", 220, 228], ["infection", "OBSERVATION", 275, 284], ["no", "UNCERTAINTY", 298, 300], ["lesions", "OBSERVATION", 301, 308], ["lung", "ANATOMY", 366, 370]]], ["This was likely an acute response to B. bronchiseptica LPS in the inoculum.", [["LPS", "CHEMICAL", 55, 58], ["B. bronchiseptica", "ORGANISM", 37, 54], ["LPS", "SIMPLE_CHEMICAL", 55, 58], ["B. bronchiseptica", "SPECIES", 37, 54], ["B. bronchiseptica", "SPECIES", 37, 54], ["an acute response", "PROBLEM", 16, 33], ["B. bronchiseptica LPS", "TREATMENT", 37, 58], ["likely", "UNCERTAINTY", 9, 15], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["bronchiseptica LPS", "OBSERVATION", 40, 58], ["inoculum", "OBSERVATION", 66, 74]]], ["Little increase in cytokine transcriptional response was noted after day 1 in these pigs.", [["pigs", "ORGANISM", 84, 88], ["cytokine", "PROTEIN", 19, 27], ["pigs", "SPECIES", 84, 88], ["pigs", "SPECIES", 84, 88], ["Little increase in cytokine transcriptional response", "PROBLEM", 0, 52], ["increase", "OBSERVATION_MODIFIER", 7, 15], ["cytokine transcriptional response", "OBSERVATION", 19, 52]]], ["In fact, at day 4 there appeared to be a down regulation of most of the cytokines examined.", [["cytokines", "PROTEIN", 72, 81], ["the cytokines", "TEST", 68, 81]]], ["It is likely that the bacteria were largely cleared from the lungs of these pigs and few, if any, lesions were seen.", [["lungs", "ANATOMY", 61, 66], ["lesions", "ANATOMY", 98, 105], ["lungs", "ORGAN", 61, 66], ["pigs", "ORGANISM", 76, 80], ["lesions", "PATHOLOGICAL_FORMATION", 98, 105], ["pigs", "SPECIES", 76, 80], ["pigs", "SPECIES", 76, 80], ["the bacteria", "PROBLEM", 18, 30], ["lesions", "PROBLEM", 98, 105], ["is likely", "UNCERTAINTY", 3, 12], ["bacteria", "OBSERVATION", 22, 30], ["lungs", "ANATOMY", 61, 66], ["few", "OBSERVATION_MODIFIER", 85, 88], ["lesions", "OBSERVATION", 98, 105]]], ["The one exception was a pig on day 10 that had significant lung lesions affecting an estimated 11% of the lung and had increased TNF-alpha, IL-6, and MCP-1 mRNA.", [["lung lesions", "ANATOMY", 59, 71], ["lung", "ANATOMY", 106, 110], ["lung lesions", "DISEASE", 59, 71], ["pig", "ORGANISM", 24, 27], ["lung lesions", "PATHOLOGICAL_FORMATION", 59, 71], ["lung", "ORGAN", 106, 110], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 129, 138], ["IL-6", "GENE_OR_GENE_PRODUCT", 140, 144], ["MCP-1", "GENE_OR_GENE_PRODUCT", 150, 155], ["TNF-alpha, IL-6, and MCP-1 mRNA", "RNA", 129, 160], ["pig", "SPECIES", 24, 27], ["pig", "SPECIES", 24, 27], ["significant lung lesions", "PROBLEM", 47, 71], ["increased TNF", "PROBLEM", 119, 132], ["IL", "TEST", 140, 142], ["MCP", "TEST", 150, 153], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["lung", "ANATOMY", 59, 63], ["lesions", "OBSERVATION", 64, 71], ["11%", "OBSERVATION_MODIFIER", 95, 98], ["lung", "ANATOMY", 106, 110], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["TNF", "OBSERVATION_MODIFIER", 129, 132], ["alpha", "OBSERVATION_MODIFIER", 133, 138]]], ["In this regard, at days 4 and 10 post-infection, lesions correlated to increased cytokine responses.", [["lesions", "ANATOMY", 49, 56], ["infection", "DISEASE", 38, 47], ["lesions", "PATHOLOGICAL_FORMATION", 49, 56], ["cytokine", "PROTEIN", 81, 89], ["infection", "PROBLEM", 38, 47], ["lesions", "PROBLEM", 49, 56], ["increased cytokine responses", "PROBLEM", 71, 99], ["infection", "OBSERVATION", 38, 47], ["lesions", "OBSERVATION", 49, 56], ["increased", "OBSERVATION_MODIFIER", 71, 80], ["cytokine responses", "OBSERVATION", 81, 99]]], ["Previous research in mice shows that IL-6 and TNF-alpha are induced in bone marrow derived macrophages 24 h after exposure, as well as in lung homogenates 12 h after exposure, to B. bronchiseptica in a toll-like receptor-4 (TLR4) dependent manner (Mann et al., 2004a) .", [["bone marrow", "ANATOMY", 71, 82], ["macrophages", "ANATOMY", 91, 102], ["lung homogenates", "ANATOMY", 138, 154], ["mice", "ORGANISM", 21, 25], ["IL-6", "GENE_OR_GENE_PRODUCT", 37, 41], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 46, 55], ["bone marrow derived macrophages", "CELL", 71, 102], ["lung", "ORGAN", 138, 142], ["B. bronchiseptica", "ORGANISM", 179, 196], ["toll-like receptor-4", "GENE_OR_GENE_PRODUCT", 202, 222], ["TLR4", "GENE_OR_GENE_PRODUCT", 224, 228], ["IL-6", "PROTEIN", 37, 41], ["TNF-alpha", "PROTEIN", 46, 55], ["bone marrow derived macrophages", "CELL_TYPE", 71, 102], ["TLR4", "PROTEIN", 224, 228], ["mice", "SPECIES", 21, 25], ["B. bronchiseptica", "SPECIES", 179, 196], ["mice", "SPECIES", 21, 25], ["B. bronchiseptica", "SPECIES", 179, 196], ["IL", "TEST", 37, 39], ["TNF", "TEST", 46, 49], ["bone marrow", "PROBLEM", 71, 82], ["bronchiseptica", "PROBLEM", 182, 196], ["alpha", "ANATOMY", 50, 55], ["bone marrow", "ANATOMY", 71, 82], ["lung", "ANATOMY", 138, 142]]], ["Furthermore, this early TNF-alpha response appears vital for limiting the extent of bacterial growth and pneumonia, permitting recovery (Mann et al., 2004b) .DiscussionPigs infected with PRCV alone displayed a limited cytokine response, that was basically restricted to an increase in MCP-1.", [["pneumonia", "DISEASE", 105, 114], ["PRCV", "CHEMICAL", 187, 191], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 24, 33], ["MCP-1", "GENE_OR_GENE_PRODUCT", 285, 290], ["TNF", "PROTEIN", 24, 27], ["PRCV", "PROTEIN", 187, 191], ["cytokine", "PROTEIN", 218, 226], ["MCP", "PROTEIN", 285, 288], ["PRCV", "SPECIES", 187, 191], ["bacterial growth", "PROBLEM", 84, 100], ["pneumonia", "PROBLEM", 105, 114], ["PRCV", "TREATMENT", 187, 191], ["MCP", "TEST", 285, 288], ["bacterial growth", "OBSERVATION", 84, 100], ["pneumonia", "OBSERVATION", 105, 114], ["increase", "OBSERVATION_MODIFIER", 273, 281]]], ["If anything, there appeared to largely be a down regulation of most of the cytokines examined.", [["cytokines", "PROTEIN", 75, 84], ["the cytokines", "TEST", 71, 84]]], ["These results agree with those of a previous study which found no increase in the bioactive levels of TNF-alpha or IL-1 in the BALF of PRCV infected pigs up to 4 days after infection (Van Reeth et al., 1999) .", [["BALF", "ANATOMY", 127, 131], ["infection", "DISEASE", 173, 182], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 102, 111], ["IL-1", "GENE_OR_GENE_PRODUCT", 115, 119], ["BALF", "ORGANISM_SUBSTANCE", 127, 131], ["PRCV", "ORGANISM", 135, 139], ["pigs", "ORGANISM", 149, 153], ["TNF-alpha", "PROTEIN", 102, 111], ["IL-1", "PROTEIN", 115, 119], ["pigs", "SPECIES", 149, 153], ["PRCV", "SPECIES", 135, 139], ["pigs", "SPECIES", 149, 153], ["a previous study", "TEST", 34, 50], ["TNF", "TEST", 102, 105], ["IL", "TEST", 115, 117], ["infection", "PROBLEM", 173, 182], ["no", "UNCERTAINTY", 63, 65], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["bioactive levels", "OBSERVATION", 82, 98], ["TNF", "ANATOMY", 102, 105], ["BALF", "ANATOMY", 127, 131], ["infected", "OBSERVATION", 140, 148]]], ["The results reported here are also similar to a recent report describing responses to SARS coronavirus in humans (Law et al., 2005) .", [["SARS coronavirus", "DISEASE", 86, 102], ["SARS coronavirus", "ORGANISM", 86, 102], ["humans", "ORGANISM", 106, 112], ["humans", "SPECIES", 106, 112], ["SARS coronavirus", "SPECIES", 86, 102], ["humans", "SPECIES", 106, 112], ["SARS coronavirus", "PROBLEM", 86, 102]]], ["Human dendritic cells responded to SARS coronavirus with low expression of the antiviral cytokines (IFN-alpha, IFN-beta, IFN-gamma and IL-12) and proinflammatory cytokines (IL-6 and TNF-alpha), but large increases in CXC chemokines that preferentially act on mononuclear cells (MIP-1a, RANTES, IP-10 and MCP-1).", [["dendritic cells", "ANATOMY", 6, 21], ["mononuclear cells", "ANATOMY", 259, 276], ["SARS coronavirus", "DISEASE", 35, 51], ["Human", "ORGANISM", 0, 5], ["dendritic cells", "CELL", 6, 21], ["SARS coronavirus", "ORGANISM", 35, 51], ["IFN-alpha", "GENE_OR_GENE_PRODUCT", 100, 109], ["IFN-beta", "GENE_OR_GENE_PRODUCT", 111, 119], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 121, 130], ["IL-12", "GENE_OR_GENE_PRODUCT", 135, 140], ["IL-6", "GENE_OR_GENE_PRODUCT", 173, 177], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 182, 191], ["CXC", "GENE_OR_GENE_PRODUCT", 217, 220], ["mononuclear cells", "CELL", 259, 276], ["MIP-1a", "GENE_OR_GENE_PRODUCT", 278, 284], ["RANTES", "GENE_OR_GENE_PRODUCT", 286, 292], ["IP-10", "GENE_OR_GENE_PRODUCT", 294, 299], ["MCP-1", "GENE_OR_GENE_PRODUCT", 304, 309], ["Human dendritic cells", "CELL_TYPE", 0, 21], ["antiviral cytokines", "PROTEIN", 79, 98], ["IFN-alpha, IFN-beta, IFN-gamma and IL-12", "PROTEIN", 100, 140], ["proinflammatory cytokines", "PROTEIN", 146, 171], ["IL-6", "PROTEIN", 173, 177], ["TNF-alpha", "PROTEIN", 182, 191], ["CXC chemokines", "PROTEIN", 217, 231], ["mononuclear cells", "CELL_TYPE", 259, 276], ["MIP", "PROTEIN", 278, 281], ["RANTES", "PROTEIN", 286, 292], ["IP-10", "PROTEIN", 294, 299], ["MCP", "PROTEIN", 304, 307], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["SARS coronavirus", "SPECIES", 35, 51], ["Human dendritic cells", "PROBLEM", 0, 21], ["SARS coronavirus", "PROBLEM", 35, 51], ["the antiviral cytokines", "PROBLEM", 75, 98], ["IFN", "TEST", 100, 103], ["alpha", "TEST", 104, 109], ["IFN", "TEST", 111, 114], ["beta", "TEST", 115, 119], ["IFN", "TEST", 121, 124], ["IL", "TEST", 135, 137], ["proinflammatory cytokines", "TEST", 146, 171], ["IL", "TEST", 173, 175], ["TNF", "TEST", 182, 185], ["large increases in CXC chemokines", "PROBLEM", 198, 231], ["mononuclear cells", "TEST", 259, 276], ["MIP", "TEST", 278, 281], ["RANTES", "TEST", 286, 292], ["IP", "TEST", 294, 296], ["MCP", "TEST", 304, 307], ["dendritic cells", "OBSERVATION", 6, 21], ["low expression", "OBSERVATION_MODIFIER", 57, 71], ["antiviral cytokines", "OBSERVATION", 79, 98], ["proinflammatory cytokines", "ANATOMY", 146, 171], ["large", "OBSERVATION_MODIFIER", 198, 203], ["increases", "OBSERVATION_MODIFIER", 204, 213], ["CXC chemokines", "OBSERVATION", 217, 231]]], ["Of these CXC chemokines, induction was strongest for MCP-1 and IP-10.", [["CXC", "GENE_OR_GENE_PRODUCT", 9, 12], ["MCP-1", "GENE_OR_GENE_PRODUCT", 53, 58], ["IP-10", "GENE_OR_GENE_PRODUCT", 63, 68], ["CXC chemokines", "PROTEIN", 9, 23], ["MCP", "PROTEIN", 53, 56], ["these CXC chemokines", "TEST", 3, 23], ["MCP", "TEST", 53, 56], ["IP", "TEST", 63, 65], ["CXC chemokines", "OBSERVATION", 9, 23]]], ["Additionally, MCP-1 was also found to be elevated in SARS patients as well (Huang et al., 2005) .", [["SARS", "DISEASE", 53, 57], ["MCP-1", "GENE_OR_GENE_PRODUCT", 14, 19], ["patients", "ORGANISM", 58, 66], ["MCP", "PROTEIN", 14, 17], ["patients", "SPECIES", 58, 66], ["MCP", "TEST", 14, 17], ["elevated", "OBSERVATION", 41, 49]]], ["MCP-1 is important for the recruitment and activation of macrophages and has been shown to influence viral load in an influenza model (Dawson et al., 2000) .", [["macrophages", "ANATOMY", 57, 68], ["influenza", "DISEASE", 118, 127], ["MCP-1", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophages", "CELL", 57, 68], ["MCP-1", "PROTEIN", 0, 5], ["macrophages", "CELL_TYPE", 57, 68], ["MCP", "TEST", 0, 3], ["macrophages", "PROBLEM", 57, 68], ["recruitment", "OBSERVATION", 27, 38]]], ["The increase in MCP-1 in 1 pig at day 1 seemed to be positively correlated with microscopic lesions seen in that pig, while at 10 days post-infection the pig with the largest percentage of lung affected had no increase in MCP-1, and the other 3 pigs all had significant increases in this cytokine and little to no lung lesions.", [["lesions", "ANATOMY", 92, 99], ["lung", "ANATOMY", 189, 193], ["lung lesions", "ANATOMY", 314, 326], ["lung lesions", "DISEASE", 314, 326], ["MCP-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["pig", "ORGANISM", 27, 30], ["lesions", "PATHOLOGICAL_FORMATION", 92, 99], ["pig", "ORGANISM", 113, 116], ["pig", "ORGANISM", 154, 157], ["lung", "ORGAN", 189, 193], ["MCP-1", "GENE_OR_GENE_PRODUCT", 222, 227], ["pigs", "ORGANISM", 245, 249], ["lung lesions", "CANCER", 314, 326], ["MCP", "PROTEIN", 16, 19], ["MCP", "PROTEIN", 222, 225], ["cytokine", "PROTEIN", 288, 296], ["pig", "SPECIES", 27, 30], ["pig", "SPECIES", 113, 116], ["pig", "SPECIES", 154, 157], ["pigs", "SPECIES", 245, 249], ["pig", "SPECIES", 27, 30], ["pig", "SPECIES", 113, 116], ["pig", "SPECIES", 154, 157], ["pigs", "SPECIES", 245, 249], ["MCP", "TEST", 16, 19], ["microscopic lesions", "PROBLEM", 80, 99], ["MCP", "TEST", 222, 225], ["this cytokine", "PROBLEM", 283, 296], ["lung lesions", "PROBLEM", 314, 326], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["MCP", "OBSERVATION_MODIFIER", 16, 19], ["lesions", "OBSERVATION", 92, 99], ["largest", "OBSERVATION_MODIFIER", 167, 174], ["percentage", "OBSERVATION_MODIFIER", 175, 185], ["lung", "ANATOMY", 189, 193], ["no", "UNCERTAINTY", 207, 209], ["increase", "OBSERVATION_MODIFIER", 210, 218], ["significant", "OBSERVATION_MODIFIER", 258, 269], ["increases", "OBSERVATION_MODIFIER", 270, 279], ["little", "OBSERVATION_MODIFIER", 301, 307], ["no", "UNCERTAINTY", 311, 313], ["lung", "ANATOMY", 314, 318], ["lesions", "OBSERVATION", 319, 326]]], ["Thus, lesions at 10 days post-infection seemed to be inversely correlated with the level of MCP-1 produced.DiscussionOn day 1 post-infection, the cytokine response in coinfected pigs was most like that of pigs infected with B. bronchiseptica alone, in that there was a general increase in the transcriptional response to all cytokines tested.", [["lesions", "ANATOMY", 6, 13], ["infection", "DISEASE", 131, 140], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["MCP-1", "GENE_OR_GENE_PRODUCT", 92, 97], ["pigs", "ORGANISM", 178, 182], ["pigs", "ORGANISM", 205, 209], ["B. bronchiseptica", "ORGANISM", 224, 241], ["MCP", "PROTEIN", 92, 95], ["cytokine", "PROTEIN", 146, 154], ["cytokines", "PROTEIN", 325, 334], ["pigs", "SPECIES", 178, 182], ["pigs", "SPECIES", 205, 209], ["B. bronchiseptica", "SPECIES", 224, 241], ["pigs", "SPECIES", 178, 182], ["pigs", "SPECIES", 205, 209], ["B. bronchiseptica", "SPECIES", 224, 241], ["lesions", "PROBLEM", 6, 13], ["MCP", "TEST", 92, 95], ["post-infection", "PROBLEM", 126, 140], ["the cytokine response", "PROBLEM", 142, 163], ["coinfected pigs", "TREATMENT", 167, 182], ["B. bronchiseptica", "TREATMENT", 224, 241], ["a general increase", "PROBLEM", 267, 285], ["lesions", "OBSERVATION", 6, 13], ["infection", "OBSERVATION", 131, 140], ["increase", "OBSERVATION_MODIFIER", 277, 285], ["transcriptional response", "OBSERVATION", 293, 317]]], ["Again, this may largely be due to the response to bacterial LPS.", [["LPS", "CHEMICAL", 60, 63], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["bacterial LPS", "PROBLEM", 50, 63], ["may largely be due to", "UNCERTAINTY", 12, 33], ["bacterial LPS", "OBSERVATION", 50, 63]]], ["However, unlike the pigs that were challenged with bacteria alone, bacteria were isolated from some of the coinfected pigs and lesions were seen in all of the coinfected pigs as compared to pigs infected with bacteria or virus alone.", [["lesions", "ANATOMY", 127, 134], ["pigs", "ORGANISM", 20, 24], ["pigs", "ORGANISM", 118, 122], ["lesions", "PATHOLOGICAL_FORMATION", 127, 134], ["pigs", "ORGANISM", 170, 174], ["pigs", "ORGANISM", 190, 194], ["pigs", "SPECIES", 20, 24], ["pigs", "SPECIES", 118, 122], ["pigs", "SPECIES", 170, 174], ["pigs", "SPECIES", 190, 194], ["pigs", "SPECIES", 20, 24], ["pigs", "SPECIES", 118, 122], ["pigs", "SPECIES", 170, 174], ["pigs", "SPECIES", 190, 194], ["bacteria", "PROBLEM", 51, 59], ["bacteria", "PROBLEM", 67, 75], ["the coinfected pigs", "PROBLEM", 103, 122], ["lesions", "PROBLEM", 127, 134], ["bacteria", "PROBLEM", 209, 217], ["virus", "PROBLEM", 221, 226], ["coinfected pigs", "OBSERVATION", 107, 122], ["lesions", "OBSERVATION", 127, 134], ["coinfected pigs", "OBSERVATION", 159, 174]]], ["The coinfected pigs responded with an increase to more cytokines per pig and quantitatively greater, on average, to IL-6 and MCP-1, than did pigs infected with the bacteria alone.", [["pigs", "ORGANISM", 15, 19], ["pig", "ORGANISM", 69, 72], ["IL-6", "GENE_OR_GENE_PRODUCT", 116, 120], ["MCP-1", "GENE_OR_GENE_PRODUCT", 125, 130], ["pigs", "ORGANISM", 141, 145], ["cytokines", "PROTEIN", 55, 64], ["IL-6", "PROTEIN", 116, 120], ["MCP", "PROTEIN", 125, 128], ["pigs", "SPECIES", 15, 19], ["pig", "SPECIES", 69, 72], ["pigs", "SPECIES", 141, 145], ["pigs", "SPECIES", 15, 19], ["pig", "SPECIES", 69, 72], ["pigs", "SPECIES", 141, 145], ["The coinfected pigs", "TREATMENT", 0, 19], ["IL", "TEST", 116, 118], ["MCP", "TEST", 125, 128], ["the bacteria", "PROBLEM", 160, 172], ["coinfected", "OBSERVATION", 4, 14], ["greater", "OBSERVATION_MODIFIER", 92, 99]]], ["This might explain the increase in the severity of lesions observed early in the coinfected pigs compared to the pigs infected with bacteria or virus alone.", [["lesions", "ANATOMY", 51, 58], ["lesions", "PATHOLOGICAL_FORMATION", 51, 58], ["pigs", "ORGANISM", 92, 96], ["pigs", "ORGANISM", 113, 117], ["pigs", "SPECIES", 92, 96], ["pigs", "SPECIES", 113, 117], ["pigs", "SPECIES", 92, 96], ["pigs", "SPECIES", 113, 117], ["the severity of lesions", "PROBLEM", 35, 58], ["the coinfected pigs", "TREATMENT", 77, 96], ["bacteria", "PROBLEM", 132, 140], ["virus", "PROBLEM", 144, 149], ["increase", "OBSERVATION_MODIFIER", 23, 31], ["severity", "OBSERVATION_MODIFIER", 39, 47], ["lesions", "OBSERVATION", 51, 58], ["bacteria", "OBSERVATION", 132, 140]]], ["Whether or not this early cytokine response in coinfected pigs, which was not typical of pigs infected with the virus alone, might have altered the host response to PRCV resulting in the decreased clearance of the virus observed in the second experiment, warrants further investigation.DiscussionThe increased transcriptional response of MCP-1 on day 4, and IL-6, MCP-1, IL-8 and IL-1beta on day 10 post-infection in coinfected pigs demonstrates an enhanced response of proinflammatory cytokines compared to what is seen with either of the pathogens alone.", [["PRCV", "CHEMICAL", 165, 169], ["infection", "DISEASE", 404, 413], ["pigs", "ORGANISM", 58, 62], ["pigs", "ORGANISM", 89, 93], ["PRCV", "ORGANISM", 165, 169], ["MCP-1", "GENE_OR_GENE_PRODUCT", 338, 343], ["IL-6", "GENE_OR_GENE_PRODUCT", 358, 362], ["MCP-1", "GENE_OR_GENE_PRODUCT", 364, 369], ["IL-8", "GENE_OR_GENE_PRODUCT", 371, 375], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 380, 388], ["pigs", "ORGANISM", 428, 432], ["cytokine", "PROTEIN", 26, 34], ["MCP", "PROTEIN", 338, 341], ["IL-6", "PROTEIN", 358, 362], ["MCP", "PROTEIN", 364, 367], ["IL-1beta", "PROTEIN", 380, 388], ["proinflammatory cytokines", "PROTEIN", 470, 495], ["pigs", "SPECIES", 58, 62], ["pigs", "SPECIES", 89, 93], ["pigs", "SPECIES", 428, 432], ["pigs", "SPECIES", 58, 62], ["pigs", "SPECIES", 89, 93], ["PRCV", "SPECIES", 165, 169], ["pigs", "SPECIES", 428, 432], ["coinfected pigs", "TREATMENT", 47, 62], ["PRCV", "TREATMENT", 165, 169], ["the decreased clearance of the virus", "PROBLEM", 183, 219], ["further investigation", "TEST", 264, 285], ["MCP", "TEST", 338, 341], ["IL", "TEST", 358, 360], ["MCP", "TEST", 364, 367], ["IL", "TEST", 371, 373], ["IL-1beta", "TREATMENT", 380, 388], ["infection", "PROBLEM", 404, 413], ["coinfected pigs", "TREATMENT", 417, 432], ["proinflammatory cytokines", "PROBLEM", 470, 495], ["the pathogens", "PROBLEM", 536, 549], ["coinfected pigs", "OBSERVATION", 47, 62], ["host response", "OBSERVATION", 148, 161], ["decreased", "OBSERVATION_MODIFIER", 187, 196], ["infection", "OBSERVATION", 404, 413], ["enhanced", "OBSERVATION_MODIFIER", 449, 457], ["response", "OBSERVATION_MODIFIER", 458, 466], ["proinflammatory cytokines", "OBSERVATION", 470, 495], ["pathogens", "OBSERVATION", 540, 549]]], ["A previously proposed hypothesis suggested that proinflammatory cytokines, particularly TNFalpha, produced during exposure to PRCV and bacterial LPS might be responsible for more severe clinical respiratory signs in pigs .", [["respiratory", "ANATOMY", 195, 206], ["LPS", "CHEMICAL", 145, 148], ["respiratory signs", "DISEASE", 195, 212], ["TNFalpha", "GENE_OR_GENE_PRODUCT", 88, 96], ["PRCV", "GENE_OR_GENE_PRODUCT", 126, 130], ["LPS", "SIMPLE_CHEMICAL", 145, 148], ["pigs", "ORGANISM", 216, 220], ["proinflammatory cytokines", "PROTEIN", 48, 73], ["TNFalpha", "PROTEIN", 88, 96], ["pigs", "SPECIES", 216, 220], ["PRCV", "SPECIES", 126, 130], ["pigs", "SPECIES", 216, 220], ["A previously proposed hypothesis", "PROBLEM", 0, 32], ["proinflammatory cytokines", "PROBLEM", 48, 73], ["TNFalpha", "PROBLEM", 88, 96], ["PRCV", "TREATMENT", 126, 130], ["bacterial LPS", "PROBLEM", 135, 148], ["more severe clinical respiratory signs in pigs", "PROBLEM", 174, 220], ["proinflammatory cytokines", "OBSERVATION", 48, 73], ["bacterial LPS", "OBSERVATION", 135, 148], ["respiratory signs", "OBSERVATION", 195, 212]]], ["Although the results reported here do not point specifically to TNF-alpha, the lung lesions in coinfected pigs support this hypothesis.", [["lung lesions", "ANATOMY", 79, 91], ["lung lesions", "DISEASE", 79, 91], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 64, 73], ["lung lesions", "PATHOLOGICAL_FORMATION", 79, 91], ["pigs", "ORGANISM", 106, 110], ["TNF-alpha", "PROTEIN", 64, 73], ["pigs", "SPECIES", 106, 110], ["TNF", "TEST", 64, 67], ["the lung lesions", "PROBLEM", 75, 91], ["coinfected pigs", "TREATMENT", 95, 110], ["lung", "ANATOMY", 79, 83], ["lesions", "OBSERVATION", 84, 91], ["coinfected", "OBSERVATION", 95, 105]]], ["In another study, exposing human macrophages to SARS coronavirus and subsequent suboptimal LPS led to a dramatic increase in IL-6 over what was observed with cells exposed to either virus or LPS alone (Tseng et al., 2005) .", [["macrophages", "ANATOMY", 33, 44], ["cells", "ANATOMY", 158, 163], ["SARS", "DISEASE", 48, 52], ["LPS", "CHEMICAL", 91, 94], ["LPS", "CHEMICAL", 191, 194], ["human", "ORGANISM", 27, 32], ["macrophages", "CELL", 33, 44], ["SARS coronavirus", "ORGANISM", 48, 64], ["LPS", "SIMPLE_CHEMICAL", 91, 94], ["IL-6", "GENE_OR_GENE_PRODUCT", 125, 129], ["cells", "CELL", 158, 163], ["LPS", "SIMPLE_CHEMICAL", 191, 194], ["human macrophages", "CELL_TYPE", 27, 44], ["IL-6", "PROTEIN", 125, 129], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["SARS coronavirus", "SPECIES", 48, 64], ["another study", "TEST", 3, 16], ["SARS coronavirus", "PROBLEM", 48, 64], ["subsequent suboptimal LPS", "PROBLEM", 69, 94], ["a dramatic increase in IL", "PROBLEM", 102, 127], ["dramatic", "OBSERVATION_MODIFIER", 104, 112], ["increase", "OBSERVATION_MODIFIER", 113, 121]]], ["Overall, the data presented here does not implicate a single cytokine or chemokine in causing more severe lung disease in coinfected animals than in PRCV or B. bronchiseptica infection alone.DiscussionUltimately, the early interaction of pathogens with the innate immune system and its subsequent influence on the adaptive immune response is critical in determining the outcome of infection.", [["lung", "ANATOMY", 106, 110], ["lung disease", "DISEASE", 106, 118], ["B. bronchiseptica infection", "DISEASE", 157, 184], ["infection", "DISEASE", 381, 390], ["lung", "ORGAN", 106, 110], ["PRCV", "ORGANISM", 149, 153], ["B. bronchiseptica", "ORGANISM", 157, 174], ["cytokine", "PROTEIN", 61, 69], ["chemokine", "PROTEIN", 73, 82], ["B. bronchiseptica", "SPECIES", 157, 174], ["PRCV", "SPECIES", 149, 153], ["B. bronchiseptica", "SPECIES", 157, 174], ["more severe lung disease", "PROBLEM", 94, 118], ["B. bronchiseptica infection", "PROBLEM", 157, 184], ["pathogens", "PROBLEM", 238, 247], ["the innate immune system", "TREATMENT", 253, 277], ["infection", "PROBLEM", 381, 390], ["severe", "OBSERVATION_MODIFIER", 99, 105], ["lung", "ANATOMY", 106, 110], ["disease", "OBSERVATION", 111, 118], ["bronchiseptica", "OBSERVATION_MODIFIER", 160, 174], ["infection", "OBSERVATION", 175, 184], ["infection", "OBSERVATION", 381, 390]]], ["The host has evolved specific mechanisms to deal with diverse classes of pathogens in order to induce the most effective response.", [["pathogens", "PROBLEM", 73, 82], ["pathogens", "OBSERVATION", 73, 82]]], ["In addition to the innate mechanisms, such as epithelial barriers, muco-ciliary clearance, and antimicrobial substances, that are ubiquitously and constitutively present, innate responses induced through TLR receptors, which recognize conserved molecular patterns present in microorganisms, can stimulate specific responses to different pathogens.", [["epithelial", "ANATOMY", 46, 56], ["ciliary", "ANATOMY", 72, 79], ["epithelial", "TISSUE", 46, 56], ["ciliary", "MULTI-TISSUE_STRUCTURE", 72, 79], ["TLR receptors", "GENE_OR_GENE_PRODUCT", 204, 217], ["TLR receptors", "PROTEIN", 204, 217], ["epithelial barriers", "TREATMENT", 46, 65], ["muco-ciliary clearance", "TREATMENT", 67, 89], ["antimicrobial substances", "TREATMENT", 95, 119], ["microorganisms", "PROBLEM", 275, 289], ["different pathogens", "PROBLEM", 327, 346]]], ["For example, neutrophils usually dominate the initial inflammatory infiltrate subsequent to bacterial infections, while viral infection is often characterized by primarily mononuclear infiltration.", [["neutrophils", "ANATOMY", 13, 24], ["mononuclear", "ANATOMY", 172, 183], ["bacterial infections", "DISEASE", 92, 112], ["viral infection", "DISEASE", 120, 135], ["neutrophils", "CELL", 13, 24], ["mononuclear", "CELL", 172, 183], ["neutrophils", "CELL_TYPE", 13, 24], ["neutrophils", "TEST", 13, 24], ["the initial inflammatory infiltrate", "PROBLEM", 42, 77], ["bacterial infections", "PROBLEM", 92, 112], ["viral infection", "PROBLEM", 120, 135], ["mononuclear infiltration", "PROBLEM", 172, 196], ["neutrophils", "OBSERVATION", 13, 24], ["initial", "OBSERVATION_MODIFIER", 46, 53], ["inflammatory", "OBSERVATION_MODIFIER", 54, 66], ["infiltrate", "OBSERVATION", 67, 77], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["infections", "OBSERVATION", 102, 112], ["viral", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135], ["primarily", "OBSERVATION_MODIFIER", 162, 171], ["mononuclear infiltration", "OBSERVATION", 172, 196]]], ["In this study, the cytokine response in coinfected pigs was unique compared to the cytokine response in pigs infected with either agent by itself, suggesting that the alteration in the innate response, which has developed over time to deal with these pathogens, may be one mechanism through which coinfection alters the disease outcome.", [["coinfection", "DISEASE", 297, 308], ["pigs", "ORGANISM", 51, 55], ["pigs", "ORGANISM", 104, 108], ["cytokine", "PROTEIN", 19, 27], ["cytokine", "PROTEIN", 83, 91], ["pigs", "SPECIES", 51, 55], ["pigs", "SPECIES", 104, 108], ["pigs", "SPECIES", 51, 55], ["pigs", "SPECIES", 104, 108], ["this study", "TEST", 3, 13], ["coinfected pigs", "TREATMENT", 40, 55], ["these pathogens", "PROBLEM", 245, 260], ["the disease outcome", "PROBLEM", 316, 335], ["coinfected pigs", "OBSERVATION", 40, 55], ["innate response", "OBSERVATION", 185, 200], ["pathogens", "OBSERVATION", 251, 260], ["coinfection", "OBSERVATION", 297, 308]]]], "PMC7276875": [["While its use has certainly increased during this time, certain factors are important when selecting an off\u2010the\u2010shelf platform\u2010:Stability over smartphones and computers with different operating systems so that educators and STs can participate at work, home or in commute.User\u2010friendly \u201cscreen\u2010sharing\u201d and \u201cvoice\u2010over\u201d features to minimise technical difficulties.", [["different operating systems", "TREATMENT", 174, 201], ["technical difficulties", "PROBLEM", 341, 363], ["increased", "OBSERVATION_MODIFIER", 28, 37]]], ["These are difficult to rectify remotely and quickly dampen the enthusiasm of both educator and learner.Online security by password protecting meetings, manually admitting guests, locking meetings and removing unknown participants.Text chat and icons.", [["participants", "SPECIES", 217, 229]]]], "3d58d745527f659d92507b306273ccb909f9bcf0": [["INTRODUCTIONB. anthracis, the causative agent of anthrax, belongs to the taxonomical group of B. cereus, which includes six closely related species, namely, B. cereus, B. anthracis, B. thuringiensis, B. mycoides, B. pseudomycoides, and B. weihenstephanensis.", [["anthrax", "DISEASE", 49, 56], ["anthracis", "ORGANISM", 15, 24], ["B. cereus", "ORGANISM", 94, 103], ["B. cereus", "ORGANISM", 157, 166], ["B. anthracis", "ORGANISM", 168, 180], ["B. thuringiensis", "ORGANISM", 182, 198], ["B. mycoides", "ORGANISM", 200, 211], ["B. pseudomycoides", "ORGANISM", 213, 230], ["B. weihenstephanensis", "ORGANISM", 236, 257], ["anthracis", "SPECIES", 15, 24], ["B. cereus", "SPECIES", 94, 103], ["B. cereus", "SPECIES", 157, 166], ["B. anthracis", "SPECIES", 168, 180], ["B. thuringiensis", "SPECIES", 182, 198], ["B. mycoides", "SPECIES", 200, 211], ["B. pseudomycoides", "SPECIES", 213, 230], ["B. weihenstephanensis", "SPECIES", 236, 257], ["anthracis", "SPECIES", 15, 24], ["B. cereus", "SPECIES", 94, 103], ["B. cereus", "SPECIES", 157, 166], ["B. anthracis", "SPECIES", 168, 180], ["B. thuringiensis", "SPECIES", 182, 198], ["B. mycoides", "SPECIES", 200, 211], ["B. pseudomycoides", "SPECIES", 213, 230], ["B. weihenstephanensis", "SPECIES", 236, 257], ["anthracis", "PROBLEM", 15, 24], ["anthrax", "PROBLEM", 49, 56], ["B. cereus", "PROBLEM", 94, 103], ["six closely related species", "PROBLEM", 120, 147], ["B. weihenstephanensis", "PROBLEM", 236, 257]]], ["B. anthracis is an obligate pathogen of humans and herbivorous mammals, in contrast to all other species in the group.", [["B. anthracis", "ORGANISM", 0, 12], ["humans", "ORGANISM", 40, 46], ["B. anthracis", "SPECIES", 0, 12], ["humans", "SPECIES", 40, 46], ["B. anthracis", "SPECIES", 0, 12], ["humans", "SPECIES", 40, 46], ["herbivorous mammals", "PROBLEM", 51, 70], ["obligate", "OBSERVATION_MODIFIER", 19, 27], ["pathogen", "OBSERVATION", 28, 36], ["herbivorous mammals", "OBSERVATION", 51, 70]]], ["Identification of individual species from the B. cereus group is a complex task, since the genomic sequences of B. anthracis, B. cereus, and B. thuringiensis show virtually no differences when analyzed using a wide range of methods.", [["B. cereus", "ORGANISM", 46, 55], ["B. anthracis", "ORGANISM", 112, 124], ["B. cereus", "ORGANISM", 126, 135], ["B. thuringiensis", "ORGANISM", 141, 157], ["B. cereus group", "SPECIES", 46, 61], ["B. anthracis", "SPECIES", 112, 124], ["B. cereus", "SPECIES", 126, 135], ["B. thuringiensis", "SPECIES", 141, 157], ["B. cereus", "SPECIES", 46, 55], ["B. anthracis", "SPECIES", 112, 124], ["B. cereus", "SPECIES", 126, 135], ["B. thuringiensis", "SPECIES", 141, 157], ["individual species", "PROBLEM", 18, 36], ["a complex task", "PROBLEM", 65, 79], ["B. cereus", "PROBLEM", 126, 135], ["B. thuringiensis", "TEST", 141, 157], ["a wide range of methods", "TREATMENT", 208, 231], ["individual species", "OBSERVATION", 18, 36]]], ["Analysis of polymorphisms in 16S-23S rRNA and multilocus sequence typing [1, 2] revealed only minor differences between the genomes of these bacteria.INTRODUCTIONCertain chromosomal mutations and the presence of two virulence plasmids distinguish B. anthracis from other members of the group (importantly, plasmidfree strains lose virulence), and these features are used for the design of primers for amplification-based detection of the causative agent of anthrax.", [["chromosomal", "ANATOMY", 170, 181], ["anthrax", "DISEASE", 457, 464], ["16S-23S", "GENE_OR_GENE_PRODUCT", 29, 36], ["chromosomal", "CELLULAR_COMPONENT", 170, 181], ["B. anthracis", "ORGANISM", 247, 259], ["anthrax", "ORGANISM", 457, 464], ["16S", "DNA", 29, 32], ["virulence plasmids", "DNA", 216, 234], ["B. anthracis", "SPECIES", 247, 259], ["B. anthracis", "SPECIES", 247, 259], ["Analysis", "TEST", 0, 8], ["polymorphisms", "TEST", 12, 25], ["16S", "TEST", 29, 32], ["23S rRNA", "TEST", 33, 41], ["multilocus sequence typing", "TEST", 46, 72], ["these bacteria", "PROBLEM", 135, 149], ["chromosomal mutations", "PROBLEM", 170, 191], ["two virulence plasmids", "PROBLEM", 212, 234], ["amplification", "TEST", 401, 414], ["anthrax", "PROBLEM", 457, 464], ["minor", "OBSERVATION_MODIFIER", 94, 99], ["differences", "OBSERVATION", 100, 111], ["bacteria", "OBSERVATION", 141, 149], ["chromosomal mutations", "OBSERVATION", 170, 191]]], ["The genome of virulent B. anthracis strains is made up of a 5.23-Mb chromosome and two multicopy virulence plasmids pXO1 and pXO2.", [["chromosome", "ANATOMY", 68, 78], ["plasmids", "ANATOMY", 107, 115], ["virulent", "ORGANISM", 14, 22], ["B. anthracis strains", "ORGANISM", 23, 43], ["chromosome", "CELLULAR_COMPONENT", 68, 78], ["5.23-Mb chromosome", "DNA", 60, 78], ["multicopy virulence plasmids", "DNA", 87, 115], ["pXO1", "DNA", 116, 120], ["pXO2", "DNA", 125, 129], ["B. anthracis", "SPECIES", 23, 35], ["B. anthracis", "SPECIES", 23, 35], ["virulent B. anthracis strains", "PROBLEM", 14, 43], ["a 5.23-Mb chromosome", "PROBLEM", 58, 78], ["two multicopy virulence plasmids", "TREATMENT", 83, 115], ["pXO2", "TREATMENT", 125, 129], ["virulent", "OBSERVATION_MODIFIER", 14, 22], ["virulence plasmids", "OBSERVATION", 97, 115]]], ["The pXO1 plasmid (184 kbp) contains genes that encode a toxin composed by a protective antigen (pag), a lethal factor (lef), and an edema factor (cya).", [["edema", "DISEASE", 132, 137], ["pXO1", "GENE_OR_GENE_PRODUCT", 4, 8], ["pag", "GENE_OR_GENE_PRODUCT", 96, 99], ["lef", "GENE_OR_GENE_PRODUCT", 119, 122], ["edema factor", "GENE_OR_GENE_PRODUCT", 132, 144], ["cya", "GENE_OR_GENE_PRODUCT", 146, 149], ["pXO1 plasmid", "DNA", 4, 16], ["toxin", "PROTEIN", 56, 61], ["protective antigen", "PROTEIN", 76, 94], ["pag", "PROTEIN", 96, 99], ["lethal factor", "PROTEIN", 104, 117], ["lef", "PROTEIN", 119, 122], ["edema factor", "PROTEIN", 132, 144], ["cya", "PROTEIN", 146, 149], ["The pXO1 plasmid", "TREATMENT", 0, 16], ["a toxin", "PROBLEM", 54, 61], ["an edema factor", "PROBLEM", 129, 144], ["edema", "OBSERVATION", 132, 137]]], ["The pXO2 plasmid (97 kbp) harbors structural (cap) genes involved in the synthesis of the antiphagocytic poly-D-glutamine capsular antigen.", [["poly-D-glutamine", "CHEMICAL", 105, 121], ["poly-D-glutamine", "CHEMICAL", 105, 121], ["pXO2", "GENE_OR_GENE_PRODUCT", 4, 8], ["glutamine capsular antigen", "GENE_OR_GENE_PRODUCT", 112, 138], ["pXO2 plasmid", "DNA", 4, 16], ["structural (cap) genes", "DNA", 34, 56], ["antiphagocytic poly-D-glutamine capsular antigen", "PROTEIN", 90, 138], ["The pXO2 plasmid", "TREATMENT", 0, 16], ["structural (cap) genes", "PROBLEM", 34, 56], ["the antiphagocytic poly", "TEST", 86, 109], ["D-glutamine capsular antigen", "TREATMENT", 110, 138]]], ["Intraspecies differentiation of strains of the anthrax pathogen can only be performed if single nucleotide polymorphisms (SNPs) are analyzed, since B. anthracis strains that show the greatest genomic differences are still characterized by more than 99.99% identity between the nucleotide sequences [3, 4] .", [["anthrax", "DISEASE", 47, 54], ["nucleotide", "CHEMICAL", 277, 287], ["anthrax", "ORGANISM", 47, 54], ["B. anthracis strains", "ORGANISM", 148, 168], ["nucleotide sequences", "DNA", 277, 297], ["B. anthracis", "SPECIES", 148, 160], ["B. anthracis", "SPECIES", 148, 160], ["strains", "PROBLEM", 32, 39], ["the anthrax pathogen", "PROBLEM", 43, 63], ["single nucleotide polymorphisms (SNPs)", "PROBLEM", 89, 127], ["B. anthracis strains", "PROBLEM", 148, 168], ["the nucleotide sequences", "TEST", 273, 297], ["greatest", "OBSERVATION_MODIFIER", 183, 191]]], ["Plasmids with a similar genetic structure have been found in other species of the genus Bacillus, including species that do not belong to the B. cereus group, such as B. circulans and a strain similar to B. luciferensis [5] .INTRODUCTIONReports of the presence of complete sets of virulence genes that encode a three-component toxin and a polyglutamic-acid capsule in B. cereus and B. thuringiensis can partly explain the existence of \"anthraxlike\" diseases of human beings and animals reported in the recent decades.", [["polyglutamic-acid", "CHEMICAL", 339, 356], ["diseases of human beings", "DISEASE", 449, 473], ["polyglutamic-acid", "CHEMICAL", 339, 356], ["B. cereus", "ORGANISM", 142, 151], ["B. circulans", "ORGANISM", 167, 179], ["B. luciferensis", "ORGANISM", 204, 219], ["B. cereus", "ORGANISM", 368, 377], ["B. thuringiensis", "ORGANISM", 382, 398], ["human", "ORGANISM", 461, 466], ["virulence genes", "DNA", 281, 296], ["B. cereus group", "SPECIES", 142, 157], ["B. circulans", "SPECIES", 167, 179], ["B. luciferensis", "SPECIES", 204, 219], ["B. cereus", "SPECIES", 368, 377], ["B. thuringiensis", "SPECIES", 382, 398], ["human", "SPECIES", 461, 466], ["B. cereus", "SPECIES", 142, 151], ["B. circulans", "SPECIES", 167, 179], ["B. luciferensis", "SPECIES", 204, 219], ["B. cereus", "SPECIES", 368, 377], ["B. thuringiensis", "SPECIES", 382, 398], ["human", "SPECIES", 461, 466], ["Plasmids", "TREATMENT", 0, 8], ["a similar genetic structure", "PROBLEM", 14, 41], ["the genus Bacillus", "PROBLEM", 78, 96], ["species", "PROBLEM", 108, 115], ["a strain", "PROBLEM", 184, 192], ["virulence genes", "PROBLEM", 281, 296], ["a polyglutamic-acid capsule", "TREATMENT", 337, 364], ["genus Bacillus", "ANATOMY", 82, 96]]], ["These diseases are caused by virulent strains of B. cereus (G9241, 03BB102, 3BB108, 03BB87, E33L, B17, 3a, and CI) and B. thuringiensis (97-27) [6] [7] [8] [9] [10] .", [["B. cereus", "ORGANISM", 49, 58], ["B. thuringiensis", "ORGANISM", 119, 135], ["97-27) [6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 137, 164], ["B. cereus", "SPECIES", 49, 58], ["B. thuringiensis", "SPECIES", 119, 135], ["B. cereus", "SPECIES", 49, 58], ["B. thuringiensis", "SPECIES", 119, 135], ["These diseases", "PROBLEM", 0, 14], ["virulent strains of B. cereus", "PROBLEM", 29, 58], ["BB102", "TEST", 69, 74], ["E33L", "TEST", 92, 96], ["B17", "TEST", 98, 101], ["CI", "TEST", 111, 113], ["B. thuringiensis", "TEST", 119, 135], ["diseases", "OBSERVATION", 6, 14], ["virulent", "OBSERVATION_MODIFIER", 29, 37]]], ["Natural genetic exchange of virulence plasmids between B. anthracis and other bacilli can underlie the emergence of virulent B. cereus and B. thuringiensis strains.", [["B. anthracis", "ORGANISM", 55, 67], ["B. cereus", "ORGANISM", 125, 134], ["B. thuringiensis strains", "ORGANISM", 139, 163], ["virulence plasmids", "DNA", 28, 46], ["B. anthracis", "SPECIES", 55, 67], ["B. cereus", "SPECIES", 125, 134], ["B. thuringiensis", "SPECIES", 139, 155], ["B. anthracis", "SPECIES", 55, 67], ["B. cereus", "SPECIES", 125, 134], ["B. thuringiensis", "SPECIES", 139, 155], ["virulence plasmids", "TREATMENT", 28, 46], ["B. anthracis", "PROBLEM", 55, 67], ["other bacilli", "PROBLEM", 72, 85], ["virulent B. cereus", "PROBLEM", 116, 134], ["B. thuringiensis strains", "PROBLEM", 139, 163]]], ["The experimental data available to date are not sufficient to prove such exchange, but the implementation of plasmid transfer in the lab-EXPERIMENTAL WORKSoratory does not present any serious difficulties, since mobility genes and genes with a conjugative function have been found on the pXO2 plasmid [11] [12] [13] .", [["mobility genes", "DNA", 212, 226], ["pXO2 plasmid", "DNA", 288, 300], ["any serious difficulties", "PROBLEM", 180, 204]]], ["The isolation of monoplasmid, diplasmid, and plasmidfree B. anthracis strains from the environment and the possibility of construction of such strains in the laboratory also provide indirect evidence for the hypothesis mentioned above.EXPERIMENTAL WORKSIn view of the above, it is necessary to develop and implement new methods that could distinguish between B. anthracis, on one the hand, and atypical strains and other species of saprophytic bacilli, as well as \"anthracellar\" human-and animal-disease pathogens (that have a much lower epidemic significance than the anthrax microbe), on the other hand.", [["hand", "ANATOMY", 384, 388], ["human-and animal-disease pathogens", "DISEASE", 479, 513], ["anthrax", "DISEASE", 569, 576], ["monoplasmid", "GENE_OR_GENE_PRODUCT", 17, 28], ["diplasmid", "GENE_OR_GENE_PRODUCT", 30, 39], ["plasmidfree B. anthracis strains", "ORGANISM", 45, 77], ["B. anthracis", "ORGANISM", 359, 371], ["hand", "ORGANISM_SUBDIVISION", 384, 388], ["human", "ORGANISM", 479, 484], ["B. anthracis", "SPECIES", 57, 69], ["B. anthracis", "SPECIES", 359, 371], ["human", "SPECIES", 479, 484], ["B. anthracis", "SPECIES", 57, 69], ["B. anthracis", "SPECIES", 359, 371], ["human", "SPECIES", 479, 484], ["monoplasmid", "TREATMENT", 17, 28], ["diplasmid", "TREATMENT", 30, 39], ["plasmidfree B. anthracis strains", "PROBLEM", 45, 77], ["such strains", "PROBLEM", 138, 150], ["the hypothesis", "PROBLEM", 204, 218], ["B. anthracis", "PROBLEM", 359, 371], ["atypical strains", "PROBLEM", 394, 410], ["saprophytic bacilli", "PROBLEM", 432, 451], ["animal-disease pathogens", "PROBLEM", 489, 513], ["hand", "ANATOMY", 384, 388], ["saprophytic bacilli", "OBSERVATION", 432, 451]]], ["These methods are highly suited for epidemiological investigations of outbreaks and laboratory diagnosis of infectious diseases with clinical symptoms similar to those of anthrax.EXPERIMENTAL WORKSLoop isothermal DNA amplification (LAMP) is a promising method of microorganism detection and differentiation.", [["infectious diseases", "DISEASE", 108, 127], ["anthrax", "DISEASE", 171, 178], ["DNA", "CELLULAR_COMPONENT", 213, 216], ["epidemiological investigations", "TEST", 36, 66], ["infectious diseases", "PROBLEM", 108, 127], ["clinical symptoms", "PROBLEM", 133, 150], ["anthrax", "PROBLEM", 171, 178], ["EXPERIMENTAL WORKSLoop isothermal DNA amplification", "TREATMENT", 179, 230], ["microorganism detection", "PROBLEM", 263, 286]]], ["The reaction involves chain replacement and requires a DNA polymerase (Bst-polymerase in most cases) and a constant temperature of 60-65\u00b0C [14, 15] .", [["DNA", "CELLULAR_COMPONENT", 55, 58], ["Bst-polymerase", "GENE_OR_GENE_PRODUCT", 71, 85], ["DNA polymerase", "PROTEIN", 55, 69], ["Bst-polymerase", "PROTEIN", 71, 85], ["The reaction", "PROBLEM", 0, 12], ["chain replacement", "TREATMENT", 22, 39], ["a DNA polymerase", "TEST", 53, 69], ["Bst-polymerase", "TEST", 71, 85], ["a constant temperature", "TEST", 105, 127], ["chain replacement", "OBSERVATION", 22, 39]]], ["Therefore, isothermal amplification does not require a thermocycler, in contrast to polymerase chain reaction (PCR), which involves successive cycles of temperature change.", [["isothermal amplification", "TEST", 11, 35], ["a thermocycler", "TREATMENT", 53, 67], ["PCR", "TEST", 111, 114], ["temperature change", "PROBLEM", 153, 171]]], ["The tube with the reaction mixture is incubated at a temperature of 60-65\u00b0C in a conventional water bath or a solid thermostat block.", [["tube", "ANATOMY", 4, 8], ["tube", "TISSUE", 4, 8], ["The tube", "TREATMENT", 0, 8], ["the reaction mixture", "TREATMENT", 14, 34], ["a conventional water bath", "TREATMENT", 79, 104], ["a solid thermostat block", "TREATMENT", 108, 132], ["tube", "OBSERVATION", 4, 8], ["solid thermostat block", "OBSERVATION", 110, 132]]], ["Synthesis of the target sequence requires two or three pairs of primers.", [["target sequence", "DNA", 17, 32]]], ["The forward (F3) and reverse (B3) outer primers are used when the chain is replaced.", [["forward (F3) and reverse (B3) outer primers", "DNA", 4, 47], ["The forward (F3)", "TREATMENT", 0, 16], ["reverse (B3) outer primers", "TREATMENT", 21, 47]]], ["The forward (FIP) and reverse (BIP) internal primers have a more complex structure and participate in the formation of loop structures [16] .", [["forward (FIP) and reverse (BIP) internal primers", "DNA", 4, 52], ["reverse (BIP) internal primers", "TREATMENT", 22, 52], ["more", "OBSERVATION_MODIFIER", 60, 64], ["complex", "OBSERVATION_MODIFIER", 65, 72], ["structure", "OBSERVATION", 73, 82], ["loop", "OBSERVATION_MODIFIER", 119, 123]]], ["A number of LAMP-based tests for the detection of microbial and viral pathogens of infectious diseases, including tuberculosis [17, 18] , leptospirosis [19] , Staphylococcus aureus [20] , listeriosis [21] , cholera [22] , swine influenza virus H1N1 [23] , hepatitis B virus [24] , and anthrax [25] [26] [27] [28] [29] have been developed in recent years.EXPERIMENTAL WORKSThe possibility of LAMP-based detection of B. anthracis spores was tested in [25] .", [["spores", "ANATOMY", 428, 434], ["infectious diseases", "DISEASE", 83, 102], ["tuberculosis", "DISEASE", 114, 126], ["leptospirosis", "DISEASE", 138, 151], ["Staphylococcus aureus", "DISEASE", 159, 180], ["listeriosis", "DISEASE", 188, 199], ["cholera", "DISEASE", 207, 214], ["influenza virus H1N1", "DISEASE", 228, 248], ["hepatitis B", "DISEASE", 256, 267], ["anthrax", "DISEASE", 285, 292], ["Staphylococcus aureus", "ORGANISM", 159, 180], ["cholera [22", "ORGANISM", 207, 218], ["swine influenza virus H1N1 [23", "ORGANISM", 222, 252], ["hepatitis B virus", "ORGANISM", 256, 273], ["anthrax [25] [26] [27] [28] [29]", "SIMPLE_CHEMICAL", 285, 317], ["B. anthracis", "ORGANISM", 415, 427], ["Staphylococcus aureus", "SPECIES", 159, 180], ["swine influenza virus H1N1", "SPECIES", 222, 248], ["hepatitis B virus", "SPECIES", 256, 273], ["B. anthracis", "SPECIES", 415, 427], ["Staphylococcus aureus", "SPECIES", 159, 180], ["swine influenza virus H1N1", "SPECIES", 222, 248], ["hepatitis B virus", "SPECIES", 256, 273], ["B. anthracis", "SPECIES", 415, 427], ["LAMP-based tests", "TEST", 12, 28], ["the detection", "TEST", 33, 46], ["microbial and viral pathogens of infectious diseases", "PROBLEM", 50, 102], ["tuberculosis", "PROBLEM", 114, 126], ["leptospirosis", "TEST", 138, 151], ["Staphylococcus aureus", "PROBLEM", 159, 180], ["listeriosis", "PROBLEM", 188, 199], ["cholera", "PROBLEM", 207, 214], ["swine influenza virus H1N1", "PROBLEM", 222, 248], ["hepatitis B virus", "PROBLEM", 256, 273], ["anthrax", "TEST", 285, 292], ["LAMP", "TEST", 391, 395], ["B. anthracis spores", "PROBLEM", 415, 434], ["viral pathogens", "OBSERVATION", 64, 79], ["infectious", "OBSERVATION", 83, 93], ["Staphylococcus aureus", "OBSERVATION", 159, 180]]], ["Three sets of six pairs of primers were designed for the study of targeted fragments of the pXO1 and pXO2 plasmids (pag and capB, respectively) and a fragment of the chromosome.", [["plasmids", "ANATOMY", 106, 114], ["chromosome", "ANATOMY", 166, 176], ["pXO1", "GENE_OR_GENE_PRODUCT", 92, 96], ["pXO2", "GENE_OR_GENE_PRODUCT", 101, 105], ["pag", "GENE_OR_GENE_PRODUCT", 116, 119], ["capB", "GENE_OR_GENE_PRODUCT", 124, 128], ["chromosome", "CELLULAR_COMPONENT", 166, 176], ["targeted fragments", "DNA", 66, 84], ["pXO1 and pXO2 plasmids", "DNA", 92, 114], ["pag", "DNA", 116, 119], ["capB", "DNA", 124, 128], ["chromosome", "DNA", 166, 176], ["the study", "TEST", 53, 62], ["the pXO1 and pXO2 plasmids", "TREATMENT", 88, 114], ["capB", "TEST", 124, 128], ["a fragment of the chromosome", "PROBLEM", 148, 176]]], ["Thirteen B. anthracis strains were identified by LAMP with these primers (a positive result was obtained with at least two of three primer sets), and the analysis of 33 heterologous strains yielded negative results.", [["B. anthracis", "ORGANISM", 9, 21], ["B. anthracis", "SPECIES", 9, 21], ["B. anthracis", "SPECIES", 9, 21], ["Thirteen B. anthracis strains", "PROBLEM", 0, 29], ["these primers", "TEST", 59, 72], ["the analysis", "TEST", 150, 162], ["heterologous strains", "TEST", 169, 189]]], ["Notably, the primers that targeted a chromosomal fragment had a less than 100% specificity and yielded positive results with some other Bacillus species, and this presented a risk of false positive results.EXPERIMENTAL WORKSDNA fragments of plasmids pXO1 (pag) and pXO2 (capB) were used as targets in another study of LAMPbased detection of strains of the anthrax pathogen [26] .", [["chromosomal fragment", "ANATOMY", 37, 57], ["plasmids", "ANATOMY", 241, 249], ["anthrax", "DISEASE", 356, 363], ["chromosomal", "CELLULAR_COMPONENT", 37, 48], ["pXO1", "GENE_OR_GENE_PRODUCT", 250, 254], ["pag", "GENE_OR_GENE_PRODUCT", 256, 259], ["pXO2", "GENE_OR_GENE_PRODUCT", 265, 269], ["capB", "GENE_OR_GENE_PRODUCT", 271, 275], ["EXPERIMENTAL WORKSDNA fragments", "DNA", 206, 237], ["plasmids", "DNA", 241, 249], ["pXO1", "DNA", 250, 254], ["pag", "DNA", 256, 259], ["pXO2", "DNA", 265, 269], ["capB", "DNA", 271, 275], ["the primers", "PROBLEM", 9, 20], ["a chromosomal fragment", "PROBLEM", 35, 57], ["some other Bacillus species", "PROBLEM", 125, 152], ["false positive results", "PROBLEM", 183, 205], ["plasmids pXO1", "TREATMENT", 241, 254], ["pXO2 (capB)", "TREATMENT", 265, 276], ["strains", "PROBLEM", 341, 348], ["the anthrax pathogen", "PROBLEM", 352, 372], ["fragment", "OBSERVATION_MODIFIER", 49, 57], ["Bacillus species", "OBSERVATION", 136, 152]]], ["Three B. anthracis strains, three B. cereus strains, one B. thuringiensis strain, and one B. subtilis strain were used to test the specificity of primer sets [26] .EXPERIMENTAL WORKSWe chose novel chromosomal targets [30] in order to avoid false positive signals from the DNA of bacilli of the B. cereus group upon the detection of B. anthracis and, thus, to distinguish B. anthracis from closely related species.", [["chromosomal", "ANATOMY", 197, 208], ["B. anthracis strains", "ORGANISM", 6, 26], ["B. cereus strains", "ORGANISM", 34, 51], ["B. thuringiensis strain", "ORGANISM", 57, 80], ["B. subtilis strain", "ORGANISM", 90, 108], ["chromosomal", "CELLULAR_COMPONENT", 197, 208], ["DNA", "CELLULAR_COMPONENT", 272, 275], ["B. cereus", "ORGANISM", 294, 303], ["B. anthracis", "ORGANISM", 332, 344], ["B. anthracis", "ORGANISM", 371, 383], ["B. anthracis", "SPECIES", 6, 18], ["B. cereus", "SPECIES", 34, 43], ["B. thuringiensis", "SPECIES", 57, 73], ["B. subtilis", "SPECIES", 90, 101], ["B. cereus group", "SPECIES", 294, 309], ["B. anthracis", "SPECIES", 332, 344], ["B. anthracis", "SPECIES", 371, 383], ["B. anthracis", "SPECIES", 6, 18], ["B. cereus", "SPECIES", 34, 43], ["B. thuringiensis", "SPECIES", 57, 73], ["B. subtilis", "SPECIES", 90, 101], ["B. cereus", "SPECIES", 294, 303], ["B. anthracis", "SPECIES", 332, 344], ["B. anthracis", "SPECIES", 371, 383], ["Three B. anthracis strains", "PROBLEM", 0, 26], ["three B. cereus strains", "PROBLEM", 28, 51], ["one B. thuringiensis strain", "PROBLEM", 53, 80], ["one B. subtilis strain", "PROBLEM", 86, 108], ["false positive signals", "PROBLEM", 240, 262], ["B. anthracis", "PROBLEM", 332, 344], ["B. anthracis", "PROBLEM", 371, 383], ["anthracis strains", "OBSERVATION", 9, 26]]], ["The selection of primers for chromosomal and plasmid DNA targets was performed with rigid requirements imposed on the stability of the 3' end of the F2 region and the 5' end of the F1c region of the FIP primer, as well as on the stability of the 3' end of the B2 region and the 5' end of the B1c region of the BIP primer.EXPERIMENTAL WORKSIt should be noted that LAMP has great potential for the design of tests for field use, since the reaction is isothermal and fast.", [["chromosomal", "ANATOMY", 29, 40], ["plasmid", "ANATOMY", 45, 52], ["chromosomal", "CELLULAR_COMPONENT", 29, 40], ["plasmid", "CELLULAR_COMPONENT", 45, 52], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["3' end", "CELLULAR_COMPONENT", 135, 141], ["F2 region", "CELLULAR_COMPONENT", 149, 158], ["5' end", "CELLULAR_COMPONENT", 167, 173], ["3' end", "CELLULAR_COMPONENT", 246, 252], ["3' end", "DNA", 135, 141], ["F2 region", "DNA", 149, 158], ["5' end", "DNA", 167, 173], ["F1c region", "DNA", 181, 191], ["FIP primer", "DNA", 199, 209], ["3' end", "DNA", 246, 252], ["B2 region", "DNA", 260, 269], ["5' end", "DNA", 278, 284], ["B1c region", "DNA", 292, 302], ["BIP primer", "DNA", 310, 320], ["The selection of primers", "TREATMENT", 0, 24], ["chromosomal and plasmid DNA targets", "TREATMENT", 29, 64], ["rigid requirements", "PROBLEM", 84, 102], ["tests", "TEST", 406, 411], ["the reaction", "PROBLEM", 433, 445], ["stability", "OBSERVATION_MODIFIER", 118, 127], ["F2", "ANATOMY", 149, 151], ["region", "ANATOMY_MODIFIER", 152, 158], ["FIP primer", "OBSERVATION", 199, 209], ["stability", "OBSERVATION_MODIFIER", 229, 238], ["B2", "ANATOMY", 260, 262], ["region", "ANATOMY_MODIFIER", 263, 269], ["BIP primer", "OBSERVATION", 310, 320]]], ["Such tests are highly appropriate for a number of epidemiological tasks, such as the identification of pathogens in the environment.EXPERIMENTAL WORKSThe aim of the present work consisted in the development of a LAMP-based method for species-specific detection of DNA of B. anthracis strains with original primers and a thermostable DNA polymerase.MATERIAL AND METHODSBacterial strains.", [["DNA", "CELLULAR_COMPONENT", 264, 267], ["B. anthracis strains", "ORGANISM", 271, 291], ["DNA", "CELLULAR_COMPONENT", 333, 336], ["thermostable DNA polymerase", "PROTEIN", 320, 347], ["B. anthracis", "SPECIES", 271, 283], ["B. anthracis", "SPECIES", 271, 283], ["Such tests", "TEST", 0, 10], ["a LAMP", "TEST", 210, 216], ["species", "PROBLEM", 234, 241], ["DNA", "PROBLEM", 264, 267], ["B. anthracis strains", "PROBLEM", 271, 291], ["original primers", "PROBLEM", 297, 313], ["a thermostable DNA polymerase", "PROBLEM", 318, 347], ["METHODSBacterial strains", "PROBLEM", 361, 385], ["METHODSBacterial strains", "OBSERVATION", 361, 385]]], ["Strains of various bacterial species used in the present study were obtained from the microorganism collection of the Obolensk Research Center of Applied Microbiology and Biotechnology (Russia).", [["various bacterial species", "PROBLEM", 11, 36], ["the present study", "TEST", 45, 62], ["various", "OBSERVATION_MODIFIER", 11, 18], ["bacterial species", "OBSERVATION", 19, 36]]], ["Characteristics of the strains, including the presence of specific genes, are listed in Table 1 .MATERIAL AND METHODSCultivation.", [["the strains", "PROBLEM", 19, 30], ["METHODSCultivation", "TEST", 110, 128], ["METHODSCultivation", "OBSERVATION", 110, 128]]], ["Ampoules with B. anthracis cultures were opened, and 0.9% sodium-chloride solution was added at 0.5 mL per ampoule.", [["sodium-chloride", "CHEMICAL", 58, 73], ["sodium-chloride", "CHEMICAL", 58, 73], ["B. anthracis", "ORGANISM", 14, 26], ["sodium-chloride", "SIMPLE_CHEMICAL", 58, 73], ["B. anthracis cultures", "CELL_LINE", 14, 35], ["B. anthracis", "SPECIES", 14, 26], ["B. anthracis", "SPECIES", 14, 26], ["B. anthracis cultures", "TEST", 14, 35], ["0.9% sodium-chloride solution", "TREATMENT", 53, 82]]], ["Suspensions of B. anthracis microbes were plated on L-agar Petri dishes with bacterial loops and incubated for 18 h at 37 \u00b1 1\u00b0C. Suspensions in 2 mL of 0.9% sodium-chloride solution were prepared separately from each culture.", [["sodium-chloride", "CHEMICAL", 157, 172], ["sodium-chloride", "CHEMICAL", 157, 172], ["B. anthracis", "ORGANISM", 15, 27], ["sodium-chloride solution", "SIMPLE_CHEMICAL", 157, 181], ["B. anthracis", "SPECIES", 15, 27], ["B. anthracis", "SPECIES", 15, 27], ["B. anthracis microbes", "PROBLEM", 15, 36], ["L-agar Petri dishes", "TREATMENT", 52, 71], ["bacterial loops", "PROBLEM", 77, 92], ["0.9% sodium-chloride solution", "TREATMENT", 152, 181], ["each culture", "TEST", 212, 224], ["bacterial loops", "OBSERVATION", 77, 92]]], ["Suspension turbidity corresponded to 10 turbidity units of the industry standard (OSO 42-28-59-86P according to Tarasevich GISK), this being equivalent to 1 \u00d7 10 8 million B. anthracis cells/mL.", [["cells", "ANATOMY", 185, 190], ["B. anthracis cells", "CELL", 172, 190], ["B. anthracis", "SPECIES", 172, 184], ["B. anthracis", "SPECIES", 172, 184], ["Suspension turbidity", "PROBLEM", 0, 20]]], ["Thermolysate preparation.", [["Thermolysate preparation", "TREATMENT", 0, 24]]], ["The suspensions of 18-h agar cultures were incubated in a thermostat at 100\u00b0C for 30 min, cooled on ice for 10 min, and centrifuged.", [["The suspensions", "TEST", 0, 15], ["agar cultures", "TEST", 24, 37], ["a thermostat", "TREATMENT", 56, 68]]], ["The supernatant was used as the template.MATERIAL AND METHODSDNA isolation.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["METHODSDNA isolation", "TREATMENT", 54, 74], ["METHODSDNA isolation", "OBSERVATION", 54, 74]]], ["A commercial DNK-sorb-B kit (OAO InterLabServis) was used for DNA isolation.", [["DNK-sorb-B", "CHEMICAL", 13, 23], ["DNK", "SIMPLE_CHEMICAL", 13, 16], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["DNK", "PROTEIN", 13, 16], ["sorb", "PROTEIN", 17, 21], ["B kit", "PROTEIN", 22, 27], ["A commercial DNK", "TREATMENT", 0, 16], ["sorb-B kit (OAO InterLabServis)", "TREATMENT", 17, 48], ["DNA isolation", "TREATMENT", 62, 75]]], ["Safety requirements 1, 2 were adhered to during these operations.", [["these operations", "TREATMENT", 48, 64]]], ["Primer Explorer 3 software (http://primerexplorer.jp/elamp3.0.0/index.htmL) was used to design the primers.", [["Primer Explorer 3 software", "DNA", 0, 26], ["the primers", "TREATMENT", 95, 106]]], ["BLAST software (http://blast.ncbi.nlm.nih.gov/Blast.cgi) was used to test primer specificity.", [["BLAST software", "TEST", 0, 14], ["test primer specificity", "TEST", 69, 92]]], ["The primers were synthesized and purified by Sintol (Moscow, Russia).", [["Sintol", "SIMPLE_CHEMICAL", 45, 51]]], ["The reaction mix with Sd-polymerase had a total volume of 50 \u03bcL and contained 1\u00d7 SD buffer (Bioron, Germany), 40 units SD polymerase, 3.5 mM MgCl 2 , 0.5 mM each dNTP, four primers (0.2 \u03bcM F3, 0.2 \u03bcM B3, 0.8 \u03bcM BIP, and 0.8 \u03bcM FIP), and 5 \u03bcL template.", [["NTP", "CHEMICAL", 163, 166], ["MgCl 2", "CHEMICAL", 141, 147], ["NTP", "CHEMICAL", 163, 166], ["NTP", "SIMPLE_CHEMICAL", 163, 166], ["Sd-polymerase", "PROTEIN", 22, 35], ["The reaction mix", "PROBLEM", 0, 16], ["a total volume", "TEST", 40, 54], ["3.5 mM MgCl", "TREATMENT", 134, 145], ["dNTP", "TREATMENT", 162, 166], ["four primers", "TREATMENT", 168, 180], ["5 \u03bcL template", "TREATMENT", 237, 250]]], ["The reaction was performed at 60\u00b0C for 60 min after 2 min of incubation at 92\u00b0C in a Tertsik thermocycler (DNK-Tekhnologiya).", [["The reaction", "PROBLEM", 0, 12], ["incubation", "TREATMENT", 61, 71], ["a Tertsik thermocycler", "TREATMENT", 83, 105]]], ["LAMP products were subjected to electrophoresis in 1.2% agarose gel in TAE buffer and visualized in an UV transilluminator at a wavelength of 260 nm.MATERIAL AND METHODSImplementation of polymerase chain reaction.", [["agarose", "SIMPLE_CHEMICAL", 56, 63], ["LAMP products", "TREATMENT", 0, 13], ["electrophoresis", "TEST", 32, 47], ["1.2% agarose gel", "TREATMENT", 51, 67], ["TAE buffer", "TREATMENT", 71, 81], ["polymerase chain reaction", "PROBLEM", 187, 212], ["polymerase chain reaction", "OBSERVATION", 187, 212]]], ["The reaction mix (25 \u03bcL) for the synthesis of a 204-bp chromosomal fragment (dhp73.019) contained 1\u00d7 reaction buffer, 1.5 mM MgCl 2 , 0.25 mM each dNTP, 0.2 \u03bcM primers chBA20F3 and chBA20B3, and 5 \u03bcL template.", [["MgCl", "CHEMICAL", 125, 129], ["dNTP", "CHEMICAL", 147, 151], ["MgCl", "CHEMICAL", 125, 129], ["dNTP", "CHEMICAL", 147, 151], ["MgCl 2", "SIMPLE_CHEMICAL", 125, 131], ["dNTP", "SIMPLE_CHEMICAL", 147, 151], ["chBA20B3", "SIMPLE_CHEMICAL", 181, 189], ["204-bp chromosomal fragment", "DNA", 48, 75], ["The reaction mix", "TEST", 0, 16], ["the synthesis", "TEST", 29, 42], ["bp chromosomal fragment", "PROBLEM", 52, 75], ["MgCl", "TEST", 125, 129], ["dNTP", "TEST", 147, 151], ["\u03bcM primers chBA20F3", "TREATMENT", 157, 176], ["chBA20B3", "TREATMENT", 181, 189], ["5 \u03bcL template", "TREATMENT", 195, 208]]], ["The reaction was performed in a Tertsik thermocycler (DNK-Tekhnologiya) according to the following program: initial denaturation at 94\u00b0C for 2 min, 35 cycles of amplification (denaturation at 94\u00b0C for 15 s, primer annealing at 54\u00b0C for 20 s, and elongation at 72\u00b0C for 20 s), and the final stage of amplification for 2 min at 72\u00b0C. PCR products were subjected to electrophoresis in 1.2% agarose gel in TAE buffer and visualized in a UV transilluminator at a wavelength of 260 nm.MATERIAL AND METHODSReproducibility.", [["agarose", "SIMPLE_CHEMICAL", 387, 394], ["The reaction", "PROBLEM", 0, 12], ["a Tertsik thermocycler", "TREATMENT", 30, 52], ["initial denaturation", "PROBLEM", 108, 128], ["amplification (denaturation", "TREATMENT", 161, 188], ["elongation", "TEST", 246, 256], ["PCR products", "TREATMENT", 332, 344], ["electrophoresis", "TEST", 363, 378], ["1.2% agarose gel", "TREATMENT", 382, 398], ["TAE buffer", "TREATMENT", 402, 412], ["a UV transilluminator", "TREATMENT", 431, 452], ["METHODSReproducibility", "PROBLEM", 492, 514], ["METHODSReproducibility", "OBSERVATION", 492, 514]]], ["All experiments, including the cultivation of B. anthracis strains, DNA isolation, PCR, and LAMP, were repeated at least three times.RESULTS AND DISCUSSIONTarget selection and primer design.", [["B. anthracis", "ORGANISM", 46, 58], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["B. anthracis", "SPECIES", 46, 58], ["B. anthracis", "SPECIES", 46, 58], ["B. anthracis strains", "PROBLEM", 46, 66], ["DNA isolation", "TEST", 68, 81], ["PCR", "TEST", 83, 86], ["LAMP", "TEST", 92, 96]]], ["A large number of primers that target chromosomal loci of the patho-gen DNA are currently available for PCR detection and identification of B. anthracis.", [["chromosomal", "ANATOMY", 38, 49], ["chromosomal", "CELLULAR_COMPONENT", 38, 49], ["DNA", "CELLULAR_COMPONENT", 72, 75], ["B. anthracis", "ORGANISM", 140, 152], ["patho-gen DNA", "DNA", 62, 75], ["B. anthracis", "SPECIES", 140, 152], ["B. anthracis", "SPECIES", 140, 152], ["A large number of primers", "PROBLEM", 0, 25], ["PCR detection", "TEST", 104, 117], ["B. anthracis", "PROBLEM", 140, 152], ["large", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["chromosomal loci", "OBSERVATION", 38, 54]]], ["Wide use of specific primers is usually followed by the discovery of new strains that lack the target sequences or contain single nucleotide polymorphisms that have a significant effect on the properties of the target sequence.", [["target sequences", "DNA", 95, 111], ["target sequence", "DNA", 211, 226], ["specific primers", "TREATMENT", 12, 28], ["new strains", "PROBLEM", 69, 80], ["single nucleotide polymorphisms", "PROBLEM", 123, 154], ["significant", "OBSERVATION_MODIFIER", 167, 178]]], ["Sometimes the target sequences are detected in the strains of closely related species, and this necessitates additional analysis for the identification of more specific loci.", [["the target sequences", "TEST", 10, 30], ["additional analysis", "TEST", 109, 128]]], ["We combined bioinformatic analysis with subtractive hybridization data presented in [30] to select 28 speciesspecific DNA fragments of B. anthracis.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["B. anthracis", "ORGANISM", 135, 147], ["speciesspecific DNA fragments", "DNA", 102, 131], ["B. anthracis", "SPECIES", 135, 147], ["B. anthracis", "SPECIES", 135, 147], ["bioinformatic analysis", "TEST", 12, 34], ["subtractive hybridization data", "TEST", 40, 70]]], ["Two of these sequences (dhp73.019 and dhp73.017) were selected as chromosomal targets, and two pairs of primers (F3-B3 and FIP-BIP) for LAMP amplification of DNA were designed for each sequence.RESULTS AND DISCUSSIONThe pagA gene on the pXO1 plasmid and the CapABC gene on the pXO2 plasmid were selected as the plasmid targets, and two pairs of LAMP primers were designed for these targets as well.RESULTS AND DISCUSSIONOptimization of the loop isothermal amplification procedure.", [["chromosomal", "ANATOMY", 66, 77], ["plasmid", "ANATOMY", 282, 289], ["plasmid", "ANATOMY", 311, 318], ["chromosomal", "CELLULAR_COMPONENT", 66, 77], ["FIP-BIP", "GENE_OR_GENE_PRODUCT", 123, 130], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["pagA", "GENE_OR_GENE_PRODUCT", 220, 224], ["pXO1", "GENE_OR_GENE_PRODUCT", 237, 241], ["CapABC", "GENE_OR_GENE_PRODUCT", 258, 264], ["pXO2", "GENE_OR_GENE_PRODUCT", 277, 281], ["dhp73.019", "DNA", 24, 33], ["F3", "DNA", 113, 115], ["B3", "DNA", 116, 118], ["FIP", "DNA", 123, 126], ["BIP", "DNA", 127, 130], ["pagA gene", "DNA", 220, 229], ["pXO1 plasmid", "DNA", 237, 249], ["CapABC gene", "DNA", 258, 269], ["pXO2 plasmid", "DNA", 277, 289], ["plasmid targets", "DNA", 311, 326], ["LAMP primers", "DNA", 345, 357], ["these sequences", "TEST", 7, 22], ["dhp", "TEST", 38, 41], ["primers", "TEST", 104, 111], ["F3", "TEST", 113, 115], ["LAMP amplification of DNA", "TEST", 136, 161], ["the pXO1 plasmid", "TREATMENT", 233, 249], ["the CapABC gene", "TREATMENT", 254, 269], ["the pXO2 plasmid", "TREATMENT", 273, 289], ["the plasmid targets", "TEST", 307, 326], ["LAMP primers", "TEST", 345, 357], ["the loop isothermal amplification procedure", "TREATMENT", 436, 479]]], ["Bst or Bsm polymerases used in LAMP can elongate a new DNA strand and displace the previous one, in contrast to the enzymes used in conventional PCR [31, 32] .", [["Bst", "GENE_OR_GENE_PRODUCT", 0, 3], ["Bsm", "GENE_OR_GENE_PRODUCT", 7, 10], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["Bst", "PROTEIN", 0, 3], ["Bsm polymerases", "PROTEIN", 7, 22], ["enzymes", "PROTEIN", 116, 123], ["Bsm polymerases", "PROBLEM", 7, 22], ["a new DNA strand", "PROBLEM", 49, 65], ["the enzymes", "TEST", 112, 123], ["conventional PCR", "TEST", 132, 148]]], ["SD polymerase, a recently constructed mutant form of Taq polymerase, is also capable of strand displacement, but has a higher thermostability than Bst and Bsm polymerases, and, therefore, the initial high-temperature denaturation of DNA that increases reaction efficiency can be performed when this enzyme is used [33] .", [["SD polymerase", "GENE_OR_GENE_PRODUCT", 0, 13], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 53, 67], ["Bst", "GENE_OR_GENE_PRODUCT", 147, 150], ["Bsm polymerases", "GENE_OR_GENE_PRODUCT", 155, 170], ["DNA", "CELLULAR_COMPONENT", 233, 236], ["SD polymerase", "PROTEIN", 0, 13], ["Taq polymerase", "PROTEIN", 53, 67], ["Bst", "PROTEIN", 147, 150], ["Bsm polymerases", "PROTEIN", 155, 170], ["SD polymerase", "PROBLEM", 0, 13], ["Taq polymerase", "PROBLEM", 53, 67], ["strand displacement", "PROBLEM", 88, 107], ["a higher thermostability than Bst and Bsm polymerases", "PROBLEM", 117, 170], ["the initial high-temperature denaturation of DNA", "PROBLEM", 188, 236], ["reaction efficiency", "PROBLEM", 252, 271], ["this enzyme", "TEST", 294, 305], ["strand displacement", "OBSERVATION", 88, 107]]], ["Bst and SD polymerases were used in the present study in order to identify the most suitable enzyme for LAMP.", [["Bst", "GENE_OR_GENE_PRODUCT", 0, 3], ["SD polymerases", "GENE_OR_GENE_PRODUCT", 8, 22], ["Bst and SD polymerases", "PROTEIN", 0, 22], ["SD polymerases", "TREATMENT", 8, 22]]], ["Bst polymerase was used at first.", [["Bst polymerase", "GENE_OR_GENE_PRODUCT", 0, 14], ["Bst polymerase", "PROTEIN", 0, 14], ["Bst polymerase", "TEST", 0, 14]]], ["Regardless of the numerous changes of amplification parameters, such as the concentrations of Mg 2+ , Bst polymerase, and dNTPs, primer ratio, the presence of betaine, and reaction temperature (in the range of 50-68\u00b0C), there were no positive results (characteristic \"ladder\" patterns on the electrophoregram).", [["Mg", "CHEMICAL", 94, 96], ["dNTPs", "CHEMICAL", 122, 127], ["betaine", "CHEMICAL", 159, 166], ["Mg 2+", "CHEMICAL", 94, 99], ["dNTPs", "CHEMICAL", 122, 127], ["betaine", "CHEMICAL", 159, 166], ["Mg 2+", "SIMPLE_CHEMICAL", 94, 99], ["Bst polymerase", "GENE_OR_GENE_PRODUCT", 102, 116], ["dNTPs", "SIMPLE_CHEMICAL", 122, 127], ["betaine", "SIMPLE_CHEMICAL", 159, 166], ["Bst polymerase", "PROTEIN", 102, 116], ["amplification parameters", "TEST", 38, 62], ["Mg", "TEST", 94, 96], ["Bst polymerase", "TEST", 102, 116], ["dNTPs", "TEST", 122, 127], ["primer ratio", "TEST", 129, 141], ["reaction temperature", "TEST", 172, 192], ["positive results", "PROBLEM", 234, 250], ["no", "UNCERTAINTY", 231, 233]]], ["PCR with the F3-B3 external primer pair and Taq polymerase yielded a fragment of the expected size.", [["Taq polymerase", "GENE_OR_GENE_PRODUCT", 44, 58], ["F3-B3 external primer pair", "DNA", 13, 39], ["Taq polymerase", "PROTEIN", 44, 58], ["PCR", "TEST", 0, 3], ["the F3", "TEST", 9, 15], ["external primer pair", "TEST", 19, 39], ["Taq polymerase", "TEST", 44, 58], ["fragment", "OBSERVATION_MODIFIER", 69, 77], ["expected", "OBSERVATION_MODIFIER", 85, 93], ["size", "OBSERVATION_MODIFIER", 94, 98]]], ["LAMP with Bst polymerase and this amplicon (instead of native DNA) as template yielded a characteristic ladder of bands (data not shown) on the electrophoregram.", [["Bst polymerase", "GENE_OR_GENE_PRODUCT", 10, 24], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["Bst polymerase", "PROTEIN", 10, 24], ["native DNA", "DNA", 55, 65], ["LAMP with Bst polymerase", "TEST", 0, 24], ["this amplicon", "TREATMENT", 29, 42], ["native DNA", "TREATMENT", 55, 65], ["a characteristic ladder of bands", "PROBLEM", 87, 119]]], ["Replacement of Bst polymerase by a more thermostable SD polymerase for LAMP allowed for preheating of the reaction mixture at 92\u00b0C that provided for efficient amplification of both chromosomal and plasmid fragments of the native B. anthracis DNA.", [["chromosomal", "ANATOMY", 181, 192], ["fragments", "ANATOMY", 205, 214], ["Bst polymerase", "GENE_OR_GENE_PRODUCT", 15, 29], ["SD polymerase", "GENE_OR_GENE_PRODUCT", 53, 66], ["chromosomal", "CELLULAR_COMPONENT", 181, 192], ["B. anthracis", "ORGANISM", 229, 241], ["DNA", "CELLULAR_COMPONENT", 242, 245], ["Bst polymerase", "PROTEIN", 15, 29], ["thermostable SD polymerase", "PROTEIN", 40, 66], ["plasmid fragments", "DNA", 197, 214], ["native B. anthracis DNA", "DNA", 222, 245], ["B. anthracis", "SPECIES", 229, 241], ["B. anthracis", "SPECIES", 229, 241], ["Replacement of Bst polymerase", "TREATMENT", 0, 29], ["a more thermostable SD polymerase", "TREATMENT", 33, 66], ["the reaction mixture", "PROBLEM", 102, 122], ["both chromosomal and plasmid fragments", "PROBLEM", 176, 214], ["plasmid fragments", "OBSERVATION", 197, 214], ["anthracis DNA", "OBSERVATION", 232, 245]]], ["SD polymerase was used in the further experiments that included incubation of the reaction mix at 92\u00b0C for 2 min.RESULTS AND DISCUSSIONA number of parameters were varied in order to identify optimal conditions for LAMP.", [["SD polymerase", "PROTEIN", 0, 13], ["SD polymerase", "PROBLEM", 0, 13], ["the reaction mix", "TREATMENT", 78, 94]]], ["The primer ratio that yielded the best results was 10 pmol of external primers B3 and F3 and 40 pmol of internal primers FIP and BIP.", [["The primer ratio", "TEST", 0, 16], ["external primers B3", "TEST", 62, 81], ["internal primers FIP", "TEST", 104, 124], ["primers FIP", "OBSERVATION", 113, 124]]], ["8 for the stabilization of AT and GC pairs had a positive effect on amplification quality as well.", [["AT and GC pairs", "DNA", 27, 42], ["positive effect", "OBSERVATION_MODIFIER", 49, 64]]], ["LAMP of chromosomal DNA.", [["chromosomal", "ANATOMY", 8, 19], ["chromosomal DNA", "CELLULAR_COMPONENT", 8, 23], ["chromosomal DNA", "DNA", 8, 23], ["chromosomal DNA", "PROBLEM", 8, 23], ["chromosomal DNA", "OBSERVATION", 8, 23]]], ["Detection of chromosomal DNA of the anthrax pathogen was performed with B. anthracis strains that varied with regard to the degree of pathogenicity and plasmid composition.", [["chromosomal", "ANATOMY", 13, 24], ["plasmid", "ANATOMY", 152, 159], ["anthrax", "DISEASE", 36, 43], ["chromosomal", "CELLULAR_COMPONENT", 13, 24], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["B. anthracis strains", "ORGANISM", 72, 92], ["B. anthracis", "SPECIES", 72, 84], ["B. anthracis", "SPECIES", 72, 84], ["chromosomal DNA", "PROBLEM", 13, 28], ["the anthrax pathogen", "PROBLEM", 32, 52], ["B. anthracis strains", "PROBLEM", 72, 92], ["pathogenicity", "PROBLEM", 134, 147], ["plasmid composition", "PROBLEM", 152, 171], ["chromosomal DNA", "OBSERVATION", 13, 28], ["pathogenicity", "OBSERVATION", 134, 147], ["plasmid composition", "OBSERVATION", 152, 171]]], ["Diplasmid strains (pXO1 + /pXO2 + ), monoplasmid strains (pXO1 -/pXO2 + and pXO1 + /pXO2 -), and plasmid-free strains (pXO1 -/pXO2 -) were used.", [["strains", "ANATOMY", 49, 56], ["pXO1", "PROTEIN", 76, 80], ["pXO2", "PROTEIN", 84, 88], ["Diplasmid strains", "PROBLEM", 0, 17], ["pXO1", "TEST", 19, 23], ["pXO2", "TEST", 27, 31], ["monoplasmid strains", "PROBLEM", 37, 56], ["pXO1", "TEST", 58, 62], ["pXO2", "TEST", 65, 69], ["pXO1", "TEST", 76, 80], ["pXO2", "TEST", 84, 88], ["free strains", "PROBLEM", 105, 117]]], ["Strains of closely related species of bacilli were used in the experiments as well (Table 1) .RESULTS AND DISCUSSIONA fragment of B. anthracis chromosomal sequence dhp73.019 was amplified with the chBA20 set of four primers, and a fragment of the dhp73.017 chromosomal sequence was amplified with the chBA188 primer set.", [["chromosomal", "ANATOMY", 143, 154], ["chromosomal", "ANATOMY", 257, 268], ["bacilli", "ORGANISM_SUBSTANCE", 38, 45], ["B. anthracis", "ORGANISM", 130, 142], ["chromosomal", "CELLULAR_COMPONENT", 143, 154], ["dhp73.017", "GENE_OR_GENE_PRODUCT", 247, 256], ["chromosomal", "CELLULAR_COMPONENT", 257, 268], ["dhp73.019", "DNA", 164, 173], ["chBA20 set", "DNA", 197, 207], ["dhp73.017 chromosomal sequence", "DNA", 247, 277], ["chBA188 primer set", "DNA", 301, 319], ["B. anthracis", "SPECIES", 130, 142], ["B. anthracis", "SPECIES", 130, 142], ["bacilli", "PROBLEM", 38, 45], ["B. anthracis chromosomal sequence dhp", "TEST", 130, 167], ["four primers", "TREATMENT", 211, 223], ["a fragment of the dhp73.017 chromosomal sequence", "PROBLEM", 229, 277], ["closely related", "OBSERVATION_MODIFIER", 11, 26], ["species", "OBSERVATION_MODIFIER", 27, 34], ["bacilli", "OBSERVATION", 38, 45]]], ["Both primer sets detected chromosomal fragments with both purified DNA and DNA from thermolysates of specific B. anthracis strain cultures as templates.", [["chromosomal fragments", "ANATOMY", 26, 47], ["cultures", "ANATOMY", 130, 138], ["chromosomal", "CELLULAR_COMPONENT", 26, 37], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA", "CELLULAR_COMPONENT", 75, 78], ["B. anthracis", "ORGANISM", 110, 122], ["primer sets", "DNA", 5, 16], ["chromosomal fragments", "DNA", 26, 47], ["purified DNA", "DNA", 58, 70], ["B. anthracis", "SPECIES", 110, 122], ["B. anthracis", "SPECIES", 110, 122], ["chromosomal fragments", "PROBLEM", 26, 47], ["both purified DNA", "PROBLEM", 53, 70], ["DNA", "PROBLEM", 75, 78], ["thermolysates", "TREATMENT", 84, 97], ["specific B. anthracis strain cultures", "TEST", 101, 138], ["chromosomal fragments", "OBSERVATION", 26, 47], ["purified DNA", "OBSERVATION", 58, 70]]], ["Amplification with both primer sets was successfully used to differentiate between B. anthracis and other species of bacilli (B. cereus and B. thuringiensis, Fig. 1) .RESULTS AND DISCUSSIONPCR amplification of chromosomal DNA fragments from B. anthracis.", [["chromosomal", "ANATOMY", 210, 221], ["B. anthracis", "ORGANISM", 83, 95], ["B. cereus", "ORGANISM", 126, 135], ["B. thuringiensis", "ORGANISM", 140, 156], ["chromosomal", "CELLULAR_COMPONENT", 210, 221], ["DNA", "CELLULAR_COMPONENT", 222, 225], ["B. anthracis", "ORGANISM", 241, 253], ["chromosomal DNA fragments", "DNA", 210, 235], ["B. anthracis", "SPECIES", 83, 95], ["B. cereus", "SPECIES", 126, 135], ["B. thuringiensis", "SPECIES", 140, 156], ["B. anthracis", "SPECIES", 241, 253], ["B. anthracis", "SPECIES", 83, 95], ["B. cereus", "SPECIES", 126, 135], ["B. thuringiensis", "SPECIES", 140, 156], ["B. anthracis", "SPECIES", 241, 253], ["Amplification with both primer sets", "TREATMENT", 0, 35], ["B. anthracis", "PROBLEM", 83, 95], ["bacilli (B. cereus", "PROBLEM", 117, 135], ["chromosomal DNA fragments", "PROBLEM", 210, 235], ["DNA fragments", "OBSERVATION", 222, 235]]], ["The results of isothermal amplification of chromosomal DNA fragments from bacilli were compared to the results of conventional PCR.", [["chromosomal", "ANATOMY", 43, 54], ["fragments", "ANATOMY", 59, 68], ["chromosomal", "CELLULAR_COMPONENT", 43, 54], ["DNA", "CELLULAR_COMPONENT", 55, 58], ["chromosomal DNA fragments", "DNA", 43, 68], ["isothermal amplification", "TREATMENT", 15, 39], ["chromosomal DNA fragments", "PROBLEM", 43, 68], ["bacilli", "PROBLEM", 74, 81], ["conventional PCR", "TEST", 114, 130]]], ["Specific PCR with the external F3-B3 chBA20 primer pair and Taq polymerase yielded a fragment of the expected length (204 bp, Fig. 2 ).RESULTS AND DISCUSSIONThis specific fragment was only formed in samples that contained DNA from the strains of the species B. anthracis, and all other samples either contained no amplicons or contained non-specific amplification products with a length that differed from the expected value.RESULTS AND DISCUSSIONAs shown in Fig. 2 , a positive signal was obtained with DNA samples of plasmid-free strains B. anthracis STI RI F4, Lange1, and 513/1.", [["samples", "ANATOMY", 199, 206], ["samples", "ANATOMY", 286, 293], ["samples", "ANATOMY", 508, 515], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 60, 74], ["samples", "CANCER", 199, 206], ["DNA", "CELLULAR_COMPONENT", 222, 225], ["B. anthracis", "ORGANISM", 258, 270], ["DNA", "CELLULAR_COMPONENT", 504, 507], ["B. anthracis", "ORGANISM", 540, 552], ["STI RI F4", "ORGANISM", 553, 562], ["Lange1", "GENE_OR_GENE_PRODUCT", 564, 570], ["external F3-B3 chBA20 primer pair", "DNA", 22, 55], ["Taq polymerase", "PROTEIN", 60, 74], ["non-specific amplification products", "PROTEIN", 337, 372], ["B. anthracis", "SPECIES", 258, 270], ["B. anthracis", "SPECIES", 540, 552], ["B. anthracis", "SPECIES", 258, 270], ["B. anthracis", "SPECIES", 540, 552], ["Specific PCR", "TEST", 0, 12], ["the external F3", "TEST", 18, 33], ["Taq polymerase", "TEST", 60, 74], ["a fragment", "PROBLEM", 83, 93], ["bp", "TEST", 122, 124], ["specific fragment", "PROBLEM", 162, 179], ["DNA", "PROBLEM", 222, 225], ["the species B. anthracis", "PROBLEM", 246, 270], ["all other samples", "TEST", 276, 293], ["amplicons", "PROBLEM", 314, 323], ["non-specific amplification products", "TREATMENT", 337, 372], ["DNA samples", "TEST", 504, 515], ["plasmid", "TEST", 519, 526], ["Lange1", "TEST", 564, 570], ["fragment", "OBSERVATION_MODIFIER", 85, 93], ["length", "OBSERVATION_MODIFIER", 110, 116]]], ["Plasmid-free B. anthracis strains would not be detected if only plasmid-specific primers were used.", [["Plasmid-free", "ORGANISM", 0, 12], ["B. anthracis strains", "ORGANISM", 13, 33], ["plasmid", "DNA", 64, 71], ["B. anthracis", "SPECIES", 13, 25], ["B. anthracis", "SPECIES", 13, 25], ["Plasmid", "TREATMENT", 0, 7], ["free B. anthracis strains", "PROBLEM", 8, 33]]], ["Notably, primers suggested for chromosomal DNA in [25] yielded positive results with DNA from B. mycoides and B. cereus strains (F3502/73 and 421-4, respectively).", [["chromosomal", "ANATOMY", 31, 42], ["chromosomal", "CELLULAR_COMPONENT", 31, 42], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["DNA", "CELLULAR_COMPONENT", 85, 88], ["B. mycoides", "ORGANISM", 94, 105], ["B. cereus strains", "ORGANISM", 110, 127], ["B. mycoides", "SPECIES", 94, 105], ["B. cereus", "SPECIES", 110, 119], ["B. mycoides", "SPECIES", 94, 105], ["B. cereus", "SPECIES", 110, 119], ["chromosomal DNA", "PROBLEM", 31, 46], ["DNA", "PROBLEM", 85, 88], ["B. mycoides", "PROBLEM", 94, 105], ["B. cereus strains", "PROBLEM", 110, 127]]], ["Our experiments did not yield any positive results with strains that did not belong to the B. anthracis species, this being indicative of a high diagnostic value of primers that we designed for targets on B. anthracis chromosome.RESULTS AND DISCUSSIONStudies of strains 10 and 32 performed earlier in our laboratory addressed the character of growth of the microbes in liquid and solid nutrient media, virulence for mice, and sensitivity to three anthrax-specific bacteriophages.", [["chromosome", "ANATOMY", 218, 228], ["B. anthracis species", "ORGANISM", 91, 111], ["B. anthracis", "ORGANISM", 205, 217], ["chromosome", "CELLULAR_COMPONENT", 218, 228], ["mice", "ORGANISM", 416, 420], ["B. anthracis chromosome", "DNA", 205, 228], ["B. anthracis", "SPECIES", 91, 103], ["B. anthracis", "SPECIES", 205, 217], ["mice", "SPECIES", 416, 420], ["B. anthracis", "SPECIES", 91, 103], ["B. anthracis", "SPECIES", 205, 217], ["mice", "SPECIES", 416, 420], ["strains", "PROBLEM", 56, 63], ["the B. anthracis species", "PROBLEM", 87, 111], ["a high diagnostic value of primers", "PROBLEM", 138, 172], ["B. anthracis chromosome", "PROBLEM", 205, 228], ["strains", "PROBLEM", 262, 269], ["the microbes in liquid and solid nutrient media", "TREATMENT", 353, 400]]], ["However, the results of these studies were insufficient for unambiguous assignment of these strains to a species.", [["these studies", "TEST", 24, 37], ["these strains", "PROBLEM", 86, 99]]], ["The present study did not yield positive amplification results with primers that targeted the chromosomal loci of the anthrax pathogen, this being in agreement with the published results of single-primer PCR and VNTR typing [34, 35] that did not support the assignment of strains 10 and 32 to the B. anthracis species.RESULTS AND DISCUSSIONThus, the B. anthracis species can be distinguished from B. cereus and B. thuringiensis and, in particular, from the highly homologous strains of B. cereus Dakar and B. cereus var anthracoides 217 and 6691, by LAMP with primers that target chromosomal DNA fragments (chBA20-B3 and chBA20-F3).", [["chromosomal", "ANATOMY", 94, 105], ["chromosomal", "ANATOMY", 580, 591], ["anthrax", "DISEASE", 118, 125], ["chromosomal", "CELLULAR_COMPONENT", 94, 105], ["B. anthracis species", "ORGANISM", 297, 317], ["B. anthracis species", "ORGANISM", 350, 370], ["B. cereus", "ORGANISM", 397, 406], ["B. thuringiensis", "ORGANISM", 411, 427], ["B. cereus Dakar", "ORGANISM", 486, 501], ["B. cereus", "ORGANISM", 506, 515], ["var anthracoides 217", "ORGANISM", 516, 536], ["6691", "CELL", 541, 545], ["chromosomal", "CELLULAR_COMPONENT", 580, 591], ["DNA", "CELLULAR_COMPONENT", 592, 595], ["chBA20-B3", "GENE_OR_GENE_PRODUCT", 607, 616], ["chBA20-F3", "GENE_OR_GENE_PRODUCT", 621, 630], ["chromosomal DNA fragments", "DNA", 580, 605], ["chBA20", "DNA", 607, 613], ["B3", "DNA", 614, 616], ["chBA20", "DNA", 621, 627], ["F3", "DNA", 628, 630], ["B. anthracis", "SPECIES", 297, 309], ["B. anthracis", "SPECIES", 350, 362], ["B. cereus", "SPECIES", 397, 406], ["B. thuringiensis", "SPECIES", 411, 427], ["B. cereus", "SPECIES", 486, 495], ["B. cereus var", "SPECIES", 506, 519], ["anthracoides", "SPECIES", 520, 532], ["B. anthracis", "SPECIES", 297, 309], ["B. anthracis", "SPECIES", 350, 362], ["B. cereus", "SPECIES", 397, 406], ["B. thuringiensis", "SPECIES", 411, 427], ["B. cereus", "SPECIES", 486, 495], ["B. cereus var anthracoides", "SPECIES", 506, 532], ["The present study", "TEST", 0, 17], ["positive amplification results with primers", "PROBLEM", 32, 75], ["single-primer PCR", "TEST", 190, 207], ["VNTR typing", "TEST", 212, 223], ["strains", "PROBLEM", 272, 279], ["the B. anthracis species", "PROBLEM", 346, 370], ["B. cereus", "PROBLEM", 397, 406], ["B. thuringiensis", "PROBLEM", 411, 427], ["target chromosomal DNA fragments", "PROBLEM", 573, 605], ["chBA20", "TEST", 607, 613], ["chBA20", "TEST", 621, 627], ["DNA fragments", "OBSERVATION", 592, 605]]], ["Therefore, these primers can be regarded as very promising components of LAMP-based test kits for the identification of the anthrax pathogen.RESULTS AND DISCUSSIONIsothermal amplification of plasmid DNA fragments.", [["fragments", "ANATOMY", 203, 212], ["anthrax", "DISEASE", 124, 131], ["DNA", "CELLULAR_COMPONENT", 199, 202], ["plasmid DNA fragments", "DNA", 191, 212], ["these primers", "TREATMENT", 11, 24], ["LAMP-based test kits", "TEST", 73, 93], ["the anthrax pathogen", "PROBLEM", 120, 140], ["plasmid DNA fragments", "PROBLEM", 191, 212], ["anthrax", "OBSERVATION", 124, 131], ["plasmid DNA fragments", "OBSERVATION", 191, 212]]], ["Plasmid pXO1.", [["pXO1", "PROTEIN", 8, 12], ["Plasmid pXO1", "TREATMENT", 0, 12]]], ["The results of comparative analysis of DNA samples of diplasmid, monoplasmid, and plasmid-free B. anthracis strains and saprophytic representatives of the genus Bacillus by loop isothermal amplification reaction with primers to DNA fragments localized on the plasmid pXO1 are shown in Fig. 3 .RESULTS AND DISCUSSIONFragments of the pagA gene from B. anthracis plasmid pXO1 were amplified using pagBA272 (Fig. 3 ) and pagBA997 (data not shown) primer sets.", [["samples", "ANATOMY", 43, 50], ["diplasmid", "ANATOMY", 54, 63], ["monoplasmid", "ANATOMY", 65, 76], ["plasmid", "ANATOMY", 259, 266], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["diplasmid", "GENE_OR_GENE_PRODUCT", 54, 63], ["plasmid-free", "ORGANISM", 82, 94], ["B. anthracis strains", "ORGANISM", 95, 115], ["DNA", "CELLULAR_COMPONENT", 228, 231], ["pXO1", "GENE_OR_GENE_PRODUCT", 267, 271], ["pagA", "GENE_OR_GENE_PRODUCT", 332, 336], ["B. anthracis", "ORGANISM", 347, 359], ["pXO1", "GENE_OR_GENE_PRODUCT", 368, 372], ["diplasmid, monoplasmid, and plasmid", "DNA", 54, 89], ["DNA fragments", "DNA", 228, 241], ["plasmid pXO1", "DNA", 259, 271], ["pagA gene", "DNA", 332, 341], ["B. anthracis plasmid pXO1", "DNA", 347, 372], ["pagBA272", "DNA", 394, 402], ["pagBA997", "DNA", 417, 425], ["B. anthracis", "SPECIES", 95, 107], ["B. anthracis", "SPECIES", 347, 359], ["B. anthracis", "SPECIES", 95, 107], ["B. anthracis", "SPECIES", 347, 359], ["comparative analysis", "TEST", 15, 35], ["DNA samples", "TEST", 39, 50], ["diplasmid", "TEST", 54, 63], ["monoplasmid", "TEST", 65, 76], ["plasmid-free B. anthracis strains", "PROBLEM", 82, 115], ["saprophytic", "PROBLEM", 120, 131], ["the genus Bacillus", "PROBLEM", 151, 169], ["loop isothermal amplification reaction", "PROBLEM", 173, 211], ["primers", "TREATMENT", 217, 224], ["DNA fragments", "PROBLEM", 228, 241], ["the plasmid pXO1", "TREATMENT", 255, 271], ["the pagA gene", "TREATMENT", 328, 341], ["B. anthracis plasmid pXO1", "TREATMENT", 347, 372], ["pagBA272", "TEST", 394, 402], ["genus Bacillus", "ANATOMY", 155, 169]]], ["The target fragment of the pagA gene was amplified in all samples from strains that harbored the pXO1 plasmid, whereas no amplification occurred if DNA from strains that lacked the pXO1 plasmid was used.", [["samples", "ANATOMY", 58, 65], ["plasmid", "ANATOMY", 102, 109], ["pagA", "GENE_OR_GENE_PRODUCT", 27, 31], ["pXO1", "GENE_OR_GENE_PRODUCT", 97, 101], ["DNA", "CELLULAR_COMPONENT", 148, 151], ["pXO1", "GENE_OR_GENE_PRODUCT", 181, 185], ["pagA gene", "DNA", 27, 36], ["pXO1 plasmid", "DNA", 97, 109], ["pXO1 plasmid", "DNA", 181, 193], ["The target fragment of the pagA gene", "TREATMENT", 0, 36], ["the pXO1 plasmid", "TREATMENT", 93, 109], ["amplification", "PROBLEM", 122, 135], ["DNA", "PROBLEM", 148, 151], ["strains", "PROBLEM", 157, 164], ["the pXO1 plasmid", "TREATMENT", 177, 193], ["target", "OBSERVATION_MODIFIER", 4, 10], ["fragment", "OBSERVATION_MODIFIER", 11, 19]]], ["A weak signal of the product was observed in some experiments with the pagBA997 primer set and DNA from B. cereus var. anthracoides 217 as the template, this probably being indicative of a lower specificity of this primer set relatively to the pagBA272 primer set.RESULTS AND DISCUSSIONPlasmid pXO2.", [["DNA", "CELLULAR_COMPONENT", 95, 98], ["B. cereus", "ORGANISM", 104, 113], ["pagBA272", "GENE_OR_GENE_PRODUCT", 244, 252], ["pagBA997 primer set", "DNA", 71, 90], ["pagBA272 primer set", "DNA", 244, 263], ["B. cereus var", "SPECIES", 104, 117], ["anthracoides", "SPECIES", 119, 131], ["B. cereus var", "SPECIES", 104, 117], ["A weak signal of the product", "PROBLEM", 0, 28], ["anthracoides", "TEST", 119, 131], ["a lower specificity of this primer", "PROBLEM", 187, 221], ["weak", "OBSERVATION_MODIFIER", 2, 6], ["probably being indicative", "UNCERTAINTY", 158, 183]]], ["Primer sets capBA194 and capBA31 were used to amplify fragments of the CapABC gene from the pXO2 plasmid of B. anthracis (data not shown).", [["capBA194", "GENE_OR_GENE_PRODUCT", 12, 20], ["capBA31", "GENE_OR_GENE_PRODUCT", 25, 32], ["CapABC", "GENE_OR_GENE_PRODUCT", 71, 77], ["pXO2", "GENE_OR_GENE_PRODUCT", 92, 96], ["B. anthracis", "ORGANISM", 108, 120], ["Primer sets", "DNA", 0, 11], ["capBA194", "DNA", 12, 20], ["capBA31", "DNA", 25, 32], ["CapABC gene", "DNA", 71, 82], ["pXO2 plasmid", "DNA", 92, 104], ["B. anthracis", "SPECIES", 108, 120], ["B. anthracis", "SPECIES", 108, 120], ["Primer sets capBA194", "TREATMENT", 0, 20], ["capBA31", "TREATMENT", 25, 32], ["the CapABC gene", "TREATMENT", 67, 82], ["the pXO2 plasmid", "TREATMENT", 88, 104]]], ["LAMP products appeared on the electrophoregram if DNA from strains that carried the pXO2 plasmid was used, in contrast to the results of amplification of DNA from strains that lacked the plasmid.RESULTS AND DISCUSSIONThe results of amplification of DNA from the strains of B. anthracis and other representatives of the genus Bacillus with the primer set capBA194 that targeted the CapABC gene from the pXO2 plasmid are shown in Fig. 4 .", [["plasmid", "ANATOMY", 187, 194], ["pXO2 plasmid", "ANATOMY", 402, 414], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["pXO2", "GENE_OR_GENE_PRODUCT", 84, 88], ["DNA", "CELLULAR_COMPONENT", 154, 157], ["DNA", "CELLULAR_COMPONENT", 249, 252], ["B. anthracis", "ORGANISM", 273, 285], ["capBA194", "GENE_OR_GENE_PRODUCT", 354, 362], ["CapABC", "GENE_OR_GENE_PRODUCT", 381, 387], ["pXO2", "GENE_OR_GENE_PRODUCT", 402, 406], ["pXO2 plasmid", "DNA", 84, 96], ["plasmid", "DNA", 187, 194], ["primer set capBA194", "DNA", 343, 362], ["CapABC gene", "DNA", 381, 392], ["pXO2 plasmid", "DNA", 402, 414], ["B. anthracis", "SPECIES", 273, 285], ["B. anthracis", "SPECIES", 273, 285], ["LAMP products", "TREATMENT", 0, 13], ["DNA", "PROBLEM", 50, 53], ["strains", "PROBLEM", 59, 66], ["the pXO2 plasmid", "TREATMENT", 80, 96], ["DNA from strains", "PROBLEM", 154, 170], ["the plasmid", "TREATMENT", 183, 194], ["DNA", "PROBLEM", 249, 252], ["B. anthracis", "PROBLEM", 273, 285], ["the genus Bacillus", "PROBLEM", 315, 333], ["the primer set capBA194", "TREATMENT", 339, 362], ["the CapABC gene", "TREATMENT", 377, 392], ["the pXO2 plasmid", "TREATMENT", 398, 414]]], ["PCR with the capBA31 primer set yielded similar results.RESULTS AND DISCUSSIONThus, both primer sets (capBA194 and capBA31) allowed for reproducible synthesis of the characteristic LAMP product when DNA from di-and monoplas- 4 5 6 7 8 9 10 11 12 13 14 15 17 16 18 19 mid strains that carried the pXO2 plasmid was analyzed.", [["DNA", "CELLULAR_COMPONENT", 199, 202], ["pXO2", "GENE_OR_GENE_PRODUCT", 296, 300], ["capBA31 primer set", "DNA", 13, 31], ["primer sets", "DNA", 89, 100], ["capBA194", "DNA", 102, 110], ["capBA31", "DNA", 115, 122], ["di-and monoplas- 4 5 6 7 8 9 10 11 12 13 14 15 17 16 18 19 mid strains", "DNA", 208, 278], ["pXO2 plasmid", "DNA", 296, 308], ["PCR", "TEST", 0, 3], ["the capBA31 primer set", "TEST", 9, 31], ["DNA from di-and monoplas", "TEST", 199, 223], ["19 mid strains", "PROBLEM", 264, 278], ["the pXO2 plasmid", "TREATMENT", 292, 308]]], ["Assessment of the sensitivity of chBA20 primers for LAMP and PCR detection of B. anthracis.", [["chBA20", "GENE_OR_GENE_PRODUCT", 33, 39], ["B. anthracis", "ORGANISM", 78, 90], ["chBA20 primers", "DNA", 33, 47], ["B. anthracis", "SPECIES", 78, 90], ["B. anthracis", "SPECIES", 78, 90], ["chBA20 primers", "TEST", 33, 47], ["LAMP", "TEST", 52, 56], ["PCR detection", "TEST", 61, 74], ["B. anthracis", "PROBLEM", 78, 90]]], ["The sensitivity of F3-B3 chBA20 primers for PCR detection of B. anthracis chromosome fragment dhp73.019 in DNA samples from B. anthracis STI-1 was sufficient for amplification of the target fragment from 6 ng, 600, 60, and 6 pg of total DNA.", [["samples", "ANATOMY", 111, 118], ["B. anthracis", "ORGANISM", 61, 73], ["DNA", "CELLULAR_COMPONENT", 107, 110], ["B. anthracis STI-1", "ORGANISM", 124, 142], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["F3-B3 chBA20 primers", "DNA", 19, 39], ["B. anthracis chromosome fragment dhp73.019", "DNA", 61, 103], ["target fragment", "DNA", 183, 198], ["B. anthracis", "SPECIES", 61, 73], ["B. anthracis STI", "SPECIES", 124, 140], ["B. anthracis", "SPECIES", 61, 73], ["B. anthracis STI-1", "SPECIES", 124, 142], ["The sensitivity", "TEST", 0, 15], ["F3", "TEST", 19, 21], ["B3 chBA20 primers", "TEST", 22, 39], ["PCR detection", "TEST", 44, 57], ["B. anthracis chromosome fragment dhp", "TEST", 61, 97], ["DNA samples", "TEST", 107, 118], ["B. anthracis STI", "TEST", 124, 140], ["the target fragment", "PROBLEM", 179, 198], ["total DNA", "PROBLEM", 231, 240]]], ["The sensitivity of LAMP with the chBA20 set of primers was similar (data not shown).", [["chBA20", "DNA", 33, 39], ["LAMP", "TEST", 19, 23], ["the chBA20 set of primers", "TEST", 29, 54]]], ["Thus, the sensitivity of LAMP with primers for the detection of B. anthracis chromosomal region dhp73.019 was comparable to that of PCR.RESULTS AND DISCUSSIONThe possibility of detection of unusual B. anthracis strains or other bacilli that cause \"anthrax-like\" diseases of humans and animals, as well as the possibility of detection of saprophyte isolates with a genomic sequence highly similar (up to 99.9% identity) to the \"classical\" strains of anthrax pathogen should be taken into account upon laboratory diagnosis and epidemiological investigation of infectious diseases with clinical symptoms similar to anthrax.", [["chromosomal", "ANATOMY", 77, 88], ["anthrax", "DISEASE", 248, 255], ["anthrax pathogen", "DISEASE", 449, 465], ["infectious diseases", "DISEASE", 558, 577], ["anthrax", "DISEASE", 612, 619], ["B. anthracis", "ORGANISM", 64, 76], ["chromosomal", "CELLULAR_COMPONENT", 77, 88], ["B. anthracis strains", "ORGANISM", 198, 218], ["humans", "ORGANISM", 274, 280], ["anthrax", "ORGANISM", 449, 456], ["dhp73.019", "DNA", 96, 105], ["B. anthracis", "SPECIES", 64, 76], ["B. anthracis", "SPECIES", 198, 210], ["humans", "SPECIES", 274, 280], ["B. anthracis", "SPECIES", 64, 76], ["B. anthracis", "SPECIES", 198, 210], ["humans", "SPECIES", 274, 280], ["LAMP with primers", "TREATMENT", 25, 42], ["the detection", "TEST", 47, 60], ["B. anthracis chromosomal region dhp", "TEST", 64, 99], ["PCR", "TEST", 132, 135], ["unusual B. anthracis strains", "PROBLEM", 190, 218], ["other bacilli", "PROBLEM", 222, 235], ["anthrax", "PROBLEM", 248, 255], ["\" diseases of humans", "PROBLEM", 260, 280], ["saprophyte isolates", "PROBLEM", 337, 356], ["a genomic sequence", "TEST", 362, 380], ["anthrax pathogen", "PROBLEM", 449, 465], ["laboratory diagnosis", "TEST", 500, 520], ["epidemiological investigation", "TEST", 525, 554], ["infectious diseases", "PROBLEM", 558, 577], ["clinical symptoms", "PROBLEM", 583, 600], ["anthrax", "PROBLEM", 612, 619]]], ["The currently used identification methods based on DNA detection require expensive devices, well-equipped laboratories, and qualified personnel.", [["DNA", "CELLULAR_COMPONENT", 51, 54], ["identification methods", "TEST", 19, 41], ["DNA detection", "TEST", 51, 64], ["expensive devices", "TREATMENT", 73, 90]]], ["The LAMP method is suitable for use in field studies and poorly equipped laboratories due to its simplicity and high speed of analysis.", [["The LAMP method", "TREATMENT", 0, 15], ["field studies", "TEST", 39, 52]]], ["Therefore, the present study involved an attempt to develop a test for the identification of the anthrax pathogen and discrimination between this pathogen and closely related species.", [["anthrax", "DISEASE", 97, 104], ["the present study", "TEST", 11, 28], ["a test", "TEST", 60, 66], ["the anthrax pathogen", "PROBLEM", 93, 113], ["this pathogen", "PROBLEM", 141, 154]]], ["The results of detection and identification of B. anthracis strains in loop isothermal DNA amplification (LAMP) reaction with original primers, optimized conditions, and thermostable DNA polymerase are presented.", [["B. anthracis", "ORGANISM", 47, 59], ["DNA", "CELLULAR_COMPONENT", 87, 90], ["DNA", "CELLULAR_COMPONENT", 183, 186], ["thermostable DNA polymerase", "PROTEIN", 170, 197], ["B. anthracis", "SPECIES", 47, 59], ["B. anthracis", "SPECIES", 47, 59], ["detection", "TEST", 15, 24], ["B. anthracis strains", "PROBLEM", 47, 67], ["loop isothermal DNA amplification", "TREATMENT", 71, 104], ["original primers", "TREATMENT", 126, 142], ["thermostable DNA polymerase", "PROBLEM", 170, 197]]], ["Reproducible detection of targets specific for chromosomal and plasmid DNA of B. anthracis strains has been demonstrated.", [["chromosomal", "ANATOMY", 47, 58], ["plasmid", "ANATOMY", 63, 70], ["chromosomal", "CELLULAR_COMPONENT", 47, 58], ["plasmid", "CELLULAR_COMPONENT", 63, 70], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["B. anthracis strains", "ORGANISM", 78, 98], ["plasmid DNA", "DNA", 63, 74], ["B. anthracis", "SPECIES", 78, 90], ["B. anthracis", "SPECIES", 78, 90], ["chromosomal and plasmid DNA", "PROBLEM", 47, 74], ["B. anthracis strains", "PROBLEM", 78, 98]]], ["No cross reaction with DNA from strains of other species of the B. cereus group was observed.RESULTS AND DISCUSSIONThe sensitivity of LAMP-based detection of the anthrax pathogen is of great importance, especially for field studies.", [["anthrax", "DISEASE", 162, 169], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["B. cereus", "ORGANISM", 64, 73], ["anthrax", "ORGANISM", 162, 169], ["B. cereus group", "SPECIES", 64, 79], ["B. cereus", "SPECIES", 64, 73], ["cross reaction", "PROBLEM", 3, 17], ["DNA", "PROBLEM", 23, 26], ["the B. cereus group", "PROBLEM", 60, 79], ["LAMP", "TEST", 134, 138], ["the anthrax pathogen", "PROBLEM", 158, 178], ["field studies", "TEST", 218, 231], ["cross reaction", "OBSERVATION", 3, 17]]], ["The sensitivity of LAMP with primers that targeted a fragment of B. anthracis chromosome was the same as that of PCR.", [["chromosome", "ANATOMY", 78, 88], ["B. anthracis", "ORGANISM", 65, 77], ["chromosome", "CELLULAR_COMPONENT", 78, 88], ["B. anthracis chromosome", "DNA", 65, 88], ["B. anthracis", "SPECIES", 65, 77], ["B. anthracis", "SPECIES", 65, 77], ["LAMP with primers", "TREATMENT", 19, 36], ["a fragment of B. anthracis chromosome", "PROBLEM", 51, 88], ["PCR", "TEST", 113, 116]]], ["Importantly, the amount of LAMP products is higher than that of PCR products formed in a reaction mix with the same amount of template, and therefore visualization of the reaction products in the former case can be performed without specialized equipment.", [["LAMP products", "PROTEIN", 27, 40], ["LAMP products", "TREATMENT", 27, 40], ["PCR products", "TREATMENT", 64, 76], ["a reaction mix", "TREATMENT", 87, 101], ["the reaction products", "TREATMENT", 167, 188], ["amount", "OBSERVATION_MODIFIER", 17, 23], ["LAMP products", "OBSERVATION", 27, 40], ["higher", "OBSERVATION_MODIFIER", 44, 50], ["amount", "OBSERVATION_MODIFIER", 116, 122], ["template", "OBSERVATION_MODIFIER", 126, 134], ["reaction products", "OBSERVATION", 171, 188]]], ["Research on the visualization of LAMP products without specialized equipment is currently in progress.", [["LAMP products", "PROTEIN", 33, 46], ["LAMP products", "TREATMENT", 33, 46]]], ["The introduction of an additional pair of loop primers is planned in order to increase the sensitivity of isothermal amplification.", [["an additional pair of loop primers", "TREATMENT", 20, 54], ["isothermal amplification", "TREATMENT", 106, 130]]], ["This modification may allow for an increase in product yield and a decrease in the reaction time.RESULTS AND DISCUSSIONThe optimized reaction of loop isothermal DNA amplification is intended for use in the development of test systems for clinical and field diagnostics of the anthrax pathogen.", [["anthrax", "DISEASE", 276, 283], ["DNA", "CELLULAR_COMPONENT", 161, 164], ["an increase in product yield", "PROBLEM", 32, 60], ["a decrease in the reaction time", "PROBLEM", 65, 96], ["loop isothermal DNA amplification", "TREATMENT", 145, 178], ["test systems", "TEST", 221, 233], ["the anthrax pathogen", "PROBLEM", 272, 292], ["increase", "OBSERVATION_MODIFIER", 35, 43], ["decrease", "OBSERVATION_MODIFIER", 67, 75], ["loop", "OBSERVATION_MODIFIER", 145, 149]]], ["These test systems will be easy to use and will not require sophisticated equipment.CONFLICT OF INTERESTThe authors declare no conflict of interest.ACKNOWLEDGMENTSThis work was supported by state contract no. 13-D (\"Diagnostics, Development, and Implementation of New Diagnostic Tools and Technologies for the Detection and Identification of Pathogenic Biological Objects\").", [["These test systems", "TEST", 0, 18], ["sophisticated equipment", "TREATMENT", 60, 83], ["the Detection", "TEST", 306, 319]]]], "PMC7449888": [["WHO defines health workers as \u201call people engaged in actions whose primary intent is to enhance health\u201d (1, 2).", [["people", "SPECIES", 35, 41]]], ["Health service providers comprises the people who deliver services, such as physicians, nurses, midwifes, laboratory technician etc. Health service providers account for 67% of all health workers globally.", [["people", "ORGANISM", 39, 45], ["people", "SPECIES", 39, 45]]], ["Health management and support workers covers people who are not engaged in the direct provision of services, such as administrative professionals, computing professionals, clerical workers, drivers etc.(1).", [["people", "ORGANISM", 45, 51], ["people", "SPECIES", 45, 51]]], ["NSE is generally defined based upon its differences from standard employment, which is considered as full-time and permanent work with a contract between the worker and employer (1).", [["NSE", "GENE_OR_GENE_PRODUCT", 0, 3], ["NSE", "PROTEIN", 0, 3], ["generally defined", "OBSERVATION_MODIFIER", 7, 24]]], ["NSE includes fixed-term, part-time, on-call, agency-related employment, dependent self-employment, dispatch, and temporary employment (5, 4).", [["NSE", "GENE_OR_GENE_PRODUCT", 0, 3], ["NSE", "PROTEIN", 0, 3]]], ["There is no data available at global level for reporting on NSE in health sector (1), but some studies in different countries showed that non-standard forms of employment, such as part time employment, in the health sector are also increasing, despite their challenging characteristics as a vital part of the sector (7, 8, 9, 10, 11).", [["NSE", "GENE_OR_GENE_PRODUCT", 60, 63], ["some studies", "TEST", 90, 102], ["no", "UNCERTAINTY", 9, 11], ["increasing", "OBSERVATION_MODIFIER", 232, 242]]], ["NSE has been considered to have a positive impact on economic growth, but it is also often referred to as precarious employment due to potential adverse consequences regarding the health and well-being of workers (13).", [["NSE", "GENE_OR_GENE_PRODUCT", 0, 3], ["NSE", "PROTEIN", 0, 3], ["a positive impact on economic growth", "PROBLEM", 32, 68]]], ["NSE can have a variety of effects depending on the type of work arrangement, the individual employee profile, and the context of the workplace, sector, and country.", [["NSE", "GENE_OR_GENE_PRODUCT", 0, 3], ["NSE", "PROTEIN", 0, 3]]], ["There are few studies assessing the impacts of NSE in the health sector.", [["NSE", "GENE_OR_GENE_PRODUCT", 47, 50], ["few studies", "TEST", 10, 21], ["few", "OBSERVATION_MODIFIER", 10, 13]]], ["According to these studies part time working, which is a form of NSE, affected many aspects of the health sector.", [["NSE", "GENE_OR_GENE_PRODUCT", 65, 68]]], ["These effects were either positive or negative, such as increasing the productivity, hence contributing to the quality of services (14), or achieving higher patient outcomes in preventive services such as cancer screening or diabetic management (15), and adverse implications for the workforce such as more negative perceptions regarding workplace (less autonomy, fewer opportunities for self-development) and less favorable work attitudes (less engagement, job involvement, and affective commitment (16), or on the contrary better psychological well-being and more satisfaction(17); these effects have been increasingly discussed globally in many studies.", [["cancer", "ANATOMY", 205, 211], ["cancer", "DISEASE", 205, 211], ["diabetic", "DISEASE", 225, 233], ["patient", "ORGANISM", 157, 164], ["cancer", "CANCER", 205, 211], ["patient", "SPECIES", 157, 164], ["preventive services", "TREATMENT", 177, 196], ["cancer screening", "TEST", 205, 221], ["diabetic management", "TREATMENT", 225, 244]]], ["However, there are many other negative and positive consequences of NSE for communities, organizations, institutions, and individuals, which should be discussed and considered.", [["NSE", "GENE_OR_GENE_PRODUCT", 68, 71], ["negative", "OBSERVATION", 30, 38], ["positive consequences", "OBSERVATION_MODIFIER", 43, 64]]], ["Specifically, the impacts of NSE on the disaster preparedness of health systems, particularly on hospitals\u2019 emergency and disaster plans, have not been adequately studied thus far.", [["NSE", "GENE_OR_GENE_PRODUCT", 29, 32]]], ["NSE-related data and the potential influences of its procedures also need to be evaluated both during and after the pandemic to gain knowledge and learn lessons for better planning and preparedness for future events.", [["NSE", "GENE_OR_GENE_PRODUCT", 0, 3], ["NSE", "PROTEIN", 0, 3], ["NSE", "TEST", 0, 3], ["its procedures", "TREATMENT", 49, 63]]], ["Considering that the number of people affected by disasters and the estimated damage caused by them has risen since the middle of the twentieth century (18), hospitals should be better prepared to face emergencies and disasters and overcome various challenges during this process.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["the estimated damage", "PROBLEM", 64, 84], ["damage", "OBSERVATION", 78, 84]]], ["Inclusiveness of workforce, evaluation of needs, and keeping all capacities active and effective through a comprehensive occupational health and safety approach will empower the workforce in the health sector, which has a vital function during normal times as well as disasters.", [["evaluation", "TEST", 28, 38]]], ["Thus, this short communication paper identifies and discusses the neglected issue of NSE in hospital emergency and disaster planning to point out a further research need.IntroductionAll sorts of natural and technological hazards and complex emergencies have direct or indirect effects on human health and well-being.", [["NSE", "GENE_OR_GENE_PRODUCT", 85, 88], ["human", "ORGANISM", 288, 293], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 288, 293]]], ["The recent pandemic has indicated once again that health systems have a vital role in responding to these disasters, and hospitals are among the primary components of health systems.", [["pandemic", "OBSERVATION", 11, 19]]], ["The impacts of disasters on the health systems include unexpectedly high numbers of deaths, injuries, or illnesses in the affected community; destruction of local health infrastructure and routine health services; effects on the environment leading to the danger of communicable diseases and food shortages; mental health problems; and spontaneous or organized population movements (19).", [["deaths", "DISEASE", 84, 90], ["injuries", "DISEASE", 92, 100], ["communicable diseases", "DISEASE", 266, 287], ["injuries", "PROBLEM", 92, 100], ["illnesses", "PROBLEM", 105, 114], ["communicable diseases", "PROBLEM", 266, 287], ["mental health problems", "PROBLEM", 308, 330]]], ["Hospitals differ from other workplaces in many ways, especially in the context of disasters due the impact of disasters on the health systems.", [["disasters", "OBSERVATION", 110, 119]]], ["However, they can face structural and non-structural damages due to various hazards, and, consequently, health services may be affected when they are most in need.", [["non-structural damages", "PROBLEM", 38, 60], ["non-structural damages", "OBSERVATION", 38, 60]]], ["More than 6,400 patients from six hospitals and 31 residential care facilities in New York were evacuated during the Hurricane Sandy in 2012.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24]]], ["Any destruction or damage to hospitals may lead to severe social consequences, such as the loss of trust in local authorities and exposing patients and health workers to further vulnerabilities (20).IntroductionThus, hospitals require special attention in the disaster preparedness of communities.", [["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 139, 147], ["Any destruction", "PROBLEM", 0, 15], ["damage", "PROBLEM", 19, 25], ["severe social consequences", "PROBLEM", 51, 77], ["destruction", "OBSERVATION", 4, 15], ["severe", "OBSERVATION_MODIFIER", 51, 57]]], ["Many factors, such as limited resources, lack of political will, and deficiency in communal/institutional/individual support or awareness, have an impact on health systems and hospitals.", [["deficiency", "PROBLEM", 69, 79]]], ["In addition to these commonly discussed factors, changes in the work relationships of NSE might complicate the challenges of making hospitals resilient to hazards and prepared for disasters, if they are not considered during the preparedness process.", [["NSE", "DISEASE", 86, 89], ["NSE", "GENE_OR_GENE_PRODUCT", 86, 89]]]]}